id	sid	tid	token	lemma	pos
admet-295	1	1	doi	doi	NOUN
admet-295	1	2	:	:	PUNCT
admet-295	1	3	10.5599	10.5599	NUM
admet-295	1	4	/	/	SYM
admet-295	1	5	admet.4.3.295	admet.4.3.295	NOUN
admet-295	1	6	212	212	NUM
admet-295	1	7	admet	admet	X
admet-295	1	8	&	&	CCONJ
admet-295	1	9	dmpk	dmpk	PROPN
admet-295	1	10	4(3	4(3	NUM
admet-295	1	11	)	)	PUNCT
admet-295	1	12	(	(	PUNCT
admet-295	1	13	2016	2016	NUM
admet-295	1	14	)	)	PUNCT
admet-295	1	15	212	212	NUM
admet-295	1	16	-	-	SYM
admet-295	1	17	231	231	NUM
admet-295	1	18	;	;	PUNCT
admet-295	1	19	doi	doi	NOUN
admet-295	1	20	:	:	PUNCT
admet-295	1	21	10.5599	10.5599	NUM
admet-295	1	22	/	/	SYM
admet-295	1	23	admet.4.3.295	admet.4.3.295	NOUN
admet-295	1	24	open	open	ADJ
admet-295	1	25	access	access	NOUN
admet-295	1	26	:	:	PUNCT
admet-295	1	27	issn	issn	PROPN
admet-295	1	28	:	:	PUNCT
admet-295	1	29	1848	1848	NUM
admet-295	1	30	-	-	SYM
admet-295	1	31	7718	7718	NUM
admet-295	1	32	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-295	1	33	review	review	VERB
admet-295	1	34	cardiovascular	cardiovascular	ADJ
admet-295	1	35	safety	safety	NOUN
admet-295	1	36	of	of	ADP
admet-295	1	37	protein	protein	NOUN
admet-295	1	38	kinase	kinase	PROPN
admet-295	1	39	inhibitors	inhibitor	NOUN
admet-295	1	40	:	:	PUNCT
admet-295	1	41	putting	put	VERB
admet-295	1	42	their	their	PRON
admet-295	1	43	“	"	PUNCT
admet-295	1	44	qt	qt	NOUN
admet-295	1	45	-	-	PUNCT
admet-295	1	46	phobia	phobia	NOUN
admet-295	1	47	”	"	PUNCT
admet-295	1	48	in	in	ADP
admet-295	1	49	perspective	perspective	NOUN
admet-295	1	50	rashmi	rashmi	PROPN
admet-295	1	51	r	r	PROPN
admet-295	1	52	shah	shah	PROPN
admet-295	1	53	pharmaceutical	pharmaceutical	NOUN
admet-295	1	54	consultant	consultant	NOUN
admet-295	1	55	,	,	PUNCT
admet-295	1	56	8	8	NUM
admet-295	1	57	birchdale	birchdale	NOUN
admet-295	1	58	,	,	PUNCT
admet-295	1	59	gerrards	gerrards	PROPN
admet-295	1	60	cross	cross	PROPN
admet-295	1	61	,	,	PUNCT
admet-295	1	62	buckinghamshire	buckinghamshire	ADJ
admet-295	1	63	,	,	PUNCT
admet-295	1	64	uk	uk	PROPN
admet-295	1	65	e	e	NOUN
admet-295	1	66	-	-	NOUN
admet-295	1	67	mail	mail	NOUN
admet-295	1	68	:	:	PUNCT
admet-295	1	69	clinical.safety@hotmail.co.uk	clinical.safety@hotmail.co.uk	NUM
admet-295	1	70	,	,	PUNCT
admet-295	1	71	tel	tel	INTJ
admet-295	1	72	.	.	PUNCT
admet-295	2	1	+	+	CCONJ
admet-295	2	2	(	(	PUNCT
admet-295	2	3	44	44	NUM
admet-295	2	4	)	)	PUNCT
admet-295	2	5	1753	1753	NUM
admet-295	2	6	886348	886348	NUM
admet-295	2	7	received	receive	VERB
admet-295	2	8	:	:	PUNCT
admet-295	2	9	may	may	AUX
admet-295	2	10	17	17	NUM
admet-295	2	11	,	,	PUNCT
admet-295	2	12	2016	2016	NUM
admet-295	2	13	;	;	PUNCT
admet-295	2	14	revised	revise	VERB
admet-295	2	15	:	:	PUNCT
admet-295	2	16	july	july	PROPN
admet-295	2	17	12	12	NUM
admet-295	2	18	,	,	PUNCT
admet-295	2	19	2016	2016	NUM
admet-295	2	20	;	;	PUNCT
admet-295	2	21	published	publish	VERB
admet-295	2	22	:	:	PUNCT
admet-295	2	23	september	september	PROPN
admet-295	2	24	30	30	NUM
admet-295	2	25	,	,	PUNCT
admet-295	2	26	2016	2016	NUM
admet-295	2	27	abstract	abstract	ADV
admet-295	2	28	many	many	ADJ
admet-295	2	29	potentially	potentially	ADV
admet-295	2	30	valuable	valuable	ADJ
admet-295	2	31	drugs	drug	NOUN
admet-295	2	32	,	,	PUNCT
admet-295	2	33	including	include	VERB
admet-295	2	34	protein	protein	NOUN
admet-295	2	35	kinase	kinase	NOUN
admet-295	2	36	inhibitors	inhibitor	NOUN
admet-295	2	37	(	(	PUNCT
admet-295	2	38	pki	pki	PROPN
admet-295	2	39	)	)	PUNCT
admet-295	2	40	,	,	PUNCT
admet-295	2	41	risk	risk	NOUN
admet-295	2	42	being	be	AUX
admet-295	2	43	dropped	drop	VERB
admet-295	2	44	from	from	ADP
admet-295	2	45	further	further	ADJ
admet-295	2	46	development	development	NOUN
admet-295	2	47	,	,	PUNCT
admet-295	2	48	without	without	ADP
admet-295	2	49	exploration	exploration	NOUN
admet-295	2	50	of	of	ADP
admet-295	2	51	their	their	PRON
admet-295	2	52	clinical	clinical	ADJ
admet-295	2	53	benefits	benefit	NOUN
admet-295	2	54	,	,	PUNCT
admet-295	2	55	if	if	SCONJ
admet-295	2	56	early	early	ADJ
admet-295	2	57	studies	study	NOUN
admet-295	2	58	show	show	VERB
admet-295	2	59	these	these	DET
admet-295	2	60	drugs	drug	NOUN
admet-295	2	61	to	to	PART
admet-295	2	62	inhibit	inhibit	VERB
admet-295	2	63	herg	herg	PROPN
admet-295	2	64	channel	channel	NOUN
admet-295	2	65	and	and	CCONJ
admet-295	2	66	therefore	therefore	ADV
admet-295	2	67	,	,	PUNCT
admet-295	2	68	to	to	PART
admet-295	2	69	have	have	VERB
admet-295	2	70	a	a	DET
admet-295	2	71	potential	potential	NOUN
admet-295	2	72	for	for	ADP
admet-295	2	73	prolonging	prolong	VERB
admet-295	2	74	ventricular	ventricular	ADJ
admet-295	2	75	repolarisation	repolarisation	NOUN
admet-295	2	76	(	(	PUNCT
admet-295	2	77	qt	qt	NOUN
admet-295	2	78	interval	interval	NOUN
admet-295	2	79	)	)	PUNCT
admet-295	2	80	.	.	PUNCT
admet-295	3	1	this	this	DET
admet-295	3	2	qtphobia	qtphobia	PROPN
admet-295	3	3	results	result	VERB
admet-295	3	4	from	from	ADP
admet-295	3	5	a	a	DET
admet-295	3	6	perceived	perceive	VERB
admet-295	3	7	possibility	possibility	NOUN
admet-295	3	8	of	of	ADP
admet-295	3	9	the	the	DET
admet-295	3	10	clinical	clinical	ADJ
admet-295	3	11	risks	risk	NOUN
admet-295	3	12	of	of	ADP
admet-295	3	13	qt	qt	NOUN
admet-295	3	14	-	-	PUNCT
admet-295	3	15	related	relate	VERB
admet-295	3	16	ventricular	ventricular	ADJ
admet-295	3	17	proarrhythmia	proarrhythmia	NOUN
admet-295	3	18	,	,	PUNCT
admet-295	3	19	further	far	ADV
admet-295	3	20	aggravated	aggravate	VERB
admet-295	3	21	by	by	ADP
admet-295	3	22	uncertainties	uncertainty	NOUN
admet-295	3	23	surrounding	surround	VERB
admet-295	3	24	the	the	DET
admet-295	3	25	regulatory	regulatory	ADJ
admet-295	3	26	evaluation	evaluation	NOUN
admet-295	3	27	of	of	ADP
admet-295	3	28	the	the	DET
admet-295	3	29	risk	risk	NOUN
admet-295	3	30	and	and	CCONJ
admet-295	3	31	either	either	PRON
admet-295	3	32	approvability	approvability	NOUN
admet-295	3	33	or	or	CCONJ
admet-295	3	34	restrictive	restrictive	ADJ
admet-295	3	35	labelling	labelling	NOUN
admet-295	3	36	of	of	ADP
admet-295	3	37	the	the	DET
admet-295	3	38	drug	drug	NOUN
admet-295	3	39	concerned	concern	VERB
admet-295	3	40	.	.	PUNCT
admet-295	4	1	in	in	ADP
admet-295	4	2	reality	reality	NOUN
admet-295	4	3	,	,	PUNCT
admet-295	4	4	qt	qt	NOUN
admet-295	4	5	interval	interval	NOUN
admet-295	4	6	prolongation	prolongation	NOUN
admet-295	4	7	per	per	X
admet-295	4	8	se	se	X
admet-295	4	9	is	be	AUX
admet-295	4	10	only	only	ADV
admet-295	4	11	an	an	DET
admet-295	4	12	imperfect	imperfect	ADJ
admet-295	4	13	surrogate	surrogate	NOUN
admet-295	4	14	of	of	ADP
admet-295	4	15	the	the	DET
admet-295	4	16	proarrhythmia	proarrhythmia	NOUN
admet-295	4	17	risk	risk	NOUN
admet-295	4	18	which	which	PRON
admet-295	4	19	is	be	AUX
admet-295	4	20	much	much	ADV
admet-295	4	21	smaller	small	ADJ
admet-295	4	22	than	than	ADP
admet-295	4	23	perceived	perceive	VERB
admet-295	4	24	and	and	CCONJ
admet-295	4	25	compared	compare	VERB
admet-295	4	26	to	to	ADP
admet-295	4	27	their	their	PRON
admet-295	4	28	other	other	ADJ
admet-295	4	29	cardiovascular	cardiovascular	ADJ
admet-295	4	30	and	and	CCONJ
admet-295	4	31	non	non	ADJ
admet-295	4	32	-	-	ADJ
admet-295	4	33	cardiovascular	cardiovascular	ADJ
admet-295	4	34	risks	risk	NOUN
admet-295	4	35	.	.	PUNCT
admet-295	5	1	pki	pki	NOUN
admet-295	5	2	-	-	ADJ
admet-295	5	3	induced	induced	ADJ
admet-295	5	4	clinical	clinical	ADJ
admet-295	5	5	hepatotoxicity	hepatotoxicity	NOUN
admet-295	5	6	,	,	PUNCT
admet-295	5	7	also	also	ADV
admet-295	5	8	evaluated	evaluate	VERB
admet-295	5	9	on	on	ADP
admet-295	5	10	the	the	DET
admet-295	5	11	basis	basis	NOUN
admet-295	5	12	of	of	ADP
admet-295	5	13	surrogate	surrogate	ADJ
admet-295	5	14	markers	marker	NOUN
admet-295	5	15	(	(	PUNCT
admet-295	5	16	serum	serum	NOUN
admet-295	5	17	transaminases	transaminase	NOUN
admet-295	5	18	and	and	CCONJ
admet-295	5	19	bilirubin	bilirubin	NOUN
admet-295	5	20	)	)	PUNCT
admet-295	5	21	is	be	AUX
admet-295	5	22	another	another	DET
admet-295	5	23	risk	risk	NOUN
admet-295	5	24	that	that	PRON
admet-295	5	25	far	far	ADV
admet-295	5	26	exceeds	exceed	VERB
admet-295	5	27	any	any	DET
admet-295	5	28	risk	risk	NOUN
admet-295	5	29	arising	arise	VERB
admet-295	5	30	from	from	ADP
admet-295	5	31	pkiinduced	pkiinduce	VERB
admet-295	5	32	qt	qt	NOUN
admet-295	5	33	interval	interval	NOUN
admet-295	5	34	prolongation	prolongation	NOUN
admet-295	5	35	.	.	PUNCT
admet-295	6	1	this	this	DET
admet-295	6	2	review	review	NOUN
admet-295	6	3	of	of	ADP
admet-295	6	4	the	the	DET
admet-295	6	5	currently	currently	ADV
admet-295	6	6	approved	approve	VERB
admet-295	6	7	28	28	NUM
admet-295	6	8	pkis	pki	NOUN
admet-295	6	9	places	place	NOUN
admet-295	6	10	the	the	DET
admet-295	6	11	qt	qt	NOUN
admet-295	6	12	-	-	PUNCT
admet-295	6	13	phobia	phobia	NOUN
admet-295	6	14	surrounding	surround	VERB
admet-295	6	15	the	the	DET
admet-295	6	16	development	development	NOUN
admet-295	6	17	of	of	ADP
admet-295	6	18	pkis	pki	NOUN
admet-295	6	19	in	in	ADP
admet-295	6	20	its	its	PRON
admet-295	6	21	perspective	perspective	NOUN
admet-295	6	22	by	by	ADP
admet-295	6	23	juxta	juxta	PROPN
admet-295	6	24	-	-	PUNCT
admet-295	6	25	positioning	position	VERB
admet-295	6	26	their	their	PRON
admet-295	6	27	potential	potential	NOUN
admet-295	6	28	to	to	PART
admet-295	6	29	induce	induce	VERB
admet-295	6	30	ventricular	ventricular	ADJ
admet-295	6	31	dysfunction	dysfunction	NOUN
admet-295	6	32	,	,	PUNCT
admet-295	6	33	arterial	arterial	ADJ
admet-295	6	34	thrombotic	thrombotic	ADJ
admet-295	6	35	events	event	NOUN
admet-295	6	36	and	and	CCONJ
admet-295	6	37	hepatotoxicity	hepatotoxicity	NOUN
admet-295	6	38	.	.	PUNCT
admet-295	7	1	available	available	ADJ
admet-295	7	2	evidence	evidence	NOUN
admet-295	7	3	suggests	suggest	VERB
admet-295	7	4	that	that	SCONJ
admet-295	7	5	herg	herg	PROPN
admet-295	7	6	channel	channel	NOUN
admet-295	7	7	may	may	AUX
admet-295	7	8	prove	prove	VERB
admet-295	7	9	to	to	PART
admet-295	7	10	be	be	AUX
admet-295	7	11	a	a	DET
admet-295	7	12	valuable	valuable	ADJ
admet-295	7	13	therapeutic	therapeutic	ADJ
admet-295	7	14	target	target	NOUN
admet-295	7	15	in	in	ADP
admet-295	7	16	oncology	oncology	NOUN
admet-295	7	17	.	.	PUNCT
admet-295	8	1	therefore	therefore	ADV
admet-295	8	2	,	,	PUNCT
admet-295	8	3	the	the	DET
admet-295	8	4	development	development	NOUN
admet-295	8	5	,	,	PUNCT
admet-295	8	6	approval	approval	NOUN
admet-295	8	7	and	and	CCONJ
admet-295	8	8	labelling	labelling	NOUN
admet-295	8	9	of	of	ADP
admet-295	8	10	such	such	ADJ
admet-295	8	11	vital	vital	ADJ
admet-295	8	12	oncology	oncology	NOUN
admet-295	8	13	drugs	drug	NOUN
admet-295	8	14	requires	require	VERB
admet-295	8	15	careful	careful	ADJ
admet-295	8	16	assessment	assessment	NOUN
admet-295	8	17	of	of	ADP
admet-295	8	18	their	their	PRON
admet-295	8	19	benefits	benefit	NOUN
admet-295	8	20	and	and	CCONJ
admet-295	8	21	their	their	PRON
admet-295	8	22	risk	risk	NOUN
admet-295	8	23	/	/	SYM
admet-295	8	24	benefit	benefit	NOUN
admet-295	8	25	generally	generally	ADV
admet-295	8	26	,	,	PUNCT
admet-295	8	27	without	without	ADP
admet-295	8	28	being	be	AUX
admet-295	8	29	overtly	overtly	ADV
admet-295	8	30	consumed	consume	VERB
admet-295	8	31	by	by	ADP
admet-295	8	32	their	their	PRON
admet-295	8	33	potential	potential	ADJ
admet-295	8	34	qt	qt	NOUN
admet-295	8	35	-	-	PUNCT
admet-295	8	36	liability	liability	NOUN
admet-295	8	37	,	,	PUNCT
admet-295	8	38	in	in	ADP
admet-295	8	39	terms	term	NOUN
admet-295	8	40	of	of	ADP
admet-295	8	41	their	their	PRON
admet-295	8	42	more	more	ADV
admet-295	8	43	direct	direct	ADJ
admet-295	8	44	consequences	consequence	NOUN
admet-295	8	45	on	on	ADP
admet-295	8	46	clinically	clinically	ADV
admet-295	8	47	relevant	relevant	ADJ
admet-295	8	48	endpoints	endpoint	NOUN
admet-295	8	49	of	of	ADP
admet-295	8	50	morbidity	morbidity	NOUN
admet-295	8	51	,	,	PUNCT
admet-295	8	52	mortality	mortality	NOUN
admet-295	8	53	and	and	CCONJ
admet-295	8	54	quality	quality	NOUN
admet-295	8	55	of	of	ADP
admet-295	8	56	life	life	NOUN
admet-295	8	57	.	.	PUNCT
admet-295	9	1	keywords	keyword	NOUN
admet-295	9	2	arterial	arterial	ADJ
admet-295	9	3	thrombotic	thrombotic	ADJ
admet-295	9	4	events	event	NOUN
admet-295	9	5	;	;	PUNCT
admet-295	9	6	cardiotoxicity	cardiotoxicity	NOUN
admet-295	9	7	;	;	PUNCT
admet-295	9	8	hepatotoxicity	hepatotoxicity	NOUN
admet-295	9	9	;	;	PUNCT
admet-295	9	10	herg	herg	PROPN
admet-295	9	11	channel	channel	PROPN
admet-295	9	12	;	;	PUNCT
admet-295	9	13	left	leave	VERB
admet-295	9	14	ventricular	ventricular	ADJ
admet-295	9	15	dysfunction	dysfunction	NOUN
admet-295	9	16	;	;	PUNCT
admet-295	9	17	proarrhythmias	proarrhythmia	NOUN
admet-295	9	18	,	,	PUNCT
admet-295	9	19	qt	qt	NOUN
admet-295	9	20	interval	interval	NOUN
admet-295	9	21	;	;	PUNCT
admet-295	9	22	transaminases	transaminase	NOUN
admet-295	9	23	;	;	PUNCT
admet-295	9	24	torsade	torsade	NOUN
admet-295	9	25	de	de	X
admet-295	9	26	pointes	pointe	NOUN
admet-295	9	27	;	;	PUNCT
admet-295	9	28	protein	protein	NOUN
admet-295	9	29	kinase	kinase	NOUN
admet-295	9	30	inhibitors	inhibitor	NOUN
admet-295	9	31	introduction	introduction	NOUN
admet-295	9	32	treatment	treatment	NOUN
admet-295	9	33	of	of	ADP
admet-295	9	34	various	various	ADJ
admet-295	9	35	cancers	cancer	NOUN
admet-295	9	36	has	have	AUX
admet-295	9	37	been	be	AUX
admet-295	9	38	significantly	significantly	ADV
admet-295	9	39	revolutionized	revolutionize	VERB
admet-295	9	40	by	by	ADP
admet-295	9	41	the	the	DET
admet-295	9	42	development	development	NOUN
admet-295	9	43	of	of	ADP
admet-295	9	44	small	small	ADJ
admet-295	9	45	molecule	molecule	NOUN
admet-295	9	46	protein	protein	NOUN
admet-295	9	47	kinase	kinase	NOUN
admet-295	9	48	inhibitors	inhibitor	NOUN
admet-295	9	49	(	(	PUNCT
admet-295	9	50	pkis	pkis	PROPN
admet-295	9	51	)	)	PUNCT
admet-295	9	52	,	,	PUNCT
admet-295	9	53	a	a	DET
admet-295	9	54	vast	vast	ADJ
admet-295	9	55	majority	majority	NOUN
admet-295	9	56	of	of	ADP
admet-295	9	57	them	they	PRON
admet-295	9	58	in	in	ADP
admet-295	9	59	current	current	ADJ
admet-295	9	60	clinical	clinical	ADJ
admet-295	9	61	use	use	NOUN
admet-295	9	62	being	be	AUX
admet-295	9	63	tyrosine	tyrosine	ADJ
admet-295	9	64	kinase	kinase	PROPN
admet-295	9	65	inhibitors	inhibitor	NOUN
admet-295	9	66	.	.	PUNCT
admet-295	10	1	the	the	DET
admet-295	10	2	perceived	perceive	VERB
admet-295	10	3	benefits	benefit	NOUN
admet-295	10	4	of	of	ADP
admet-295	10	5	these	these	DET
admet-295	10	6	highly	highly	ADV
admet-295	10	7	targeted	target	VERB
admet-295	10	8	agents	agent	NOUN
admet-295	10	9	have	have	AUX
admet-295	10	10	led	lead	VERB
admet-295	10	11	regulatory	regulatory	ADJ
admet-295	10	12	authorities	authority	NOUN
admet-295	10	13	to	to	PART
admet-295	10	14	approve	approve	VERB
admet-295	10	15	a	a	DET
admet-295	10	16	majority	majority	NOUN
admet-295	10	17	of	of	ADP
admet-295	10	18	them	they	PRON
admet-295	10	19	on	on	ADP
admet-295	10	20	an	an	DET
admet-295	10	21	expedited	expedited	ADJ
admet-295	10	22	or	or	CCONJ
admet-295	10	23	priority	priority	NOUN
admet-295	10	24	basis	basis	NOUN
admet-295	10	25	,	,	PUNCT
admet-295	10	26	often	often	ADV
admet-295	10	27	on	on	ADP
admet-295	10	28	limited	limited	ADJ
admet-295	10	29	preliminary	preliminary	ADJ
admet-295	10	30	data	datum	NOUN
admet-295	10	31	indicative	indicative	ADJ
admet-295	10	32	of	of	ADP
admet-295	10	33	their	their	PRON
admet-295	10	34	safety	safety	NOUN
admet-295	10	35	,	,	PUNCT
admet-295	10	36	efficacy	efficacy	NOUN
admet-295	10	37	and	and	CCONJ
admet-295	10	38	a	a	DET
admet-295	10	39	favourable	favourable	ADJ
admet-295	10	40	risk	risk	NOUN
admet-295	10	41	/	/	SYM
admet-295	10	42	benefit	benefit	NOUN
admet-295	10	43	ratio	ratio	NOUN
admet-295	10	44	[	[	X
admet-295	10	45	1	1	NUM
admet-295	10	46	-	-	SYM
admet-295	10	47	3	3	NUM
admet-295	10	48	]	]	PUNCT
admet-295	10	49	.	.	PUNCT
admet-295	11	1	often	often	ADV
admet-295	11	2	,	,	PUNCT
admet-295	11	3	such	such	ADJ
admet-295	11	4	approvals	approval	NOUN
admet-295	11	5	are	be	AUX
admet-295	11	6	associated	associate	VERB
admet-295	11	7	with	with	ADP
admet-295	11	8	requirements	requirement	NOUN
admet-295	11	9	for	for	ADP
admet-295	11	10	appropriate	appropriate	ADJ
admet-295	11	11	post	post	ADJ
admet-295	11	12	-	-	ADJ
admet-295	11	13	approval	approval	ADJ
admet-295	11	14	studies	study	NOUN
admet-295	11	15	to	to	PART
admet-295	11	16	substantiate	substantiate	VERB
admet-295	11	17	these	these	DET
admet-295	11	18	early	early	ADJ
admet-295	11	19	expectations	expectation	NOUN
admet-295	11	20	.	.	PUNCT
admet-295	12	1	as	as	ADP
admet-295	12	2	of	of	ADP
admet-295	12	3	31	31	NUM
admet-295	12	4	may	may	PROPN
admet-295	12	5	2016	2016	NUM
admet-295	12	6	,	,	PUNCT
admet-295	12	7	27	27	NUM
admet-295	12	8	such	such	ADJ
admet-295	12	9	agents	agent	NOUN
admet-295	12	10	have	have	AUX
admet-295	12	11	been	be	AUX
admet-295	12	12	approved	approve	VERB
admet-295	12	13	by	by	ADP
admet-295	12	14	the	the	DET
admet-295	12	15	us	us	PROPN
admet-295	12	16	food	food	NOUN
admet-295	12	17	and	and	CCONJ
admet-295	12	18	drug	drug	PROPN
admet-295	12	19	administration	administration	PROPN
admet-295	12	20	(	(	PUNCT
admet-295	12	21	fda	fda	PROPN
admet-295	12	22	)	)	PUNCT
admet-295	12	23	for	for	ADP
admet-295	12	24	use	use	NOUN
admet-295	12	25	in	in	ADP
admet-295	12	26	oncology	oncology	NOUN
admet-295	12	27	indications	indication	NOUN
admet-295	12	28	,	,	PUNCT
admet-295	12	29	beginning	begin	VERB
admet-295	12	30	with	with	ADP
admet-295	12	31	the	the	DET
admet-295	12	32	first	first	ADJ
admet-295	12	33	approval	approval	NOUN
admet-295	12	34	of	of	ADP
admet-295	12	35	imatinib	imatinib	NOUN
admet-295	12	36	in	in	ADP
admet-295	12	37	may	may	PROPN
admet-295	12	38	2001	2001	NUM
admet-295	12	39	.	.	PUNCT
admet-295	13	1	two	two	NUM
admet-295	13	2	additional	additional	ADJ
admet-295	13	3	pkis	pki	NOUN
admet-295	13	4	have	have	AUX
admet-295	13	5	also	also	ADV
admet-295	13	6	been	be	AUX
admet-295	13	7	approved	approve	VERB
admet-295	13	8	by	by	ADP
admet-295	13	9	the	the	DET
admet-295	13	10	fda	fda	PROPN
admet-295	13	11	but	but	CCONJ
admet-295	13	12	for	for	ADP
admet-295	13	13	non	non	ADJ
admet-295	13	14	-	-	ADJ
admet-295	13	15	oncology	oncology	ADJ
admet-295	13	16	indications	indication	NOUN
admet-295	13	17	–	–	PUNCT
admet-295	13	18	tofacitinib	tofacitinib	NOUN
admet-295	13	19	and	and	CCONJ
admet-295	13	20	nintedanib	nintedanib	NOUN
admet-295	13	21	for	for	ADP
admet-295	13	22	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-295	13	23	mailto:clinical.safety@hotmail.co.uk	mailto:clinical.safety@hotmail.co.uk	NOUN
admet-295	13	24	admet	admet	PROPN
admet-295	13	25	&	&	CCONJ
admet-295	13	26	dmpk	dmpk	PROPN
admet-295	13	27	4(3	4(3	NUM
admet-295	13	28	)	)	PUNCT
admet-295	13	29	(	(	PUNCT
admet-295	13	30	2016	2016	NUM
admet-295	13	31	)	)	PUNCT
admet-295	13	32	212	212	NUM
admet-295	13	33	-	-	SYM
admet-295	13	34	231	231	NUM
admet-295	13	35	pkis	pki	NOUN
admet-295	13	36	and	and	CCONJ
admet-295	13	37	qt	qt	NOUN
admet-295	13	38	-	-	PUNCT
admet-295	13	39	phobia	phobia	NOUN
admet-295	13	40	doi	doi	NOUN
admet-295	13	41	:	:	PUNCT
admet-295	13	42	10.5599	10.5599	NUM
admet-295	13	43	/	/	SYM
admet-295	13	44	admet.4.3.295	admet.4.3.295	NOUN
admet-295	13	45	213	213	NUM
admet-295	13	46	the	the	DET
admet-295	13	47	treatments	treatment	NOUN
admet-295	13	48	of	of	ADP
admet-295	13	49	rheumatoid	rheumatoid	NOUN
admet-295	13	50	arthritis	arthritis	NOUN
admet-295	13	51	and	and	CCONJ
admet-295	13	52	of	of	ADP
admet-295	13	53	idiopathic	idiopathic	ADJ
admet-295	13	54	pulmonary	pulmonary	ADJ
admet-295	13	55	fibrosis	fibrosis	NOUN
admet-295	13	56	,	,	PUNCT
admet-295	13	57	respectively	respectively	ADV
admet-295	13	58	.	.	PUNCT
admet-295	14	1	in	in	ADP
admet-295	14	2	the	the	DET
admet-295	14	3	european	european	PROPN
admet-295	14	4	union	union	PROPN
admet-295	14	5	(	(	PUNCT
admet-295	14	6	eu	eu	PROPN
admet-295	14	7	)	)	PUNCT
admet-295	14	8	,	,	PUNCT
admet-295	14	9	however	however	ADV
admet-295	14	10	,	,	PUNCT
admet-295	14	11	nintedanib	nintedanib	NOUN
admet-295	14	12	is	be	AUX
admet-295	14	13	also	also	ADV
admet-295	14	14	approved	approve	VERB
admet-295	14	15	for	for	ADP
admet-295	14	16	non	non	ADJ
admet-295	14	17	-	-	ADJ
admet-295	14	18	small	small	ADJ
admet-295	14	19	cell	cell	NOUN
admet-295	14	20	lung	lung	NOUN
admet-295	14	21	cancer	cancer	NOUN
admet-295	14	22	and	and	CCONJ
admet-295	14	23	at	at	ADP
admet-295	14	24	the	the	DET
admet-295	14	25	time	time	NOUN
admet-295	14	26	of	of	ADP
admet-295	14	27	writing	writing	NOUN
admet-295	14	28	,	,	PUNCT
admet-295	14	29	one	one	NUM
admet-295	14	30	of	of	ADP
admet-295	14	31	the	the	DET
admet-295	14	32	29	29	NUM
admet-295	14	33	agents	agent	NOUN
admet-295	14	34	(	(	PUNCT
admet-295	14	35	alectinib	alectinib	NOUN
admet-295	14	36	)	)	PUNCT
admet-295	14	37	approved	approve	VERB
admet-295	14	38	by	by	ADP
admet-295	14	39	the	the	DET
admet-295	14	40	fda	fda	PROPN
admet-295	14	41	was	be	AUX
admet-295	14	42	still	still	ADV
admet-295	14	43	under	under	ADP
admet-295	14	44	review	review	NOUN
admet-295	14	45	,	,	PUNCT
admet-295	14	46	whereas	whereas	SCONJ
admet-295	14	47	tofacitinib	tofacitinib	NOUN
admet-295	14	48	had	have	AUX
admet-295	14	49	been	be	AUX
admet-295	14	50	rejected	reject	VERB
admet-295	14	51	for	for	ADP
admet-295	14	52	approval	approval	NOUN
admet-295	14	53	,	,	PUNCT
admet-295	14	54	by	by	ADP
admet-295	14	55	the	the	DET
admet-295	14	56	european	european	PROPN
admet-295	14	57	medicines	medicines	PROPN
admet-295	14	58	agency	agency	NOUN
admet-295	14	59	(	(	PUNCT
admet-295	14	60	ema	ema	PROPN
admet-295	14	61	)	)	PUNCT
admet-295	14	62	.	.	PUNCT
admet-295	15	1	in	in	ADP
admet-295	15	2	addition	addition	NOUN
admet-295	15	3	to	to	ADP
admet-295	15	4	the	the	DET
admet-295	15	5	development	development	NOUN
admet-295	15	6	of	of	ADP
admet-295	15	7	new	new	ADJ
admet-295	15	8	pkis	pki	NOUN
admet-295	15	9	,	,	PUNCT
admet-295	15	10	the	the	DET
admet-295	15	11	agents	agent	NOUN
admet-295	15	12	already	already	ADV
admet-295	15	13	approved	approve	VERB
admet-295	15	14	for	for	ADP
admet-295	15	15	one	one	NUM
admet-295	15	16	cancer	cancer	NOUN
admet-295	15	17	are	be	AUX
admet-295	15	18	also	also	ADV
admet-295	15	19	being	be	AUX
admet-295	15	20	tested	test	VERB
admet-295	15	21	for	for	ADP
admet-295	15	22	their	their	PRON
admet-295	15	23	potential	potential	ADJ
admet-295	15	24	therapeutic	therapeutic	ADJ
admet-295	15	25	benefits	benefit	NOUN
admet-295	15	26	in	in	ADP
admet-295	15	27	other	other	ADJ
admet-295	15	28	cancers	cancer	NOUN
admet-295	15	29	and	and	CCONJ
admet-295	15	30	the	the	DET
admet-295	15	31	range	range	NOUN
admet-295	15	32	of	of	ADP
admet-295	15	33	oncology	oncology	NOUN
admet-295	15	34	indications	indication	NOUN
admet-295	15	35	for	for	ADP
admet-295	15	36	many	many	ADJ
admet-295	15	37	of	of	ADP
admet-295	15	38	these	these	DET
admet-295	15	39	previously	previously	ADV
admet-295	15	40	approved	approve	VERB
admet-295	15	41	agents	agent	NOUN
admet-295	15	42	is	be	AUX
admet-295	15	43	gradually	gradually	ADV
admet-295	15	44	expanding	expand	VERB
admet-295	15	45	[	[	X
admet-295	15	46	4	4	NUM
admet-295	15	47	-	-	SYM
admet-295	15	48	7	7	NUM
admet-295	15	49	]	]	PUNCT
admet-295	15	50	.	.	PUNCT
admet-295	16	1	for	for	ADP
admet-295	16	2	example	example	NOUN
admet-295	16	3	,	,	PUNCT
admet-295	16	4	imatinib	imatinib	NOUN
admet-295	16	5	,	,	PUNCT
admet-295	16	6	initially	initially	ADV
admet-295	16	7	approved	approve	VERB
admet-295	16	8	for	for	ADP
admet-295	16	9	use	use	NOUN
admet-295	16	10	in	in	ADP
admet-295	16	11	chronic	chronic	ADJ
admet-295	16	12	myeloid	myeloid	NOUN
admet-295	16	13	leukaemia	leukaemia	NOUN
admet-295	16	14	,	,	PUNCT
admet-295	16	15	now	now	ADV
admet-295	16	16	enjoys	enjoy	VERB
admet-295	16	17	no	no	DET
admet-295	16	18	less	less	ADJ
admet-295	16	19	than	than	ADP
admet-295	16	20	seven	seven	NUM
admet-295	16	21	distinct	distinct	ADJ
admet-295	16	22	indications	indication	NOUN
admet-295	16	23	.	.	PUNCT
admet-295	17	1	the	the	DET
admet-295	17	2	approval	approval	NOUN
admet-295	17	3	dates	date	NOUN
admet-295	17	4	and	and	CCONJ
admet-295	17	5	the	the	DET
admet-295	17	6	broad	broad	ADJ
admet-295	17	7	cancer	cancer	NOUN
admet-295	17	8	-	-	PUNCT
admet-295	17	9	specific	specific	ADJ
admet-295	17	10	indications	indication	NOUN
admet-295	17	11	of	of	ADP
admet-295	17	12	the	the	DET
admet-295	17	13	agents	agent	NOUN
admet-295	17	14	approved	approve	VERB
admet-295	17	15	by	by	ADP
admet-295	17	16	the	the	DET
admet-295	17	17	fda	fda	PROPN
admet-295	17	18	and/or	and/or	CCONJ
admet-295	17	19	the	the	DET
admet-295	17	20	ema	ema	PROPN
admet-295	17	21	are	be	AUX
admet-295	17	22	shown	show	VERB
admet-295	17	23	in	in	ADP
admet-295	17	24	table	table	NOUN
admet-295	17	25	1	1	NUM
admet-295	17	26	.	.	PUNCT
admet-295	18	1	unfortunately	unfortunately	ADV
admet-295	18	2	,	,	PUNCT
admet-295	18	3	pkis	pki	NOUN
admet-295	18	4	are	be	AUX
admet-295	18	5	also	also	ADV
admet-295	18	6	associated	associate	VERB
admet-295	18	7	with	with	ADP
admet-295	18	8	a	a	DET
admet-295	18	9	number	number	NOUN
admet-295	18	10	of	of	ADP
admet-295	18	11	adverse	adverse	ADJ
admet-295	18	12	side	side	NOUN
admet-295	18	13	effects	effect	NOUN
admet-295	18	14	,	,	PUNCT
admet-295	18	15	many	many	ADJ
admet-295	18	16	potentially	potentially	ADV
admet-295	18	17	fatal	fatal	ADJ
admet-295	18	18	,	,	PUNCT
admet-295	18	19	on	on	ADP
admet-295	18	20	cardiovascular	cardiovascular	ADJ
admet-295	18	21	system	system	NOUN
admet-295	18	22	(	(	PUNCT
admet-295	18	23	e.g.	e.g.	ADV
admet-295	18	24	qt	qt	NOUN
admet-295	18	25	interval	interval	NOUN
admet-295	18	26	prolongation	prolongation	NOUN
admet-295	18	27	of	of	ADP
admet-295	18	28	the	the	DET
admet-295	18	29	surface	surface	NOUN
admet-295	18	30	electrocardiogram	electrocardiogram	NOUN
admet-295	18	31	(	(	PUNCT
admet-295	18	32	ecg	ecg	PROPN
admet-295	18	33	)	)	PUNCT
admet-295	18	34	,	,	PUNCT
admet-295	18	35	hypertension	hypertension	NOUN
admet-295	18	36	,	,	PUNCT
admet-295	18	37	left	leave	VERB
admet-295	18	38	ventricular	ventricular	ADJ
admet-295	18	39	(	(	PUNCT
admet-295	18	40	lv	lv	NOUN
admet-295	18	41	)	)	PUNCT
admet-295	18	42	dysfunction	dysfunction	NOUN
admet-295	18	43	,	,	PUNCT
admet-295	18	44	arterial	arterial	ADJ
admet-295	18	45	thrombotic	thrombotic	ADJ
admet-295	18	46	events	event	NOUN
admet-295	18	47	(	(	PUNCT
admet-295	18	48	ates	ate	NOUN
admet-295	18	49	)	)	PUNCT
admet-295	18	50	,	,	PUNCT
admet-295	18	51	venous	venous	ADJ
admet-295	18	52	thrombo	thrombo	NOUN
admet-295	18	53	-	-	PUNCT
admet-295	18	54	embolic	embolic	NOUN
admet-295	18	55	events	event	NOUN
admet-295	18	56	,	,	PUNCT
admet-295	18	57	bleeding	bleed	VERB
admet-295	18	58	and	and	CCONJ
admet-295	18	59	symptomatic	symptomatic	ADJ
admet-295	18	60	bradycardia	bradycardia	NOUN
admet-295	18	61	)	)	PUNCT
admet-295	18	62	and	and	CCONJ
admet-295	18	63	non	non	ADJ
admet-295	18	64	-	-	ADJ
admet-295	18	65	cardiovascular	cardiovascular	ADJ
admet-295	18	66	systems	system	NOUN
admet-295	18	67	(	(	PUNCT
admet-295	18	68	such	such	ADJ
admet-295	18	69	as	as	ADP
admet-295	18	70	hepatic	hepatic	ADJ
admet-295	18	71	,	,	PUNCT
admet-295	18	72	pulmonary	pulmonary	ADJ
admet-295	18	73	,	,	PUNCT
admet-295	18	74	dermatological	dermatological	ADJ
admet-295	18	75	thyroid	thyroid	NOUN
admet-295	18	76	,	,	PUNCT
admet-295	18	77	ocular	ocular	ADJ
admet-295	18	78	and	and	CCONJ
admet-295	18	79	renal	renal	ADJ
admet-295	18	80	)	)	PUNCT
admet-295	19	1	[	[	X
admet-295	19	2	8	8	NUM
admet-295	19	3	]	]	PUNCT
admet-295	19	4	.	.	PUNCT
admet-295	20	1	many	many	ADJ
admet-295	20	2	of	of	ADP
admet-295	20	3	these	these	DET
admet-295	20	4	adverse	adverse	ADJ
admet-295	20	5	effects	effect	NOUN
admet-295	20	6	are	be	AUX
admet-295	20	7	on	on	ADP
admet-295	20	8	-	-	PUNCT
admet-295	20	9	target	target	NOUN
admet-295	20	10	effects	effect	NOUN
admet-295	20	11	which	which	PRON
admet-295	20	12	correlate	correlate	VERB
admet-295	20	13	with	with	ADP
admet-295	20	14	efficacy	efficacy	NOUN
admet-295	20	15	and	and	CCONJ
admet-295	20	16	therefore	therefore	ADV
admet-295	20	17	,	,	PUNCT
admet-295	20	18	difficult	difficult	ADJ
admet-295	20	19	to	to	PART
admet-295	20	20	avoid	avoid	VERB
admet-295	20	21	without	without	ADP
admet-295	20	22	compromising	compromise	VERB
admet-295	20	23	therapeutic	therapeutic	ADJ
admet-295	20	24	benefit	benefit	NOUN
admet-295	20	25	by	by	ADP
admet-295	20	26	simple	simple	ADJ
admet-295	20	27	dose	dose	NOUN
admet-295	20	28	reductions	reduction	NOUN
admet-295	20	29	[	[	X
admet-295	20	30	8	8	NUM
admet-295	20	31	-	-	SYM
admet-295	20	32	17	17	NUM
admet-295	20	33	]	]	PUNCT
admet-295	20	34	.	.	PUNCT
admet-295	21	1	it	it	PRON
admet-295	21	2	is	be	AUX
admet-295	21	3	beyond	beyond	ADP
admet-295	21	4	the	the	DET
admet-295	21	5	scope	scope	NOUN
admet-295	21	6	of	of	ADP
admet-295	21	7	this	this	DET
admet-295	21	8	review	review	NOUN
admet-295	21	9	to	to	PART
admet-295	21	10	discuss	discuss	VERB
admet-295	21	11	the	the	DET
admet-295	21	12	full	full	ADJ
admet-295	21	13	safety	safety	NOUN
admet-295	21	14	profile	profile	NOUN
admet-295	21	15	of	of	ADP
admet-295	21	16	pkis	pki	NOUN
admet-295	21	17	and	and	CCONJ
admet-295	21	18	the	the	DET
admet-295	21	19	interested	interested	ADJ
admet-295	21	20	reader	reader	NOUN
admet-295	21	21	is	be	AUX
admet-295	21	22	referred	refer	VERB
admet-295	21	23	to	to	ADP
admet-295	21	24	other	other	ADJ
admet-295	21	25	reviews	review	NOUN
admet-295	21	26	[	[	X
admet-295	21	27	2	2	NUM
admet-295	21	28	,	,	PUNCT
admet-295	21	29	3	3	NUM
admet-295	21	30	,	,	PUNCT
admet-295	21	31	18	18	NUM
admet-295	21	32	-	-	SYM
admet-295	21	33	39	39	NUM
admet-295	21	34	]	]	PUNCT
admet-295	21	35	.	.	PUNCT
admet-295	22	1	despite	despite	SCONJ
admet-295	22	2	this	this	DET
admet-295	22	3	constellation	constellation	NOUN
admet-295	22	4	of	of	ADP
admet-295	22	5	side	side	NOUN
admet-295	22	6	effects	effect	NOUN
admet-295	22	7	associated	associate	VERB
admet-295	22	8	with	with	ADP
admet-295	22	9	pkis	pki	NOUN
admet-295	22	10	,	,	PUNCT
admet-295	22	11	the	the	DET
admet-295	22	12	one	one	NOUN
admet-295	22	13	that	that	PRON
admet-295	22	14	has	have	AUX
admet-295	22	15	engendered	engender	VERB
admet-295	22	16	a	a	DET
admet-295	22	17	phobia	phobia	NOUN
admet-295	22	18	,	,	PUNCT
admet-295	22	19	often	often	ADV
admet-295	22	20	leading	lead	VERB
admet-295	22	21	to	to	ADP
admet-295	22	22	early	early	ADJ
admet-295	22	23	termination	termination	NOUN
admet-295	22	24	from	from	ADP
admet-295	22	25	further	further	ADJ
admet-295	22	26	development	development	NOUN
admet-295	22	27	,	,	PUNCT
admet-295	22	28	is	be	AUX
admet-295	22	29	the	the	DET
admet-295	22	30	potential	potential	NOUN
admet-295	22	31	of	of	ADP
admet-295	22	32	a	a	DET
admet-295	22	33	pki	pki	PROPN
admet-295	22	34	to	to	PART
admet-295	22	35	prolong	prolong	VERB
admet-295	22	36	the	the	DET
admet-295	22	37	qtc	qtc	PROPN
admet-295	22	38	interval	interval	NOUN
admet-295	22	39	.	.	PUNCT
admet-295	23	1	in	in	ADP
admet-295	23	2	rare	rare	ADJ
admet-295	23	3	cases	case	NOUN
admet-295	23	4	,	,	PUNCT
admet-295	23	5	prolonged	prolong	VERB
admet-295	23	6	qt	qt	NOUN
admet-295	23	7	interval	interval	NOUN
admet-295	23	8	may	may	AUX
admet-295	23	9	predispose	predispose	VERB
admet-295	23	10	the	the	DET
admet-295	23	11	patient	patient	NOUN
admet-295	23	12	to	to	ADP
admet-295	23	13	potentially	potentially	ADV
admet-295	23	14	fatal	fatal	ADJ
admet-295	23	15	ventricular	ventricular	ADJ
admet-295	23	16	tachyarrhythmias	tachyarrhythmia	NOUN
admet-295	23	17	.	.	PUNCT
admet-295	24	1	the	the	DET
admet-295	24	2	fda	fda	PROPN
admet-295	24	3	guidance	guidance	NOUN
admet-295	24	4	on	on	ADP
admet-295	24	5	pre	pre	ADJ
admet-295	24	6	-	-	ADJ
admet-295	24	7	marketing	marketing	ADJ
admet-295	24	8	risk	risk	NOUN
admet-295	24	9	evaluation	evaluation	NOUN
admet-295	24	10	and	and	CCONJ
admet-295	24	11	assessment	assessment	NOUN
admet-295	24	12	recommends	recommend	VERB
admet-295	24	13	the	the	DET
admet-295	24	14	sponsor	sponsor	NOUN
admet-295	24	15	to	to	PART
admet-295	24	16	address	address	VERB
admet-295	24	17	,	,	PUNCT
admet-295	24	18	as	as	ADP
admet-295	24	19	a	a	DET
admet-295	24	20	part	part	NOUN
admet-295	24	21	of	of	ADP
admet-295	24	22	the	the	DET
admet-295	24	23	new	new	ADJ
admet-295	24	24	drug	drug	NOUN
admet-295	24	25	application	application	NOUN
admet-295	24	26	(	(	PUNCT
admet-295	24	27	nda	nda	PROPN
admet-295	24	28	)	)	PUNCT
admet-295	24	29	for	for	ADP
admet-295	24	30	all	all	DET
admet-295	24	31	new	new	ADJ
admet-295	24	32	small	small	ADJ
admet-295	24	33	molecule	molecule	NOUN
admet-295	24	34	drugs	drug	NOUN
admet-295	24	35	,	,	PUNCT
admet-295	24	36	their	their	PRON
admet-295	24	37	potential	potential	NOUN
admet-295	24	38	for	for	ADP
admet-295	24	39	six	six	NUM
admet-295	24	40	serious	serious	ADJ
admet-295	24	41	adverse	adverse	ADJ
admet-295	24	42	effects	effect	NOUN
admet-295	24	43	,	,	PUNCT
admet-295	24	44	one	one	NUM
admet-295	24	45	of	of	ADP
admet-295	24	46	them	they	PRON
admet-295	24	47	being	be	AUX
admet-295	24	48	drug	drug	NOUN
admet-295	24	49	-	-	PUNCT
admet-295	24	50	related	relate	VERB
admet-295	24	51	qtc	qtc	PROPN
admet-295	24	52	prolongation	prolongation	NOUN
admet-295	24	53	[	[	X
admet-295	24	54	40	40	NUM
admet-295	24	55	]	]	PUNCT
admet-295	24	56	.	.	PUNCT
admet-295	25	1	the	the	DET
admet-295	25	2	others	other	NOUN
admet-295	25	3	are	be	AUX
admet-295	25	4	drug	drug	NOUN
admet-295	25	5	-	-	PUNCT
admet-295	25	6	related	relate	VERB
admet-295	25	7	liver	liver	NOUN
admet-295	25	8	toxicity	toxicity	NOUN
admet-295	25	9	,	,	PUNCT
admet-295	25	10	nephrotoxicity	nephrotoxicity	NOUN
admet-295	25	11	,	,	PUNCT
admet-295	25	12	myelotoxicity	myelotoxicity	NOUN
admet-295	25	13	,	,	PUNCT
admet-295	25	14	interactions	interaction	NOUN
admet-295	25	15	with	with	ADP
admet-295	25	16	other	other	ADJ
admet-295	25	17	drugs	drug	NOUN
admet-295	25	18	and	and	CCONJ
admet-295	25	19	polymorphic	polymorphic	ADJ
admet-295	25	20	drug	drug	NOUN
admet-295	25	21	metabolism	metabolism	NOUN
admet-295	25	22	.	.	PUNCT
admet-295	26	1	this	this	DET
admet-295	26	2	review	review	NOUN
admet-295	26	3	aims	aim	VERB
admet-295	26	4	to	to	PART
admet-295	26	5	put	put	VERB
admet-295	26	6	in	in	ADP
admet-295	26	7	perspective	perspective	NOUN
admet-295	26	8	the	the	DET
admet-295	26	9	“	"	PUNCT
admet-295	26	10	qt	qt	NOUN
admet-295	26	11	-	-	PUNCT
admet-295	26	12	phobia	phobia	NOUN
admet-295	26	13	”	"	PUNCT
admet-295	26	14	that	that	PRON
admet-295	26	15	surrounds	surround	VERB
admet-295	26	16	the	the	DET
admet-295	26	17	development	development	NOUN
admet-295	26	18	of	of	ADP
admet-295	26	19	pkis	pki	NOUN
admet-295	26	20	by	by	ADP
admet-295	26	21	highlighting	highlight	VERB
admet-295	26	22	just	just	ADV
admet-295	26	23	two	two	NUM
admet-295	26	24	of	of	ADP
admet-295	26	25	their	their	PRON
admet-295	26	26	other	other	ADJ
admet-295	26	27	more	more	ADV
admet-295	26	28	serious	serious	ADJ
admet-295	26	29	and	and	CCONJ
admet-295	26	30	relatively	relatively	ADV
admet-295	26	31	more	more	ADV
admet-295	26	32	frequent	frequent	ADJ
admet-295	26	33	cardiovascular	cardiovascular	ADJ
admet-295	26	34	effects	effect	NOUN
admet-295	26	35	,	,	PUNCT
admet-295	26	36	namely	namely	ADV
admet-295	26	37	lv	lv	VERB
admet-295	26	38	dysfunction	dysfunction	NOUN
admet-295	26	39	and	and	CCONJ
admet-295	26	40	ates	ate	NOUN
admet-295	26	41	.	.	PUNCT
admet-295	27	1	it	it	PRON
admet-295	27	2	will	will	AUX
admet-295	27	3	focus	focus	VERB
admet-295	27	4	on	on	ADP
admet-295	27	5	28	28	NUM
admet-295	27	6	oncology	oncology	NOUN
admet-295	27	7	-	-	PUNCT
admet-295	27	8	related	relate	VERB
admet-295	27	9	pkis	pki	NOUN
admet-295	27	10	including	include	VERB
admet-295	27	11	nintedanib	nintedanib	NOUN
admet-295	27	12	which	which	PRON
admet-295	27	13	enjoys	enjoy	VERB
admet-295	27	14	an	an	DET
admet-295	27	15	oncological	oncological	ADJ
admet-295	27	16	indication	indication	NOUN
admet-295	27	17	in	in	ADP
admet-295	27	18	the	the	DET
admet-295	27	19	eu	eu	PROPN
admet-295	27	20	.	.	PROPN
admet-295	27	21	for	for	ADP
admet-295	27	22	the	the	DET
admet-295	27	23	purpose	purpose	NOUN
admet-295	27	24	of	of	ADP
admet-295	27	25	this	this	DET
admet-295	27	26	review	review	NOUN
admet-295	27	27	,	,	PUNCT
admet-295	27	28	these	these	DET
admet-295	27	29	28	28	NUM
admet-295	27	30	pkis	pki	NOUN
admet-295	27	31	approved	approve	VERB
admet-295	27	32	during	during	ADP
admet-295	27	33	the	the	DET
admet-295	27	34	last	last	ADJ
admet-295	27	35	15	15	NUM
admet-295	27	36	-	-	PUNCT
admet-295	27	37	years	year	NOUN
admet-295	27	38	since	since	SCONJ
admet-295	27	39	2001	2001	NUM
admet-295	27	40	are	be	AUX
admet-295	27	41	divided	divide	VERB
admet-295	27	42	into	into	ADP
admet-295	27	43	two	two	NUM
admet-295	27	44	groups	group	NOUN
admet-295	27	45	with	with	ADP
admet-295	27	46	reference	reference	NOUN
admet-295	27	47	to	to	ADP
admet-295	27	48	the	the	DET
admet-295	27	49	dates	date	NOUN
admet-295	27	50	of	of	ADP
admet-295	27	51	their	their	PRON
admet-295	27	52	first	first	ADJ
admet-295	27	53	approval	approval	NOUN
admet-295	27	54	by	by	ADP
admet-295	27	55	the	the	DET
admet-295	27	56	us	us	PROPN
admet-295	27	57	fda	fda	PROPN
admet-295	27	58	.	.	PUNCT
admet-295	28	1	the	the	DET
admet-295	28	2	dates	date	NOUN
admet-295	28	3	selected	select	VERB
admet-295	28	4	are	be	AUX
admet-295	28	5	the	the	DET
admet-295	28	6	fda	fda	PROPN
admet-295	28	7	approval	approval	NOUN
admet-295	28	8	date	date	NOUN
admet-295	28	9	because	because	SCONJ
admet-295	28	10	typically	typically	ADV
admet-295	28	11	,	,	PUNCT
admet-295	28	12	the	the	DET
admet-295	28	13	fda	fda	PROPN
admet-295	28	14	is	be	AUX
admet-295	28	15	also	also	ADV
admet-295	28	16	the	the	DET
admet-295	28	17	authority	authority	NOUN
admet-295	28	18	that	that	PRON
admet-295	28	19	has	have	AUX
admet-295	28	20	led	lead	VERB
admet-295	28	21	the	the	DET
admet-295	28	22	way	way	NOUN
admet-295	28	23	in	in	ADP
admet-295	28	24	first	first	ADJ
admet-295	28	25	approvals	approval	NOUN
admet-295	28	26	of	of	ADP
admet-295	28	27	each	each	DET
admet-295	28	28	agent	agent	NOUN
admet-295	28	29	[	[	X
admet-295	28	30	1	1	NUM
admet-295	28	31	]	]	PUNCT
admet-295	28	32	.	.	PUNCT
admet-295	29	1	one	one	NUM
admet-295	29	2	group	group	NOUN
admet-295	29	3	includes	include	VERB
admet-295	29	4	16	16	NUM
admet-295	29	5	(	(	PUNCT
admet-295	29	6	57	57	NUM
admet-295	29	7	%	%	NOUN
admet-295	29	8	)	)	PUNCT
admet-295	29	9	agents	agent	NOUN
admet-295	29	10	approved	approve	VERB
admet-295	29	11	over	over	ADP
admet-295	29	12	11.5	11.5	NUM
admet-295	29	13	years	year	NOUN
admet-295	29	14	from	from	ADP
admet-295	29	15	may	may	PROPN
admet-295	29	16	2001	2001	NUM
admet-295	29	17	to	to	ADP
admet-295	29	18	september	september	PROPN
admet-295	29	19	2012	2012	NUM
admet-295	29	20	(	(	PUNCT
admet-295	29	21	henceforth	henceforth	ADV
admet-295	29	22	referred	refer	VERB
admet-295	29	23	to	to	ADP
admet-295	29	24	as	as	ADP
admet-295	29	25	period	period	NOUN
admet-295	29	26	1	1	NUM
admet-295	29	27	)	)	PUNCT
admet-295	29	28	and	and	CCONJ
admet-295	29	29	the	the	DET
admet-295	29	30	other	other	ADJ
admet-295	29	31	includes	include	VERB
admet-295	29	32	12	12	NUM
admet-295	29	33	(	(	PUNCT
admet-295	29	34	43	43	NUM
admet-295	29	35	%	%	NOUN
admet-295	29	36	)	)	PUNCT
admet-295	29	37	agents	agent	NOUN
admet-295	29	38	approved	approve	VERB
admet-295	29	39	more	more	ADV
admet-295	29	40	recently	recently	ADV
admet-295	29	41	during	during	ADP
admet-295	29	42	the	the	DET
admet-295	29	43	last	last	ADJ
admet-295	29	44	3.7	3.7	NUM
admet-295	29	45	years	year	NOUN
admet-295	29	46	from	from	ADP
admet-295	29	47	october	october	PROPN
admet-295	29	48	2012	2012	NUM
admet-295	29	49	to	to	ADP
admet-295	29	50	may	may	PROPN
admet-295	29	51	2016	2016	NUM
admet-295	29	52	(	(	PUNCT
admet-295	29	53	period	period	NOUN
admet-295	29	54	2	2	NUM
admet-295	29	55	)	)	PUNCT
admet-295	29	56	.	.	PUNCT
admet-295	30	1	the	the	DET
admet-295	30	2	pace	pace	NOUN
admet-295	30	3	of	of	ADP
admet-295	30	4	development	development	NOUN
admet-295	30	5	of	of	ADP
admet-295	30	6	these	these	DET
admet-295	30	7	agents	agent	NOUN
admet-295	30	8	is	be	AUX
admet-295	30	9	self	self	NOUN
admet-295	30	10	-	-	PUNCT
admet-295	30	11	evident	evident	ADJ
admet-295	30	12	;	;	PUNCT
admet-295	30	13	1.39	1.39	NUM
admet-295	30	14	agents	agent	NOUN
admet-295	30	15	per	per	ADP
admet-295	30	16	year	year	NOUN
admet-295	30	17	in	in	ADP
admet-295	30	18	period	period	NOUN
admet-295	30	19	1	1	NUM
admet-295	30	20	and	and	CCONJ
admet-295	30	21	3.24	3.24	NUM
admet-295	30	22	agents	agent	NOUN
admet-295	30	23	per	per	ADP
admet-295	30	24	year	year	NOUN
admet-295	30	25	in	in	ADP
admet-295	30	26	period	period	NOUN
admet-295	30	27	2	2	NUM
admet-295	30	28	.	.	PUNCT
admet-295	31	1	the	the	DET
admet-295	31	2	labels	label	NOUN
admet-295	31	3	of	of	ADP
admet-295	31	4	approved	approve	VERB
admet-295	31	5	pkis	pki	NOUN
admet-295	31	6	continue	continue	VERB
admet-295	31	7	to	to	PART
admet-295	31	8	evolve	evolve	VERB
admet-295	31	9	as	as	ADP
admet-295	31	10	more	more	ADJ
admet-295	31	11	data	datum	NOUN
admet-295	31	12	become	become	VERB
admet-295	31	13	available	available	ADJ
admet-295	31	14	and	and	CCONJ
admet-295	31	15	therefore	therefore	ADV
admet-295	31	16	,	,	PUNCT
admet-295	31	17	the	the	DET
admet-295	31	18	information	information	NOUN
admet-295	31	19	reviewed	review	VERB
admet-295	31	20	herein	herein	NOUN
admet-295	31	21	is	be	AUX
admet-295	31	22	sourced	source	VERB
admet-295	31	23	from	from	ADP
admet-295	31	24	a	a	DET
admet-295	31	25	variety	variety	NOUN
admet-295	31	26	of	of	ADP
admet-295	31	27	documents	document	NOUN
admet-295	31	28	referred	refer	VERB
admet-295	31	29	to	to	ADP
admet-295	31	30	in	in	ADP
admet-295	31	31	earlier	early	ADJ
admet-295	31	32	reviews	review	NOUN
admet-295	31	33	[	[	X
admet-295	31	34	1	1	NUM
admet-295	31	35	-	-	SYM
admet-295	31	36	3	3	NUM
admet-295	31	37	]	]	PUNCT
admet-295	31	38	,	,	PUNCT
admet-295	31	39	the	the	DET
admet-295	31	40	most	most	ADV
admet-295	31	41	current	current	ADJ
admet-295	31	42	updated	update	VERB
admet-295	31	43	labels	label	NOUN
admet-295	31	44	and	and	CCONJ
admet-295	31	45	the	the	DET
admet-295	31	46	author	author	NOUN
admet-295	31	47	’s	’s	PART
admet-295	31	48	overall	overall	ADJ
admet-295	31	49	assessment	assessment	NOUN
admet-295	31	50	of	of	ADP
admet-295	31	51	the	the	DET
admet-295	31	52	data	datum	NOUN
admet-295	31	53	available	available	ADJ
admet-295	31	54	.	.	PUNCT
admet-295	32	1	rashmi	rashmi	PROPN
admet-295	32	2	shah	shah	PROPN
admet-295	32	3	admet	admet	PROPN
admet-295	32	4	&	&	CCONJ
admet-295	32	5	dmpk	dmpk	PROPN
admet-295	32	6	4(3	4(3	NUM
admet-295	32	7	)	)	PUNCT
admet-295	32	8	(	(	PUNCT
admet-295	32	9	2016	2016	NUM
admet-295	32	10	)	)	PUNCT
admet-295	32	11	212	212	NUM
admet-295	32	12	-	-	SYM
admet-295	32	13	231	231	NUM
admet-295	32	14	214	214	NUM
admet-295	32	15	table	table	NOUN
admet-295	32	16	1	1	NUM
admet-295	32	17	.	.	PUNCT
admet-295	32	18	approval	approval	NOUN
admet-295	32	19	dates	date	NOUN
admet-295	32	20	and	and	CCONJ
admet-295	32	21	current	current	ADJ
admet-295	32	22	indications	indication	NOUN
admet-295	32	23	of	of	ADP
admet-295	32	24	protein	protein	NOUN
admet-295	32	25	kinase	kinase	PROPN
admet-295	32	26	inhibitors	inhibitor	NOUN
admet-295	32	27	(	(	PUNCT
admet-295	32	28	pkis	pkis	PROPN
admet-295	32	29	)	)	PUNCT
admet-295	32	30	as	as	ADP
admet-295	32	31	of	of	ADP
admet-295	32	32	31	31	NUM
admet-295	32	33	may	may	PROPN
admet-295	32	34	2016	2016	NUM
admet-295	32	35	pki	pki	PROPN
admet-295	32	36	fda	fda	PROPN
admet-295	32	37	approval	approval	PROPN
admet-295	32	38	date	date	NOUN
admet-295	32	39	eu	eu	PROPN
admet-295	32	40	approval	approval	PROPN
admet-295	32	41	date	date	NOUN
admet-295	32	42	broad	broad	ADJ
admet-295	32	43	-	-	PUNCT
admet-295	32	44	term	term	NOUN
admet-295	32	45	indication(s	indication(s	PROPN
admet-295	32	46	)	)	PUNCT
admet-295	32	47	(	(	PUNCT
admet-295	32	48	for	for	ADP
admet-295	32	49	use	use	NOUN
admet-295	32	50	in	in	ADP
admet-295	32	51	selected	select	VERB
admet-295	32	52	patients	patient	NOUN
admet-295	32	53	with	with	ADP
admet-295	32	54	)	)	PUNCT
admet-295	32	55	afatinib	afatinib	NOUN
admet-295	32	56	12	12	NUM
admet-295	32	57	july	july	PROPN
admet-295	32	58	2013	2013	NUM
admet-295	32	59	25	25	NUM
admet-295	32	60	sept	sept	PROPN
admet-295	32	61	.	.	PROPN
admet-295	32	62	2013	2013	NUM
admet-295	32	63	non	non	ADJ
admet-295	32	64	-	-	ADJ
admet-295	32	65	small	small	ADJ
admet-295	32	66	cell	cell	NOUN
admet-295	32	67	lung	lung	NOUN
admet-295	32	68	cancer	cancer	NOUN
admet-295	32	69	alectinib	alectinib	NOUN
admet-295	32	70	11	11	NUM
admet-295	32	71	dec	dec	PROPN
admet-295	32	72	.	.	PROPN
admet-295	32	73	2015	2015	NUM
admet-295	32	74	under	under	ADP
admet-295	32	75	review	review	NOUN
admet-295	32	76	non	non	ADJ
admet-295	32	77	-	-	ADJ
admet-295	32	78	small	small	ADJ
admet-295	32	79	cell	cell	NOUN
admet-295	32	80	lung	lung	NOUN
admet-295	32	81	cancer	cancer	NOUN
admet-295	32	82	axitinib	axitinib	NOUN
admet-295	32	83	27	27	NUM
admet-295	32	84	january	january	PROPN
admet-295	32	85	2012	2012	NUM
admet-295	32	86	13	13	NUM
admet-295	32	87	sept	sept	PROPN
admet-295	32	88	.	.	PROPN
admet-295	32	89	2012	2012	NUM
admet-295	32	90	renal	renal	ADJ
admet-295	32	91	cell	cell	NOUN
admet-295	32	92	carcinoma	carcinoma	NOUN
admet-295	32	93	bosutinib	bosutinib	NOUN
admet-295	32	94	4	4	NUM
admet-295	32	95	sept	sept	PROPN
admet-295	32	96	.	.	PROPN
admet-295	32	97	2012	2012	NUM
admet-295	32	98	27	27	NUM
admet-295	32	99	march	march	NOUN
admet-295	32	100	2013	2013	NUM
admet-295	32	101	cml	cml	PROPN
admet-295	32	102	cabozantinib	cabozantinib	VERB
admet-295	32	103	29	29	NUM
admet-295	32	104	nov	nov	NOUN
admet-295	32	105	.	.	PROPN
admet-295	32	106	2012	2012	NUM
admet-295	32	107	21	21	NUM
admet-295	32	108	march	march	PROPN
admet-295	32	109	2014	2014	NUM
admet-295	32	110	thyroid	thyroid	NOUN
admet-295	32	111	cancer	cancer	NOUN
admet-295	32	112	,	,	PUNCT
admet-295	32	113	renal	renal	ADJ
admet-295	32	114	cell	cell	NOUN
admet-295	32	115	carcinoma	carcinoma	NOUN
admet-295	32	116	ceritinib	ceritinib	VERB
admet-295	32	117	29	29	NUM
admet-295	32	118	april	april	PROPN
admet-295	32	119	2014	2014	NUM
admet-295	32	120	6	6	NUM
admet-295	32	121	may	may	PROPN
admet-295	32	122	2015	2015	NUM
admet-295	32	123	non	non	ADJ
admet-295	32	124	-	-	ADJ
admet-295	32	125	small	small	ADJ
admet-295	32	126	cell	cell	NOUN
admet-295	32	127	lung	lung	NOUN
admet-295	32	128	cancer	cancer	NOUN
admet-295	32	129	cobimetinib	cobimetinib	PROPN
admet-295	32	130	10	10	NUM
admet-295	32	131	nov	nov	NOUN
admet-295	32	132	.	.	PROPN
admet-295	32	133	2015	2015	NUM
admet-295	32	134	20	20	NUM
admet-295	32	135	nov	nov	PROPN
admet-295	32	136	.	.	PROPN
admet-295	32	137	2015	2015	NUM
admet-295	32	138	melanoma	melanoma	NOUN
admet-295	32	139	crizotinib	crizotinib	VERB
admet-295	32	140	26	26	NUM
admet-295	32	141	august	august	PROPN
admet-295	32	142	2011	2011	NUM
admet-295	32	143	23	23	NUM
admet-295	32	144	oct	oct	PROPN
admet-295	32	145	.	.	PROPN
admet-295	32	146	2012	2012	NUM
admet-295	32	147	non	non	ADJ
admet-295	32	148	-	-	ADJ
admet-295	32	149	small	small	ADJ
admet-295	32	150	cell	cell	NOUN
admet-295	32	151	lung	lung	NOUN
admet-295	32	152	cancer	cancer	NOUN
admet-295	32	153	dabrafenib	dabrafenib	NOUN
admet-295	32	154	29	29	NUM
admet-295	32	155	may	may	PROPN
admet-295	32	156	2013	2013	NUM
admet-295	32	157	26	26	NUM
admet-295	32	158	august	august	PROPN
admet-295	32	159	2013	2013	NUM
admet-295	32	160	melanoma	melanoma	PROPN
admet-295	32	161	dasatinib	dasatinib	NOUN
admet-295	32	162	28	28	NUM
admet-295	32	163	june	june	PROPN
admet-295	32	164	2006	2006	NUM
admet-295	32	165	20	20	NUM
admet-295	32	166	nov	nov	PROPN
admet-295	32	167	.	.	PROPN
admet-295	32	168	2006	2006	NUM
admet-295	32	169	cml	cml	PROPN
admet-295	32	170	,	,	PUNCT
admet-295	32	171	all	all	DET
admet-295	32	172	erlotinib	erlotinib	PROPN
admet-295	32	173	18	18	NUM
admet-295	32	174	nov	nov	PROPN
admet-295	32	175	.	.	PROPN
admet-295	32	176	2004	2004	NUM
admet-295	32	177	19	19	NUM
admet-295	32	178	sept	sept	PROPN
admet-295	32	179	.	.	PROPN
admet-295	32	180	2005	2005	NUM
admet-295	32	181	non	non	ADJ
admet-295	32	182	-	-	ADJ
admet-295	32	183	small	small	ADJ
admet-295	32	184	cell	cell	NOUN
admet-295	32	185	lung	lung	NOUN
admet-295	32	186	cancer	cancer	NOUN
admet-295	32	187	,	,	PUNCT
admet-295	32	188	pancreatic	pancreatic	ADJ
admet-295	32	189	cancer	cancer	NOUN
admet-295	32	190	gefitinib	gefitinib	NOUN
admet-295	32	191	5	5	NUM
admet-295	32	192	may	may	PROPN
admet-295	32	193	2003	2003	NUM
admet-295	32	194	20	20	NUM
admet-295	32	195	june	june	PROPN
admet-295	32	196	2009	2009	NUM
admet-295	32	197	non	non	ADJ
admet-295	32	198	-	-	ADJ
admet-295	32	199	small	small	ADJ
admet-295	32	200	cell	cell	NOUN
admet-295	32	201	lung	lung	NOUN
admet-295	32	202	cancer	cancer	NOUN
admet-295	32	203	ibrutinib	ibrutinib	NOUN
admet-295	32	204	13	13	NUM
admet-295	32	205	nov	nov	PROPN
admet-295	32	206	.	.	PROPN
admet-295	32	207	2013	2013	NUM
admet-295	32	208	21	21	NUM
admet-295	32	209	oct	oct	PROPN
admet-295	32	210	.	.	PROPN
admet-295	32	211	2014	2014	NUM
admet-295	32	212	mantle	mantle	NOUN
admet-295	32	213	cell	cell	NOUN
admet-295	32	214	lymphoma	lymphoma	NOUN
admet-295	32	215	,	,	PUNCT
admet-295	32	216	cll	cll	PROPN
admet-295	32	217	,	,	PUNCT
admet-295	32	218	waldenström	waldenström	PROPN
admet-295	32	219	’s	’s	PART
admet-295	32	220	macroglobulinaemia	macroglobulinaemia	VERB
admet-295	32	221	imatinib	imatinib	NOUN
admet-295	32	222	10	10	NUM
admet-295	32	223	may	may	AUX
admet-295	32	224	2001	2001	NUM
admet-295	32	225	11	11	NUM
admet-295	32	226	nov	nov	PROPN
admet-295	32	227	.	.	PROPN
admet-295	32	228	2001	2001	NUM
admet-295	32	229	cml	cml	PROPN
admet-295	32	230	,	,	PUNCT
admet-295	32	231	all	all	PRON
admet-295	32	232	,	,	PUNCT
admet-295	32	233	gist	gist	NOUN
admet-295	32	234	,	,	PUNCT
admet-295	32	235	mastocytosis	mastocytosis	NOUN
admet-295	32	236	,	,	PUNCT
admet-295	32	237	hypereosinophilic	hypereosinophilic	ADJ
admet-295	32	238	syndrome	syndrome	NOUN
admet-295	32	239	,	,	PUNCT
admet-295	32	240	myelodysplastic	myelodysplastic	ADJ
admet-295	32	241	/	/	SYM
admet-295	32	242	myeloproliferative	myeloproliferative	ADJ
admet-295	32	243	disease	disease	NOUN
admet-295	32	244	,	,	PUNCT
admet-295	32	245	dermatofibrosarcoma	dermatofibrosarcoma	NOUN
admet-295	32	246	protuberans	protuberan	NOUN
admet-295	32	247	lapatinib	lapatinib	VERB
admet-295	32	248	13	13	NUM
admet-295	32	249	march	march	NOUN
admet-295	32	250	2007	2007	NUM
admet-295	32	251	10	10	NUM
admet-295	32	252	june	june	PROPN
admet-295	32	253	2008	2008	NUM
admet-295	32	254	breast	breast	NOUN
admet-295	32	255	cancer	cancer	NOUN
admet-295	32	256	lenvatinib	lenvatinib	VERB
admet-295	32	257	13	13	NUM
admet-295	32	258	february	february	PROPN
admet-295	32	259	2015	2015	NUM
admet-295	32	260	28	28	NUM
admet-295	32	261	may	may	AUX
admet-295	32	262	2015	2015	NUM
admet-295	32	263	thyroid	thyroid	NOUN
admet-295	32	264	cancer	cancer	NOUN
admet-295	32	265	nilotinib	nilotinib	NOUN
admet-295	32	266	29	29	NUM
admet-295	32	267	october	october	PROPN
admet-295	32	268	2007	2007	NUM
admet-295	32	269	19	19	NUM
admet-295	32	270	nov	nov	PROPN
admet-295	32	271	.	.	PROPN
admet-295	32	272	2007	2007	NUM
admet-295	33	1	cml	cml	PROPN
admet-295	33	2	nintedanib	nintedanib	PROPN
admet-295	33	3	17	17	NUM
admet-295	33	4	october	october	PROPN
admet-295	33	5	2014	2014	NUM
admet-295	33	6	(	(	PUNCT
admet-295	33	7	not	not	PART
admet-295	33	8	applicable	applicable	ADJ
admet-295	33	9	)	)	PUNCT
admet-295	33	10	15	15	NUM
admet-295	33	11	jan	jan	PROPN
admet-295	33	12	.	.	PROPN
admet-295	33	13	2015	2015	NUM
admet-295	33	14	21	21	NUM
admet-295	33	15	nov	nov	PROPN
admet-295	33	16	.	.	PROPN
admet-295	33	17	2014	2014	NUM
admet-295	33	18	idiopathic	idiopathic	ADJ
admet-295	33	19	pulmonary	pulmonary	ADJ
admet-295	33	20	fibrosis	fibrosis	NOUN
admet-295	33	21	non	non	ADJ
admet-295	33	22	-	-	ADJ
admet-295	33	23	small	small	ADJ
admet-295	33	24	cell	cell	NOUN
admet-295	33	25	lung	lung	NOUN
admet-295	33	26	cancer	cancer	NOUN
admet-295	33	27	osimertinib	osimertinib	NOUN
admet-295	33	28	13	13	NUM
admet-295	33	29	nov	nov	NOUN
admet-295	33	30	.	.	PROPN
admet-295	33	31	2015	2015	NUM
admet-295	33	32	2	2	NUM
admet-295	33	33	feb	feb	X
admet-295	33	34	.	.	PROPN
admet-295	33	35	2016	2016	NUM
admet-295	33	36	non	non	ADJ
admet-295	33	37	-	-	ADJ
admet-295	33	38	small	small	ADJ
admet-295	33	39	cell	cell	NOUN
admet-295	33	40	lung	lung	NOUN
admet-295	33	41	cancer	cancer	NOUN
admet-295	33	42	pazopanib	pazopanib	NOUN
admet-295	33	43	19	19	NUM
admet-295	33	44	october	october	PROPN
admet-295	33	45	2009	2009	NUM
admet-295	33	46	14	14	NUM
admet-295	33	47	june	june	PROPN
admet-295	33	48	2010	2010	NUM
admet-295	33	49	renal	renal	ADJ
admet-295	33	50	cell	cell	NOUN
admet-295	33	51	carcinoma	carcinoma	NOUN
admet-295	33	52	,	,	PUNCT
admet-295	33	53	soft	soft	ADJ
admet-295	33	54	tissue	tissue	NOUN
admet-295	33	55	sarcoma	sarcoma	NOUN
admet-295	33	56	ponatinib	ponatinib	VERB
admet-295	33	57	14	14	NUM
admet-295	33	58	dec	dec	PROPN
admet-295	33	59	.	.	PROPN
admet-295	33	60	2012	2012	NUM
admet-295	33	61	1	1	NUM
admet-295	33	62	july	july	PROPN
admet-295	33	63	2013	2013	NUM
admet-295	33	64	cml	cml	PROPN
admet-295	33	65	,	,	PUNCT
admet-295	33	66	all	all	PRON
admet-295	33	67	regorafeniib	regorafeniib	ADJ
admet-295	33	68	27	27	NUM
admet-295	33	69	sept	sept	PROPN
admet-295	33	70	.	.	PROPN
admet-295	33	71	2012	2012	NUM
admet-295	33	72	26	26	NUM
admet-295	33	73	august	august	PROPN
admet-295	33	74	2013	2013	NUM
admet-295	33	75	colorectal	colorectal	ADJ
admet-295	33	76	cancer	cancer	NOUN
admet-295	33	77	,	,	PUNCT
admet-295	33	78	gist	gist	NOUN
admet-295	33	79	ruxolitinib	ruxolitinib	NOUN
admet-295	33	80	16	16	NUM
admet-295	33	81	nov	nov	PROPN
admet-295	33	82	.	.	PROPN
admet-295	33	83	2011	2011	NUM
admet-295	33	84	23	23	NUM
admet-295	33	85	august	august	PROPN
admet-295	33	86	2012	2012	NUM
admet-295	33	87	myelofibrosis	myelofibrosis	NOUN
admet-295	33	88	,	,	PUNCT
admet-295	33	89	polycythaemia	polycythaemia	NOUN
admet-295	33	90	vera	vera	NOUN
admet-295	33	91	rubra	rubra	NOUN
admet-295	33	92	sorafenib	sorafenib	NOUN
admet-295	33	93	20	20	NUM
admet-295	33	94	dec	dec	PROPN
admet-295	33	95	.	.	PROPN
admet-295	33	96	2005	2005	NUM
admet-295	33	97	19	19	NUM
admet-295	33	98	july	july	PROPN
admet-295	33	99	2006	2006	NUM
admet-295	33	100	hepatocellular	hepatocellular	ADJ
admet-295	33	101	carcinoma	carcinoma	NOUN
admet-295	33	102	,	,	PUNCT
admet-295	33	103	renal	renal	ADJ
admet-295	33	104	cell	cell	NOUN
admet-295	33	105	carcinoma	carcinoma	NOUN
admet-295	33	106	,	,	PUNCT
admet-295	33	107	thyroid	thyroid	NOUN
admet-295	33	108	cancer	cancer	NOUN
admet-295	33	109	sunitinib	sunitinib	NOUN
admet-295	33	110	26	26	NUM
admet-295	33	111	january	january	PROPN
admet-295	33	112	2006	2006	NUM
admet-295	33	113	19	19	NUM
admet-295	33	114	july	july	PROPN
admet-295	33	115	2006	2006	NUM
admet-295	33	116	renal	renal	ADJ
admet-295	33	117	cell	cell	NOUN
admet-295	33	118	carcinoma	carcinoma	NOUN
admet-295	33	119	,	,	PUNCT
admet-295	33	120	gist	gist	NOUN
admet-295	33	121	,	,	PUNCT
admet-295	33	122	pancreatic	pancreatic	ADJ
admet-295	33	123	neuroendocrine	neuroendocrine	ADJ
admet-295	33	124	tumour	tumour	NOUN
admet-295	33	125	trametinib	trametinib	NOUN
admet-295	33	126	29	29	NUM
admet-295	33	127	may	may	PROPN
admet-295	33	128	2013	2013	NUM
admet-295	33	129	30	30	NUM
admet-295	33	130	june	june	PROPN
admet-295	33	131	2014	2014	NUM
admet-295	33	132	melanoma	melanoma	NOUN
admet-295	33	133	vandetanib	vandetanib	NOUN
admet-295	33	134	6	6	NUM
admet-295	33	135	april	april	PROPN
admet-295	33	136	2011	2011	NUM
admet-295	33	137	17	17	NUM
admet-295	33	138	feb	feb	X
admet-295	33	139	.	.	PROPN
admet-295	33	140	2012	2012	NUM
admet-295	33	141	thyroid	thyroid	NOUN
admet-295	33	142	cancer	cancer	NOUN
admet-295	33	143	vemurafenib	vemurafenib	PROPN
admet-295	33	144	17	17	NUM
admet-295	33	145	august	august	PROPN
admet-295	33	146	2011	2011	NUM
admet-295	33	147	17	17	NUM
admet-295	33	148	feb	feb	X
admet-295	33	149	.	.	PROPN
admet-295	34	1	2012	2012	NUM
admet-295	34	2	melanoma	melanoma	PROPN
admet-295	34	3	tofacitinib	tofacitinib	NOUN
admet-295	34	4	6	6	NUM
admet-295	34	5	november	november	PROPN
admet-295	34	6	2012	2012	NUM
admet-295	34	7	refused	refuse	VERB
admet-295	34	8	on	on	ADP
admet-295	34	9	26	26	NUM
admet-295	34	10	april	april	PROPN
admet-295	34	11	2013	2013	NUM
admet-295	34	12	rheumatoid	rheumatoid	NOUN
admet-295	34	13	arthritis	arthritis	NOUN
admet-295	34	14	all	all	DET
admet-295	34	15	=	=	SYM
admet-295	34	16	acute	acute	ADJ
admet-295	34	17	lymphoblastic	lymphoblastic	ADJ
admet-295	34	18	leukaemia	leukaemia	NOUN
admet-295	34	19	;	;	PUNCT
admet-295	34	20	cml	cml	PROPN
admet-295	34	21	=	=	SYM
admet-295	34	22	chronic	chronic	ADJ
admet-295	34	23	myeloid	myeloid	NOUN
admet-295	34	24	leukaemia	leukaemia	NOUN
admet-295	34	25	;	;	PUNCT
admet-295	34	26	gist	gist	NOUN
admet-295	34	27	=	=	SYM
admet-295	34	28	gastrointestinal	gastrointestinal	ADJ
admet-295	34	29	stromal	stromal	ADJ
admet-295	34	30	tumours	tumour	NOUN
admet-295	34	31	;	;	PUNCT
admet-295	34	32	cll	cll	PROPN
admet-295	34	33	=	=	SYM
admet-295	34	34	chronic	chronic	ADJ
admet-295	34	35	lymphocytic	lymphocytic	ADJ
admet-295	34	36	leukaemia	leukaemia	NOUN
admet-295	34	37	admet	admet	PROPN
admet-295	34	38	&	&	CCONJ
admet-295	34	39	dmpk	dmpk	PROPN
admet-295	34	40	4(3	4(3	NUM
admet-295	34	41	)	)	PUNCT
admet-295	34	42	(	(	PUNCT
admet-295	34	43	2016	2016	NUM
admet-295	34	44	)	)	PUNCT
admet-295	34	45	212	212	NUM
admet-295	34	46	-	-	SYM
admet-295	34	47	231	231	NUM
admet-295	34	48	pkis	pki	NOUN
admet-295	34	49	and	and	CCONJ
admet-295	34	50	qt	qt	NOUN
admet-295	34	51	-	-	PUNCT
admet-295	34	52	phobia	phobia	NOUN
admet-295	34	53	doi	doi	NOUN
admet-295	34	54	:	:	PUNCT
admet-295	34	55	10.5599	10.5599	NUM
admet-295	34	56	/	/	SYM
admet-295	34	57	admet.4.3.295	admet.4.3.295	NOUN
admet-295	34	58	215	215	NUM
admet-295	34	59	background	background	NOUN
admet-295	34	60	to	to	ADP
admet-295	34	61	qt	qt	NOUN
admet-295	34	62	-	-	PUNCT
admet-295	34	63	phobia	phobia	NOUN
admet-295	34	64	the	the	DET
admet-295	34	65	qt	qt	NOUN
admet-295	34	66	interval	interval	NOUN
admet-295	34	67	measured	measure	VERB
admet-295	34	68	on	on	ADP
admet-295	34	69	the	the	DET
admet-295	34	70	ecg	ecg	PROPN
admet-295	34	71	varies	vary	VERB
admet-295	34	72	with	with	ADP
admet-295	34	73	the	the	DET
admet-295	34	74	heart	heart	NOUN
admet-295	34	75	rate	rate	NOUN
admet-295	34	76	and	and	CCONJ
admet-295	34	77	therefore	therefore	ADV
admet-295	34	78	requires	require	VERB
admet-295	34	79	correction	correction	NOUN
admet-295	34	80	to	to	PART
admet-295	34	81	compute	compute	VERB
admet-295	34	82	a	a	DET
admet-295	34	83	heart	heart	NOUN
admet-295	34	84	rate	rate	NOUN
admet-295	34	85	-	-	PUNCT
admet-295	34	86	corrected	correct	VERB
admet-295	34	87	qt	qt	NOUN
admet-295	34	88	interval	interval	NOUN
admet-295	34	89	(	(	PUNCT
admet-295	34	90	qtc	qtc	PROPN
admet-295	34	91	interval	interval	NOUN
admet-295	34	92	)	)	PUNCT
admet-295	34	93	to	to	PART
admet-295	34	94	determine	determine	VERB
admet-295	34	95	the	the	DET
admet-295	34	96	effect	effect	NOUN
admet-295	34	97	of	of	ADP
admet-295	34	98	an	an	DET
admet-295	34	99	intervention	intervention	NOUN
admet-295	34	100	.	.	PUNCT
admet-295	35	1	the	the	DET
admet-295	35	2	correction	correction	NOUN
admet-295	35	3	formula	formula	VERB
admet-295	35	4	most	most	ADV
admet-295	35	5	widely	widely	ADV
admet-295	35	6	used	use	VERB
admet-295	35	7	for	for	ADP
admet-295	35	8	regulatory	regulatory	ADJ
admet-295	35	9	submissions	submission	NOUN
admet-295	35	10	and	and	CCONJ
admet-295	35	11	safety	safety	NOUN
admet-295	35	12	assessment	assessment	NOUN
admet-295	35	13	is	be	AUX
admet-295	35	14	the	the	DET
admet-295	35	15	fridericia	fridericia	NOUN
admet-295	35	16	,	,	PUNCT
admet-295	35	17	study	study	NOUN
admet-295	35	18	population	population	NOUN
admet-295	35	19	-	-	PUNCT
admet-295	35	20	specific	specific	ADJ
admet-295	35	21	or	or	CCONJ
admet-295	35	22	individual	individual	ADJ
admet-295	35	23	subject	subject	ADJ
admet-295	35	24	-	-	PUNCT
admet-295	35	25	specific	specific	ADJ
admet-295	35	26	correction	correction	NOUN
admet-295	35	27	formula	formula	NOUN
admet-295	35	28	to	to	PART
admet-295	35	29	compute	compute	VERB
admet-295	35	30	qtcf	qtcf	PROPN
admet-295	35	31	,	,	PUNCT
admet-295	35	32	qtcp	qtcp	PROPN
admet-295	35	33	or	or	CCONJ
admet-295	35	34	qtci	qtci	NOUN
admet-295	35	35	interval	interval	NOUN
admet-295	35	36	,	,	PUNCT
admet-295	35	37	respectively	respectively	ADV
admet-295	35	38	.	.	PUNCT
admet-295	36	1	qtc	qtc	PROPN
admet-295	36	2	interval	interval	NOUN
admet-295	36	3	prolongation	prolongation	NOUN
admet-295	36	4	per	per	ADP
admet-295	36	5	se	se	X
admet-295	36	6	is	be	AUX
admet-295	36	7	not	not	PART
admet-295	36	8	harmful	harmful	ADJ
admet-295	36	9	.	.	PUNCT
admet-295	37	1	however	however	ADV
admet-295	37	2	,	,	PUNCT
admet-295	37	3	at	at	ADP
admet-295	37	4	the	the	DET
admet-295	37	5	level	level	NOUN
admet-295	37	6	of	of	ADP
admet-295	37	7	an	an	DET
admet-295	37	8	individual	individual	ADJ
admet-295	37	9	patient	patient	NOUN
admet-295	37	10	,	,	PUNCT
admet-295	37	11	prolonged	prolong	VERB
admet-295	37	12	qtc	qtc	PROPN
admet-295	37	13	interval	interval	NOUN
admet-295	37	14	,	,	PUNCT
admet-295	37	15	when	when	SCONJ
admet-295	37	16	excessive	excessive	ADJ
admet-295	37	17	(	(	PUNCT
admet-295	37	18	typically	typically	ADV
admet-295	37	19	significantly	significantly	ADV
admet-295	37	20	greater	great	ADJ
admet-295	37	21	than	than	ADP
admet-295	37	22	500	500	NUM
admet-295	37	23	ms	ms	NOUN
admet-295	37	24	)	)	PUNCT
admet-295	37	25	and/or	and/or	CCONJ
admet-295	37	26	in	in	ADP
admet-295	37	27	presence	presence	NOUN
admet-295	37	28	of	of	ADP
admet-295	37	29	certain	certain	ADJ
admet-295	37	30	risk	risk	NOUN
admet-295	37	31	factors	factor	NOUN
admet-295	37	32	,	,	PUNCT
admet-295	37	33	induces	induce	VERB
admet-295	37	34	a	a	DET
admet-295	37	35	potentially	potentially	ADV
admet-295	37	36	fatal	fatal	ADJ
admet-295	37	37	form	form	NOUN
admet-295	37	38	of	of	ADP
admet-295	37	39	ventricular	ventricular	ADJ
admet-295	37	40	tachyarrhythmia	tachyarrhythmia	PROPN
admet-295	37	41	,	,	PUNCT
admet-295	37	42	known	know	VERB
admet-295	37	43	as	as	ADP
admet-295	37	44	torsade	torsade	NOUN
admet-295	37	45	de	de	ADP
admet-295	37	46	pointes	pointe	NOUN
admet-295	37	47	(	(	PUNCT
admet-295	37	48	tdp	tdp	NOUN
admet-295	37	49	)	)	PUNCT
admet-295	38	1	[	[	X
admet-295	38	2	41,42	41,42	NOUN
admet-295	38	3	]	]	PUNCT
admet-295	38	4	.	.	PUNCT
admet-295	39	1	although	although	SCONJ
admet-295	39	2	typically	typically	ADV
admet-295	39	3	of	of	ADP
admet-295	39	4	short	short	ADJ
admet-295	39	5	duration	duration	NOUN
admet-295	39	6	,	,	PUNCT
admet-295	39	7	asymptomatic	asymptomatic	ADJ
admet-295	39	8	and	and	CCONJ
admet-295	39	9	self	self	NOUN
admet-295	39	10	-	-	PUNCT
admet-295	39	11	terminating	terminate	VERB
admet-295	39	12	,	,	PUNCT
admet-295	39	13	tdp	tdp	NOUN
admet-295	39	14	is	be	AUX
admet-295	39	15	infrequently	infrequently	ADV
admet-295	39	16	sustained	sustain	VERB
admet-295	39	17	and	and	CCONJ
admet-295	39	18	symptomatic	symptomatic	ADJ
admet-295	39	19	in	in	ADP
admet-295	39	20	a	a	DET
admet-295	39	21	small	small	ADJ
admet-295	39	22	proportion	proportion	NOUN
admet-295	39	23	of	of	ADP
admet-295	39	24	cases	case	NOUN
admet-295	39	25	and	and	CCONJ
admet-295	39	26	in	in	ADP
admet-295	39	27	20	20	NUM
admet-295	39	28	%	%	NOUN
admet-295	39	29	or	or	CCONJ
admet-295	39	30	so	so	ADV
admet-295	39	31	of	of	ADP
admet-295	39	32	these	these	DET
admet-295	39	33	patients	patient	NOUN
admet-295	39	34	,	,	PUNCT
admet-295	39	35	it	it	PRON
admet-295	39	36	degenerates	degenerate	VERB
admet-295	39	37	into	into	ADP
admet-295	39	38	ventricular	ventricular	ADJ
admet-295	39	39	fibrillation	fibrillation	NOUN
admet-295	39	40	,	,	PUNCT
admet-295	39	41	leading	lead	VERB
admet-295	39	42	to	to	ADP
admet-295	39	43	death	death	NOUN
admet-295	40	1	[	[	X
admet-295	40	2	43,44	43,44	X
admet-295	40	3	]	]	X
admet-295	40	4	.	.	PUNCT
admet-295	41	1	historically	historically	ADV
admet-295	41	2	,	,	PUNCT
admet-295	41	3	this	this	DET
admet-295	41	4	proarrhythmia	proarrhythmia	NOUN
admet-295	41	5	(	(	PUNCT
admet-295	41	6	or	or	CCONJ
admet-295	41	7	the	the	DET
admet-295	41	8	potential	potential	NOUN
admet-295	41	9	thereof	thereof	ADV
admet-295	41	10	)	)	PUNCT
admet-295	41	11	has	have	AUX
admet-295	41	12	been	be	AUX
admet-295	41	13	responsible	responsible	ADJ
admet-295	41	14	for	for	ADP
admet-295	41	15	about	about	ADV
admet-295	41	16	a	a	DET
admet-295	41	17	third	third	NOUN
admet-295	41	18	of	of	ADP
admet-295	41	19	the	the	DET
admet-295	41	20	drug	drug	NOUN
admet-295	41	21	withdrawals	withdrawal	NOUN
admet-295	41	22	from	from	ADP
admet-295	41	23	the	the	DET
admet-295	41	24	market	market	NOUN
admet-295	42	1	[	[	X
admet-295	42	2	45	45	NUM
admet-295	42	3	,	,	PUNCT
admet-295	42	4	46	46	NUM
admet-295	42	5	]	]	PUNCT
admet-295	42	6	.	.	PUNCT
admet-295	43	1	the	the	DET
admet-295	43	2	approval	approval	NOUN
admet-295	43	3	of	of	ADP
admet-295	43	4	many	many	ADJ
admet-295	43	5	others	other	NOUN
admet-295	43	6	has	have	AUX
admet-295	43	7	been	be	AUX
admet-295	43	8	either	either	ADV
admet-295	43	9	delayed	delay	VERB
admet-295	43	10	or	or	CCONJ
admet-295	43	11	associated	associate	VERB
admet-295	43	12	with	with	ADP
admet-295	43	13	prescribing	prescribing	NOUN
admet-295	43	14	restrictions	restriction	NOUN
admet-295	43	15	in	in	ADP
admet-295	43	16	terms	term	NOUN
admet-295	43	17	of	of	ADP
admet-295	43	18	narrow	narrow	ADJ
admet-295	43	19	indication(s	indication(s	NOUN
admet-295	43	20	)	)	PUNCT
admet-295	43	21	,	,	PUNCT
admet-295	43	22	contraindications	contraindication	NOUN
admet-295	43	23	and/or	and/or	CCONJ
admet-295	43	24	warnings	warning	NOUN
admet-295	43	25	and	and	CCONJ
admet-295	43	26	monitoring	monitor	VERB
admet-295	43	27	precautions	precaution	NOUN
admet-295	43	28	[	[	X
admet-295	43	29	47	47	NUM
admet-295	43	30	]	]	PUNCT
admet-295	43	31	.	.	PUNCT
admet-295	44	1	arising	arise	VERB
admet-295	44	2	from	from	ADP
admet-295	44	3	this	this	DET
admet-295	44	4	historical	historical	ADJ
admet-295	44	5	experience	experience	NOUN
admet-295	44	6	with	with	ADP
admet-295	44	7	a	a	DET
admet-295	44	8	large	large	ADJ
admet-295	44	9	number	number	NOUN
admet-295	44	10	of	of	ADP
admet-295	44	11	drugs	drug	NOUN
admet-295	44	12	across	across	ADP
admet-295	44	13	a	a	DET
admet-295	44	14	wide	wide	ADJ
admet-295	44	15	range	range	NOUN
admet-295	44	16	of	of	ADP
admet-295	44	17	pharmacological	pharmacological	ADJ
admet-295	44	18	and	and	CCONJ
admet-295	44	19	therapeutic	therapeutic	ADJ
admet-295	44	20	classes	class	NOUN
admet-295	44	21	including	include	VERB
admet-295	44	22	oncology	oncology	NOUN
admet-295	44	23	,	,	PUNCT
admet-295	44	24	the	the	DET
admet-295	44	25	potential	potential	NOUN
admet-295	44	26	of	of	ADP
admet-295	44	27	new	new	ADJ
admet-295	44	28	drugs	drug	NOUN
admet-295	44	29	to	to	PART
admet-295	44	30	prolong	prolong	VERB
admet-295	44	31	the	the	DET
admet-295	44	32	qtc	qtc	PROPN
admet-295	44	33	interval	interval	NOUN
admet-295	44	34	and	and	CCONJ
admet-295	44	35	induce	induce	VERB
admet-295	44	36	tdp	tdp	NOUN
admet-295	44	37	is	be	AUX
admet-295	44	38	one	one	NUM
admet-295	44	39	principal	principal	ADJ
admet-295	44	40	safety	safety	NOUN
admet-295	44	41	issue	issue	NOUN
admet-295	44	42	that	that	PRON
admet-295	44	43	has	have	AUX
admet-295	44	44	continued	continue	VERB
admet-295	44	45	to	to	PART
admet-295	44	46	worry	worry	VERB
admet-295	44	47	the	the	DET
admet-295	44	48	regulatory	regulatory	ADJ
admet-295	44	49	authorities	authority	NOUN
admet-295	44	50	over	over	ADP
admet-295	44	51	the	the	DET
admet-295	44	52	last	last	ADJ
admet-295	44	53	two	two	NUM
admet-295	44	54	decades	decade	NOUN
admet-295	44	55	,	,	PUNCT
admet-295	44	56	although	although	SCONJ
admet-295	44	57	qtc	qtc	PROPN
admet-295	44	58	interval	interval	NOUN
admet-295	44	59	prolongation	prolongation	NOUN
admet-295	44	60	per	per	X
admet-295	44	61	se	se	X
admet-295	44	62	does	do	AUX
admet-295	44	63	not	not	PART
admet-295	44	64	correlate	correlate	VERB
admet-295	44	65	well	well	ADV
admet-295	44	66	with	with	ADP
admet-295	44	67	torsadogenic	torsadogenic	ADJ
admet-295	44	68	potential	potential	NOUN
admet-295	44	69	.	.	PUNCT
admet-295	45	1	this	this	DET
admet-295	45	2	imperfect	imperfect	ADJ
admet-295	45	3	correlation	correlation	NOUN
admet-295	45	4	between	between	ADP
admet-295	45	5	qt	qt	NOUN
admet-295	45	6	prolongation	prolongation	NOUN
admet-295	45	7	and	and	CCONJ
admet-295	45	8	risk	risk	NOUN
admet-295	45	9	of	of	ADP
admet-295	45	10	tdp	tdp	NOUN
admet-295	45	11	is	be	AUX
admet-295	45	12	explained	explain	VERB
admet-295	45	13	by	by	ADP
admet-295	45	14	the	the	DET
admet-295	45	15	fact	fact	NOUN
admet-295	45	16	that	that	SCONJ
admet-295	45	17	whereas	whereas	SCONJ
admet-295	45	18	qt	qt	NOUN
admet-295	45	19	prolongation	prolongation	NOUN
admet-295	45	20	results	result	NOUN
admet-295	45	21	from	from	ADP
admet-295	45	22	blockade	blockade	NOUN
admet-295	45	23	of	of	ADP
admet-295	45	24	human	human	ADJ
admet-295	45	25	ether	ether	NOUN
admet-295	45	26	-	-	PUNCT
admet-295	45	27	a	a	DET
admet-295	45	28	-	-	PUNCT
admet-295	45	29	go	go	NOUN
admet-295	45	30	-	-	PUNCT
admet-295	45	31	go	go	NOUN
admet-295	45	32	(	(	PUNCT
admet-295	45	33	herg	herg	PROPN
admet-295	45	34	)	)	PUNCT
admet-295	45	35	channel	channel	NOUN
admet-295	45	36	and	and	CCONJ
admet-295	45	37	prolongation	prolongation	NOUN
admet-295	45	38	of	of	ADP
admet-295	45	39	action	action	NOUN
admet-295	45	40	potential	potential	ADJ
admet-295	45	41	duration	duration	NOUN
admet-295	45	42	(	(	PUNCT
admet-295	45	43	apd	apd	PROPN
admet-295	45	44	)	)	PUNCT
admet-295	45	45	,	,	PUNCT
admet-295	45	46	tdp	tdp	NOUN
admet-295	45	47	is	be	AUX
admet-295	45	48	a	a	DET
admet-295	45	49	triggered	trigger	VERB
admet-295	45	50	activity	activity	NOUN
admet-295	45	51	arising	arise	VERB
admet-295	45	52	from	from	ADP
admet-295	45	53	early	early	ADJ
admet-295	45	54	afterdepolarizations	afterdepolarization	NOUN
admet-295	45	55	(	(	PUNCT
admet-295	45	56	eads	ead	NOUN
admet-295	45	57	)	)	PUNCT
admet-295	45	58	and	and	CCONJ
admet-295	45	59	the	the	DET
admet-295	45	60	risk	risk	NOUN
admet-295	45	61	of	of	ADP
admet-295	45	62	eads	ead	NOUN
admet-295	45	63	followed	follow	VERB
admet-295	45	64	by	by	ADP
admet-295	45	65	tdp	tdp	NOUN
admet-295	45	66	is	be	AUX
admet-295	45	67	modulated	modulate	VERB
admet-295	45	68	by	by	ADP
admet-295	45	69	other	other	ADJ
admet-295	45	70	ancillary	ancillary	ADJ
admet-295	45	71	properties	property	NOUN
admet-295	45	72	of	of	ADP
admet-295	45	73	the	the	DET
admet-295	45	74	drug	drug	NOUN
admet-295	45	75	,	,	PUNCT
admet-295	45	76	such	such	ADJ
admet-295	45	77	as	as	ADP
admet-295	45	78	blockade	blockade	NOUN
admet-295	45	79	of	of	ADP
admet-295	45	80	calcium	calcium	NOUN
admet-295	45	81	or	or	CCONJ
admet-295	45	82	late	late	ADJ
admet-295	45	83	sodium	sodium	NOUN
admet-295	45	84	currents	current	NOUN
admet-295	45	85	or	or	CCONJ
admet-295	45	86	autonomic	autonomic	ADJ
admet-295	45	87	receptors	receptor	NOUN
admet-295	45	88	[	[	X
admet-295	45	89	48	48	NUM
admet-295	45	90	-	-	SYM
admet-295	45	91	51	51	NUM
admet-295	45	92	]	]	PUNCT
admet-295	45	93	.	.	PUNCT
admet-295	46	1	ranolazine	ranolazine	PROPN
admet-295	46	2	(	(	PUNCT
admet-295	46	3	an	an	DET
admet-295	46	4	antianginal	antianginal	ADJ
admet-295	46	5	drug	drug	NOUN
admet-295	46	6	)	)	PUNCT
admet-295	46	7	and	and	CCONJ
admet-295	46	8	sertindole	sertindole	NOUN
admet-295	46	9	(	(	PUNCT
admet-295	46	10	a	a	DET
admet-295	46	11	neuroleptic	neuroleptic	ADJ
admet-295	46	12	agent	agent	NOUN
admet-295	46	13	)	)	PUNCT
admet-295	46	14	best	well	ADV
admet-295	46	15	illustrate	illustrate	VERB
admet-295	46	16	the	the	DET
admet-295	46	17	role	role	NOUN
admet-295	46	18	of	of	ADP
admet-295	46	19	late	late	ADJ
admet-295	46	20	sodium	sodium	NOUN
admet-295	46	21	current	current	ADJ
admet-295	46	22	and	and	CCONJ
admet-295	46	23	α	α	PRON
admet-295	46	24	-	-	PUNCT
admet-295	46	25	blocking	block	VERB
admet-295	46	26	activities	activity	NOUN
admet-295	46	27	,	,	PUNCT
admet-295	46	28	respectively	respectively	ADV
admet-295	46	29	,	,	PUNCT
admet-295	46	30	in	in	ADP
admet-295	46	31	modulating	modulate	VERB
admet-295	46	32	the	the	DET
admet-295	46	33	risk	risk	NOUN
admet-295	46	34	of	of	ADP
admet-295	46	35	tdp	tdp	NOUN
admet-295	46	36	following	follow	VERB
admet-295	46	37	qt	qt	NOUN
admet-295	46	38	interval	interval	NOUN
admet-295	46	39	prolongation	prolongation	NOUN
admet-295	47	1	[	[	X
admet-295	47	2	52	52	NUM
admet-295	47	3	-	-	SYM
admet-295	47	4	56	56	NUM
admet-295	47	5	]	]	PUNCT
admet-295	47	6	.	.	PUNCT
admet-295	48	1	in	in	ADP
admet-295	48	2	essence	essence	NOUN
admet-295	48	3	,	,	PUNCT
admet-295	48	4	therefore	therefore	ADV
admet-295	48	5	,	,	PUNCT
admet-295	48	6	tdp	tdp	NOUN
admet-295	48	7	and	and	CCONJ
admet-295	48	8	fatality	fatality	NOUN
admet-295	48	9	following	follow	VERB
admet-295	48	10	drug	drug	NOUN
admet-295	48	11	-	-	PUNCT
admet-295	48	12	induced	induce	VERB
admet-295	48	13	qtc	qtc	PROPN
admet-295	48	14	prolongation	prolongation	NOUN
admet-295	48	15	are	be	AUX
admet-295	48	16	events	event	NOUN
admet-295	48	17	that	that	PRON
admet-295	48	18	are	be	AUX
admet-295	48	19	much	much	ADV
admet-295	48	20	rarer	rare	ADJ
admet-295	48	21	than	than	SCONJ
admet-295	48	22	would	would	AUX
admet-295	48	23	be	be	AUX
admet-295	48	24	anticipated	anticipate	VERB
admet-295	48	25	.	.	PUNCT
admet-295	49	1	for	for	ADP
admet-295	49	2	example	example	NOUN
admet-295	49	3	,	,	PUNCT
admet-295	49	4	laksman	laksman	NOUN
admet-295	49	5	et	et	PROPN
admet-295	49	6	al	al	PROPN
admet-295	49	7	.	.	PUNCT
admet-295	50	1	[	[	X
admet-295	50	2	57	57	NUM
admet-295	50	3	]	]	PUNCT
admet-295	50	4	have	have	AUX
admet-295	50	5	reported	report	VERB
admet-295	50	6	that	that	SCONJ
admet-295	50	7	,	,	PUNCT
admet-295	50	8	among	among	ADP
admet-295	50	9	172	172	NUM
admet-295	50	10	inhospital	inhospital	ADJ
admet-295	50	11	patients	patient	NOUN
admet-295	50	12	with	with	ADP
admet-295	50	13	qtc	qtc	PROPN
admet-295	50	14	interval	interval	NOUN
admet-295	50	15	>	>	X
admet-295	50	16	550	550	NUM
admet-295	50	17	ms	ms	NOUN
admet-295	50	18	,	,	PUNCT
admet-295	50	19	in	in	ADP
admet-295	50	20	-	-	PUNCT
admet-295	50	21	hospital	hospital	NOUN
admet-295	50	22	mortality	mortality	NOUN
admet-295	50	23	was	be	AUX
admet-295	50	24	29	29	NUM
admet-295	50	25	%	%	NOUN
admet-295	50	26	,	,	PUNCT
admet-295	50	27	with	with	ADP
admet-295	50	28	only	only	ADV
admet-295	50	29	4	4	NUM
admet-295	50	30	%	%	NOUN
admet-295	50	31	of	of	ADP
admet-295	50	32	patients	patient	NOUN
admet-295	50	33	experiencing	experience	VERB
admet-295	50	34	arrhythmic	arrhythmic	ADJ
admet-295	50	35	deaths	death	NOUN
admet-295	50	36	,	,	PUNCT
admet-295	50	37	all	all	PRON
admet-295	50	38	of	of	ADP
admet-295	50	39	which	which	PRON
admet-295	50	40	were	be	AUX
admet-295	50	41	attributed	attribute	VERB
admet-295	50	42	to	to	ADP
admet-295	50	43	secondary	secondary	ADJ
admet-295	50	44	causes	cause	NOUN
admet-295	50	45	.	.	PUNCT
admet-295	51	1	in	in	ADP
admet-295	51	2	a	a	DET
admet-295	51	3	vast	vast	ADJ
admet-295	51	4	majority	majority	NOUN
admet-295	51	5	of	of	ADP
admet-295	51	6	cases	case	NOUN
admet-295	51	7	,	,	PUNCT
admet-295	51	8	drug	drug	NOUN
admet-295	51	9	-	-	PUNCT
admet-295	51	10	induced	induce	VERB
admet-295	51	11	prolongation	prolongation	NOUN
admet-295	51	12	of	of	ADP
admet-295	51	13	the	the	DET
admet-295	51	14	qtc	qtc	PROPN
admet-295	51	15	interval	interval	NOUN
admet-295	51	16	results	result	NOUN
admet-295	51	17	from	from	ADP
admet-295	51	18	delayed	delay	VERB
admet-295	51	19	ventricular	ventricular	ADJ
admet-295	51	20	repolarization	repolarization	NOUN
admet-295	51	21	due	due	ADP
admet-295	51	22	to	to	ADP
admet-295	51	23	inhibition	inhibition	NOUN
admet-295	51	24	of	of	ADP
admet-295	51	25	the	the	DET
admet-295	51	26	(	(	PUNCT
admet-295	51	27	major	major	ADJ
admet-295	51	28	)	)	PUNCT
admet-295	51	29	outward	outward	VERB
admet-295	51	30	repolarizing	repolarize	VERB
admet-295	51	31	potassium	potassium	NOUN
admet-295	51	32	current	current	NOUN
admet-295	51	33	mediated	mediate	VERB
admet-295	51	34	by	by	ADP
admet-295	51	35	herg	herg	PROPN
admet-295	51	36	subunit	subunit	NOUN
admet-295	51	37	of	of	ADP
admet-295	51	38	the	the	DET
admet-295	51	39	rapid	rapid	ADJ
admet-295	51	40	component	component	NOUN
admet-295	51	41	of	of	ADP
admet-295	51	42	the	the	DET
admet-295	51	43	delayed	delay	VERB
admet-295	51	44	rectifier	rectifier	NOUN
admet-295	51	45	channel	channel	NOUN
admet-295	51	46	(	(	PUNCT
admet-295	51	47	ikr	ikr	PROPN
admet-295	51	48	)	)	PUNCT
admet-295	52	1	[	[	X
admet-295	52	2	58	58	NUM
admet-295	52	3	]	]	PUNCT
admet-295	52	4	.	.	PUNCT
admet-295	53	1	non	non	ADJ
admet-295	53	2	-	-	ADJ
admet-295	53	3	antiarrhythmic	antiarrhythmic	ADJ
admet-295	53	4	drugs	drug	NOUN
admet-295	53	5	can	can	AUX
admet-295	53	6	be	be	AUX
admet-295	53	7	characterised	characterise	VERB
admet-295	53	8	for	for	ADP
admet-295	53	9	this	this	DET
admet-295	53	10	off	off	ADP
admet-295	53	11	-	-	PUNCT
admet-295	53	12	target	target	NOUN
admet-295	53	13	undesirable	undesirable	ADJ
admet-295	53	14	pharmacological	pharmacological	ADJ
admet-295	53	15	property	property	NOUN
admet-295	53	16	in	in	ADP
admet-295	53	17	nonclinical	nonclinical	ADJ
admet-295	53	18	in	in	ADP
admet-295	53	19	vitro	vitro	X
admet-295	53	20	and	and	CCONJ
admet-295	53	21	in	in	ADP
admet-295	53	22	vivo	vivo	ADJ
admet-295	53	23	studies	study	NOUN
admet-295	53	24	as	as	ADV
admet-295	53	25	well	well	ADV
admet-295	53	26	as	as	ADP
admet-295	53	27	clinical	clinical	ADJ
admet-295	53	28	in	in	ADP
admet-295	53	29	vivo	vivo	ADJ
admet-295	53	30	studies	study	NOUN
admet-295	53	31	.	.	PUNCT
admet-295	54	1	not	not	PART
admet-295	54	2	surprisingly	surprisingly	ADV
admet-295	54	3	,	,	PUNCT
admet-295	54	4	therefore	therefore	ADV
admet-295	54	5	,	,	PUNCT
admet-295	54	6	regulatory	regulatory	ADJ
admet-295	54	7	authorities	authority	NOUN
admet-295	54	8	have	have	AUX
admet-295	54	9	reacted	react	VERB
admet-295	54	10	to	to	ADP
admet-295	54	11	this	this	DET
admet-295	54	12	potential	potential	NOUN
admet-295	54	13	by	by	ADP
admet-295	54	14	promulgating	promulgate	VERB
admet-295	54	15	guidelines	guideline	NOUN
admet-295	54	16	for	for	ADP
admet-295	54	17	pre	pre	ADJ
admet-295	54	18	-	-	ADJ
admet-295	54	19	approval	approval	ADJ
admet-295	54	20	characterisation	characterisation	NOUN
admet-295	54	21	of	of	ADP
admet-295	54	22	all	all	DET
admet-295	54	23	new	new	ADJ
admet-295	54	24	drugs	drug	NOUN
admet-295	54	25	with	with	ADP
admet-295	54	26	systemic	systemic	ADJ
admet-295	54	27	bioavailability	bioavailability	NOUN
admet-295	54	28	for	for	ADP
admet-295	54	29	their	their	PRON
admet-295	54	30	“	"	PUNCT
admet-295	54	31	qt	qt	NOUN
admet-295	54	32	-	-	PUNCT
admet-295	54	33	liability	liability	NOUN
admet-295	54	34	”	"	PUNCT
admet-295	55	1	[	[	X
admet-295	55	2	47	47	NUM
admet-295	55	3	,	,	PUNCT
admet-295	55	4	59	59	NUM
admet-295	55	5	-	-	SYM
admet-295	55	6	62	62	NUM
admet-295	55	7	]	]	PUNCT
admet-295	55	8	.	.	PUNCT
admet-295	56	1	this	this	PRON
admet-295	56	2	is	be	AUX
admet-295	56	3	the	the	DET
admet-295	56	4	only	only	ADJ
admet-295	56	5	adverse	adverse	ADJ
admet-295	56	6	drug	drug	NOUN
admet-295	56	7	effect	effect	NOUN
admet-295	56	8	that	that	PRON
admet-295	56	9	has	have	AUX
admet-295	56	10	called	call	VERB
admet-295	56	11	for	for	ADP
admet-295	56	12	specifically	specifically	ADV
admet-295	56	13	targeted	target	VERB
admet-295	56	14	and	and	CCONJ
admet-295	56	15	internationally	internationally	ADV
admet-295	56	16	harmonised	harmonise	VERB
admet-295	56	17	detailed	detailed	ADJ
admet-295	56	18	guidelines	guideline	NOUN
admet-295	56	19	[	[	X
admet-295	56	20	60	60	NUM
admet-295	56	21	,	,	PUNCT
admet-295	56	22	61	61	NUM
admet-295	56	23	]	]	PUNCT
admet-295	56	24	.	.	PUNCT
admet-295	57	1	clinically	clinically	ADV
admet-295	57	2	,	,	PUNCT
admet-295	57	3	this	this	DET
admet-295	57	4	qt	qt	NOUN
admet-295	57	5	-	-	PUNCT
admet-295	57	6	liability	liability	NOUN
admet-295	57	7	is	be	AUX
admet-295	57	8	determined	determine	VERB
admet-295	57	9	in	in	ADP
admet-295	57	10	a	a	DET
admet-295	57	11	formal	formal	ADJ
admet-295	57	12	and	and	CCONJ
admet-295	57	13	dedicated	dedicated	ADJ
admet-295	57	14	study	study	NOUN
admet-295	57	15	,	,	PUNCT
admet-295	57	16	referred	refer	VERB
admet-295	57	17	to	to	ADP
admet-295	57	18	as	as	ADP
admet-295	57	19	the	the	DET
admet-295	57	20	thorough	thorough	ADJ
admet-295	57	21	qt	qt	NOUN
admet-295	57	22	(	(	PUNCT
admet-295	57	23	tqt	tqt	ADV
admet-295	57	24	)	)	PUNCT
admet-295	57	25	study	study	NOUN
admet-295	57	26	,	,	PUNCT
admet-295	57	27	that	that	PRON
admet-295	57	28	includes	include	VERB
admet-295	57	29	two	two	NUM
admet-295	57	30	dose	dose	NOUN
admet-295	57	31	levels	level	NOUN
admet-295	57	32	of	of	ADP
admet-295	57	33	the	the	DET
admet-295	57	34	investigational	investigational	ADJ
admet-295	57	35	drug	drug	NOUN
admet-295	57	36	,	,	PUNCT
admet-295	57	37	a	a	DET
admet-295	57	38	placebo	placebo	NOUN
admet-295	57	39	and	and	CCONJ
admet-295	57	40	an	an	DET
admet-295	57	41	active	active	ADJ
admet-295	57	42	control	control	NOUN
admet-295	57	43	.	.	PUNCT
admet-295	58	1	in	in	ADP
admet-295	58	2	order	order	NOUN
admet-295	58	3	to	to	PART
admet-295	58	4	avoid	avoid	VERB
admet-295	58	5	any	any	DET
admet-295	58	6	false	false	ADJ
admet-295	58	7	negatives	negative	NOUN
admet-295	58	8	and	and	CCONJ
admet-295	58	9	as	as	ADP
admet-295	58	10	a	a	DET
admet-295	58	11	matter	matter	NOUN
admet-295	58	12	of	of	ADP
admet-295	58	13	precaution	precaution	NOUN
admet-295	58	14	,	,	PUNCT
admet-295	58	15	the	the	DET
admet-295	58	16	threshold	threshold	NOUN
admet-295	58	17	of	of	ADP
admet-295	58	18	regulatory	regulatory	ADJ
admet-295	58	19	concern	concern	NOUN
admet-295	58	20	for	for	ADP
admet-295	58	21	a	a	DET
admet-295	58	22	maximum	maximum	ADJ
admet-295	58	23	mean	mean	ADJ
admet-295	58	24	increase	increase	NOUN
admet-295	58	25	in	in	ADP
admet-295	58	26	qtc	qtc	PROPN
admet-295	58	27	interval	interval	NOUN
admet-295	58	28	from	from	ADP
admet-295	58	29	baseline	baseline	NOUN
admet-295	58	30	in	in	ADP
admet-295	58	31	the	the	DET
admet-295	58	32	tqt	tqt	PROPN
admet-295	58	33	study	study	NOUN
admet-295	58	34	has	have	AUX
admet-295	58	35	been	be	AUX
admet-295	58	36	(	(	PUNCT
admet-295	58	37	arbitrarily	arbitrarily	ADV
admet-295	58	38	)	)	PUNCT
admet-295	58	39	set	set	VERB
admet-295	58	40	low	low	ADV
admet-295	58	41	at	at	ADP
admet-295	58	42	around	around	ADV
admet-295	58	43	5	5	NUM
admet-295	58	44	ms	ms	NOUN
admet-295	58	45	as	as	SCONJ
admet-295	58	46	evidenced	evidence	VERB
admet-295	58	47	by	by	ADP
admet-295	58	48	an	an	DET
admet-295	58	49	upper	upper	ADJ
admet-295	58	50	bound	bound	NOUN
admet-295	58	51	of	of	ADP
admet-295	58	52	the	the	DET
admet-295	58	53	95	95	NUM
admet-295	58	54	%	%	NOUN
admet-295	58	55	confidence	confidence	NOUN
admet-295	58	56	interval	interval	NOUN
admet-295	58	57	(	(	PUNCT
admet-295	58	58	ci	ci	NOUN
admet-295	58	59	)	)	PUNCT
admet-295	58	60	around	around	ADP
admet-295	58	61	the	the	DET
admet-295	58	62	mean	mean	ADJ
admet-295	58	63	effect	effect	NOUN
admet-295	58	64	on	on	ADP
admet-295	58	65	qtc	qtc	PROPN
admet-295	58	66	of	of	ADP
admet-295	58	67	10	10	NUM
admet-295	58	68	ms	ms	PROPN
admet-295	58	69	rashmi	rashmi	PROPN
admet-295	58	70	shah	shah	PROPN
admet-295	58	71	admet	admet	PROPN
admet-295	58	72	&	&	CCONJ
admet-295	58	73	dmpk	dmpk	PROPN
admet-295	58	74	4(3	4(3	NUM
admet-295	58	75	)	)	PUNCT
admet-295	58	76	(	(	PUNCT
admet-295	58	77	2016	2016	NUM
admet-295	58	78	)	)	PUNCT
admet-295	58	79	212	212	NUM
admet-295	58	80	-	-	SYM
admet-295	58	81	231	231	NUM
admet-295	58	82	216	216	NUM
admet-295	58	83	[	[	X
admet-295	58	84	61	61	NUM
admet-295	58	85	]	]	PUNCT
admet-295	58	86	.	.	PUNCT
admet-295	59	1	however	however	ADV
admet-295	59	2	,	,	PUNCT
admet-295	59	3	qtc	qtc	PROPN
admet-295	59	4	prolongation	prolongation	NOUN
admet-295	59	5	is	be	AUX
admet-295	59	6	an	an	DET
admet-295	59	7	imperfect	imperfect	ADJ
admet-295	59	8	surrogate	surrogate	NOUN
admet-295	59	9	of	of	ADP
admet-295	59	10	torsadogenesis	torsadogenesis	NOUN
admet-295	59	11	and	and	CCONJ
admet-295	59	12	therefore	therefore	ADV
admet-295	59	13	,	,	PUNCT
admet-295	59	14	it	it	PRON
admet-295	59	15	is	be	AUX
admet-295	59	16	acknowledged	acknowledge	VERB
admet-295	59	17	by	by	ADP
admet-295	59	18	all	all	PRON
admet-295	59	19	concerned	concerned	ADJ
admet-295	59	20	(	(	PUNCT
admet-295	59	21	including	include	VERB
admet-295	59	22	the	the	DET
admet-295	59	23	regulatory	regulatory	ADJ
admet-295	59	24	authorities	authority	NOUN
admet-295	59	25	)	)	PUNCT
admet-295	59	26	that	that	SCONJ
admet-295	59	27	a	a	DET
admet-295	59	28	drug	drug	NOUN
admet-295	59	29	endowed	endow	VERB
admet-295	59	30	with	with	ADP
admet-295	59	31	qt	qt	NOUN
admet-295	59	32	-	-	PUNCT
admet-295	59	33	liability	liability	NOUN
admet-295	59	34	does	do	AUX
admet-295	59	35	not	not	PART
admet-295	59	36	necessarily	necessarily	ADV
admet-295	59	37	mean	mean	VERB
admet-295	59	38	that	that	SCONJ
admet-295	59	39	the	the	DET
admet-295	59	40	drug	drug	NOUN
admet-295	59	41	is	be	AUX
admet-295	59	42	proarrhythmic	proarrhythmic	ADJ
admet-295	59	43	;	;	PUNCT
admet-295	59	44	a	a	DET
admet-295	59	45	breach	breach	NOUN
admet-295	59	46	of	of	ADP
admet-295	59	47	the	the	DET
admet-295	59	48	above	above	ADJ
admet-295	59	49	regulatory	regulatory	ADJ
admet-295	59	50	threshold	threshold	NOUN
admet-295	59	51	simply	simply	ADV
admet-295	59	52	calls	call	VERB
admet-295	59	53	for	for	ADP
admet-295	59	54	more	more	ADV
admet-295	59	55	diligent	diligent	ADJ
admet-295	59	56	and	and	CCONJ
admet-295	59	57	intensive	intensive	ADJ
admet-295	59	58	ecg	ecg	PROPN
admet-295	59	59	monitoring	monitoring	NOUN
admet-295	59	60	in	in	ADP
admet-295	59	61	subsequent	subsequent	ADJ
admet-295	59	62	clinical	clinical	ADJ
admet-295	59	63	trials	trial	NOUN
admet-295	59	64	.	.	PUNCT
admet-295	60	1	nevertheless	nevertheless	ADV
admet-295	60	2	,	,	PUNCT
admet-295	60	3	the	the	DET
admet-295	60	4	sponsors	sponsor	NOUN
admet-295	60	5	have	have	AUX
admet-295	60	6	frequently	frequently	ADV
admet-295	60	7	reacted	react	VERB
admet-295	60	8	by	by	ADP
admet-295	60	9	terminating	terminate	VERB
admet-295	60	10	further	further	ADJ
admet-295	60	11	development	development	NOUN
admet-295	60	12	of	of	ADP
admet-295	60	13	new	new	ADJ
admet-295	60	14	agents	agent	NOUN
admet-295	60	15	,	,	PUNCT
admet-295	60	16	often	often	ADV
admet-295	60	17	on	on	ADP
admet-295	60	18	the	the	DET
admet-295	60	19	basis	basis	NOUN
admet-295	60	20	of	of	ADP
admet-295	60	21	an	an	DET
admet-295	60	22	early	early	ADJ
admet-295	60	23	in	in	ADP
admet-295	60	24	vitro	vitro	X
admet-295	60	25	herg	herg	PROPN
admet-295	60	26	study	study	NOUN
admet-295	60	27	or	or	CCONJ
admet-295	60	28	first	first	ADJ
admet-295	60	29	-	-	PUNCT
admet-295	60	30	in	in	ADP
admet-295	60	31	-	-	PUNCT
admet-295	60	32	human	human	ADJ
admet-295	60	33	study	study	NOUN
admet-295	60	34	,	,	PUNCT
admet-295	60	35	because	because	SCONJ
admet-295	60	36	of	of	ADP
admet-295	60	37	the	the	DET
admet-295	60	38	fears	fear	NOUN
admet-295	60	39	and	and	CCONJ
admet-295	60	40	regulatory	regulatory	ADJ
admet-295	60	41	uncertainties	uncertainty	NOUN
admet-295	60	42	surrounding	surround	VERB
admet-295	60	43	the	the	DET
admet-295	60	44	possible	possible	ADJ
admet-295	60	45	finding	finding	NOUN
admet-295	60	46	of	of	ADP
admet-295	60	47	a	a	DET
admet-295	60	48	modest	modest	ADJ
admet-295	60	49	but	but	CCONJ
admet-295	60	50	often	often	ADV
admet-295	60	51	clinically	clinically	ADV
admet-295	60	52	irrelevant	irrelevant	ADJ
admet-295	60	53	breach	breach	NOUN
admet-295	60	54	of	of	ADP
admet-295	60	55	the	the	DET
admet-295	60	56	regulatory	regulatory	ADJ
admet-295	60	57	threshold	threshold	NOUN
admet-295	60	58	by	by	ADP
admet-295	60	59	the	the	DET
admet-295	60	60	drug	drug	NOUN
admet-295	60	61	concerned	concern	VERB
admet-295	60	62	in	in	ADP
admet-295	60	63	what	what	PRON
admet-295	60	64	is	be	AUX
admet-295	60	65	a	a	DET
admet-295	60	66	cost	cost	NOUN
admet-295	60	67	-	-	PUNCT
admet-295	60	68	ineffective	ineffective	ADJ
admet-295	60	69	and	and	CCONJ
admet-295	60	70	resource	resource	NOUN
admet-295	60	71	-	-	PUNCT
admet-295	60	72	intensive	intensive	ADJ
admet-295	60	73	tqt	tqt	PROPN
admet-295	60	74	study	study	NOUN
admet-295	60	75	.	.	PUNCT
admet-295	61	1	qtc	qtc	PROPN
admet-295	61	2	-	-	PUNCT
admet-295	61	3	liability	liability	NOUN
admet-295	61	4	of	of	ADP
admet-295	61	5	protein	protein	NOUN
admet-295	61	6	kinase	kinase	PROPN
admet-295	61	7	inhibitors	inhibitor	NOUN
admet-295	61	8	overall	overall	ADV
admet-295	61	9	,	,	PUNCT
admet-295	61	10	as	as	SCONJ
admet-295	61	11	shown	show	VERB
admet-295	61	12	in	in	ADP
admet-295	61	13	table	table	NOUN
admet-295	61	14	2	2	NUM
admet-295	61	15	,	,	PUNCT
admet-295	61	16	11	11	NUM
admet-295	61	17	(	(	PUNCT
admet-295	61	18	39	39	NUM
admet-295	61	19	%	%	NOUN
admet-295	61	20	)	)	PUNCT
admet-295	61	21	of	of	ADP
admet-295	61	22	the	the	DET
admet-295	61	23	28	28	NUM
admet-295	61	24	pkis	pki	NOUN
admet-295	61	25	have	have	VERB
admet-295	61	26	the	the	DET
admet-295	61	27	potential	potential	NOUN
admet-295	61	28	to	to	PART
admet-295	61	29	prolong	prolong	VERB
admet-295	61	30	the	the	DET
admet-295	61	31	qtc	qtc	PROPN
admet-295	61	32	interval	interval	NOUN
admet-295	61	33	to	to	ADP
admet-295	61	34	a	a	DET
admet-295	61	35	variable	variable	ADJ
admet-295	61	36	extent	extent	NOUN
admet-295	61	37	.	.	PUNCT
admet-295	62	1	these	these	DET
admet-295	62	2	11	11	NUM
admet-295	62	3	agents	agent	NOUN
admet-295	62	4	are	be	AUX
admet-295	62	5	considered	consider	VERB
admet-295	62	6	to	to	PART
admet-295	62	7	have	have	VERB
admet-295	62	8	the	the	DET
admet-295	62	9	qt	qt	NOUN
admet-295	62	10	-	-	PUNCT
admet-295	62	11	liability	liability	NOUN
admet-295	62	12	on	on	ADP
admet-295	62	13	the	the	DET
admet-295	62	14	basis	basis	NOUN
admet-295	62	15	that	that	SCONJ
admet-295	62	16	their	their	PRON
admet-295	62	17	qtc	qtc	PROPN
admet-295	62	18	effect	effect	NOUN
admet-295	62	19	had	have	AUX
admet-295	62	20	breached	breach	VERB
admet-295	62	21	the	the	DET
admet-295	62	22	above	above	ADJ
admet-295	62	23	very	very	ADV
admet-295	62	24	conservative	conservative	ADJ
admet-295	62	25	threshold	threshold	NOUN
admet-295	62	26	of	of	ADP
admet-295	62	27	regulatory	regulatory	ADJ
admet-295	62	28	concern	concern	NOUN
admet-295	62	29	;	;	PUNCT
admet-295	62	30	as	as	ADP
admet-295	62	31	a	a	DET
admet-295	62	32	result	result	NOUN
admet-295	62	33	,	,	PUNCT
admet-295	62	34	the	the	DET
admet-295	62	35	labels	label	NOUN
admet-295	62	36	of	of	ADP
admet-295	62	37	two	two	NUM
admet-295	62	38	(	(	PUNCT
admet-295	62	39	nilotinib	nilotinib	NOUN
admet-295	62	40	and	and	CCONJ
admet-295	62	41	vandetanib	vandetanib	NOUN
admet-295	62	42	)	)	PUNCT
admet-295	62	43	carry	carry	VERB
admet-295	62	44	a	a	DET
admet-295	62	45	black	black	ADJ
admet-295	62	46	box	box	NOUN
admet-295	62	47	warning	warning	NOUN
admet-295	62	48	.	.	PUNCT
admet-295	63	1	interestingly	interestingly	ADV
admet-295	63	2	,	,	PUNCT
admet-295	63	3	qtc	qtc	PROPN
admet-295	63	4	-	-	PUNCT
admet-295	63	5	liability	liability	NOUN
admet-295	63	6	is	be	AUX
admet-295	63	7	reported	report	VERB
admet-295	63	8	for	for	ADP
admet-295	63	9	eight	eight	NUM
admet-295	63	10	(	(	PUNCT
admet-295	63	11	50	50	NUM
admet-295	63	12	%	%	NOUN
admet-295	63	13	)	)	PUNCT
admet-295	63	14	of	of	ADP
admet-295	63	15	the	the	DET
admet-295	63	16	16	16	NUM
admet-295	63	17	agents	agent	NOUN
admet-295	63	18	approved	approve	VERB
admet-295	63	19	in	in	ADP
admet-295	63	20	period	period	NOUN
admet-295	63	21	1	1	NUM
admet-295	63	22	in	in	ADP
admet-295	63	23	contrast	contrast	NOUN
admet-295	63	24	to	to	ADP
admet-295	63	25	only	only	ADV
admet-295	63	26	3	3	NUM
admet-295	63	27	(	(	PUNCT
admet-295	63	28	25	25	NUM
admet-295	63	29	%	%	NOUN
admet-295	63	30	)	)	PUNCT
admet-295	63	31	of	of	ADP
admet-295	63	32	the	the	DET
admet-295	63	33	12	12	NUM
admet-295	63	34	approved	approve	VERB
admet-295	63	35	in	in	ADP
admet-295	63	36	period	period	NOUN
admet-295	63	37	2	2	NUM
admet-295	63	38	,	,	PUNCT
admet-295	63	39	possibly	possibly	ADV
admet-295	63	40	suggesting	suggest	VERB
admet-295	63	41	early	early	ADJ
admet-295	63	42	termination	termination	NOUN
admet-295	63	43	of	of	ADP
admet-295	63	44	pkis	pki	NOUN
admet-295	63	45	from	from	ADP
admet-295	63	46	development	development	NOUN
admet-295	63	47	during	during	ADP
admet-295	63	48	period	period	NOUN
admet-295	63	49	2	2	NUM
admet-295	63	50	due	due	ADP
admet-295	63	51	to	to	ADP
admet-295	63	52	this	this	DET
admet-295	63	53	pharmacological	pharmacological	ADJ
admet-295	63	54	property	property	NOUN
admet-295	63	55	.	.	PUNCT
admet-295	64	1	however	however	ADV
admet-295	64	2	,	,	PUNCT
admet-295	64	3	experience	experience	NOUN
admet-295	64	4	with	with	ADP
admet-295	64	5	qtc	qtc	PROPN
admet-295	64	6	-	-	PUNCT
admet-295	64	7	prolonging	prolong	VERB
admet-295	64	8	drugs	drug	NOUN
admet-295	64	9	that	that	PRON
admet-295	64	10	are	be	AUX
admet-295	64	11	known	know	VERB
admet-295	64	12	to	to	PART
admet-295	64	13	be	be	AUX
admet-295	64	14	torsadogenic	torsadogenic	ADJ
admet-295	64	15	and	and	CCONJ
admet-295	64	16	nontorsadogenic	nontorsadogenic	ADJ
admet-295	64	17	has	have	AUX
admet-295	64	18	shown	show	VERB
admet-295	64	19	that	that	SCONJ
admet-295	64	20	drugs	drug	NOUN
admet-295	64	21	associated	associate	VERB
admet-295	64	22	with	with	ADP
admet-295	64	23	maximum	maximum	ADJ
admet-295	64	24	mean	mean	ADJ
admet-295	64	25	placebo	placebo	NOUN
admet-295	64	26	-	-	PUNCT
admet-295	64	27	corrected	correct	VERB
admet-295	64	28	increases	increase	NOUN
admet-295	64	29	of	of	ADP
admet-295	64	30	6	6	NUM
admet-295	64	31	-	-	SYM
admet-295	64	32	10	10	NUM
admet-295	64	33	ms	ms	NOUN
admet-295	64	34	are	be	AUX
admet-295	64	35	unlikely	unlikely	ADJ
admet-295	64	36	to	to	PART
admet-295	64	37	be	be	AUX
admet-295	64	38	torsadogenic	torsadogenic	ADJ
admet-295	64	39	whereas	whereas	SCONJ
admet-295	64	40	drugs	drug	NOUN
admet-295	64	41	associated	associate	VERB
admet-295	64	42	with	with	ADP
admet-295	64	43	increases	increase	NOUN
admet-295	64	44	of	of	ADP
admet-295	64	45	16	16	NUM
admet-295	64	46	-	-	SYM
admet-295	64	47	20	20	NUM
admet-295	64	48	ms	ms	NOUN
admet-295	64	49	are	be	AUX
admet-295	64	50	probably	probably	ADV
admet-295	64	51	torsadogenic	torsadogenic	ADJ
admet-295	64	52	[	[	X
admet-295	64	53	63	63	NUM
admet-295	64	54	]	]	PUNCT
admet-295	64	55	.	.	PUNCT
admet-295	65	1	lin	lin	PROPN
admet-295	65	2	and	and	CCONJ
admet-295	65	3	kung	kung	PROPN
admet-295	65	4	have	have	AUX
admet-295	65	5	also	also	ADV
admet-295	65	6	summarized	summarize	VERB
admet-295	65	7	data	datum	NOUN
admet-295	65	8	which	which	PRON
admet-295	65	9	suggest	suggest	VERB
admet-295	65	10	that	that	SCONJ
admet-295	65	11	a	a	DET
admet-295	65	12	mean	mean	NOUN
admet-295	65	13	qtc	qtc	PROPN
admet-295	65	14	increase	increase	NOUN
admet-295	65	15	of	of	ADP
admet-295	65	16	19.3	19.3	NUM
admet-295	65	17	ms	ms	NOUN
admet-295	65	18	associated	associate	VERB
admet-295	65	19	with	with	ADP
admet-295	65	20	strong	strong	ADJ
admet-295	65	21	torsadogens	torsadogen	NOUN
admet-295	65	22	is	be	AUX
admet-295	65	23	significantly	significantly	ADV
admet-295	65	24	greater	great	ADJ
admet-295	65	25	than	than	ADP
admet-295	65	26	the	the	DET
admet-295	65	27	8.0	8.0	NUM
admet-295	65	28	ms	ms	NOUN
admet-295	65	29	for	for	ADP
admet-295	65	30	borderline	borderline	NOUN
admet-295	65	31	torsadogens	torsadogen	NOUN
admet-295	65	32	[	[	X
admet-295	65	33	64	64	NUM
admet-295	65	34	]	]	PUNCT
admet-295	65	35	.	.	PUNCT
admet-295	66	1	by	by	ADP
admet-295	66	2	comparison	comparison	NOUN
admet-295	66	3	with	with	ADP
admet-295	66	4	known	know	VERB
admet-295	66	5	non	non	ADJ
admet-295	66	6	-	-	ADJ
admet-295	66	7	pki	pki	ADJ
admet-295	66	8	torsadogens	torsadogen	NOUN
admet-295	66	9	,	,	PUNCT
admet-295	66	10	the	the	DET
admet-295	66	11	qtc	qtc	PROPN
admet-295	66	12	effect	effect	NOUN
admet-295	66	13	of	of	ADP
admet-295	66	14	majority	majority	NOUN
admet-295	66	15	of	of	ADP
admet-295	66	16	the	the	DET
admet-295	66	17	pkis	pki	NOUN
admet-295	66	18	that	that	PRON
admet-295	66	19	prolong	prolong	VERB
admet-295	66	20	the	the	DET
admet-295	66	21	qtc	qtc	PROPN
admet-295	66	22	interval	interval	NOUN
admet-295	66	23	(	(	PUNCT
admet-295	66	24	often	often	ADV
admet-295	66	25	determined	determine	VERB
admet-295	66	26	at	at	ADP
admet-295	66	27	supratherapeutic	supratherapeutic	ADJ
admet-295	66	28	doses	dose	NOUN
admet-295	66	29	)	)	PUNCT
admet-295	66	30	appears	appear	VERB
admet-295	66	31	to	to	PART
admet-295	66	32	be	be	AUX
admet-295	66	33	relatively	relatively	ADV
admet-295	66	34	mild	mild	ADJ
admet-295	66	35	/	/	SYM
admet-295	66	36	modest	modest	ADJ
admet-295	66	37	with	with	ADP
admet-295	66	38	a	a	DET
admet-295	66	39	maximum	maximum	ADJ
admet-295	66	40	mean	mean	ADJ
admet-295	66	41	effect	effect	NOUN
admet-295	66	42	of	of	ADP
admet-295	66	43	around	around	ADV
admet-295	66	44	10	10	NUM
admet-295	66	45	ms	ms	NOUN
admet-295	66	46	(	(	PUNCT
admet-295	66	47	95	95	NUM
admet-295	66	48	%	%	NOUN
admet-295	66	49	upper	upper	ADJ
admet-295	66	50	bound	bind	VERB
admet-295	66	51	around	around	ADP
admet-295	66	52	their	their	PRON
admet-295	66	53	mean	mean	ADJ
admet-295	66	54	effects	effect	NOUN
admet-295	66	55	being	be	AUX
admet-295	66	56	around	around	ADV
admet-295	66	57	15	15	NUM
admet-295	66	58	ms	ms	NOUN
admet-295	66	59	)	)	PUNCT
admet-295	66	60	.	.	PUNCT
admet-295	67	1	six	six	NUM
admet-295	67	2	pkis	pki	NOUN
admet-295	67	3	(	(	PUNCT
admet-295	67	4	osimertinib	osimertinib	NOUN
admet-295	67	5	,	,	PUNCT
admet-295	67	6	ceritinib	ceritinib	NOUN
admet-295	67	7	,	,	PUNCT
admet-295	67	8	sunitinib	sunitinib	PROPN
admet-295	67	9	,	,	PUNCT
admet-295	67	10	lapatinib	lapatinib	PROPN
admet-295	67	11	,	,	PUNCT
admet-295	67	12	nilotinib	nilotinib	NOUN
admet-295	67	13	and	and	CCONJ
admet-295	67	14	vandetanib	vandetanib	PROPN
admet-295	67	15	)	)	PUNCT
admet-295	67	16	appear	appear	VERB
admet-295	67	17	to	to	PART
admet-295	67	18	have	have	VERB
admet-295	67	19	somewhat	somewhat	ADV
admet-295	67	20	larger	large	ADJ
admet-295	67	21	effects	effect	NOUN
admet-295	67	22	with	with	ADP
admet-295	67	23	a	a	DET
admet-295	67	24	maximum	maximum	ADJ
admet-295	67	25	mean	mean	ADJ
admet-295	67	26	effect	effect	NOUN
admet-295	67	27	ranging	range	VERB
admet-295	67	28	from	from	ADP
admet-295	67	29	13.5	13.5	NUM
admet-295	67	30	to	to	ADP
admet-295	67	31	34.7	34.7	NUM
admet-295	67	32	ms	ms	NOUN
admet-295	67	33	(	(	PUNCT
admet-295	67	34	95	95	NUM
admet-295	67	35	%	%	NOUN
admet-295	67	36	upper	upper	ADJ
admet-295	67	37	bound	bind	VERB
admet-295	67	38	around	around	ADP
admet-295	67	39	the	the	DET
admet-295	67	40	mean	mean	ADJ
admet-295	67	41	effect	effect	NOUN
admet-295	67	42	being	be	AUX
admet-295	67	43	17.6	17.6	NUM
admet-295	67	44	,	,	PUNCT
admet-295	67	45	22.2	22.2	NUM
admet-295	67	46	,	,	PUNCT
admet-295	67	47	22.4	22.4	NUM
admet-295	67	48	,	,	PUNCT
admet-295	67	49	23.4	23.4	NUM
admet-295	67	50	,	,	PUNCT
admet-295	67	51	25.8	25.8	NUM
admet-295	67	52	and	and	CCONJ
admet-295	67	53	36.4	36.4	NUM
admet-295	67	54	ms	ms	NOUN
admet-295	67	55	respectively	respectively	ADV
admet-295	67	56	)	)	PUNCT
admet-295	68	1	[	[	X
admet-295	68	2	2,3	2,3	NUM
admet-295	68	3	]	]	PUNCT
admet-295	68	4	.	.	PUNCT
admet-295	69	1	however	however	ADV
admet-295	69	2	,	,	PUNCT
admet-295	69	3	since	since	SCONJ
admet-295	69	4	some	some	PRON
admet-295	69	5	of	of	ADP
admet-295	69	6	these	these	DET
admet-295	69	7	effects	effect	NOUN
admet-295	69	8	are	be	AUX
admet-295	69	9	not	not	PART
admet-295	69	10	placebo	placebo	NOUN
admet-295	69	11	-	-	PUNCT
admet-295	69	12	corrected	correct	VERB
admet-295	69	13	,	,	PUNCT
admet-295	69	14	the	the	DET
admet-295	69	15	true	true	ADJ
admet-295	69	16	extent	extent	NOUN
admet-295	69	17	of	of	ADP
admet-295	69	18	the	the	DET
admet-295	69	19	drug	drug	NOUN
admet-295	69	20	’s	’s	PART
admet-295	69	21	qtc	qtc	PROPN
admet-295	69	22	-	-	PUNCT
admet-295	69	23	prolonging	prolong	VERB
admet-295	69	24	effect	effect	NOUN
admet-295	69	25	remains	remain	VERB
admet-295	69	26	uncertain	uncertain	ADJ
admet-295	69	27	.	.	PUNCT
admet-295	70	1	therefore	therefore	ADV
admet-295	70	2	,	,	PUNCT
admet-295	70	3	it	it	PRON
admet-295	70	4	is	be	AUX
admet-295	70	5	interesting	interesting	ADJ
admet-295	70	6	to	to	PART
admet-295	70	7	note	note	VERB
admet-295	70	8	that	that	SCONJ
admet-295	70	9	the	the	DET
admet-295	70	10	number	number	NOUN
admet-295	70	11	of	of	ADP
admet-295	70	12	patients	patient	NOUN
admet-295	70	13	receiving	receive	VERB
admet-295	70	14	any	any	PRON
admet-295	70	15	of	of	ADP
admet-295	70	16	these	these	DET
admet-295	70	17	pkis	pki	NOUN
admet-295	70	18	who	who	PRON
admet-295	70	19	developed	develop	VERB
admet-295	70	20	a	a	DET
admet-295	70	21	qtc	qtc	PROPN
admet-295	70	22	interval	interval	NOUN
admet-295	70	23	prolongation	prolongation	NOUN
admet-295	70	24	>	>	X
admet-295	70	25	500	500	NUM
admet-295	70	26	ms	ms	NOUN
admet-295	70	27	is	be	AUX
admet-295	70	28	typically	typically	ADV
admet-295	70	29	well	well	ADV
admet-295	70	30	below	below	ADP
admet-295	70	31	0.5	0.5	NUM
admet-295	70	32	%	%	NOUN
admet-295	70	33	except	except	SCONJ
admet-295	70	34	lapatinib	lapatinib	NOUN
admet-295	70	35	(	(	PUNCT
admet-295	70	36	6	6	NUM
admet-295	70	37	%	%	NOUN
admet-295	70	38	)	)	PUNCT
admet-295	70	39	and	and	CCONJ
admet-295	70	40	vandetanib	vandetanib	NOUN
admet-295	70	41	(	(	PUNCT
admet-295	70	42	4.3	4.3	NUM
admet-295	70	43	%	%	NOUN
admet-295	70	44	)	)	PUNCT
admet-295	71	1	[	[	X
admet-295	71	2	2	2	NUM
admet-295	71	3	]	]	PUNCT
admet-295	71	4	.	.	PUNCT
admet-295	72	1	in	in	ADP
admet-295	72	2	pre	pre	ADJ
admet-295	72	3	-	-	ADJ
admet-295	72	4	approval	approval	ADJ
admet-295	72	5	clinical	clinical	ADJ
admet-295	72	6	trials	trial	NOUN
admet-295	72	7	,	,	PUNCT
admet-295	72	8	only	only	ADV
admet-295	72	9	pazopanib	pazopanib	NOUN
admet-295	72	10	and	and	CCONJ
admet-295	72	11	vandetanib	vandetanib	NOUN
admet-295	72	12	were	be	AUX
admet-295	72	13	each	each	PRON
admet-295	72	14	associated	associate	VERB
admet-295	72	15	with	with	ADP
admet-295	72	16	two	two	NUM
admet-295	72	17	cases	case	NOUN
admet-295	72	18	of	of	ADP
admet-295	72	19	tdp	tdp	NOUN
admet-295	72	20	,	,	PUNCT
admet-295	72	21	although	although	SCONJ
admet-295	72	22	the	the	DET
admet-295	72	23	causal	causal	PROPN
admet-295	72	24	association	association	NOUN
admet-295	72	25	with	with	ADP
admet-295	72	26	pazopanib	pazopanib	NOUN
admet-295	72	27	in	in	ADP
admet-295	72	28	one	one	NUM
admet-295	72	29	case	case	NOUN
admet-295	72	30	appeared	appear	VERB
admet-295	72	31	uncertain	uncertain	ADJ
admet-295	72	32	since	since	SCONJ
admet-295	72	33	the	the	DET
admet-295	72	34	patient	patient	NOUN
admet-295	72	35	was	be	AUX
admet-295	72	36	also	also	ADV
admet-295	72	37	receiving	receive	VERB
admet-295	72	38	amiodarone	amiodarone	NOUN
admet-295	72	39	[	[	X
admet-295	72	40	2	2	NUM
admet-295	72	41	]	]	PUNCT
admet-295	72	42	.	.	PUNCT
admet-295	73	1	in	in	ADP
admet-295	73	2	a	a	DET
admet-295	73	3	dedicated	dedicated	ADJ
admet-295	73	4	qt	qt	NOUN
admet-295	73	5	study	study	NOUN
admet-295	73	6	as	as	SCONJ
admet-295	73	7	required	require	VERB
admet-295	73	8	by	by	ADP
admet-295	73	9	the	the	DET
admet-295	73	10	regulatory	regulatory	ADJ
admet-295	73	11	guidance	guidance	NOUN
admet-295	73	12	,	,	PUNCT
admet-295	73	13	the	the	DET
admet-295	73	14	maximum	maximum	ADJ
admet-295	73	15	mean	mean	ADJ
admet-295	73	16	increase	increase	NOUN
admet-295	73	17	in	in	ADP
admet-295	73	18	baseline	baseline	NOUN
admet-295	73	19	-	-	PUNCT
admet-295	73	20	adjusted	adjust	VERB
admet-295	73	21	,	,	PUNCT
admet-295	73	22	time	time	NOUN
admet-295	73	23	-	-	PUNCT
admet-295	73	24	matched	match	VERB
admet-295	73	25	qtcf	qtcf	NOUN
admet-295	73	26	interval	interval	NOUN
admet-295	73	27	in	in	ADP
admet-295	73	28	pazopanibtreated	pazopanibtreate	VERB
admet-295	73	29	patients	patient	NOUN
admet-295	73	30	versus	versus	ADP
admet-295	73	31	placebo	placebo	NOUN
admet-295	73	32	was	be	AUX
admet-295	73	33	only	only	ADV
admet-295	73	34	4.4	4.4	NUM
admet-295	73	35	ms	ms	NOUN
admet-295	73	36	(	(	PUNCT
admet-295	73	37	95	95	NUM
admet-295	73	38	%	%	NOUN
admet-295	73	39	upper	upper	ADJ
admet-295	73	40	bound	bind	VERB
admet-295	73	41	11.2	11.2	NUM
admet-295	73	42	ms	ms	NOUN
admet-295	73	43	)	)	PUNCT
admet-295	74	1	[	[	X
admet-295	74	2	65	65	NUM
admet-295	74	3	]	]	SYM
admet-295	74	4	.	.	PUNCT
admet-295	75	1	mixed	mix	VERB
admet-295	75	2	-	-	PUNCT
admet-295	75	3	effects	effect	NOUN
admet-295	75	4	modelling	modelling	NOUN
admet-295	75	5	did	do	AUX
admet-295	75	6	not	not	PART
admet-295	75	7	indicate	indicate	VERB
admet-295	75	8	a	a	DET
admet-295	75	9	significant	significant	ADJ
admet-295	75	10	concentration	concentration	NOUN
admet-295	75	11	-	-	PUNCT
admet-295	75	12	dependent	dependent	ADJ
admet-295	75	13	effect	effect	NOUN
admet-295	75	14	of	of	ADP
admet-295	75	15	pazopanib	pazopanib	NOUN
admet-295	75	16	or	or	CCONJ
admet-295	75	17	its	its	PRON
admet-295	75	18	metabolites	metabolite	NOUN
admet-295	75	19	on	on	ADP
admet-295	75	20	qtcf	qtcf	VERB
admet-295	75	21	interval	interval	NOUN
admet-295	75	22	.	.	PUNCT
admet-295	76	1	admet	admet	PROPN
admet-295	76	2	&	&	CCONJ
admet-295	76	3	dmpk	dmpk	PROPN
admet-295	76	4	4(3	4(3	NUM
admet-295	76	5	)	)	PUNCT
admet-295	76	6	(	(	PUNCT
admet-295	76	7	2016	2016	NUM
admet-295	76	8	)	)	PUNCT
admet-295	76	9	212	212	NUM
admet-295	76	10	-	-	SYM
admet-295	76	11	231	231	NUM
admet-295	76	12	pkis	pki	NOUN
admet-295	76	13	and	and	CCONJ
admet-295	76	14	qt	qt	NOUN
admet-295	76	15	-	-	PUNCT
admet-295	76	16	phobia	phobia	NOUN
admet-295	76	17	doi	doi	NOUN
admet-295	76	18	:	:	PUNCT
admet-295	76	19	10.5599	10.5599	NUM
admet-295	76	20	/	/	SYM
admet-295	76	21	admet.4.3.295	admet.4.3.295	NOUN
admet-295	76	22	217	217	NUM
admet-295	76	23	table	table	NOUN
admet-295	76	24	2	2	NUM
admet-295	76	25	.	.	NOUN
admet-295	76	26	trend	trend	NOUN
admet-295	76	27	analysis	analysis	NOUN
admet-295	76	28	of	of	ADP
admet-295	76	29	selected	select	VERB
admet-295	76	30	toxic	toxic	ADJ
admet-295	76	31	effects	effect	NOUN
admet-295	76	32	of	of	ADP
admet-295	76	33	protein	protein	NOUN
admet-295	76	34	kinase	kinase	PROPN
admet-295	76	35	inhibitors	inhibitor	NOUN
admet-295	76	36	(	(	PUNCT
admet-295	76	37	pkis	pkis	PROPN
admet-295	76	38	)	)	PUNCT
admet-295	76	39	with	with	ADP
admet-295	76	40	reference	reference	NOUN
admet-295	76	41	to	to	ADP
admet-295	76	42	approval	approval	NOUN
admet-295	76	43	period	period	NOUN
admet-295	76	44	protein	protein	NOUN
admet-295	76	45	kinase	kinase	PROPN
admet-295	76	46	inhibitor	inhibitor	NOUN
admet-295	76	47	period	period	NOUN
admet-295	76	48	1	1	NUM
admet-295	76	49	(	(	PUNCT
admet-295	76	50	may	may	PROPN
admet-295	76	51	2001	2001	NUM
admet-295	76	52	–	–	PUNCT
admet-295	76	53	september	september	PROPN
admet-295	76	54	2012	2012	NUM
admet-295	76	55	)	)	PUNCT
admet-295	76	56	number	number	NOUN
admet-295	76	57	of	of	ADP
admet-295	76	58	pkis	pki	NOUN
admet-295	76	59	approved	approve	VERB
admet-295	76	60	=	=	SYM
admet-295	76	61	16	16	NUM
admet-295	76	62	period	period	NOUN
admet-295	76	63	2	2	NUM
admet-295	76	64	(	(	PUNCT
admet-295	76	65	october	october	PROPN
admet-295	76	66	2012	2012	NUM
admet-295	76	67	–	–	PUNCT
admet-295	76	68	may	may	AUX
admet-295	76	69	2016	2016	NUM
admet-295	76	70	)	)	PUNCT
admet-295	76	71	number	number	NOUN
admet-295	76	72	of	of	ADP
admet-295	76	73	pkis	pki	NOUN
admet-295	76	74	approved	approve	VERB
admet-295	76	75	=	=	NOUN
admet-295	76	76	12	12	NUM
admet-295	76	77	qt	qt	NOUN
admet-295	76	78	effect	effect	NOUN
admet-295	76	79	hepatotoxicity	hepatotoxicity	NOUN
admet-295	76	80	lv	lv	PROPN
admet-295	76	81	dysfunction	dysfunction	NOUN
admet-295	76	82	arterial	arterial	NOUN
admet-295	76	83	effects	effect	NOUN
admet-295	76	84	qt	qt	ADP
admet-295	76	85	effect	effect	NOUN
admet-295	76	86	hepatotoxicity	hepatotoxicity	NOUN
admet-295	76	87	lv	lv	PROPN
admet-295	76	88	dysfunction	dysfunction	NOUN
admet-295	76	89	arterial	arterial	NOUN
admet-295	76	90	effects	effect	NOUN
admet-295	76	91	afatinib	afatinib	NOUN
admet-295	76	92	*	*	PUNCT
admet-295	76	93	*	*	PUNCT
admet-295	76	94			PROPN
admet-295	76	95			PROPN
admet-295	76	96	alectinib	alectinib	NOUN
admet-295	76	97	*	*	PUNCT
admet-295	76	98	*	*	PUNCT
admet-295	76	99			NOUN
admet-295	76	100	axitinib	axitinib	NOUN
admet-295	76	101	*	*	PUNCT
admet-295	76	102			PROPN
admet-295	76	103			PROPN
admet-295	76	104			NOUN
admet-295	76	105			NOUN
admet-295	76	106	bosutinib	bosutinib	NOUN
admet-295	76	107	*	*	PUNCT
admet-295	76	108			PROPN
admet-295	76	109			PROPN
admet-295	76	110	cabozantinib	cabozantinib	VERB
admet-295	76	111	*	*	PROPN
admet-295	76	112	*	*	PUNCT
admet-295	76	113			PROPN
admet-295	76	114			PROPN
admet-295	76	115	ceritinib	ceritinib	VERB
admet-295	76	116	*	*	PUNCT
admet-295	76	117	*	*	PROPN
admet-295	76	118			PROPN
admet-295	76	119			PROPN
admet-295	76	120	cobimetinib	cobimetinib	NOUN
admet-295	76	121	*	*	PUNCT
admet-295	76	122	*	*	PROPN
admet-295	76	123			PROPN
admet-295	76	124			PROPN
admet-295	76	125	crizotinib	crizotinib	VERB
admet-295	76	126	*	*	PUNCT
admet-295	76	127			PROPN
admet-295	76	128			PROPN
admet-295	76	129			PROPN
admet-295	76	130			PROPN
admet-295	76	131	dabrafenib	dabrafenib	VERB
admet-295	76	132	*	*	PUNCT
admet-295	76	133	*	*	PUNCT
admet-295	76	134			PROPN
admet-295	76	135			NOUN
admet-295	76	136	dasatinib	dasatinib	VERB
admet-295	76	137	*	*	PUNCT
admet-295	76	138			PROPN
admet-295	76	139			PROPN
admet-295	76	140	erlotinib	erlotinib	VERB
admet-295	76	141	*	*	PUNCT
admet-295	76	142			PROPN
admet-295	76	143			NOUN
admet-295	76	144	gefitinib	gefitinib	NOUN
admet-295	76	145	*	*	PUNCT
admet-295	76	146			PROPN
admet-295	76	147			PROPN
admet-295	76	148	ibrutinib	ibrutinib	VERB
admet-295	76	149	*	*	PUNCT
admet-295	77	1	*	*	NOUN
admet-295	77	2	imatinib	imatinib	NOUN
admet-295	77	3	*	*	PUNCT
admet-295	77	4			PROPN
admet-295	77	5			NOUN
admet-295	77	6			PROPN
admet-295	77	7			PUNCT
admet-295	77	8	lapatinib	lapatinib	VERB
admet-295	77	9	*	*	PUNCT
admet-295	77	10			PROPN
admet-295	77	11			NOUN
admet-295	77	12			PROPN
admet-295	77	13			PROPN
admet-295	77	14			PROPN
admet-295	77	15	lenvatinib	lenvatinib	VERB
admet-295	77	16	*	*	PROPN
admet-295	77	17	*	*	PROPN
admet-295	77	18			PROPN
admet-295	77	19			PROPN
admet-295	77	20			PROPN
admet-295	77	21	nilotinib	nilotinib	NOUN
admet-295	77	22	*	*	PUNCT
admet-295	77	23			PROPN
admet-295	77	24			PROPN
admet-295	77	25			PROPN
admet-295	77	26			PROPN
admet-295	77	27			PROPN
admet-295	77	28			PROPN
admet-295	77	29			NOUN
admet-295	77	30	nintedanib	nintedanib	VERB
admet-295	77	31	*	*	PUNCT
admet-295	77	32	*	*	PUNCT
admet-295	77	33			PROPN
admet-295	77	34			PROPN
admet-295	77	35	osimertinib	osimertinib	VERB
admet-295	77	36	*	*	PUNCT
admet-295	77	37	*	*	PUNCT
admet-295	77	38			PROPN
admet-295	77	39			PROPN
admet-295	77	40	pazopanib	pazopanib	NOUN
admet-295	77	41	*	*	PUNCT
admet-295	77	42			PROPN
admet-295	77	43			PROPN
admet-295	77	44			PROPN
admet-295	77	45			PROPN
admet-295	77	46			PROPN
admet-295	77	47	ponatinib	ponatinib	VERB
admet-295	77	48	*	*	NOUN
admet-295	77	49	*	*	PUNCT
admet-295	77	50			PROPN
admet-295	77	51			PROPN
admet-295	77	52			NOUN
admet-295	77	53			NOUN
admet-295	78	1			PROPN
admet-295	78	2	regorafeniib	regorafeniib	NOUN
admet-295	78	3	*	*	PUNCT
admet-295	78	4			PROPN
admet-295	78	5			PROPN
admet-295	78	6			PROPN
admet-295	78	7	ruxolitinib	ruxolitinib	VERB
admet-295	78	8	*	*	PUNCT
admet-295	78	9	sorafenib	sorafenib	PROPN
admet-295	78	10	*	*	PUNCT
admet-295	78	11			PROPN
admet-295	78	12			NOUN
admet-295	78	13			PROPN
admet-295	78	14			PROPN
admet-295	78	15	sunitinib	sunitinib	NOUN
admet-295	78	16	*	*	PUNCT
admet-295	78	17			PROPN
admet-295	78	18			NOUN
admet-295	78	19			PROPN
admet-295	78	20			PROPN
admet-295	78	21			PROPN
admet-295	78	22			PROPN
admet-295	78	23			NOUN
admet-295	78	24	trametinib	trametinib	VERB
admet-295	78	25	*	*	PUNCT
admet-295	79	1	*	*	PUNCT
admet-295	79	2			PROPN
admet-295	79	3	vandetanib	vandetanib	NOUN
admet-295	79	4	*	*	PUNCT
admet-295	79	5			PROPN
admet-295	80	1			PROPN
admet-295	80	2			PROPN
admet-295	80	3			PROPN
admet-295	80	4	vemurafenib	vemurafenib	VERB
admet-295	80	5	*	*	PUNCT
admet-295	80	6			PROPN
admet-295	80	7			PROPN
admet-295	80	8	pkis	pki	NOUN
admet-295	80	9	with	with	ADP
admet-295	80	10	the	the	DET
admet-295	80	11	effect	effect	NOUN
admet-295	80	12	50	50	NUM
admet-295	80	13	%	%	NOUN
admet-295	80	14	75	75	NUM
admet-295	80	15	%	%	NOUN
admet-295	80	16	63	63	NUM
admet-295	80	17	%	%	NOUN
admet-295	80	18	63	63	NUM
admet-295	80	19	%	%	NOUN
admet-295	80	20	25	25	NUM
admet-295	80	21	%	%	NOUN
admet-295	80	22	58	58	NUM
admet-295	80	23	%	%	NOUN
admet-295	80	24	58	58	NUM
admet-295	80	25	%	%	NOUN
admet-295	80	26	33	33	NUM
admet-295	80	27	%	%	NOUN
admet-295	80	28	*	*	PUNCT
admet-295	81	1	pki	pki	NOUN
admet-295	81	2	approved	approve	VERB
admet-295	81	3	in	in	ADP
admet-295	81	4	period	period	NOUN
admet-295	81	5	1	1	NUM
admet-295	81	6	;	;	PUNCT
admet-295	81	7	*	*	PUNCT
admet-295	81	8	*	*	PUNCT
admet-295	81	9	pki	pki	NOUN
admet-295	81	10	approved	approve	VERB
admet-295	81	11	in	in	ADP
admet-295	81	12	period	period	NOUN
admet-295	81	13	2	2	NUM
admet-295	81	14	;	;	PUNCT
admet-295	81	15			NUM
admet-295	81	16	with	with	ADP
admet-295	81	17	black	black	ADJ
admet-295	81	18	box	box	PROPN
admet-295	81	19	warning	warning	NOUN
admet-295	81	20	;	;	PUNCT
admet-295	81	21			PUNCT
admet-295	81	22	post	post	ADJ
admet-295	81	23	-	-	ADJ
admet-295	81	24	approval	approval	ADJ
admet-295	81	25	addition	addition	NOUN
admet-295	81	26	or	or	CCONJ
admet-295	81	27	revision	revision	NOUN
admet-295	81	28	the	the	DET
admet-295	81	29	rarity	rarity	NOUN
admet-295	81	30	of	of	ADP
admet-295	81	31	qt	qt	NOUN
admet-295	81	32	-	-	PUNCT
admet-295	81	33	related	relate	VERB
admet-295	81	34	proarrhythmia	proarrhythmia	NOUN
admet-295	81	35	risk	risk	NOUN
admet-295	81	36	of	of	ADP
admet-295	81	37	pkis	pki	NOUN
admet-295	81	38	is	be	AUX
admet-295	81	39	further	far	ADV
admet-295	81	40	corroborated	corroborate	VERB
admet-295	81	41	by	by	ADP
admet-295	81	42	post	post	ADJ
admet-295	81	43	-	-	ADJ
admet-295	81	44	marketing	marketing	ADJ
admet-295	81	45	data	datum	NOUN
admet-295	81	46	.	.	PUNCT
admet-295	82	1	during	during	ADP
admet-295	82	2	the	the	DET
admet-295	82	3	post	post	ADJ
admet-295	82	4	-	-	ADJ
admet-295	82	5	marketing	marketing	ADJ
admet-295	82	6	use	use	NOUN
admet-295	82	7	of	of	ADP
admet-295	82	8	16	16	NUM
admet-295	82	9	pkis	pki	NOUN
admet-295	82	10	approved	approve	VERB
admet-295	82	11	in	in	ADP
admet-295	82	12	period	period	NOUN
admet-295	82	13	1	1	NUM
admet-295	82	14	and	and	CCONJ
admet-295	82	15	for	for	ADP
admet-295	82	16	which	which	PRON
admet-295	82	17	some	some	DET
admet-295	82	18	data	datum	NOUN
admet-295	82	19	are	be	AUX
admet-295	82	20	available	available	ADJ
admet-295	82	21	,	,	PUNCT
admet-295	82	22	there	there	PRON
admet-295	82	23	were	be	VERB
admet-295	82	24	a	a	DET
admet-295	82	25	total	total	NOUN
admet-295	82	26	of	of	ADP
admet-295	82	27	463	463	NUM
admet-295	82	28	reports	report	NOUN
admet-295	82	29	of	of	ADP
admet-295	82	30	qt	qt	NOUN
admet-295	82	31	interval	interval	NOUN
admet-295	82	32	prolongation	prolongation	NOUN
admet-295	82	33	but	but	CCONJ
admet-295	82	34	only	only	ADV
admet-295	82	35	20	20	NUM
admet-295	82	36	reports	report	NOUN
admet-295	82	37	of	of	ADP
admet-295	82	38	tdp	tdp	NOUN
admet-295	82	39	;	;	PUNCT
admet-295	82	40	only	only	ADV
admet-295	82	41	vandetanib	vandetanib	NOUN
admet-295	82	42	was	be	AUX
admet-295	82	43	associated	associate	VERB
admet-295	82	44	with	with	ADP
admet-295	82	45	significant	significant	ADJ
admet-295	82	46	risk	risk	NOUN
admet-295	82	47	of	of	ADP
admet-295	82	48	tdp	tdp	NOUN
admet-295	82	49	[	[	X
admet-295	82	50	3	3	NUM
admet-295	82	51	]	]	PUNCT
admet-295	82	52	.	.	PUNCT
admet-295	83	1	spontaneous	spontaneous	ADJ
admet-295	83	2	reporting	reporting	NOUN
admet-295	83	3	data	datum	NOUN
admet-295	83	4	must	must	AUX
admet-295	83	5	of	of	ADP
admet-295	83	6	course	course	NOUN
admet-295	83	7	be	be	AUX
admet-295	83	8	interpreted	interpret	VERB
admet-295	83	9	with	with	ADP
admet-295	83	10	great	great	ADJ
admet-295	83	11	caution	caution	NOUN
admet-295	83	12	but	but	CCONJ
admet-295	83	13	although	although	SCONJ
admet-295	83	14	crizotinib	crizotinib	NOUN
admet-295	83	15	,	,	PUNCT
admet-295	83	16	dasatinib	dasatinib	NOUN
admet-295	83	17	,	,	PUNCT
admet-295	83	18	vandetanib	vandetanib	NOUN
admet-295	83	19	and	and	CCONJ
admet-295	83	20	nilotinib	nilotinib	NOUN
admet-295	83	21	were	be	AUX
admet-295	83	22	associated	associate	VERB
admet-295	83	23	with	with	ADP
admet-295	83	24	14	14	NUM
admet-295	83	25	,	,	PUNCT
admet-295	83	26	35	35	NUM
admet-295	83	27	,	,	PUNCT
admet-295	83	28	57	57	NUM
admet-295	83	29	and	and	CCONJ
admet-295	83	30	246	246	NUM
admet-295	83	31	reports	report	NOUN
admet-295	83	32	of	of	ADP
admet-295	83	33	qtc	qtc	PROPN
admet-295	83	34	interval	interval	NOUN
admet-295	83	35	prolongation	prolongation	NOUN
admet-295	83	36	during	during	ADP
admet-295	83	37	their	their	PRON
admet-295	83	38	post	post	ADJ
admet-295	83	39	-	-	ADJ
admet-295	83	40	marketing	marketing	ADJ
admet-295	83	41	use	use	NOUN
admet-295	83	42	,	,	PUNCT
admet-295	83	43	the	the	DET
admet-295	83	44	corresponding	correspond	VERB
admet-295	83	45	number	number	NOUN
admet-295	83	46	of	of	ADP
admet-295	83	47	reports	report	NOUN
admet-295	83	48	of	of	ADP
admet-295	83	49	tdp	tdp	NOUN
admet-295	83	50	were	be	AUX
admet-295	83	51	only	only	ADV
admet-295	83	52	0	0	NUM
admet-295	83	53	,	,	PUNCT
admet-295	83	54	1	1	NUM
admet-295	83	55	,	,	PUNCT
admet-295	83	56	2	2	NUM
admet-295	83	57	and	and	CCONJ
admet-295	83	58	3	3	NUM
admet-295	83	59	,	,	PUNCT
admet-295	83	60	respectively	respectively	ADV
admet-295	83	61	,	,	PUNCT
admet-295	83	62	thus	thus	ADV
admet-295	83	63	further	far	ADV
admet-295	83	64	emphasising	emphasise	VERB
admet-295	83	65	that	that	SCONJ
admet-295	83	66	not	not	PART
admet-295	83	67	all	all	DET
admet-295	83	68	events	event	NOUN
admet-295	83	69	rashmi	rashmi	PROPN
admet-295	83	70	shah	shah	PROPN
admet-295	83	71	admet	admet	PROPN
admet-295	83	72	&	&	CCONJ
admet-295	83	73	dmpk	dmpk	PROPN
admet-295	83	74	4(3	4(3	NUM
admet-295	83	75	)	)	PUNCT
admet-295	83	76	(	(	PUNCT
admet-295	83	77	2016	2016	NUM
admet-295	83	78	)	)	PUNCT
admet-295	83	79	212	212	NUM
admet-295	83	80	-	-	SYM
admet-295	83	81	231	231	NUM
admet-295	83	82	218	218	NUM
admet-295	83	83	of	of	ADP
admet-295	83	84	qt	qt	NOUN
admet-295	83	85	interval	interval	NOUN
admet-295	83	86	prolongations	prolongation	NOUN
admet-295	83	87	degenerate	degenerate	VERB
admet-295	83	88	into	into	ADP
admet-295	83	89	tdp	tdp	NOUN
admet-295	83	90	and	and	CCONJ
admet-295	83	91	the	the	DET
admet-295	83	92	rarity	rarity	NOUN
admet-295	83	93	of	of	ADP
admet-295	83	94	this	this	DET
admet-295	83	95	potentially	potentially	ADV
admet-295	83	96	fatal	fatal	ADJ
admet-295	83	97	proarrhythmia	proarrhythmia	NOUN
admet-295	83	98	.	.	PUNCT
admet-295	84	1	although	although	SCONJ
admet-295	84	2	there	there	PRON
admet-295	84	3	were	be	VERB
admet-295	84	4	a	a	DET
admet-295	84	5	total	total	NOUN
admet-295	84	6	of	of	ADP
admet-295	84	7	220	220	NUM
admet-295	84	8	reports	report	NOUN
admet-295	84	9	of	of	ADP
admet-295	84	10	sudden	sudden	ADJ
admet-295	84	11	death	death	NOUN
admet-295	84	12	,	,	PUNCT
admet-295	84	13	there	there	PRON
admet-295	84	14	was	be	VERB
admet-295	84	15	similar	similar	ADJ
admet-295	84	16	discordance	discordance	NOUN
admet-295	84	17	between	between	ADP
admet-295	84	18	the	the	DET
admet-295	84	19	qt	qt	NOUN
admet-295	84	20	-	-	PUNCT
admet-295	84	21	liability	liability	NOUN
admet-295	84	22	of	of	ADP
admet-295	84	23	a	a	DET
admet-295	84	24	drug	drug	NOUN
admet-295	84	25	and	and	CCONJ
admet-295	84	26	the	the	DET
admet-295	84	27	number	number	NOUN
admet-295	84	28	of	of	ADP
admet-295	84	29	reports	report	NOUN
admet-295	84	30	of	of	ADP
admet-295	84	31	sudden	sudden	ADJ
admet-295	84	32	death	death	NOUN
admet-295	84	33	associated	associate	VERB
admet-295	84	34	with	with	ADP
admet-295	84	35	it	it	PRON
admet-295	84	36	.	.	PUNCT
admet-295	85	1	kloth	kloth	PROPN
admet-295	85	2	et	et	PROPN
admet-295	85	3	al	al	PROPN
admet-295	85	4	.	.	PUNCT
admet-295	86	1	[	[	X
admet-295	86	2	66	66	NUM
admet-295	86	3	]	]	PUNCT
admet-295	86	4	have	have	AUX
admet-295	86	5	also	also	ADV
admet-295	86	6	reported	report	VERB
admet-295	86	7	a	a	DET
admet-295	86	8	post	post	ADJ
admet-295	86	9	-	-	ADJ
admet-295	86	10	marketing	marketing	ADJ
admet-295	86	11	observational	observational	ADJ
admet-295	86	12	study	study	NOUN
admet-295	86	13	of	of	ADP
admet-295	86	14	363	363	NUM
admet-295	86	15	patients	patient	NOUN
admet-295	86	16	who	who	PRON
admet-295	86	17	were	be	AUX
admet-295	86	18	eligible	eligible	ADJ
admet-295	86	19	for	for	ADP
admet-295	86	20	the	the	DET
admet-295	86	21	analyses	analysis	NOUN
admet-295	86	22	of	of	ADP
admet-295	86	23	qtc	qtc	PROPN
admet-295	86	24	interval	interval	NOUN
admet-295	86	25	before	before	ADV
admet-295	86	26	and	and	CCONJ
admet-295	86	27	during	during	ADP
admet-295	86	28	treatment	treatment	NOUN
admet-295	86	29	with	with	ADP
admet-295	86	30	erlotinib	erlotinib	NOUN
admet-295	86	31	,	,	PUNCT
admet-295	86	32	gefitinib	gefitinib	NOUN
admet-295	86	33	,	,	PUNCT
admet-295	86	34	imatinib	imatinib	NOUN
admet-295	86	35	,	,	PUNCT
admet-295	86	36	lapatinib	lapatinib	PROPN
admet-295	86	37	,	,	PUNCT
admet-295	86	38	pazopanib	pazopanib	NOUN
admet-295	86	39	,	,	PUNCT
admet-295	86	40	sorafenib	sorafenib	NOUN
admet-295	86	41	,	,	PUNCT
admet-295	86	42	sunitinib	sunitinib	NOUN
admet-295	86	43	or	or	CCONJ
admet-295	86	44	vemurafenib	vemurafenib	NOUN
admet-295	86	45	.	.	PUNCT
admet-295	87	1	the	the	DET
admet-295	87	2	median	median	ADJ
admet-295	87	3	on	on	ADP
admet-295	87	4	-	-	PUNCT
admet-295	87	5	treatment	treatment	NOUN
admet-295	87	6	time	time	NOUN
admet-295	87	7	before	before	SCONJ
admet-295	87	8	the	the	DET
admet-295	87	9	ecg	ecg	PROPN
admet-295	87	10	was	be	AUX
admet-295	87	11	performed	perform	VERB
admet-295	87	12	was	be	AUX
admet-295	87	13	43	43	NUM
admet-295	87	14	days	day	NOUN
admet-295	87	15	.	.	PUNCT
admet-295	88	1	mean	mean	VERB
admet-295	88	2	(	(	PUNCT
admet-295	88	3	range	range	NOUN
admet-295	88	4	)	)	PUNCT
admet-295	88	5	qtc	qtc	PROPN
admet-295	88	6	intervals	interval	NOUN
admet-295	88	7	were	be	AUX
admet-295	88	8	401	401	NUM
admet-295	88	9	(	(	PUNCT
admet-295	88	10	388–415	388–415	NUM
admet-295	88	11	)	)	PUNCT
admet-295	88	12	ms	ms	NOUN
admet-295	88	13	at	at	ADP
admet-295	88	14	baseline	baseline	NOUN
admet-295	88	15	and	and	CCONJ
admet-295	88	16	415	415	NUM
admet-295	88	17	(	(	PUNCT
admet-295	88	18	397–431	397–431	NUM
admet-295	88	19	)	)	PUNCT
admet-295	88	20	ms	ms	NOUN
admet-295	88	21	following	follow	VERB
admet-295	88	22	therapy	therapy	NOUN
admet-295	88	23	.	.	PUNCT
admet-295	89	1	a	a	DET
admet-295	89	2	total	total	NOUN
admet-295	89	3	of	of	ADP
admet-295	89	4	33	33	NUM
admet-295	89	5	patients	patient	NOUN
admet-295	89	6	(	(	PUNCT
admet-295	89	7	9.1	9.1	NUM
admet-295	89	8	%	%	NOUN
admet-295	89	9	)	)	PUNCT
admet-295	89	10	were	be	AUX
admet-295	89	11	characterised	characterise	VERB
admet-295	89	12	by	by	ADP
admet-295	89	13	an	an	DET
admet-295	89	14	increased	increase	VERB
admet-295	89	15	grade	grade	NOUN
admet-295	89	16	of	of	ADP
admet-295	89	17	common	common	ADJ
admet-295	89	18	terminology	terminology	NOUN
admet-295	89	19	criteria	criterion	NOUN
admet-295	89	20	for	for	ADP
admet-295	89	21	adverse	adverse	ADJ
admet-295	89	22	events	event	NOUN
admet-295	89	23	(	(	PUNCT
admet-295	89	24	ctcae	ctcae	NOUN
admet-295	89	25	)	)	PUNCT
admet-295	89	26	.	.	PUNCT
admet-295	90	1	only	only	ADV
admet-295	90	2	two	two	NUM
admet-295	90	3	individuals	individual	NOUN
admet-295	90	4	passed	pass	VERB
admet-295	90	5	from	from	ADP
admet-295	90	6	grade	grade	NOUN
admet-295	90	7	1	1	NUM
admet-295	90	8	to	to	ADP
admet-295	90	9	grade	grade	NOUN
admet-295	90	10	2	2	NUM
admet-295	90	11	or	or	CCONJ
admet-295	90	12	3	3	NUM
admet-295	90	13	and	and	CCONJ
admet-295	90	14	nine	nine	NUM
admet-295	90	15	patients	patient	NOUN
admet-295	90	16	(	(	PUNCT
admet-295	90	17	2.5	2.5	NUM
admet-295	90	18	%	%	NOUN
admet-295	90	19	)	)	PUNCT
admet-295	90	20	had	have	VERB
admet-295	90	21	a	a	DET
admet-295	90	22	decrease	decrease	NOUN
admet-295	90	23	in	in	ADP
admet-295	90	24	their	their	PRON
admet-295	90	25	ctcae	ctcae	NOUN
admet-295	90	26	grade	grade	NOUN
admet-295	90	27	for	for	ADP
admet-295	90	28	qtc	qtc	PROPN
admet-295	90	29	interval	interval	NOUN
admet-295	90	30	.	.	PUNCT
admet-295	91	1	however	however	ADV
admet-295	91	2	,	,	PUNCT
admet-295	91	3	321	321	NUM
admet-295	91	4	(	(	PUNCT
admet-295	91	5	88.4	88.4	NUM
admet-295	91	6	%	%	NOUN
admet-295	91	7	)	)	PUNCT
admet-295	91	8	patients	patient	NOUN
admet-295	91	9	did	do	AUX
admet-295	91	10	not	not	PART
admet-295	91	11	have	have	VERB
admet-295	91	12	a	a	DET
admet-295	91	13	change	change	NOUN
admet-295	91	14	in	in	ADP
admet-295	91	15	their	their	PRON
admet-295	91	16	ctcae	ctcae	NOUN
admet-295	91	17	grade	grade	NOUN
admet-295	91	18	after	after	ADP
admet-295	91	19	the	the	DET
admet-295	91	20	start	start	NOUN
admet-295	91	21	of	of	ADP
admet-295	91	22	pki	pki	PROPN
admet-295	91	23	treatment	treatment	NOUN
admet-295	91	24	.	.	PUNCT
admet-295	92	1	only	only	ADV
admet-295	92	2	five	five	NUM
admet-295	92	3	patients	patient	NOUN
admet-295	92	4	(	(	PUNCT
admet-295	92	5	1.4	1.4	NUM
admet-295	92	6	%	%	NOUN
admet-295	92	7	)	)	PUNCT
admet-295	92	8	developed	develop	VERB
admet-295	92	9	qtc	qtc	PROPN
admet-295	92	10			NUM
admet-295	92	11	500	500	NUM
admet-295	92	12	ms	ms	NOUN
admet-295	92	13	after	after	ADP
admet-295	92	14	starting	start	VERB
admet-295	92	15	the	the	DET
admet-295	92	16	therapy	therapy	NOUN
admet-295	92	17	,	,	PUNCT
admet-295	92	18	with	with	ADP
admet-295	92	19	all	all	PRON
admet-295	92	20	of	of	ADP
admet-295	92	21	them	they	PRON
admet-295	92	22	experiencing	experience	VERB
admet-295	92	23	an	an	DET
admet-295	92	24	increase	increase	NOUN
admet-295	92	25	of	of	ADP
admet-295	92	26	100	100	PROPN
admet-295	92	27	ms	ms	PROPN
admet-295	92	28	from	from	ADP
admet-295	92	29	baseline	baseline	PROPN
admet-295	92	30	.	.	PUNCT
admet-295	93	1	despite	despite	SCONJ
admet-295	93	2	this	this	DET
admet-295	93	3	marked	mark	VERB
admet-295	93	4	increase	increase	NOUN
admet-295	93	5	from	from	ADP
admet-295	93	6	baseline	baseline	NOUN
admet-295	93	7	,	,	PUNCT
admet-295	93	8	none	none	NOUN
admet-295	93	9	was	be	AUX
admet-295	93	10	reported	report	VERB
admet-295	93	11	to	to	PART
admet-295	93	12	have	have	VERB
admet-295	93	13	a	a	DET
admet-295	93	14	proarrhythmia	proarrhythmia	NOUN
admet-295	93	15	.	.	PUNCT
admet-295	94	1	one	one	NUM
admet-295	94	2	potential	potential	ADJ
admet-295	94	3	explanation	explanation	NOUN
admet-295	94	4	for	for	ADP
admet-295	94	5	the	the	DET
admet-295	94	6	above	above	ADJ
admet-295	94	7	discordance	discordance	NOUN
admet-295	94	8	,	,	PUNCT
admet-295	94	9	also	also	ADV
admet-295	94	10	observed	observe	VERB
admet-295	94	11	all	all	ADV
admet-295	94	12	too	too	ADV
admet-295	94	13	often	often	ADV
admet-295	94	14	with	with	ADP
admet-295	94	15	drugs	drug	NOUN
admet-295	94	16	in	in	ADP
admet-295	94	17	other	other	ADJ
admet-295	94	18	pharmacological	pharmacological	NOUN
admet-295	94	19	or	or	CCONJ
admet-295	94	20	therapeutic	therapeutic	ADJ
admet-295	94	21	classes	class	NOUN
admet-295	94	22	,	,	PUNCT
admet-295	94	23	is	be	AUX
admet-295	94	24	that	that	SCONJ
admet-295	94	25	the	the	DET
admet-295	94	26	pkis	pkis	NOUN
admet-295	94	27	concerned	concerned	ADJ
admet-295	94	28	may	may	AUX
admet-295	94	29	have	have	VERB
admet-295	94	30	a	a	DET
admet-295	94	31	risk	risk	NOUN
admet-295	94	32	-	-	PUNCT
admet-295	94	33	mitigating	mitigate	VERB
admet-295	94	34	inhibitory	inhibitory	ADJ
admet-295	94	35	effect	effect	NOUN
admet-295	94	36	on	on	ADP
admet-295	94	37	other	other	ADJ
admet-295	94	38	ion	ion	NOUN
admet-295	94	39	currents	current	NOUN
admet-295	94	40	involved	involve	VERB
admet-295	94	41	in	in	ADP
admet-295	94	42	apd	apd	PROPN
admet-295	94	43	,	,	PUNCT
admet-295	94	44	such	such	ADJ
admet-295	94	45	as	as	ADP
admet-295	94	46	the	the	DET
admet-295	94	47	calcium	calcium	NOUN
admet-295	94	48	and/or	and/or	CCONJ
admet-295	94	49	late	late	ADJ
admet-295	94	50	sodium	sodium	NOUN
admet-295	94	51	currents	current	NOUN
admet-295	94	52	as	as	SCONJ
admet-295	94	53	explained	explain	VERB
admet-295	94	54	earlier	early	ADV
admet-295	94	55	[	[	X
admet-295	94	56	48	48	NUM
admet-295	94	57	-	-	SYM
admet-295	94	58	51	51	NUM
admet-295	94	59	]	]	PUNCT
admet-295	94	60	.	.	PUNCT
admet-295	95	1	whether	whether	SCONJ
admet-295	95	2	or	or	CCONJ
admet-295	95	3	not	not	PART
admet-295	95	4	pkis	pki	NOUN
admet-295	95	5	generally	generally	ADV
admet-295	95	6	inhibit	inhibit	VERB
admet-295	95	7	these	these	DET
admet-295	95	8	ion	ion	NOUN
admet-295	95	9	channels	channel	NOUN
admet-295	95	10	is	be	AUX
admet-295	95	11	at	at	ADP
admet-295	95	12	present	present	ADJ
admet-295	95	13	unclear	unclear	ADJ
admet-295	95	14	since	since	SCONJ
admet-295	95	15	they	they	PRON
admet-295	95	16	are	be	AUX
admet-295	95	17	not	not	PART
admet-295	95	18	routinely	routinely	ADV
admet-295	95	19	studied	study	VERB
admet-295	95	20	for	for	ADP
admet-295	95	21	these	these	DET
admet-295	95	22	effects	effect	NOUN
admet-295	95	23	.	.	PUNCT
admet-295	96	1	protein	protein	NOUN
admet-295	96	2	kinases	kinase	NOUN
admet-295	96	3	activate	activate	VERB
admet-295	96	4	downstream	downstream	ADJ
admet-295	96	5	signalling	signal	VERB
admet-295	96	6	via	via	ADP
admet-295	96	7	phosphoinositide	phosphoinositide	NOUN
admet-295	96	8	3	3	NUM
admet-295	96	9	-	-	PUNCT
admet-295	96	10	kinase	kinase	NOUN
admet-295	96	11	(	(	PUNCT
admet-295	96	12	pi3k	pi3k	PROPN
admet-295	96	13	)	)	PUNCT
admet-295	96	14	.	.	PUNCT
admet-295	97	1	the	the	DET
admet-295	97	2	complexity	complexity	NOUN
admet-295	97	3	of	of	ADP
admet-295	97	4	the	the	DET
admet-295	97	5	interactions	interaction	NOUN
admet-295	97	6	is	be	AUX
admet-295	97	7	demonstrated	demonstrate	VERB
admet-295	97	8	by	by	ADP
admet-295	97	9	one	one	NUM
admet-295	97	10	study	study	NOUN
admet-295	97	11	reporting	report	VERB
admet-295	97	12	that	that	SCONJ
admet-295	97	13	chronic	chronic	NOUN
admet-295	97	14	but	but	CCONJ
admet-295	97	15	not	not	PART
admet-295	97	16	acute	acute	ADJ
admet-295	97	17	exposure	exposure	NOUN
admet-295	97	18	to	to	ADP
admet-295	97	19	nilotinib	nilotinib	NOUN
admet-295	97	20	prolonged	prolong	VERB
admet-295	97	21	the	the	DET
admet-295	97	22	apd	apd	PROPN
admet-295	97	23	in	in	ADP
admet-295	97	24	canine	canine	NOUN
admet-295	97	25	cardiomyocytes	cardiomyocyte	NOUN
admet-295	97	26	,	,	PUNCT
admet-295	97	27	an	an	DET
admet-295	97	28	effect	effect	NOUN
admet-295	97	29	which	which	PRON
admet-295	97	30	was	be	AUX
admet-295	97	31	reversed	reverse	VERB
admet-295	97	32	by	by	ADP
admet-295	97	33	intracellular	intracellular	ADJ
admet-295	97	34	dialysis	dialysis	NOUN
admet-295	97	35	with	with	ADP
admet-295	97	36	phosphatidylinositol	phosphatidylinositol	NOUN
admet-295	97	37	3,4,5	3,4,5	NOUN
admet-295	97	38	-	-	NOUN
admet-295	97	39	trisphosphate	trisphosphate	NOUN
admet-295	97	40	(	(	PUNCT
admet-295	97	41	which	which	PRON
admet-295	97	42	is	be	AUX
admet-295	97	43	a	a	DET
admet-295	97	44	downstream	downstream	ADJ
admet-295	97	45	effector	effector	NOUN
admet-295	97	46	of	of	ADP
admet-295	97	47	pi3k	pi3k	PROPN
admet-295	97	48	)	)	PUNCT
admet-295	98	1	[	[	X
admet-295	98	2	67	67	NUM
admet-295	98	3	,	,	PUNCT
admet-295	98	4	68	68	NUM
admet-295	98	5	]	]	PUNCT
admet-295	98	6	.	.	PUNCT
admet-295	99	1	these	these	DET
admet-295	99	2	investigators	investigator	NOUN
admet-295	99	3	also	also	ADV
admet-295	99	4	observed	observe	VERB
admet-295	99	5	that	that	SCONJ
admet-295	99	6	apd	apd	PROPN
admet-295	99	7	prolongation	prolongation	NOUN
admet-295	99	8	by	by	ADP
admet-295	99	9	nilotinib	nilotinib	NOUN
admet-295	99	10	was	be	AUX
admet-295	99	11	mediated	mediate	VERB
admet-295	99	12	by	by	ADP
admet-295	99	13	decreases	decrease	NOUN
admet-295	99	14	in	in	ADP
admet-295	99	15	both	both	CCONJ
admet-295	99	16	the	the	DET
admet-295	99	17	rapid	rapid	ADJ
admet-295	99	18	(	(	PUNCT
admet-295	99	19	ikr	ikr	INTJ
admet-295	99	20	)	)	PUNCT
admet-295	99	21	and	and	CCONJ
admet-295	99	22	slow	slow	ADJ
admet-295	99	23	(	(	PUNCT
admet-295	99	24	iks	iks	PROPN
admet-295	99	25	)	)	PUNCT
admet-295	99	26	components	component	NOUN
admet-295	99	27	of	of	ADP
admet-295	99	28	the	the	DET
admet-295	99	29	delayed	delay	VERB
admet-295	99	30	rectifier	rectifier	NOUN
admet-295	99	31	potassium	potassium	NOUN
admet-295	99	32	current	current	NOUN
admet-295	99	33	,	,	PUNCT
admet-295	99	34	as	as	ADV
admet-295	99	35	well	well	ADV
admet-295	99	36	as	as	ADP
admet-295	99	37	by	by	ADP
admet-295	99	38	an	an	DET
admet-295	99	39	increase	increase	NOUN
admet-295	99	40	in	in	ADP
admet-295	99	41	late	late	ADJ
admet-295	99	42	sodium	sodium	NOUN
admet-295	99	43	current	current	NOUN
admet-295	99	44	(	(	PUNCT
admet-295	99	45	an	an	DET
admet-295	99	46	effect	effect	NOUN
admet-295	99	47	which	which	PRON
admet-295	99	48	in	in	ADP
admet-295	99	49	theory	theory	NOUN
admet-295	99	50	ought	ought	AUX
admet-295	99	51	to	to	PART
admet-295	99	52	aggravate	aggravate	VERB
admet-295	99	53	the	the	DET
admet-295	99	54	proarrhythmia	proarrhythmia	NOUN
admet-295	99	55	risk	risk	NOUN
admet-295	99	56	[	[	X
admet-295	99	57	69	69	NUM
admet-295	99	58	]	]	NUM
admet-295	99	59	)	)	PUNCT
admet-295	99	60	;	;	PUNCT
admet-295	99	61	however	however	ADV
admet-295	99	62	,	,	PUNCT
admet-295	99	63	nilotinib	nilotinib	NOUN
admet-295	99	64	also	also	ADV
admet-295	99	65	reduced	reduce	VERB
admet-295	99	66	the	the	DET
admet-295	99	67	calcium	calcium	NOUN
admet-295	99	68	current	current	NOUN
admet-295	99	69	.	.	PUNCT
admet-295	100	1	one	one	NUM
admet-295	100	2	obvious	obvious	ADJ
admet-295	100	3	and	and	CCONJ
admet-295	100	4	hitherto	hitherto	NOUN
admet-295	100	5	unquantified	unquantifie	VERB
admet-295	100	6	by	by	ADP
admet-295	100	7	-	-	PUNCT
admet-295	100	8	product	product	NOUN
admet-295	100	9	of	of	ADP
admet-295	100	10	the	the	DET
admet-295	100	11	“	"	PUNCT
admet-295	100	12	qt	qt	NOUN
admet-295	100	13	-	-	PUNCT
admet-295	100	14	phobia	phobia	NOUN
admet-295	100	15	”	"	PUNCT
admet-295	100	16	is	be	AUX
admet-295	100	17	that	that	SCONJ
admet-295	100	18	many	many	ADJ
admet-295	100	19	new	new	ADJ
admet-295	100	20	candidate	candidate	NOUN
admet-295	100	21	compounds	compound	NOUN
admet-295	100	22	are	be	AUX
admet-295	100	23	abandoned	abandon	VERB
admet-295	100	24	very	very	ADV
admet-295	100	25	early	early	ADV
admet-295	100	26	in	in	ADP
admet-295	100	27	their	their	PRON
admet-295	100	28	development	development	NOUN
admet-295	100	29	without	without	ADP
admet-295	100	30	fully	fully	ADV
admet-295	100	31	exploring	explore	VERB
admet-295	100	32	their	their	PRON
admet-295	100	33	potential	potential	NOUN
admet-295	100	34	for	for	ADP
admet-295	100	35	significant	significant	ADJ
admet-295	100	36	therapeutic	therapeutic	ADJ
admet-295	100	37	benefit	benefit	NOUN
admet-295	100	38	.	.	PUNCT
admet-295	101	1	the	the	DET
admet-295	101	2	unfortunate	unfortunate	ADJ
admet-295	101	3	reality	reality	NOUN
admet-295	101	4	,	,	PUNCT
admet-295	101	5	however	however	ADV
admet-295	101	6	,	,	PUNCT
admet-295	101	7	is	be	AUX
admet-295	101	8	that	that	SCONJ
admet-295	101	9	the	the	DET
admet-295	101	10	“	"	PUNCT
admet-295	101	11	qt	qt	NOUN
admet-295	101	12	-	-	PUNCT
admet-295	101	13	liability	liability	NOUN
admet-295	101	14	”	"	PUNCT
admet-295	101	15	of	of	ADP
admet-295	101	16	a	a	DET
admet-295	101	17	drug	drug	NOUN
admet-295	101	18	is	be	AUX
admet-295	101	19	only	only	ADV
admet-295	101	20	an	an	DET
admet-295	101	21	imperfect	imperfect	ADJ
admet-295	101	22	predictor	predictor	NOUN
admet-295	101	23	of	of	ADP
admet-295	101	24	the	the	DET
admet-295	101	25	proarrhythmia	proarrhythmia	NOUN
admet-295	101	26	risk	risk	NOUN
admet-295	101	27	,	,	PUNCT
admet-295	101	28	and	and	CCONJ
admet-295	101	29	just	just	ADV
admet-295	101	30	one	one	NUM
admet-295	101	31	component	component	NOUN
admet-295	101	32	of	of	ADP
admet-295	101	33	its	its	PRON
admet-295	101	34	much	much	ADV
admet-295	101	35	wider	wide	ADJ
admet-295	101	36	cardiovascular	cardiovascular	ADJ
admet-295	101	37	and	and	CCONJ
admet-295	101	38	overall	overall	ADJ
admet-295	101	39	safety	safety	NOUN
admet-295	101	40	.	.	PUNCT
admet-295	102	1	of	of	ADP
admet-295	102	2	equal	equal	ADJ
admet-295	102	3	concern	concern	NOUN
admet-295	102	4	with	with	ADP
admet-295	102	5	regard	regard	NOUN
admet-295	102	6	to	to	ADP
admet-295	102	7	determining	determine	VERB
admet-295	102	8	the	the	DET
admet-295	102	9	duration	duration	NOUN
admet-295	102	10	of	of	ADP
admet-295	102	11	qtc	qtc	PROPN
admet-295	102	12	interval	interval	NOUN
admet-295	102	13	in	in	ADP
admet-295	102	14	routine	routine	ADJ
admet-295	102	15	clinical	clinical	ADJ
admet-295	102	16	practice	practice	NOUN
admet-295	102	17	is	be	AUX
admet-295	102	18	the	the	DET
admet-295	102	19	fact	fact	NOUN
admet-295	102	20	that	that	SCONJ
admet-295	102	21	the	the	DET
admet-295	102	22	qtc	qtc	PROPN
admet-295	102	23	interval	interval	NOUN
admet-295	102	24	value	value	NOUN
admet-295	102	25	depends	depend	VERB
admet-295	102	26	on	on	ADP
admet-295	102	27	the	the	DET
admet-295	102	28	correction	correction	NOUN
admet-295	102	29	formula	formula	NOUN
admet-295	102	30	applied	apply	VERB
admet-295	102	31	to	to	ADP
admet-295	102	32	the	the	DET
admet-295	102	33	measured	measure	VERB
admet-295	102	34	qt	qt	NOUN
admet-295	102	35	interval	interval	NOUN
admet-295	102	36	.	.	PUNCT
admet-295	103	1	the	the	DET
admet-295	103	2	most	most	ADV
admet-295	103	3	common	common	ADJ
admet-295	103	4	formula	formula	NOUN
admet-295	103	5	applied	apply	VERB
admet-295	103	6	in	in	ADP
admet-295	103	7	routine	routine	ADJ
admet-295	103	8	clinical	clinical	ADJ
admet-295	103	9	practice	practice	NOUN
admet-295	103	10	is	be	AUX
admet-295	103	11	the	the	DET
admet-295	103	12	bazett	bazett	PROPN
admet-295	103	13	’s	’s	PART
admet-295	103	14	formula	formula	NOUN
admet-295	103	15	(	(	PUNCT
admet-295	103	16	that	that	PRON
admet-295	103	17	computes	compute	VERB
admet-295	103	18	qtcb	qtcb	VERB
admet-295	103	19	interval	interval	NOUN
admet-295	103	20	)	)	PUNCT
admet-295	103	21	which	which	PRON
admet-295	103	22	has	have	AUX
admet-295	103	23	been	be	AUX
admet-295	103	24	shown	show	VERB
admet-295	103	25	to	to	PART
admet-295	103	26	be	be	AUX
admet-295	103	27	highly	highly	ADV
admet-295	103	28	imprecise	imprecise	ADJ
admet-295	103	29	when	when	SCONJ
admet-295	103	30	there	there	PRON
admet-295	103	31	are	be	VERB
admet-295	103	32	significant	significant	ADJ
admet-295	103	33	changes	change	NOUN
admet-295	103	34	in	in	ADP
admet-295	103	35	heart	heart	NOUN
admet-295	103	36	rate	rate	NOUN
admet-295	103	37	[	[	X
admet-295	103	38	70	70	NUM
admet-295	103	39	-	-	SYM
admet-295	103	40	73	73	NUM
admet-295	103	41	]	]	PUNCT
admet-295	103	42	.	.	PUNCT
admet-295	104	1	although	although	SCONJ
admet-295	104	2	regulatory	regulatory	ADJ
admet-295	104	3	documents	document	NOUN
admet-295	104	4	and	and	CCONJ
admet-295	104	5	drug	drug	NOUN
admet-295	104	6	labels	label	NOUN
admet-295	104	7	provide	provide	VERB
admet-295	104	8	guidance	guidance	NOUN
admet-295	104	9	on	on	ADP
admet-295	104	10	dose	dose	NOUN
admet-295	104	11	adjustment	adjustment	NOUN
admet-295	104	12	in	in	ADP
admet-295	104	13	patients	patient	NOUN
admet-295	104	14	who	who	PRON
admet-295	104	15	develop	develop	VERB
admet-295	104	16	,	,	PUNCT
admet-295	104	17	or	or	CCONJ
admet-295	104	18	are	be	AUX
admet-295	104	19	at	at	ADP
admet-295	104	20	risk	risk	NOUN
admet-295	104	21	of	of	ADP
admet-295	104	22	developing	develop	VERB
admet-295	104	23	qtc	qtc	PROPN
admet-295	104	24	prolongation	prolongation	NOUN
admet-295	104	25	,	,	PUNCT
admet-295	104	26	they	they	PRON
admet-295	104	27	provide	provide	VERB
admet-295	104	28	no	no	DET
admet-295	104	29	guidance	guidance	NOUN
admet-295	104	30	on	on	ADP
admet-295	104	31	the	the	DET
admet-295	104	32	formula	formula	NOUN
admet-295	104	33	to	to	PART
admet-295	104	34	be	be	AUX
admet-295	104	35	used	use	VERB
admet-295	104	36	.	.	PUNCT
admet-295	105	1	similarly	similarly	ADV
admet-295	105	2	,	,	PUNCT
admet-295	105	3	the	the	DET
admet-295	105	4	us	us	PROPN
admet-295	105	5	national	national	PROPN
admet-295	105	6	cancer	cancer	PROPN
admet-295	105	7	institute	institute	PROPN
admet-295	105	8	,	,	PUNCT
admet-295	105	9	which	which	PRON
admet-295	105	10	has	have	AUX
admet-295	105	11	recently	recently	ADV
admet-295	105	12	modified	modify	VERB
admet-295	105	13	the	the	DET
admet-295	105	14	criteria	criterion	NOUN
admet-295	105	15	for	for	ADP
admet-295	105	16	qtc	qtc	PROPN
admet-295	105	17	interval	interval	NOUN
admet-295	105	18	in	in	ADP
admet-295	105	19	the	the	DET
admet-295	105	20	latest	late	ADJ
admet-295	105	21	version	version	NOUN
admet-295	105	22	of	of	ADP
admet-295	105	23	ctcae	ctcae	NOUN
admet-295	105	24	(	(	PUNCT
admet-295	105	25	v4.03	v4.03	NOUN
admet-295	105	26	)	)	PUNCT
admet-295	106	1	[	[	X
admet-295	106	2	74	74	NUM
admet-295	106	3	]	]	PUNCT
admet-295	106	4	,	,	PUNCT
admet-295	106	5	provides	provide	VERB
admet-295	106	6	no	no	DET
admet-295	106	7	guidance	guidance	NOUN
admet-295	106	8	on	on	ADP
admet-295	106	9	the	the	DET
admet-295	106	10	choice	choice	NOUN
admet-295	106	11	of	of	ADP
admet-295	106	12	a	a	DET
admet-295	106	13	formula	formula	NOUN
admet-295	106	14	for	for	ADP
admet-295	106	15	computing	compute	VERB
admet-295	106	16	qtc	qtc	PROPN
admet-295	106	17	interval	interval	NOUN
admet-295	106	18	duration	duration	NOUN
admet-295	106	19	.	.	PUNCT
admet-295	107	1	it	it	PRON
admet-295	107	2	is	be	AUX
admet-295	107	3	therefore	therefore	ADV
admet-295	107	4	timely	timely	ADJ
admet-295	107	5	to	to	PART
admet-295	107	6	contrast	contrast	VERB
admet-295	107	7	and	and	CCONJ
admet-295	107	8	put	put	VERB
admet-295	107	9	in	in	ADP
admet-295	107	10	perspective	perspective	NOUN
admet-295	107	11	the	the	DET
admet-295	107	12	foregoing	forego	VERB
admet-295	107	13	rarity	rarity	NOUN
admet-295	107	14	of	of	ADP
admet-295	107	15	adverse	adverse	ADJ
admet-295	107	16	clinical	clinical	ADJ
admet-295	107	17	outcomes	outcome	NOUN
admet-295	107	18	from	from	ADP
admet-295	107	19	pki	pki	ADJ
admet-295	107	20	-	-	ADJ
admet-295	107	21	related	relate	VERB
admet-295	107	22	effects	effect	NOUN
admet-295	107	23	on	on	ADP
admet-295	107	24	qtc	qtc	PROPN
admet-295	107	25	interval	interval	NOUN
admet-295	107	26	with	with	ADP
admet-295	107	27	their	their	PRON
admet-295	107	28	effects	effect	NOUN
admet-295	107	29	on	on	ADP
admet-295	107	30	two	two	NUM
admet-295	107	31	specific	specific	ADJ
admet-295	107	32	cardiovascular	cardiovascular	ADJ
admet-295	107	33	effects	effect	NOUN
admet-295	107	34	,	,	PUNCT
admet-295	107	35	lv	lv	PROPN
admet-295	107	36	dysfunction	dysfunction	NOUN
admet-295	107	37	and	and	CCONJ
admet-295	107	38	ates	ate	NOUN
admet-295	107	39	,	,	PUNCT
admet-295	107	40	which	which	PRON
admet-295	107	41	are	be	AUX
admet-295	107	42	of	of	ADP
admet-295	107	43	much	much	ADV
admet-295	107	44	greater	great	ADJ
admet-295	107	45	concern	concern	NOUN
admet-295	107	46	and	and	CCONJ
admet-295	107	47	have	have	VERB
admet-295	107	48	a	a	DET
admet-295	107	49	significant	significant	ADJ
admet-295	107	50	direct	direct	ADJ
admet-295	107	51	impact	impact	NOUN
admet-295	107	52	on	on	ADP
admet-295	107	53	morbidity	morbidity	NOUN
admet-295	107	54	,	,	PUNCT
admet-295	107	55	mortality	mortality	NOUN
admet-295	107	56	and	and	CCONJ
admet-295	107	57	risk	risk	NOUN
admet-295	107	58	/	/	SYM
admet-295	107	59	benefit	benefit	NOUN
admet-295	107	60	.	.	PUNCT
admet-295	108	1	admet	admet	PROPN
admet-295	108	2	&	&	CCONJ
admet-295	108	3	dmpk	dmpk	PROPN
admet-295	108	4	4(3	4(3	NUM
admet-295	108	5	)	)	PUNCT
admet-295	108	6	(	(	PUNCT
admet-295	108	7	2016	2016	NUM
admet-295	108	8	)	)	PUNCT
admet-295	108	9	212	212	NUM
admet-295	108	10	-	-	SYM
admet-295	108	11	231	231	NUM
admet-295	108	12	pkis	pki	NOUN
admet-295	108	13	and	and	CCONJ
admet-295	108	14	qt	qt	NOUN
admet-295	108	15	-	-	PUNCT
admet-295	108	16	phobia	phobia	NOUN
admet-295	108	17	doi	doi	NOUN
admet-295	108	18	:	:	PUNCT
admet-295	108	19	10.5599	10.5599	NUM
admet-295	108	20	/	/	SYM
admet-295	108	21	admet.4.3.295	admet.4.3.295	NOUN
admet-295	108	22	219	219	NUM
admet-295	108	23	left	leave	VERB
admet-295	108	24	ventricular	ventricular	ADJ
admet-295	108	25	dysfunction	dysfunction	NOUN
admet-295	108	26	due	due	ADP
admet-295	108	27	to	to	ADP
admet-295	108	28	protein	protein	NOUN
admet-295	108	29	kinase	kinase	NOUN
admet-295	108	30	inhibitors	inhibitor	NOUN
admet-295	108	31	left	leave	VERB
admet-295	108	32	ventricular	ventricular	ADJ
admet-295	108	33	(	(	PUNCT
admet-295	108	34	lv	lv	PROPN
admet-295	108	35	)	)	PUNCT
admet-295	108	36	dysfunction	dysfunction	NOUN
admet-295	108	37	is	be	AUX
admet-295	108	38	now	now	ADV
admet-295	108	39	a	a	DET
admet-295	108	40	well	well	ADV
admet-295	108	41	-	-	PUNCT
admet-295	108	42	recognised	recognise	VERB
admet-295	108	43	toxicity	toxicity	NOUN
admet-295	108	44	of	of	ADP
admet-295	108	45	a	a	DET
admet-295	108	46	number	number	NOUN
admet-295	108	47	of	of	ADP
admet-295	108	48	pkis	pki	NOUN
admet-295	108	49	.	.	PUNCT
admet-295	109	1	it	it	PRON
admet-295	109	2	can	can	AUX
admet-295	109	3	range	range	VERB
admet-295	109	4	from	from	ADP
admet-295	109	5	asymptomatic	asymptomatic	PROPN
admet-295	109	6	ecg	ecg	PROPN
admet-295	109	7	changes	change	NOUN
admet-295	109	8	(	(	PUNCT
admet-295	109	9	in	in	ADP
admet-295	109	10	qrs	qrs	PROPN
admet-295	109	11	and	and	CCONJ
admet-295	109	12	t	t	NOUN
admet-295	109	13	-	-	PUNCT
admet-295	109	14	waves	wave	NOUN
admet-295	109	15	and	and	CCONJ
admet-295	109	16	st	st	NOUN
admet-295	109	17	-	-	PUNCT
admet-295	109	18	segment	segment	NOUN
admet-295	109	19	)	)	PUNCT
admet-295	109	20	through	through	ADP
admet-295	109	21	decrease	decrease	NOUN
admet-295	109	22	in	in	ADP
admet-295	109	23	lv	lv	PROPN
admet-295	109	24	function	function	NOUN
admet-295	109	25	(	(	PUNCT
admet-295	109	26	detectable	detectable	ADJ
admet-295	109	27	noninvasively	noninvasively	ADV
admet-295	109	28	only	only	ADV
admet-295	109	29	by	by	ADP
admet-295	109	30	echocardiography	echocardiography	NOUN
admet-295	109	31	or	or	CCONJ
admet-295	109	32	radionuclide	radionuclide	NOUN
admet-295	109	33	techniques	technique	NOUN
admet-295	109	34	)	)	PUNCT
admet-295	109	35	to	to	PART
admet-295	109	36	clinically	clinically	ADV
admet-295	109	37	manifest	manifest	VERB
admet-295	109	38	severe	severe	ADJ
admet-295	109	39	congestive	congestive	ADJ
admet-295	109	40	heart	heart	NOUN
admet-295	109	41	failure	failure	NOUN
admet-295	109	42	(	(	PUNCT
admet-295	109	43	chf	chf	NOUN
admet-295	109	44	)	)	PUNCT
admet-295	109	45	and	and	CCONJ
admet-295	109	46	generalised	generalise	VERB
admet-295	109	47	fluid	fluid	ADJ
admet-295	109	48	retention	retention	NOUN
admet-295	109	49	[	[	X
admet-295	109	50	75	75	NUM
admet-295	109	51	-	-	SYM
admet-295	109	52	77	77	NUM
admet-295	109	53	]	]	PUNCT
admet-295	109	54	.	.	PUNCT
admet-295	110	1	although	although	SCONJ
admet-295	110	2	not	not	PART
admet-295	110	3	precisely	precisely	ADV
admet-295	110	4	known	know	VERB
admet-295	110	5	or	or	CCONJ
admet-295	110	6	understood	understand	VERB
admet-295	110	7	,	,	PUNCT
admet-295	110	8	the	the	DET
admet-295	110	9	potential	potential	ADJ
admet-295	110	10	mechanism	mechanism	NOUN
admet-295	110	11	underpinning	underpin	VERB
admet-295	110	12	this	this	DET
admet-295	110	13	effect	effect	NOUN
admet-295	110	14	has	have	AUX
admet-295	110	15	been	be	AUX
admet-295	110	16	reviewed	review	VERB
admet-295	110	17	previously	previously	ADV
admet-295	110	18	by	by	ADP
admet-295	110	19	others	other	NOUN
admet-295	110	20	[	[	X
admet-295	110	21	2	2	NUM
admet-295	110	22	,	,	PUNCT
admet-295	110	23	78	78	NUM
admet-295	110	24	-	-	SYM
admet-295	110	25	81	81	NUM
admet-295	110	26	]	]	PUNCT
admet-295	110	27	.	.	PUNCT
admet-295	111	1	post	post	NOUN
admet-295	111	2	-	-	NOUN
admet-295	111	3	approval	approval	ADJ
admet-295	111	4	,	,	PUNCT
admet-295	111	5	the	the	DET
admet-295	111	6	us	us	PROPN
admet-295	111	7	labels	label	NOUN
admet-295	111	8	of	of	ADP
admet-295	111	9	a	a	DET
admet-295	111	10	number	number	NOUN
admet-295	111	11	of	of	ADP
admet-295	111	12	pkis	pki	NOUN
admet-295	111	13	have	have	AUX
admet-295	111	14	been	be	AUX
admet-295	111	15	revised	revise	VERB
admet-295	111	16	well	well	ADV
admet-295	111	17	after	after	ADP
admet-295	111	18	their	their	PRON
admet-295	111	19	initial	initial	ADJ
admet-295	111	20	approval	approval	NOUN
admet-295	111	21	to	to	PART
admet-295	111	22	include	include	VERB
admet-295	111	23	new	new	ADJ
admet-295	111	24	warnings	warning	NOUN
admet-295	111	25	and	and	CCONJ
admet-295	111	26	precautions	precaution	NOUN
admet-295	111	27	regarding	regard	VERB
admet-295	111	28	the	the	DET
admet-295	111	29	risks	risk	NOUN
admet-295	111	30	of	of	ADP
admet-295	111	31	lv	lv	PROPN
admet-295	111	32	dysfunction	dysfunction	NOUN
admet-295	111	33	and/or	and/or	CCONJ
admet-295	111	34	fluid	fluid	ADJ
admet-295	111	35	retention	retention	NOUN
admet-295	111	36	.	.	PUNCT
admet-295	112	1	these	these	PRON
admet-295	112	2	are	be	AUX
admet-295	112	3	axitinib	axitinib	NOUN
admet-295	112	4	,	,	PUNCT
admet-295	112	5	dabrafenib	dabrafenib	NOUN
admet-295	112	6	,	,	PUNCT
admet-295	112	7	imatinib	imatinib	NOUN
admet-295	112	8	,	,	PUNCT
admet-295	112	9	nilotinib	nilotinib	NOUN
admet-295	112	10	and	and	CCONJ
admet-295	112	11	pazopanib	pazopanib	NOUN
admet-295	112	12	,	,	PUNCT
admet-295	112	13	although	although	SCONJ
admet-295	112	14	there	there	PRON
admet-295	112	15	are	be	VERB
admet-295	112	16	some	some	DET
admet-295	112	17	question	question	NOUN
admet-295	112	18	marks	mark	NOUN
admet-295	112	19	concerning	concern	VERB
admet-295	112	20	the	the	DET
admet-295	112	21	potential	potential	NOUN
admet-295	112	22	of	of	ADP
admet-295	112	23	imatinib	imatinib	NOUN
admet-295	112	24	to	to	PART
admet-295	112	25	induce	induce	VERB
admet-295	112	26	cardiac	cardiac	ADJ
admet-295	112	27	dysfunction	dysfunction	NOUN
admet-295	112	28	.	.	PUNCT
admet-295	113	1	during	during	ADP
admet-295	113	2	its	its	PRON
admet-295	113	3	post	post	ADJ
admet-295	113	4	-	-	ADJ
admet-295	113	5	marketing	marketing	ADJ
admet-295	113	6	use	use	NOUN
admet-295	113	7	as	as	ADP
admet-295	113	8	of	of	ADP
admet-295	113	9	25	25	NUM
admet-295	113	10	february	february	NOUN
admet-295	113	11	2015	2015	NUM
admet-295	113	12	,	,	PUNCT
admet-295	113	13	about	about	ADV
admet-295	113	14	14,700	14,700	NUM
admet-295	113	15	patients	patient	NOUN
admet-295	113	16	worldwide	worldwide	ADV
admet-295	113	17	had	have	AUX
admet-295	113	18	received	receive	VERB
admet-295	113	19	crizotinib	crizotinib	NOUN
admet-295	113	20	since	since	SCONJ
admet-295	113	21	its	its	PRON
admet-295	113	22	approval	approval	NOUN
admet-295	113	23	[	[	X
admet-295	113	24	82	82	NUM
admet-295	113	25	]	]	PUNCT
admet-295	113	26	.	.	PUNCT
admet-295	114	1	forty	forty	NUM
admet-295	114	2	cases	case	NOUN
admet-295	114	3	of	of	ADP
admet-295	114	4	cardiac	cardiac	ADJ
admet-295	114	5	failure	failure	NOUN
admet-295	114	6	had	have	AUX
admet-295	114	7	been	be	AUX
admet-295	114	8	reported	report	VERB
admet-295	114	9	in	in	ADP
admet-295	114	10	the	the	DET
admet-295	114	11	post	post	ADJ
admet-295	114	12	-	-	ADJ
admet-295	114	13	marketing	marketing	ADJ
admet-295	114	14	setting	setting	NOUN
admet-295	114	15	.	.	PUNCT
admet-295	115	1	a	a	DET
admet-295	115	2	review	review	NOUN
admet-295	115	3	by	by	ADP
admet-295	115	4	european	european	ADJ
admet-295	115	5	medicines	medicine	NOUN
admet-295	115	6	regulators	regulator	NOUN
admet-295	115	7	of	of	ADP
admet-295	115	8	data	datum	NOUN
admet-295	115	9	from	from	ADP
admet-295	115	10	clinical	clinical	ADJ
admet-295	115	11	trials	trial	NOUN
admet-295	115	12	and	and	CCONJ
admet-295	115	13	reports	report	NOUN
admet-295	115	14	from	from	ADP
admet-295	115	15	clinical	clinical	ADJ
admet-295	115	16	practice	practice	NOUN
admet-295	115	17	concluded	conclude	VERB
admet-295	115	18	that	that	SCONJ
admet-295	115	19	this	this	DET
admet-295	115	20	side	side	NOUN
admet-295	115	21	effect	effect	NOUN
admet-295	115	22	is	be	AUX
admet-295	115	23	common	common	ADJ
admet-295	115	24	,	,	PUNCT
admet-295	115	25	occurring	occur	VERB
admet-295	115	26	in	in	ADP
admet-295	115	27	1	1	NUM
admet-295	115	28	-	-	SYM
admet-295	115	29	10	10	NUM
admet-295	115	30	%	%	NOUN
admet-295	115	31	of	of	ADP
admet-295	115	32	the	the	DET
admet-295	115	33	patients	patient	NOUN
admet-295	115	34	taking	take	VERB
admet-295	115	35	crizotinib	crizotinib	NOUN
admet-295	115	36	[	[	X
admet-295	115	37	82	82	NUM
admet-295	115	38	]	]	PUNCT
admet-295	115	39	.	.	PUNCT
admet-295	116	1	in	in	ADP
admet-295	116	2	most	most	ADJ
admet-295	116	3	cases	case	NOUN
admet-295	116	4	,	,	PUNCT
admet-295	116	5	cardiac	cardiac	ADJ
admet-295	116	6	failure	failure	NOUN
admet-295	116	7	occurred	occur	VERB
admet-295	116	8	within	within	ADP
admet-295	116	9	one	one	NUM
admet-295	116	10	month	month	NOUN
admet-295	116	11	of	of	ADP
admet-295	116	12	starting	start	VERB
admet-295	116	13	the	the	DET
admet-295	116	14	treatment	treatment	NOUN
admet-295	116	15	and	and	CCONJ
admet-295	116	16	affected	affect	VERB
admet-295	116	17	patients	patient	NOUN
admet-295	116	18	with	with	ADP
admet-295	116	19	or	or	CCONJ
admet-295	116	20	without	without	ADP
admet-295	116	21	pre	pre	ADJ
admet-295	116	22	-	-	ADJ
admet-295	116	23	existing	exist	VERB
admet-295	116	24	cardiac	cardiac	ADJ
admet-295	116	25	disorders	disorder	NOUN
admet-295	116	26	.	.	PUNCT
admet-295	117	1	the	the	DET
admet-295	117	2	reports	report	NOUN
admet-295	117	3	included	include	VERB
admet-295	117	4	cases	case	NOUN
admet-295	117	5	where	where	SCONJ
admet-295	117	6	the	the	DET
admet-295	117	7	evidence	evidence	NOUN
admet-295	117	8	of	of	ADP
admet-295	117	9	symptoms	symptom	NOUN
admet-295	117	10	of	of	ADP
admet-295	117	11	cardiac	cardiac	ADJ
admet-295	117	12	failure	failure	NOUN
admet-295	117	13	resolved	resolve	VERB
admet-295	117	14	after	after	ADP
admet-295	117	15	stopping	stop	VERB
admet-295	117	16	crizotinib	crizotinib	NOUN
admet-295	117	17	and	and	CCONJ
admet-295	117	18	recurred	recur	VERB
admet-295	117	19	when	when	SCONJ
admet-295	117	20	it	it	PRON
admet-295	117	21	was	be	AUX
admet-295	117	22	reintroduced	reintroduce	VERB
admet-295	117	23	.	.	PUNCT
admet-295	118	1	some	some	DET
admet-295	118	2	cases	case	NOUN
admet-295	118	3	had	have	VERB
admet-295	118	4	a	a	DET
admet-295	118	5	fatal	fatal	ADJ
admet-295	118	6	outcome	outcome	NOUN
admet-295	118	7	.	.	PUNCT
admet-295	119	1	it	it	PRON
admet-295	119	2	is	be	AUX
admet-295	119	3	noteworthy	noteworthy	ADJ
admet-295	119	4	that	that	SCONJ
admet-295	119	5	in	in	ADP
admet-295	119	6	contrast	contrast	NOUN
admet-295	119	7	to	to	ADP
admet-295	119	8	the	the	DET
admet-295	119	9	revised	revise	VERB
admet-295	119	10	european	european	PROPN
admet-295	119	11	union	union	PROPN
admet-295	119	12	prescribing	prescribing	NOUN
admet-295	119	13	information	information	NOUN
admet-295	119	14	,	,	PUNCT
admet-295	119	15	the	the	DET
admet-295	119	16	most	most	ADV
admet-295	119	17	current	current	ADJ
admet-295	119	18	fda	fda	PROPN
admet-295	119	19	label	label	NOUN
admet-295	119	20	of	of	ADP
admet-295	119	21	crizotinib	crizotinib	NOUN
admet-295	119	22	(	(	PUNCT
admet-295	119	23	dated	date	VERB
admet-295	119	24	29	29	NUM
admet-295	119	25	april	april	PROPN
admet-295	119	26	2016	2016	NUM
admet-295	119	27	)	)	PUNCT
admet-295	119	28	warns	warn	VERB
admet-295	119	29	about	about	ADP
admet-295	119	30	symptomatic	symptomatic	ADJ
admet-295	119	31	bradycardia	bradycardia	NOUN
admet-295	119	32	but	but	CCONJ
admet-295	119	33	does	do	AUX
admet-295	119	34	not	not	PART
admet-295	119	35	make	make	VERB
admet-295	119	36	any	any	DET
admet-295	119	37	reference	reference	NOUN
admet-295	119	38	to	to	ADP
admet-295	119	39	cardiac	cardiac	ADJ
admet-295	119	40	failure	failure	NOUN
admet-295	119	41	[	[	X
admet-295	119	42	83	83	NUM
admet-295	119	43	]	]	PUNCT
admet-295	119	44	.	.	PUNCT
admet-295	120	1	currently	currently	ADV
admet-295	120	2	,	,	PUNCT
admet-295	120	3	17	17	NUM
admet-295	120	4	(	(	PUNCT
admet-295	120	5	60	60	NUM
admet-295	120	6	%	%	NOUN
admet-295	120	7	)	)	PUNCT
admet-295	120	8	of	of	ADP
admet-295	120	9	the	the	DET
admet-295	120	10	28	28	NUM
admet-295	120	11	pkis	pki	NOUN
admet-295	120	12	,	,	PUNCT
admet-295	120	13	approved	approve	VERB
admet-295	120	14	as	as	ADP
admet-295	120	15	of	of	ADP
admet-295	120	16	31	31	NUM
admet-295	120	17	may	may	PROPN
admet-295	120	18	2016	2016	NUM
admet-295	120	19	,	,	PUNCT
admet-295	120	20	are	be	AUX
admet-295	120	21	known	know	VERB
admet-295	120	22	to	to	PART
admet-295	120	23	induce	induce	VERB
admet-295	120	24	lv	lv	PROPN
admet-295	120	25	dysfunction	dysfunction	NOUN
admet-295	120	26	,	,	PUNCT
admet-295	120	27	often	often	ADV
admet-295	120	28	loosely	loosely	ADV
admet-295	120	29	termed	term	VERB
admet-295	120	30	as	as	ADP
admet-295	120	31	“	"	PUNCT
admet-295	120	32	cardiomyopathy	cardiomyopathy	ADJ
admet-295	120	33	”	"	PUNCT
admet-295	120	34	or	or	CCONJ
admet-295	120	35	“	"	PUNCT
admet-295	120	36	cardiotoxicity	cardiotoxicity	NOUN
admet-295	120	37	”	"	PUNCT
admet-295	120	38	,	,	PUNCT
admet-295	120	39	and	and	CCONJ
admet-295	120	40	cardiac	cardiac	ADJ
admet-295	120	41	failure	failure	NOUN
admet-295	120	42	.	.	PUNCT
admet-295	121	1	it	it	PRON
admet-295	121	2	is	be	AUX
admet-295	121	3	evident	evident	ADJ
admet-295	121	4	that	that	SCONJ
admet-295	121	5	10	10	NUM
admet-295	121	6	(	(	PUNCT
admet-295	121	7	63	63	NUM
admet-295	121	8	%	%	NOUN
admet-295	121	9	)	)	PUNCT
admet-295	121	10	were	be	AUX
admet-295	121	11	among	among	ADP
admet-295	121	12	the	the	DET
admet-295	121	13	16	16	NUM
admet-295	121	14	approved	approve	VERB
admet-295	121	15	in	in	ADP
admet-295	121	16	period	period	NOUN
admet-295	121	17	1	1	NUM
admet-295	121	18	and	and	CCONJ
admet-295	121	19	7	7	NUM
admet-295	121	20	(	(	PUNCT
admet-295	121	21	58	58	NUM
admet-295	121	22	%	%	NOUN
admet-295	121	23	)	)	PUNCT
admet-295	121	24	among	among	ADP
admet-295	121	25	the	the	DET
admet-295	121	26	12	12	NUM
admet-295	121	27	approved	approve	VERB
admet-295	121	28	in	in	ADP
admet-295	121	29	period	period	NOUN
admet-295	121	30	2	2	NUM
admet-295	121	31	.	.	PUNCT
admet-295	122	1	this	this	DET
admet-295	122	2	trend	trend	NOUN
admet-295	122	3	is	be	AUX
admet-295	122	4	in	in	ADP
admet-295	122	5	contrast	contrast	NOUN
admet-295	122	6	to	to	ADP
admet-295	122	7	the	the	DET
admet-295	122	8	substantial	substantial	ADJ
admet-295	122	9	reduction	reduction	NOUN
admet-295	122	10	in	in	ADP
admet-295	122	11	the	the	DET
admet-295	122	12	number	number	NOUN
admet-295	122	13	of	of	ADP
admet-295	122	14	qt	qt	NOUN
admet-295	122	15	-	-	PUNCT
admet-295	122	16	prolonging	prolong	VERB
admet-295	122	17	drugs	drug	NOUN
admet-295	122	18	approved	approve	VERB
admet-295	122	19	during	during	ADP
admet-295	122	20	period	period	NOUN
admet-295	122	21	2	2	NUM
admet-295	122	22	compared	compare	VERB
admet-295	122	23	to	to	ADP
admet-295	122	24	period	period	NOUN
admet-295	122	25	1	1	NUM
admet-295	122	26	(	(	PUNCT
admet-295	122	27	from	from	ADP
admet-295	122	28	50	50	NUM
admet-295	122	29	%	%	NOUN
admet-295	122	30	to	to	ADP
admet-295	122	31	25	25	NUM
admet-295	122	32	%	%	NOUN
admet-295	122	33	for	for	ADP
admet-295	122	34	qtc	qtc	PROPN
admet-295	122	35	-	-	PUNCT
admet-295	122	36	prolonging	prolong	VERB
admet-295	122	37	drugs	drug	NOUN
admet-295	122	38	versus	versus	ADP
admet-295	122	39	from	from	ADP
admet-295	122	40	63	63	NUM
admet-295	122	41	%	%	NOUN
admet-295	122	42	to	to	ADP
admet-295	122	43	58	58	NUM
admet-295	122	44	%	%	NOUN
admet-295	122	45	for	for	ADP
admet-295	122	46	drugs	drug	NOUN
admet-295	122	47	affecting	affect	VERB
admet-295	122	48	cardiac	cardiac	ADJ
admet-295	122	49	dysfunction	dysfunction	NOUN
admet-295	122	50	)	)	PUNCT
admet-295	122	51	.	.	PUNCT
admet-295	123	1	not	not	PART
admet-295	123	2	only	only	ADV
admet-295	123	3	that	that	PRON
admet-295	123	4	but	but	CCONJ
admet-295	123	5	also	also	ADV
admet-295	123	6	the	the	DET
admet-295	123	7	total	total	ADJ
admet-295	123	8	number	number	NOUN
admet-295	123	9	of	of	ADP
admet-295	123	10	pkis	pki	NOUN
admet-295	123	11	with	with	ADP
admet-295	123	12	an	an	DET
admet-295	123	13	adverse	adverse	ADJ
admet-295	123	14	effect	effect	NOUN
admet-295	123	15	on	on	ADP
admet-295	123	16	cardiac	cardiac	ADJ
admet-295	123	17	function	function	NOUN
admet-295	123	18	(	(	PUNCT
admet-295	123	19	n=17	n=17	NOUN
admet-295	123	20	;	;	PUNCT
admet-295	123	21	60	60	NUM
admet-295	123	22	%	%	NOUN
admet-295	123	23	)	)	PUNCT
admet-295	123	24	is	be	AUX
admet-295	123	25	much	much	ADV
admet-295	123	26	higher	high	ADJ
admet-295	123	27	than	than	ADP
admet-295	123	28	those	those	PRON
admet-295	123	29	with	with	ADP
admet-295	123	30	a	a	DET
admet-295	123	31	qt	qt	NOUN
admet-295	123	32	-	-	PUNCT
admet-295	123	33	liability	liability	NOUN
admet-295	123	34	(	(	PUNCT
admet-295	123	35	n=11	n=11	NOUN
admet-295	123	36	;	;	PUNCT
admet-295	123	37	39	39	NUM
admet-295	123	38	%	%	NOUN
admet-295	123	39	)	)	PUNCT
admet-295	123	40	.	.	PUNCT
admet-295	124	1	the	the	DET
admet-295	124	2	complexity	complexity	NOUN
admet-295	124	3	surrounding	surround	VERB
admet-295	124	4	the	the	DET
admet-295	124	5	estimation	estimation	NOUN
admet-295	124	6	of	of	ADP
admet-295	124	7	incidence	incidence	NOUN
admet-295	124	8	and	and	CCONJ
admet-295	124	9	interval	interval	NOUN
admet-295	124	10	to	to	ADP
admet-295	124	11	onset	onset	NOUN
admet-295	124	12	has	have	AUX
admet-295	124	13	been	be	AUX
admet-295	124	14	reviewed	review	VERB
admet-295	124	15	before	before	ADV
admet-295	124	16	since	since	SCONJ
admet-295	124	17	these	these	PRON
admet-295	124	18	depend	depend	VERB
admet-295	124	19	on	on	ADP
admet-295	124	20	the	the	DET
admet-295	124	21	dose	dose	NOUN
admet-295	124	22	of	of	ADP
admet-295	124	23	the	the	DET
admet-295	124	24	drug	drug	NOUN
admet-295	124	25	and	and	CCONJ
admet-295	124	26	the	the	DET
admet-295	124	27	criteria	criterion	NOUN
admet-295	124	28	used	use	VERB
admet-295	124	29	to	to	PART
admet-295	124	30	define	define	VERB
admet-295	124	31	lv	lv	PROPN
admet-295	124	32	dysfunction	dysfunction	NOUN
admet-295	124	33	as	as	ADV
admet-295	124	34	well	well	ADV
admet-295	124	35	as	as	ADP
admet-295	124	36	previous	previous	ADJ
admet-295	124	37	chemotherapy	chemotherapy	NOUN
admet-295	124	38	.	.	PUNCT
admet-295	125	1	in	in	ADP
admet-295	125	2	broad	broad	ADJ
admet-295	125	3	terms	term	NOUN
admet-295	125	4	,	,	PUNCT
admet-295	125	5	asymptomatic	asymptomatic	ADJ
admet-295	125	6	decrease	decrease	NOUN
admet-295	125	7	in	in	ADP
admet-295	125	8	lv	lv	PROPN
admet-295	125	9	ejection	ejection	NOUN
admet-295	125	10	fraction	fraction	NOUN
admet-295	125	11	is	be	AUX
admet-295	125	12	by	by	ADP
admet-295	125	13	far	far	ADV
admet-295	125	14	the	the	DET
admet-295	125	15	most	most	ADV
admet-295	125	16	frequent	frequent	ADJ
admet-295	125	17	.	.	PUNCT
admet-295	126	1	however	however	ADV
admet-295	126	2	,	,	PUNCT
admet-295	126	3	overt	overt	ADJ
admet-295	126	4	chf	chf	NOUN
admet-295	126	5	is	be	AUX
admet-295	126	6	not	not	PART
admet-295	126	7	uncommon	uncommon	ADJ
admet-295	126	8	with	with	ADP
admet-295	126	9	an	an	DET
admet-295	126	10	incidence	incidence	NOUN
admet-295	126	11	as	as	ADV
admet-295	126	12	high	high	ADJ
admet-295	126	13	as	as	ADP
admet-295	126	14	5	5	NUM
admet-295	126	15	-	-	SYM
admet-295	126	16	8	8	NUM
admet-295	126	17	%	%	NOUN
admet-295	126	18	with	with	ADP
admet-295	126	19	sunitinib	sunitinib	NOUN
admet-295	126	20	and	and	CCONJ
admet-295	126	21	pazopanib	pazopanib	NOUN
admet-295	126	22	.	.	PUNCT
admet-295	127	1	a	a	DET
admet-295	127	2	number	number	NOUN
admet-295	127	3	of	of	ADP
admet-295	127	4	recent	recent	ADJ
admet-295	127	5	meta	meta	NOUN
admet-295	127	6	-	-	PUNCT
admet-295	127	7	analyses	analysis	NOUN
admet-295	127	8	of	of	ADP
admet-295	127	9	clinical	clinical	ADJ
admet-295	127	10	trials	trial	NOUN
admet-295	127	11	have	have	AUX
admet-295	127	12	quantified	quantify	VERB
admet-295	127	13	the	the	DET
admet-295	127	14	risk	risk	NOUN
admet-295	127	15	of	of	ADP
admet-295	127	16	pki	pki	NOUN
admet-295	127	17	-	-	ADJ
admet-295	127	18	induced	induce	VERB
admet-295	127	19	symptomatic	symptomatic	ADJ
admet-295	127	20	cardiac	cardiac	ADJ
admet-295	127	21	failure	failure	NOUN
admet-295	127	22	[	[	X
admet-295	127	23	21,22,84	21,22,84	NUM
admet-295	127	24	]	]	PUNCT
admet-295	127	25	.	.	PUNCT
admet-295	128	1	these	these	DET
admet-295	128	2	events	event	NOUN
admet-295	128	3	are	be	AUX
admet-295	128	4	typically	typically	ADV
admet-295	128	5	categorised	categorise	VERB
admet-295	128	6	as	as	ADP
admet-295	128	7	alland	alland	NOUN
admet-295	128	8	high	high	ADJ
admet-295	128	9	-	-	PUNCT
admet-295	128	10	grade	grade	NOUN
admet-295	128	11	(	(	PUNCT
admet-295	128	12	grade	grade	NOUN
admet-295	128	13	3	3	NUM
admet-295	128	14	and	and	CCONJ
admet-295	128	15	higher	high	ADJ
admet-295	128	16	)	)	PUNCT
admet-295	128	17	as	as	SCONJ
admet-295	128	18	defined	define	VERB
admet-295	128	19	by	by	ADP
admet-295	128	20	ctcae	ctcae	PROPN
admet-295	128	21	.	.	PUNCT
admet-295	129	1	grade	grade	NOUN
admet-295	129	2	3	3	NUM
admet-295	129	3	chf	chf	NOUN
admet-295	129	4	events	event	NOUN
admet-295	129	5	require	require	VERB
admet-295	129	6	intervention	intervention	NOUN
admet-295	129	7	,	,	PUNCT
admet-295	129	8	and	and	CCONJ
admet-295	129	9	grade	grade	NOUN
admet-295	129	10	4	4	NUM
admet-295	129	11	chf	chf	NOUN
admet-295	129	12	events	event	NOUN
admet-295	129	13	usually	usually	ADV
admet-295	129	14	include	include	VERB
admet-295	129	15	life	life	NOUN
admet-295	129	16	-	-	PUNCT
admet-295	129	17	threatening	threaten	VERB
admet-295	129	18	dysfunction	dysfunction	NOUN
admet-295	129	19	.	.	PUNCT
admet-295	130	1	these	these	DET
admet-295	130	2	meta	meta	ADJ
admet-295	130	3	-	-	PUNCT
admet-295	130	4	analyses	analysis	NOUN
admet-295	130	5	reveal	reveal	VERB
admet-295	130	6	that	that	SCONJ
admet-295	130	7	overall	overall	ADJ
admet-295	130	8	,	,	PUNCT
admet-295	130	9	the	the	DET
admet-295	130	10	incidences	incidence	NOUN
admet-295	130	11	of	of	ADP
admet-295	130	12	allgrade	allgrade	ADJ
admet-295	130	13	and	and	CCONJ
admet-295	130	14	high	high	ADJ
admet-295	130	15	-	-	PUNCT
admet-295	130	16	grade	grade	NOUN
admet-295	130	17	chf	chf	NOUN
admet-295	130	18	are	be	AUX
admet-295	130	19	about	about	ADV
admet-295	130	20	2.8	2.8	NUM
admet-295	130	21	%	%	NOUN
admet-295	130	22	and	and	CCONJ
admet-295	130	23	1.1	1.1	NUM
admet-295	130	24	%	%	NOUN
admet-295	130	25	,	,	PUNCT
admet-295	130	26	respectively	respectively	ADV
admet-295	130	27	,	,	PUNCT
admet-295	130	28	with	with	ADP
admet-295	130	29	a	a	DET
admet-295	130	30	relative	relative	ADJ
admet-295	130	31	risk	risk	NOUN
admet-295	130	32	(	(	PUNCT
admet-295	130	33	rr	rr	NOUN
admet-295	130	34	)	)	PUNCT
admet-295	130	35	of	of	ADP
admet-295	130	36	2.5	2.5	NUM
admet-295	130	37	and	and	CCONJ
admet-295	130	38	1.5	1.5	NUM
admet-295	130	39	,	,	PUNCT
admet-295	130	40	respectively	respectively	ADV
admet-295	130	41	.	.	PUNCT
admet-295	131	1	the	the	DET
admet-295	131	2	risk	risk	NOUN
admet-295	131	3	appears	appear	VERB
admet-295	131	4	independent	independent	ADJ
admet-295	131	5	of	of	ADP
admet-295	131	6	tumour	tumour	NOUN
admet-295	131	7	type	type	NOUN
admet-295	131	8	or	or	CCONJ
admet-295	131	9	the	the	DET
admet-295	131	10	pki	pki	NOUN
admet-295	131	11	used	use	VERB
admet-295	131	12	.	.	PUNCT
admet-295	132	1	the	the	DET
admet-295	132	2	outcome	outcome	NOUN
admet-295	132	3	has	have	AUX
admet-295	132	4	been	be	AUX
admet-295	132	5	fatal	fatal	ADJ
admet-295	132	6	in	in	ADP
admet-295	132	7	a	a	DET
admet-295	132	8	number	number	NOUN
admet-295	132	9	of	of	ADP
admet-295	132	10	cases	case	NOUN
admet-295	132	11	whereas	whereas	SCONJ
admet-295	132	12	others	other	NOUN
admet-295	132	13	require	require	VERB
admet-295	132	14	anti	anti	ADJ
admet-295	132	15	-	-	ADJ
admet-295	132	16	failure	failure	ADJ
admet-295	132	17	therapy	therapy	NOUN
admet-295	132	18	and/or	and/or	CCONJ
admet-295	132	19	withholding	withhold	VERB
admet-295	132	20	the	the	DET
admet-295	132	21	culprit	culprit	NOUN
admet-295	132	22	pki	pki	PROPN
admet-295	132	23	.	.	PROPN
admet-295	133	1	in	in	ADP
admet-295	133	2	routine	routine	ADJ
admet-295	133	3	clinical	clinical	ADJ
admet-295	133	4	oncology	oncology	NOUN
admet-295	133	5	,	,	PUNCT
admet-295	133	6	the	the	DET
admet-295	133	7	scale	scale	NOUN
admet-295	133	8	of	of	ADP
admet-295	133	9	the	the	DET
admet-295	133	10	problem	problem	NOUN
admet-295	133	11	is	be	AUX
admet-295	133	12	likely	likely	ADV
admet-295	133	13	much	much	ADV
admet-295	133	14	higher	high	ADJ
admet-295	133	15	as	as	SCONJ
admet-295	133	16	patients	patient	NOUN
admet-295	133	17	with	with	ADP
admet-295	133	18	cardiac	cardiac	ADJ
admet-295	133	19	disease	disease	NOUN
admet-295	133	20	who	who	PRON
admet-295	133	21	are	be	AUX
admet-295	133	22	the	the	DET
admet-295	133	23	most	most	ADJ
admet-295	133	24	at	at	ADP
admet-295	133	25	risk	risk	NOUN
admet-295	133	26	of	of	ADP
admet-295	133	27	cardiotoxicity	cardiotoxicity	NOUN
admet-295	133	28	have	have	AUX
admet-295	133	29	traditionally	traditionally	ADV
admet-295	133	30	been	be	AUX
admet-295	133	31	excluded	exclude	VERB
admet-295	133	32	from	from	ADP
admet-295	133	33	pre	pre	ADJ
admet-295	133	34	-	-	ADJ
admet-295	133	35	approval	approval	ADJ
admet-295	133	36	clinical	clinical	ADJ
admet-295	133	37	trials	trial	NOUN
admet-295	133	38	.	.	PUNCT
admet-295	134	1	as	as	SCONJ
admet-295	134	2	stated	state	VERB
admet-295	134	3	above	above	ADV
admet-295	134	4	,	,	PUNCT
admet-295	134	5	four	four	NUM
admet-295	134	6	(	(	PUNCT
admet-295	134	7	23	23	NUM
admet-295	134	8	%	%	NOUN
admet-295	134	9	)	)	PUNCT
admet-295	134	10	of	of	ADP
admet-295	134	11	the	the	DET
admet-295	134	12	17	17	NUM
admet-295	134	13	pkis	pki	NOUN
admet-295	134	14	with	with	ADP
admet-295	134	15	a	a	DET
admet-295	134	16	potential	potential	NOUN
admet-295	134	17	for	for	ADP
admet-295	134	18	inducing	induce	VERB
admet-295	134	19	cardiac	cardiac	ADJ
admet-295	134	20	failure	failure	NOUN
admet-295	134	21	revealed	reveal	VERB
admet-295	134	22	this	this	DET
admet-295	134	23	risk	risk	NOUN
admet-295	134	24	rashmi	rashmi	PROPN
admet-295	134	25	shah	shah	PROPN
admet-295	134	26	admet	admet	PROPN
admet-295	134	27	&	&	CCONJ
admet-295	134	28	dmpk	dmpk	PROPN
admet-295	134	29	4(3	4(3	NUM
admet-295	134	30	)	)	PUNCT
admet-295	134	31	(	(	PUNCT
admet-295	134	32	2016	2016	NUM
admet-295	134	33	)	)	PUNCT
admet-295	134	34	212	212	NUM
admet-295	134	35	-	-	SYM
admet-295	134	36	231	231	NUM
admet-295	134	37	220	220	NUM
admet-295	134	38	during	during	ADP
admet-295	134	39	their	their	PRON
admet-295	134	40	post	post	ADJ
admet-295	134	41	-	-	ADJ
admet-295	134	42	marketing	marketing	ADJ
admet-295	134	43	use	use	NOUN
admet-295	134	44	.	.	PUNCT
admet-295	135	1	currently	currently	ADV
admet-295	135	2	,	,	PUNCT
admet-295	135	3	there	there	PRON
admet-295	135	4	are	be	VERB
admet-295	135	5	no	no	DET
admet-295	135	6	regulatory	regulatory	ADJ
admet-295	135	7	guidelines	guideline	NOUN
admet-295	135	8	for	for	ADP
admet-295	135	9	pre	pre	ADJ
admet-295	135	10	-	-	ADJ
admet-295	135	11	approval	approval	ADJ
admet-295	135	12	characterisation	characterisation	NOUN
admet-295	135	13	of	of	ADP
admet-295	135	14	a	a	DET
admet-295	135	15	drug	drug	NOUN
admet-295	135	16	for	for	ADP
admet-295	135	17	its	its	PRON
admet-295	135	18	effect	effect	NOUN
admet-295	135	19	on	on	ADP
admet-295	135	20	lv	lv	PROPN
admet-295	135	21	function	function	NOUN
admet-295	135	22	.	.	PUNCT
admet-295	136	1	however	however	ADV
admet-295	136	2	,	,	PUNCT
admet-295	136	3	as	as	ADP
admet-295	136	4	yang	yang	PROPN
admet-295	136	5	and	and	CCONJ
admet-295	136	6	papoian	papoian	NOUN
admet-295	136	7	from	from	ADP
admet-295	136	8	the	the	DET
admet-295	136	9	fda	fda	PROPN
admet-295	136	10	point	point	NOUN
admet-295	136	11	out	out	ADP
admet-295	136	12	,	,	PUNCT
admet-295	136	13	these	these	DET
admet-295	136	14	reports	report	NOUN
admet-295	136	15	of	of	ADP
admet-295	136	16	cardiac	cardiac	ADJ
admet-295	136	17	toxicity	toxicity	NOUN
admet-295	136	18	following	follow	VERB
admet-295	136	19	the	the	DET
admet-295	136	20	clinical	clinical	ADJ
admet-295	136	21	use	use	NOUN
admet-295	136	22	of	of	ADP
admet-295	136	23	pkis	pki	NOUN
admet-295	136	24	are	be	AUX
admet-295	136	25	unexpected	unexpected	ADJ
admet-295	136	26	and	and	CCONJ
admet-295	136	27	not	not	PART
admet-295	136	28	well	well	ADV
admet-295	136	29	predicted	predict	VERB
admet-295	136	30	by	by	ADP
admet-295	136	31	nonclinical	nonclinical	ADJ
admet-295	136	32	studies	study	NOUN
admet-295	136	33	[	[	X
admet-295	136	34	85	85	NUM
admet-295	136	35	]	]	PUNCT
admet-295	136	36	and	and	CCONJ
admet-295	136	37	clinical	clinical	ADJ
admet-295	136	38	findings	finding	NOUN
admet-295	136	39	have	have	AUX
admet-295	136	40	exposed	expose	VERB
admet-295	136	41	gaps	gap	NOUN
admet-295	136	42	in	in	ADP
admet-295	136	43	current	current	ADJ
admet-295	136	44	nonclinical	nonclinical	ADJ
admet-295	136	45	drug	drug	NOUN
admet-295	136	46	testing	testing	NOUN
admet-295	136	47	for	for	ADP
admet-295	136	48	predicting	predict	VERB
admet-295	136	49	the	the	DET
admet-295	136	50	development	development	NOUN
admet-295	136	51	of	of	ADP
admet-295	136	52	cardiac	cardiac	ADJ
admet-295	136	53	toxicities	toxicity	NOUN
admet-295	136	54	in	in	ADP
admet-295	136	55	humans	human	NOUN
admet-295	136	56	.	.	PUNCT
admet-295	137	1	they	they	PRON
admet-295	137	2	have	have	AUX
admet-295	137	3	suggested	suggest	VERB
admet-295	137	4	the	the	DET
admet-295	137	5	use	use	NOUN
admet-295	137	6	of	of	ADP
admet-295	137	7	cultured	cultured	ADJ
admet-295	137	8	cardiomyocytes	cardiomyocyte	NOUN
admet-295	137	9	and	and	CCONJ
admet-295	137	10	application	application	NOUN
admet-295	137	11	of	of	ADP
admet-295	137	12	isolated	isolated	ADJ
admet-295	137	13	perfused	perfused	ADJ
admet-295	137	14	heart	heart	NOUN
admet-295	137	15	methodology	methodology	NOUN
admet-295	137	16	to	to	PART
admet-295	137	17	chronic	chronic	VERB
admet-295	137	18	or	or	CCONJ
admet-295	137	19	sub	sub	ADJ
admet-295	137	20	-	-	ADJ
admet-295	137	21	chronic	chronic	ADJ
admet-295	137	22	rodent	rodent	NOUN
admet-295	137	23	studies	study	NOUN
admet-295	137	24	or	or	CCONJ
admet-295	137	25	including	include	VERB
admet-295	137	26	echocardiography	echocardiography	NOUN
admet-295	137	27	in	in	ADP
admet-295	137	28	chronic	chronic	ADJ
admet-295	137	29	large	large	ADJ
admet-295	137	30	animal	animal	NOUN
admet-295	137	31	toxicity	toxicity	NOUN
admet-295	137	32	studies	study	NOUN
admet-295	137	33	as	as	ADP
admet-295	137	34	potentially	potentially	ADV
admet-295	137	35	valuable	valuable	ADJ
admet-295	137	36	tools	tool	NOUN
admet-295	137	37	to	to	PART
admet-295	137	38	study	study	VERB
admet-295	137	39	the	the	DET
admet-295	137	40	likelihood	likelihood	NOUN
admet-295	137	41	of	of	ADP
admet-295	137	42	pki	pki	PROPN
admet-295	137	43	-	-	ADJ
admet-295	137	44	mediated	mediate	VERB
admet-295	137	45	cardiotoxicity	cardiotoxicity	NOUN
admet-295	137	46	.	.	PUNCT
admet-295	138	1	available	available	ADJ
admet-295	138	2	data	datum	NOUN
admet-295	138	3	suggest	suggest	VERB
admet-295	138	4	that	that	SCONJ
admet-295	138	5	nonclinical	nonclinical	ADJ
admet-295	138	6	studies	study	NOUN
admet-295	138	7	,	,	PUNCT
admet-295	138	8	when	when	SCONJ
admet-295	138	9	adequately	adequately	ADV
admet-295	138	10	designed	design	VERB
admet-295	138	11	to	to	PART
admet-295	138	12	address	address	VERB
admet-295	138	13	a	a	DET
admet-295	138	14	specific	specific	ADJ
admet-295	138	15	issue	issue	NOUN
admet-295	138	16	,	,	PUNCT
admet-295	138	17	are	be	AUX
admet-295	138	18	capable	capable	ADJ
admet-295	138	19	of	of	ADP
admet-295	138	20	detecting	detect	VERB
admet-295	138	21	these	these	DET
admet-295	138	22	effects	effect	NOUN
admet-295	138	23	as	as	SCONJ
admet-295	138	24	was	be	AUX
admet-295	138	25	seen	see	VERB
admet-295	138	26	in	in	ADP
admet-295	138	27	studies	study	NOUN
admet-295	138	28	with	with	ADP
admet-295	138	29	some	some	DET
admet-295	138	30	pkis	pki	NOUN
admet-295	138	31	approved	approve	VERB
admet-295	138	32	more	more	ADV
admet-295	138	33	recently	recently	ADV
admet-295	138	34	.	.	PUNCT
admet-295	139	1	for	for	ADP
admet-295	139	2	example	example	NOUN
admet-295	139	3	,	,	PUNCT
admet-295	139	4	in	in	ADP
admet-295	139	5	vivo	vivo	ADJ
admet-295	139	6	cardiac	cardiac	ADJ
admet-295	139	7	safety	safety	NOUN
admet-295	139	8	pharmacology	pharmacology	NOUN
admet-295	139	9	studies	study	NOUN
admet-295	139	10	with	with	ADP
admet-295	139	11	osimertinib	osimertinib	NOUN
admet-295	139	12	did	do	AUX
admet-295	139	13	suggest	suggest	VERB
admet-295	139	14	equivocal	equivocal	ADJ
admet-295	139	15	findings	finding	NOUN
admet-295	139	16	of	of	ADP
admet-295	139	17	decreased	decrease	VERB
admet-295	139	18	contractility	contractility	NOUN
admet-295	139	19	dogs	dog	NOUN
admet-295	139	20	and	and	CCONJ
admet-295	139	21	guinea	guinea	NOUN
admet-295	139	22	pigs	pig	NOUN
admet-295	139	23	whereas	whereas	SCONJ
admet-295	139	24	increased	increase	VERB
admet-295	139	25	findings	finding	NOUN
admet-295	139	26	of	of	ADP
admet-295	139	27	cardiomyopathy	cardiomyopathy	ADJ
admet-295	139	28	compared	compare	VERB
admet-295	139	29	to	to	ADP
admet-295	139	30	findings	finding	NOUN
admet-295	139	31	in	in	ADP
admet-295	139	32	control	control	NOUN
admet-295	139	33	animals	animal	NOUN
admet-295	139	34	were	be	AUX
admet-295	139	35	reported	report	VERB
admet-295	139	36	in	in	ADP
admet-295	139	37	the	the	DET
admet-295	139	38	4	4	NUM
admet-295	139	39	-	-	PUNCT
admet-295	139	40	week	week	NOUN
admet-295	139	41	rat	rat	NOUN
admet-295	139	42	toxicology	toxicology	NOUN
admet-295	139	43	study	study	NOUN
admet-295	139	44	with	with	ADP
admet-295	139	45	cobimetinib	cobimetinib	NOUN
admet-295	139	46	though	though	SCONJ
admet-295	139	47	no	no	DET
admet-295	139	48	other	other	ADJ
admet-295	139	49	cardiac	cardiac	ADJ
admet-295	139	50	effects	effect	NOUN
admet-295	139	51	were	be	AUX
admet-295	139	52	reported	report	VERB
admet-295	139	53	in	in	ADP
admet-295	139	54	animal	animal	NOUN
admet-295	139	55	studies	study	NOUN
admet-295	139	56	[	[	X
admet-295	139	57	86	86	NUM
admet-295	139	58	,	,	PUNCT
admet-295	139	59	87	87	NUM
admet-295	139	60	]	]	PUNCT
admet-295	139	61	.	.	PUNCT
admet-295	140	1	with	with	ADP
admet-295	140	2	regard	regard	NOUN
admet-295	140	3	to	to	ADP
admet-295	140	4	afatinib	afatinib	NOUN
admet-295	140	5	,	,	PUNCT
admet-295	140	6	a	a	DET
admet-295	140	7	decrease	decrease	NOUN
admet-295	140	8	in	in	ADP
admet-295	140	9	left	left	ADJ
admet-295	140	10	ventricular	ventricular	ADJ
admet-295	140	11	function	function	NOUN
admet-295	140	12	was	be	AUX
admet-295	140	13	noted	note	VERB
admet-295	140	14	at	at	ADP
admet-295	140	15	a	a	DET
admet-295	140	16	dose	dose	NOUN
admet-295	140	17	of	of	ADP
admet-295	140	18	30	30	NUM
admet-295	140	19	mg	mg	PROPN
admet-295	140	20	/	/	SYM
admet-295	140	21	kg	kg	PROPN
admet-295	140	22	in	in	ADP
admet-295	140	23	a	a	DET
admet-295	140	24	single	single	ADJ
admet-295	140	25	continuous	continuous	ADJ
admet-295	140	26	intravenous	intravenous	ADJ
admet-295	140	27	administration	administration	NOUN
admet-295	140	28	study	study	NOUN
admet-295	140	29	in	in	ADP
admet-295	140	30	domestic	domestic	ADJ
admet-295	140	31	pigs	pig	NOUN
admet-295	140	32	[	[	X
admet-295	140	33	88	88	NUM
admet-295	140	34	]	]	PUNCT
admet-295	140	35	.	.	PUNCT
admet-295	141	1	use	use	NOUN
admet-295	141	2	of	of	ADP
admet-295	141	3	echocardiography	echocardiography	NOUN
admet-295	141	4	unequivocally	unequivocally	ADV
admet-295	141	5	identified	identify	VERB
admet-295	141	6	sunitinib	sunitinib	NOUN
admet-295	141	7	-	-	PUNCT
admet-295	141	8	induced	induce	VERB
admet-295	141	9	cardiac	cardiac	ADJ
admet-295	141	10	lv	lv	PROPN
admet-295	141	11	dysfunction	dysfunction	NOUN
admet-295	141	12	but	but	CCONJ
admet-295	141	13	failed	fail	VERB
admet-295	141	14	to	to	PART
admet-295	141	15	detect	detect	VERB
admet-295	141	16	an	an	DET
admet-295	141	17	effect	effect	NOUN
admet-295	141	18	of	of	ADP
admet-295	141	19	bosutinib	bosutinib	NOUN
admet-295	141	20	[	[	X
admet-295	141	21	89	89	NUM
admet-295	141	22	,	,	PUNCT
admet-295	141	23	90	90	NUM
admet-295	141	24	]	]	PUNCT
admet-295	141	25	.	.	PUNCT
admet-295	142	1	although	although	SCONJ
admet-295	142	2	electrocardiography	electrocardiography	NOUN
admet-295	142	3	is	be	AUX
admet-295	142	4	widely	widely	ADV
admet-295	142	5	used	use	VERB
admet-295	142	6	to	to	PART
admet-295	142	7	study	study	VERB
admet-295	142	8	qtc	qtc	PROPN
admet-295	142	9	effects	effect	NOUN
admet-295	142	10	,	,	PUNCT
admet-295	142	11	echocardiography	echocardiography	NOUN
admet-295	142	12	has	have	AUX
admet-295	142	13	not	not	PART
admet-295	142	14	been	be	AUX
admet-295	142	15	used	use	VERB
admet-295	142	16	as	as	ADP
admet-295	142	17	frequently	frequently	ADV
admet-295	142	18	to	to	PART
admet-295	142	19	study	study	VERB
admet-295	142	20	lv	lv	PROPN
admet-295	142	21	function	function	NOUN
admet-295	142	22	in	in	ADP
admet-295	142	23	nonclinical	nonclinical	ADJ
admet-295	142	24	studies	study	NOUN
admet-295	142	25	.	.	PUNCT
admet-295	143	1	there	there	PRON
admet-295	143	2	clearly	clearly	ADV
admet-295	143	3	lies	lie	VERB
admet-295	143	4	a	a	DET
admet-295	143	5	significant	significant	ADJ
admet-295	143	6	challenge	challenge	NOUN
admet-295	143	7	in	in	ADP
admet-295	143	8	pre	pre	ADJ
admet-295	143	9	-	-	ADJ
admet-295	143	10	approval	approval	ADJ
admet-295	143	11	characterisation	characterisation	NOUN
admet-295	143	12	of	of	ADP
admet-295	143	13	a	a	DET
admet-295	143	14	drug	drug	NOUN
admet-295	143	15	for	for	ADP
admet-295	143	16	its	its	PRON
admet-295	143	17	effect	effect	NOUN
admet-295	143	18	on	on	ADP
admet-295	143	19	lv	lv	PROPN
admet-295	143	20	function	function	NOUN
admet-295	143	21	.	.	PUNCT
admet-295	144	1	recent	recent	ADJ
admet-295	144	2	studies	study	NOUN
admet-295	144	3	have	have	AUX
admet-295	144	4	shown	show	VERB
admet-295	144	5	that	that	SCONJ
admet-295	144	6	a	a	DET
admet-295	144	7	multi	multi	ADJ
admet-295	144	8	-	-	ADJ
admet-295	144	9	parameter	parameter	ADJ
admet-295	144	10	approach	approach	NOUN
admet-295	144	11	examining	examine	VERB
admet-295	144	12	both	both	DET
admet-295	144	13	cardiac	cardiac	ADJ
admet-295	144	14	cell	cell	NOUN
admet-295	144	15	health	health	NOUN
admet-295	144	16	and	and	CCONJ
admet-295	144	17	function	function	NOUN
admet-295	144	18	in	in	ADP
admet-295	144	19	human	human	ADJ
admet-295	144	20	induced	induce	VERB
admet-295	144	21	pluripotent	pluripotent	NOUN
admet-295	144	22	stem	stem	NOUN
admet-295	144	23	cell	cell	NOUN
admet-295	144	24	-	-	PUNCT
admet-295	144	25	derived	derive	VERB
admet-295	144	26	cardiomyocytes	cardiomyocyte	NOUN
admet-295	144	27	provides	provide	VERB
admet-295	144	28	a	a	DET
admet-295	144	29	comprehensive	comprehensive	ADJ
admet-295	144	30	and	and	CCONJ
admet-295	144	31	robust	robust	ADJ
admet-295	144	32	assessment	assessment	NOUN
admet-295	144	33	that	that	PRON
admet-295	144	34	can	can	AUX
admet-295	144	35	aid	aid	VERB
admet-295	144	36	in	in	ADP
admet-295	144	37	determining	determine	VERB
admet-295	144	38	potential	potential	ADJ
admet-295	144	39	cardiotoxic	cardiotoxic	ADJ
admet-295	144	40	liability	liability	NOUN
admet-295	144	41	[	[	X
admet-295	144	42	91	91	NUM
admet-295	144	43	]	]	PUNCT
admet-295	144	44	.	.	PUNCT
admet-295	145	1	arterial	arterial	ADJ
admet-295	145	2	thrombotic	thrombotic	ADJ
admet-295	145	3	events	event	NOUN
admet-295	145	4	due	due	ADP
admet-295	145	5	to	to	ADP
admet-295	145	6	protein	protein	NOUN
admet-295	145	7	kinase	kinase	NOUN
admet-295	145	8	inhibitors	inhibitor	NOUN
admet-295	145	9	among	among	ADP
admet-295	145	10	the	the	DET
admet-295	145	11	most	most	ADV
admet-295	145	12	serious	serious	ADJ
admet-295	145	13	adverse	adverse	ADJ
admet-295	145	14	effects	effect	NOUN
admet-295	145	15	of	of	ADP
admet-295	145	16	the	the	DET
admet-295	145	17	pkis	pki	NOUN
admet-295	145	18	are	be	AUX
admet-295	145	19	their	their	PRON
admet-295	145	20	prothrombotic	prothrombotic	ADJ
admet-295	145	21	effects	effect	NOUN
admet-295	145	22	as	as	SCONJ
admet-295	145	23	illustrated	illustrate	VERB
admet-295	145	24	by	by	ADP
admet-295	145	25	ponatinib	ponatinib	NOUN
admet-295	145	26	[	[	PUNCT
admet-295	145	27	reviewed	review	VERB
admet-295	145	28	in	in	ADP
admet-295	145	29	3	3	NUM
admet-295	145	30	]	]	PUNCT
admet-295	145	31	.	.	PUNCT
admet-295	146	1	following	follow	VERB
admet-295	146	2	the	the	DET
admet-295	146	3	post	post	ADJ
admet-295	146	4	-	-	ADJ
admet-295	146	5	marketing	marketing	ADJ
admet-295	146	6	experience	experience	NOUN
admet-295	146	7	with	with	ADP
admet-295	146	8	ponatinib	ponatinib	NOUN
admet-295	146	9	(	(	PUNCT
admet-295	146	10	see	see	VERB
admet-295	146	11	below	below	ADV
admet-295	146	12	)	)	PUNCT
admet-295	146	13	,	,	PUNCT
admet-295	146	14	ates	ates	PROPN
admet-295	146	15	have	have	AUX
admet-295	146	16	now	now	ADV
admet-295	146	17	emerged	emerge	VERB
admet-295	146	18	as	as	ADP
admet-295	146	19	a	a	DET
admet-295	146	20	major	major	ADJ
admet-295	146	21	safety	safety	NOUN
admet-295	146	22	concern	concern	NOUN
admet-295	146	23	with	with	ADP
admet-295	146	24	pkis	pki	NOUN
admet-295	146	25	and	and	CCONJ
admet-295	146	26	the	the	DET
admet-295	146	27	previously	previously	ADV
admet-295	146	28	approved	approve	VERB
admet-295	146	29	labels	label	NOUN
admet-295	146	30	of	of	ADP
admet-295	146	31	a	a	DET
admet-295	146	32	few	few	ADJ
admet-295	146	33	have	have	AUX
admet-295	146	34	required	require	VERB
admet-295	146	35	revisions	revision	NOUN
admet-295	146	36	to	to	PART
admet-295	146	37	reflect	reflect	VERB
admet-295	146	38	this	this	DET
admet-295	146	39	risk	risk	NOUN
admet-295	146	40	.	.	PUNCT
admet-295	147	1	ten	ten	NUM
admet-295	147	2	(	(	PUNCT
admet-295	147	3	63	63	NUM
admet-295	147	4	%	%	NOUN
admet-295	147	5	)	)	PUNCT
admet-295	147	6	of	of	ADP
admet-295	147	7	the	the	DET
admet-295	147	8	16	16	NUM
admet-295	147	9	pkis	pki	NOUN
admet-295	147	10	approved	approve	VERB
admet-295	147	11	during	during	ADP
admet-295	147	12	period	period	NOUN
admet-295	147	13	1	1	NUM
admet-295	147	14	have	have	AUX
admet-295	147	15	been	be	AUX
admet-295	147	16	reported	report	VERB
admet-295	147	17	to	to	PART
admet-295	147	18	be	be	AUX
admet-295	147	19	associated	associate	VERB
admet-295	147	20	with	with	ADP
admet-295	147	21	arterial	arterial	ADJ
admet-295	147	22	thrombosis	thrombosis	NOUN
admet-295	147	23	(	(	PUNCT
admet-295	147	24	axitinib	axitinib	NOUN
admet-295	147	25	,	,	PUNCT
admet-295	147	26	dasatinib	dasatinib	NOUN
admet-295	147	27	,	,	PUNCT
admet-295	147	28	erlotinib	erlotinib	NOUN
admet-295	147	29	,	,	PUNCT
admet-295	147	30	imatinib	imatinib	NOUN
admet-295	147	31	,	,	PUNCT
admet-295	147	32	nilotinib	nilotinib	NOUN
admet-295	147	33	,	,	PUNCT
admet-295	147	34	pazopanib	pazopanib	NOUN
admet-295	147	35	,	,	PUNCT
admet-295	147	36	regorafenib	regorafenib	NOUN
admet-295	147	37	,	,	PUNCT
admet-295	147	38	sorafenib	sorafenib	NOUN
admet-295	147	39	,	,	PUNCT
admet-295	147	40	sunitinib	sunitinib	NOUN
admet-295	147	41	and	and	CCONJ
admet-295	147	42	vandetanib	vandetanib	NOUN
admet-295	147	43	)	)	PUNCT
admet-295	147	44	.	.	PUNCT
admet-295	148	1	among	among	ADP
admet-295	148	2	the	the	DET
admet-295	148	3	12	12	NUM
admet-295	148	4	newer	new	ADJ
admet-295	148	5	pkis	pki	NOUN
admet-295	148	6	approved	approve	VERB
admet-295	148	7	in	in	ADP
admet-295	148	8	period	period	NOUN
admet-295	148	9	2	2	NUM
admet-295	148	10	,	,	PUNCT
admet-295	148	11	four	four	NUM
admet-295	148	12	(	(	PUNCT
admet-295	148	13	33	33	NUM
admet-295	148	14	%	%	NOUN
admet-295	148	15	)	)	PUNCT
admet-295	148	16	have	have	AUX
admet-295	148	17	been	be	AUX
admet-295	148	18	reported	report	VERB
admet-295	148	19	to	to	PART
admet-295	148	20	be	be	AUX
admet-295	148	21	associated	associate	VERB
admet-295	148	22	with	with	ADP
admet-295	148	23	ates	ates	PROPN
admet-295	148	24	(	(	PUNCT
admet-295	148	25	cabozantinib	cabozantinib	ADV
admet-295	148	26	,	,	PUNCT
admet-295	148	27	lenvatinib	lenvatinib	PROPN
admet-295	148	28	,	,	PUNCT
admet-295	148	29	nintedanib	nintedanib	NOUN
admet-295	148	30	,	,	PUNCT
admet-295	148	31	and	and	CCONJ
admet-295	148	32	ponatinib	ponatinib	NOUN
admet-295	148	33	,	,	PUNCT
admet-295	148	34	with	with	ADP
admet-295	148	35	the	the	DET
admet-295	148	36	last	last	ADJ
admet-295	148	37	one	one	NOUN
admet-295	148	38	carrying	carry	VERB
admet-295	148	39	a	a	DET
admet-295	148	40	black	black	ADJ
admet-295	148	41	box	box	NOUN
admet-295	148	42	warning	warning	NOUN
admet-295	148	43	)	)	PUNCT
admet-295	149	1	[	[	X
admet-295	149	2	3	3	NUM
admet-295	149	3	]	]	PUNCT
admet-295	149	4	.	.	PUNCT
admet-295	150	1	the	the	DET
admet-295	150	2	rates	rate	NOUN
admet-295	150	3	of	of	ADP
admet-295	150	4	ates	ates	PROPN
admet-295	150	5	appear	appear	VERB
admet-295	150	6	to	to	PART
admet-295	150	7	be	be	AUX
admet-295	150	8	comparable	comparable	ADJ
admet-295	150	9	for	for	ADP
admet-295	150	10	pkis	pki	NOUN
admet-295	150	11	from	from	ADP
admet-295	150	12	both	both	DET
admet-295	150	13	periods	period	NOUN
admet-295	150	14	and	and	CCONJ
admet-295	150	15	the	the	DET
admet-295	150	16	ate	ate	NOUN
admet-295	150	17	events	event	NOUN
admet-295	150	18	typically	typically	ADV
admet-295	150	19	include	include	VERB
admet-295	150	20	cerebral	cerebral	ADJ
admet-295	150	21	infarction	infarction	NOUN
admet-295	150	22	,	,	PUNCT
admet-295	150	23	cerebral	cerebral	ADJ
admet-295	150	24	ischaemia	ischaemia	PROPN
admet-295	150	25	,	,	PUNCT
admet-295	150	26	cerebrovascular	cerebrovascular	ADJ
admet-295	150	27	accidents	accident	NOUN
admet-295	150	28	(	(	PUNCT
admet-295	150	29	cva	cva	PROPN
admet-295	150	30	)	)	PUNCT
admet-295	150	31	,	,	PUNCT
admet-295	150	32	myocardial	myocardial	ADJ
admet-295	150	33	infarction	infarction	NOUN
admet-295	150	34	and	and	CCONJ
admet-295	150	35	myocardial	myocardial	ADJ
admet-295	150	36	ischaemia	ischaemia	PROPN
admet-295	150	37	.	.	PUNCT
admet-295	151	1	in	in	ADP
admet-295	151	2	pre	pre	ADJ
admet-295	151	3	-	-	ADJ
admet-295	151	4	approval	approval	ADJ
admet-295	151	5	clinical	clinical	ADJ
admet-295	151	6	trials	trial	NOUN
admet-295	151	7	,	,	PUNCT
admet-295	151	8	the	the	DET
admet-295	151	9	incidences	incidence	NOUN
admet-295	151	10	of	of	ADP
admet-295	151	11	ates	ates	PROPN
admet-295	151	12	were	be	AUX
admet-295	151	13	5	5	NUM
admet-295	151	14	%	%	NOUN
admet-295	151	15	with	with	ADP
admet-295	151	16	lenvatinib	lenvatinib	NOUN
admet-295	151	17	,	,	PUNCT
admet-295	151	18	2.5	2.5	NUM
admet-295	151	19	%	%	NOUN
admet-295	151	20	for	for	ADP
admet-295	151	21	nintedanib	nintedanib	NOUN
admet-295	151	22	and	and	CCONJ
admet-295	151	23	2	2	NUM
admet-295	151	24	%	%	NOUN
admet-295	151	25	for	for	ADP
admet-295	151	26	cabozantinib	cabozantinib	NOUN
admet-295	151	27	,	,	PUNCT
admet-295	151	28	the	the	DET
admet-295	151	29	corresponding	corresponding	ADJ
admet-295	151	30	placebo	placebo	NOUN
admet-295	151	31	rates	rate	NOUN
admet-295	151	32	being	be	AUX
admet-295	151	33	2	2	NUM
admet-295	151	34	%	%	NOUN
admet-295	151	35	,	,	PUNCT
admet-295	151	36	0.8	0.8	NUM
admet-295	151	37	%	%	NOUN
admet-295	151	38	and	and	CCONJ
admet-295	151	39	0	0	NUM
admet-295	151	40	%	%	NOUN
admet-295	151	41	respectively	respectively	ADV
admet-295	151	42	.	.	PUNCT
admet-295	152	1	thus	thus	ADV
admet-295	152	2	,	,	PUNCT
admet-295	152	3	the	the	DET
admet-295	152	4	mean	mean	ADJ
admet-295	152	5	drug	drug	NOUN
admet-295	152	6	-	-	PUNCT
admet-295	152	7	emergent	emergent	NOUN
admet-295	152	8	effect	effect	NOUN
admet-295	152	9	was	be	AUX
admet-295	152	10	of	of	ADP
admet-295	152	11	the	the	DET
admet-295	152	12	order	order	NOUN
admet-295	152	13	of	of	ADP
admet-295	152	14	2.2	2.2	NUM
admet-295	152	15	%	%	NOUN
admet-295	152	16	.	.	PUNCT
admet-295	153	1	myocardial	myocardial	ADJ
admet-295	153	2	infarction	infarction	NOUN
admet-295	153	3	was	be	AUX
admet-295	153	4	the	the	DET
admet-295	153	5	most	most	ADV
admet-295	153	6	common	common	ADJ
admet-295	153	7	adverse	adverse	ADJ
admet-295	153	8	reaction	reaction	NOUN
admet-295	153	9	,	,	PUNCT
admet-295	153	10	occurring	occur	VERB
admet-295	153	11	in	in	ADP
admet-295	153	12	1.5	1.5	NUM
admet-295	153	13	%	%	NOUN
admet-295	153	14	of	of	ADP
admet-295	153	15	nintedanib	nintedanib	NOUN
admet-295	153	16	-	-	PUNCT
admet-295	153	17	treated	treat	VERB
admet-295	153	18	patients	patient	NOUN
admet-295	153	19	compared	compare	VERB
admet-295	153	20	with	with	ADP
admet-295	153	21	0.4	0.4	NUM
admet-295	153	22	%	%	NOUN
admet-295	153	23	of	of	ADP
admet-295	153	24	placebo	placebo	NOUN
admet-295	153	25	-	-	PUNCT
admet-295	153	26	treated	treat	VERB
admet-295	153	27	patients	patient	NOUN
admet-295	153	28	.	.	PUNCT
admet-295	154	1	the	the	DET
admet-295	154	2	incidence	incidence	NOUN
admet-295	154	3	of	of	ADP
admet-295	154	4	grade	grade	NOUN
admet-295	154	5	3	3	NUM
admet-295	154	6	or	or	CCONJ
admet-295	154	7	higher	high	ADJ
admet-295	154	8	events	event	NOUN
admet-295	154	9	was	be	AUX
admet-295	154	10	3	3	NUM
admet-295	154	11	%	%	NOUN
admet-295	154	12	in	in	ADP
admet-295	154	13	lenvatinib	lenvatinib	PROPN
admet-295	154	14	-	-	PUNCT
admet-295	154	15	treated	treat	VERB
admet-295	154	16	patients	patient	NOUN
admet-295	154	17	compared	compare	VERB
admet-295	154	18	with	with	ADP
admet-295	154	19	1	1	NUM
admet-295	154	20	%	%	NOUN
admet-295	154	21	in	in	ADP
admet-295	154	22	the	the	DET
admet-295	154	23	placebo	placebo	NOUN
admet-295	154	24	group	group	NOUN
admet-295	154	25	.	.	PUNCT
admet-295	155	1	one	one	NUM
admet-295	155	2	meta	meta	ADJ
admet-295	155	3	-	-	PUNCT
admet-295	155	4	analysis	analysis	NOUN
admet-295	155	5	involving	involve	VERB
admet-295	155	6	10,255	10,255	NUM
admet-295	155	7	patients	patient	NOUN
admet-295	155	8	receiving	receive	VERB
admet-295	155	9	sunitinib	sunitinib	NOUN
admet-295	155	10	and	and	CCONJ
admet-295	155	11	sorafenib	sorafenib	NOUN
admet-295	155	12	revealed	reveal	VERB
admet-295	155	13	an	an	DET
admet-295	155	14	incidence	incidence	NOUN
admet-295	155	15	of	of	ADP
admet-295	155	16	ates	ates	PROPN
admet-295	155	17	to	to	PART
admet-295	155	18	be	be	AUX
admet-295	155	19	1.4	1.4	NUM
admet-295	155	20	%	%	NOUN
admet-295	155	21	(	(	PUNCT
admet-295	155	22	95	95	NUM
admet-295	155	23	%	%	NOUN
admet-295	155	24	ci	ci	NOUN
admet-295	155	25	:	:	PUNCT
admet-295	155	26	1.2–1.6	1.2–1.6	X
admet-295	155	27	)	)	PUNCT
admet-295	156	1	[	[	X
admet-295	156	2	23	23	NUM
admet-295	156	3	]	]	PUNCT
admet-295	156	4	.	.	PUNCT
admet-295	157	1	another	another	DET
admet-295	157	2	meta	meta	ADJ
admet-295	157	3	-	-	PUNCT
admet-295	157	4	analysis	analysis	NOUN
admet-295	157	5	involving	involve	VERB
admet-295	157	6	a	a	DET
admet-295	157	7	total	total	NOUN
admet-295	157	8	of	of	ADP
admet-295	157	9	9,711	9,711	NUM
admet-295	157	10	patients	patient	NOUN
admet-295	157	11	from	from	ADP
admet-295	157	12	19	19	NUM
admet-295	157	13	trials	trial	NOUN
admet-295	157	14	concluded	conclude	VERB
admet-295	157	15	that	that	SCONJ
admet-295	157	16	the	the	DET
admet-295	157	17	overall	overall	ADJ
admet-295	157	18	incidence	incidence	NOUN
admet-295	157	19	of	of	ADP
admet-295	157	20	ates	ates	PROPN
admet-295	157	21	was	be	AUX
admet-295	157	22	1.5	1.5	NUM
admet-295	157	23	%	%	NOUN
admet-295	157	24	(	(	PUNCT
admet-295	157	25	95	95	NUM
admet-295	157	26	%	%	NOUN
admet-295	157	27	ci	ci	NOUN
admet-295	157	28	:	:	PUNCT
admet-295	157	29	1.0–2.3	1.0–2.3	NUM
admet-295	157	30	)	)	PUNCT
admet-295	157	31	following	follow	VERB
admet-295	157	32	the	the	DET
admet-295	157	33	use	use	NOUN
admet-295	157	34	of	of	ADP
admet-295	157	35	vegfr	vegfr	ADJ
admet-295	157	36	admet	admet	PROPN
admet-295	157	37	&	&	CCONJ
admet-295	157	38	dmpk	dmpk	PROPN
admet-295	157	39	4(3	4(3	NUM
admet-295	157	40	)	)	PUNCT
admet-295	157	41	(	(	PUNCT
admet-295	157	42	2016	2016	NUM
admet-295	157	43	)	)	PUNCT
admet-295	157	44	212	212	NUM
admet-295	157	45	-	-	SYM
admet-295	157	46	231	231	NUM
admet-295	157	47	pkis	pki	NOUN
admet-295	157	48	and	and	CCONJ
admet-295	157	49	qt	qt	NOUN
admet-295	157	50	-	-	PUNCT
admet-295	157	51	phobia	phobia	NOUN
admet-295	157	52	doi	doi	NOUN
admet-295	157	53	:	:	PUNCT
admet-295	157	54	10.5599	10.5599	NUM
admet-295	157	55	/	/	SYM
admet-295	157	56	admet.4.3.295	admet.4.3.295	NOUN
admet-295	157	57	221	221	NUM
admet-295	157	58	pkis	pki	NOUN
admet-295	158	1	[	[	X
admet-295	158	2	24	24	NUM
admet-295	158	3	]	]	PUNCT
admet-295	158	4	.	.	PUNCT
admet-295	159	1	the	the	DET
admet-295	159	2	most	most	ADV
admet-295	159	3	common	common	ADJ
admet-295	159	4	ates	ate	NOUN
admet-295	159	5	were	be	AUX
admet-295	159	6	myocardial	myocardial	ADJ
admet-295	159	7	ischaemia	ischaemia	NOUN
admet-295	159	8	/	/	SYM
admet-295	159	9	infarction	infarction	NOUN
admet-295	159	10	(	(	PUNCT
admet-295	159	11	67.4	67.4	NUM
admet-295	159	12	%	%	NOUN
admet-295	159	13	)	)	PUNCT
admet-295	159	14	,	,	PUNCT
admet-295	159	15	central	central	ADJ
admet-295	159	16	nervous	nervous	ADJ
admet-295	159	17	system	system	NOUN
admet-295	159	18	ischaemia	ischaemia	NOUN
admet-295	159	19	(	(	PUNCT
admet-295	159	20	7.9	7.9	NUM
admet-295	159	21	%	%	NOUN
admet-295	159	22	)	)	PUNCT
admet-295	159	23	and	and	CCONJ
admet-295	159	24	cva	cva	PROPN
admet-295	159	25	(	(	PUNCT
admet-295	159	26	6.7	6.7	NUM
admet-295	159	27	%	%	NOUN
admet-295	159	28	)	)	PUNCT
admet-295	159	29	.	.	PUNCT
admet-295	160	1	the	the	DET
admet-295	160	2	odds	odd	NOUN
admet-295	160	3	ratio	ratio	NOUN
admet-295	160	4	(	(	PUNCT
admet-295	160	5	or	or	CCONJ
admet-295	160	6	)	)	PUNCT
admet-295	160	7	was	be	AUX
admet-295	160	8	significantly	significantly	ADV
admet-295	160	9	increased	increase	VERB
admet-295	160	10	when	when	SCONJ
admet-295	160	11	compared	compare	VERB
admet-295	160	12	with	with	ADP
admet-295	160	13	controls	control	NOUN
admet-295	160	14	(	(	PUNCT
admet-295	160	15	or	or	CCONJ
admet-295	160	16	2.26	2.26	NUM
admet-295	160	17	,	,	PUNCT
admet-295	160	18	95	95	NUM
admet-295	160	19	%	%	NOUN
admet-295	160	20	ci	ci	NOUN
admet-295	160	21	:	:	PUNCT
admet-295	160	22	1.38–3.68	1.38–3.68	NUM
admet-295	160	23	;	;	PUNCT
admet-295	160	24	p	p	PROPN
admet-295	160	25	=	=	NOUN
admet-295	160	26	0.001	0.001	NUM
admet-295	160	27	)	)	PUNCT
admet-295	160	28	and	and	CCONJ
admet-295	160	29	this	this	PRON
admet-295	160	30	did	do	AUX
admet-295	160	31	not	not	PART
admet-295	160	32	vary	vary	VERB
admet-295	160	33	significantly	significantly	ADV
admet-295	160	34	with	with	ADP
admet-295	160	35	tumour	tumour	ADJ
admet-295	160	36	types	type	NOUN
admet-295	160	37	(	(	PUNCT
admet-295	160	38	p	p	NOUN
admet-295	160	39	=	=	NOUN
admet-295	160	40	0.70	0.70	NUM
admet-295	160	41	)	)	PUNCT
admet-295	160	42	,	,	PUNCT
admet-295	160	43	vegfr	vegfr	NOUN
admet-295	160	44	pkis	pki	NOUN
admet-295	160	45	(	(	PUNCT
admet-295	160	46	p	p	NOUN
admet-295	160	47	=	=	NOUN
admet-295	160	48	0.32	0.32	NUM
admet-295	160	49	)	)	PUNCT
admet-295	160	50	,	,	PUNCT
admet-295	160	51	treatment	treatment	NOUN
admet-295	160	52	regimens	regimen	NOUN
admet-295	160	53	(	(	PUNCT
admet-295	160	54	p	p	X
admet-295	160	55	=	=	NOUN
admet-295	160	56	0.76	0.76	NUM
admet-295	160	57	)	)	PUNCT
admet-295	160	58	,	,	PUNCT
admet-295	160	59	phase	phase	NOUN
admet-295	160	60	of	of	ADP
admet-295	160	61	trials	trial	NOUN
admet-295	160	62	(	(	PUNCT
admet-295	160	63	p	p	NOUN
admet-295	160	64	=	=	NOUN
admet-295	160	65	0.37	0.37	NUM
admet-295	160	66	)	)	PUNCT
admet-295	160	67	and	and	CCONJ
admet-295	160	68	sample	sample	NOUN
admet-295	160	69	size	size	NOUN
admet-295	160	70	(	(	PUNCT
admet-295	160	71	p	p	NOUN
admet-295	160	72	=	=	NOUN
admet-295	160	73	0.89	0.89	NUM
admet-295	160	74	)	)	PUNCT
admet-295	160	75	.	.	PUNCT
admet-295	161	1	thus	thus	ADV
admet-295	161	2	,	,	PUNCT
admet-295	161	3	the	the	DET
admet-295	161	4	overall	overall	ADJ
admet-295	161	5	incidence	incidence	NOUN
admet-295	161	6	of	of	ADP
admet-295	161	7	ates	ates	PROPN
admet-295	161	8	with	with	ADP
admet-295	161	9	vegfr	vegfr	ADJ
admet-295	161	10	inhibitors	inhibitor	NOUN
admet-295	161	11	is	be	AUX
admet-295	161	12	about	about	ADV
admet-295	161	13	1.50	1.50	NUM
admet-295	161	14	%	%	NOUN
admet-295	161	15	with	with	ADP
admet-295	161	16	an	an	DET
admet-295	161	17	rr	rr	NOUN
admet-295	161	18	in	in	ADP
admet-295	161	19	the	the	DET
admet-295	161	20	region	region	NOUN
admet-295	161	21	of	of	ADP
admet-295	161	22	2.6	2.6	NUM
admet-295	161	23	.	.	PUNCT
admet-295	162	1	available	available	ADJ
admet-295	162	2	limited	limited	ADJ
admet-295	162	3	evidence	evidence	NOUN
admet-295	162	4	suggests	suggest	VERB
admet-295	162	5	that	that	SCONJ
admet-295	162	6	egfr	egfr	ADJ
admet-295	162	7	inhibitors	inhibitor	NOUN
admet-295	162	8	may	may	AUX
admet-295	162	9	not	not	PART
admet-295	162	10	be	be	AUX
admet-295	162	11	associated	associate	VERB
admet-295	162	12	with	with	ADP
admet-295	162	13	this	this	DET
admet-295	162	14	risk	risk	NOUN
admet-295	162	15	.	.	PUNCT
admet-295	163	1	in	in	ADP
admet-295	163	2	a	a	DET
admet-295	163	3	post	post	ADJ
admet-295	163	4	-	-	ADJ
admet-295	163	5	marketing	marketing	ADJ
admet-295	163	6	observational	observational	ADJ
admet-295	163	7	study	study	NOUN
admet-295	163	8	by	by	ADP
admet-295	163	9	srikanthan	srikanthan	PROPN
admet-295	163	10	et	et	PROPN
admet-295	163	11	al	al	PROPN
admet-295	163	12	.	.	PUNCT
admet-295	164	1	[	[	X
admet-295	164	2	92	92	NUM
admet-295	164	3	]	]	PUNCT
admet-295	164	4	,	,	PUNCT
admet-295	164	5	three	three	NUM
admet-295	164	6	agents	agent	NOUN
admet-295	164	7	were	be	AUX
admet-295	164	8	studied	study	VERB
admet-295	164	9	:	:	PUNCT
admet-295	164	10	erlotinib	erlotinib	NOUN
admet-295	164	11	,	,	PUNCT
admet-295	164	12	sorafenib	sorafenib	NOUN
admet-295	164	13	and	and	CCONJ
admet-295	164	14	sunitinib	sunitinib	NOUN
admet-295	164	15	.	.	PUNCT
admet-295	165	1	patients	patient	NOUN
admet-295	165	2	treated	treat	VERB
admet-295	165	3	with	with	ADP
admet-295	165	4	these	these	DET
admet-295	165	5	agents	agent	NOUN
admet-295	165	6	were	be	AUX
admet-295	165	7	compared	compare	VERB
admet-295	165	8	to	to	ADP
admet-295	165	9	128,415	128,415	NUM
admet-295	165	10	age	age	NOUN
admet-295	165	11	and	and	CCONJ
admet-295	165	12	gender	gender	NOUN
admet-295	165	13	matched	match	VERB
admet-295	165	14	individuals	individual	NOUN
admet-295	165	15	without	without	ADP
admet-295	165	16	cancer	cancer	NOUN
admet-295	165	17	who	who	PRON
admet-295	165	18	served	serve	VERB
admet-295	165	19	as	as	ADP
admet-295	165	20	controls	control	NOUN
admet-295	165	21	.	.	PUNCT
admet-295	166	1	of	of	ADP
admet-295	166	2	the	the	DET
admet-295	166	3	1,642	1,642	NUM
admet-295	166	4	pki	pki	NOUN
admet-295	166	5	-	-	VERB
admet-295	166	6	treated	treat	VERB
admet-295	166	7	patients	patient	NOUN
admet-295	166	8	followed	follow	VERB
admet-295	166	9	up	up	ADP
admet-295	166	10	,	,	PUNCT
admet-295	166	11	1.1	1.1	NUM
admet-295	166	12	%	%	NOUN
admet-295	166	13	developed	develop	VERB
admet-295	166	14	a	a	DET
admet-295	166	15	myocardial	myocardial	ADJ
admet-295	166	16	ischaemic	ischaemic	ADJ
admet-295	166	17	event	event	NOUN
admet-295	166	18	requiring	require	VERB
admet-295	166	19	hospitalization	hospitalization	NOUN
admet-295	166	20	,	,	PUNCT
admet-295	166	21	0.7	0.7	NUM
admet-295	166	22	%	%	NOUN
admet-295	166	23	developed	develop	VERB
admet-295	166	24	a	a	DET
admet-295	166	25	cva	cva	NOUN
admet-295	166	26	requiring	require	VERB
admet-295	166	27	hospitalization	hospitalization	NOUN
admet-295	166	28	and	and	CCONJ
admet-295	166	29	1,184	1,184	NUM
admet-295	166	30	(	(	PUNCT
admet-295	166	31	72.1	72.1	NUM
admet-295	166	32	%	%	NOUN
admet-295	166	33	)	)	PUNCT
admet-295	166	34	died	die	VERB
admet-295	166	35	.	.	PUNCT
admet-295	167	1	61	61	NUM
admet-295	167	2	%	%	NOUN
admet-295	167	3	of	of	ADP
admet-295	167	4	the	the	DET
admet-295	167	5	myocardial	myocardial	ADJ
admet-295	167	6	ischaemic	ischaemic	ADJ
admet-295	167	7	event	event	NOUN
admet-295	167	8	events	event	NOUN
admet-295	167	9	and	and	CCONJ
admet-295	167	10	73	73	NUM
admet-295	167	11	%	%	NOUN
admet-295	167	12	of	of	ADP
admet-295	167	13	the	the	DET
admet-295	167	14	cva	cva	PROPN
admet-295	167	15	events	event	NOUN
admet-295	167	16	were	be	AUX
admet-295	167	17	associated	associate	VERB
admet-295	167	18	with	with	ADP
admet-295	167	19	erlotinib	erlotinib	NOUN
admet-295	167	20	,	,	PUNCT
admet-295	167	21	and	and	CCONJ
admet-295	167	22	these	these	DET
admet-295	167	23	proportions	proportion	NOUN
admet-295	167	24	closely	closely	ADV
admet-295	167	25	mirrored	mirror	VERB
admet-295	167	26	the	the	DET
admet-295	167	27	relative	relative	ADJ
admet-295	167	28	frequency	frequency	NOUN
admet-295	167	29	of	of	ADP
admet-295	167	30	drug	drug	NOUN
admet-295	167	31	use	use	NOUN
admet-295	167	32	in	in	ADP
admet-295	167	33	the	the	DET
admet-295	167	34	population	population	NOUN
admet-295	167	35	.	.	PUNCT
admet-295	168	1	cardiovascular	cardiovascular	ADJ
admet-295	168	2	events	event	NOUN
admet-295	168	3	predominantly	predominantly	ADV
admet-295	168	4	occurred	occur	VERB
admet-295	168	5	late	late	ADV
admet-295	168	6	in	in	ADP
admet-295	168	7	follow	follow	NOUN
admet-295	168	8	-	-	PUNCT
admet-295	168	9	up	up	NOUN
admet-295	168	10	.	.	PUNCT
admet-295	169	1	when	when	SCONJ
admet-295	169	2	patients	patient	NOUN
admet-295	169	3	with	with	ADP
admet-295	169	4	and	and	CCONJ
admet-295	169	5	without	without	ADP
admet-295	169	6	baseline	baseline	ADJ
admet-295	169	7	ischaemic	ischaemic	ADJ
admet-295	169	8	heart	heart	NOUN
admet-295	169	9	disease	disease	NOUN
admet-295	169	10	were	be	AUX
admet-295	169	11	compared	compare	VERB
admet-295	169	12	,	,	PUNCT
admet-295	169	13	3.3	3.3	NUM
admet-295	169	14	%	%	NOUN
admet-295	169	15	versus	versus	ADP
admet-295	169	16	0.5	0.5	NUM
admet-295	169	17	%	%	NOUN
admet-295	169	18	,	,	PUNCT
admet-295	169	19	respectively	respectively	ADV
admet-295	169	20	,	,	PUNCT
admet-295	169	21	developed	develop	VERB
admet-295	169	22	a	a	DET
admet-295	169	23	myocardial	myocardial	ADJ
admet-295	169	24	ischaemic	ischaemic	ADJ
admet-295	169	25	event	event	NOUN
admet-295	169	26	and	and	CCONJ
admet-295	169	27	1.2	1.2	NUM
admet-295	169	28	%	%	NOUN
admet-295	169	29	versus	versus	ADP
admet-295	169	30	0.5	0.5	NUM
admet-295	169	31	%	%	NOUN
admet-295	169	32	,	,	PUNCT
admet-295	169	33	respectively	respectively	ADV
admet-295	169	34	,	,	PUNCT
admet-295	169	35	developed	developed	ADJ
admet-295	169	36	cva	cva	PROPN
admet-295	169	37	.	.	PUNCT
admet-295	170	1	however	however	ADV
admet-295	170	2	,	,	PUNCT
admet-295	170	3	the	the	DET
admet-295	170	4	mortality	mortality	NOUN
admet-295	170	5	rates	rate	NOUN
admet-295	170	6	were	be	AUX
admet-295	170	7	no	no	ADV
admet-295	170	8	different	different	ADJ
admet-295	170	9	(	(	PUNCT
admet-295	170	10	72.5	72.5	NUM
admet-295	170	11	%	%	NOUN
admet-295	170	12	vs.	vs.	ADP
admet-295	170	13	72.0	72.0	NUM
admet-295	170	14	%	%	NOUN
admet-295	170	15	,	,	PUNCT
admet-295	170	16	respectively	respectively	ADV
admet-295	170	17	)	)	PUNCT
admet-295	170	18	.	.	PUNCT
admet-295	171	1	these	these	DET
admet-295	171	2	investigators	investigator	NOUN
admet-295	171	3	summarised	summarise	VERB
admet-295	171	4	that	that	SCONJ
admet-295	171	5	individuals	individual	NOUN
admet-295	171	6	treated	treat	VERB
admet-295	171	7	with	with	ADP
admet-295	171	8	pkis	pki	NOUN
admet-295	171	9	have	have	VERB
admet-295	171	10	a	a	DET
admet-295	171	11	significantly	significantly	ADV
admet-295	171	12	higher	high	ADJ
admet-295	171	13	hazard	hazard	NOUN
admet-295	171	14	of	of	ADP
admet-295	171	15	death	death	NOUN
admet-295	171	16	relative	relative	ADJ
admet-295	171	17	to	to	ADP
admet-295	171	18	the	the	DET
admet-295	171	19	general	general	ADJ
admet-295	171	20	population	population	NOUN
admet-295	171	21	but	but	CCONJ
admet-295	171	22	cause	cause	NOUN
admet-295	171	23	-	-	PUNCT
admet-295	171	24	specific	specific	ADJ
admet-295	171	25	hazards	hazard	NOUN
admet-295	171	26	of	of	ADP
admet-295	171	27	ischaemic	ischaemic	ADJ
admet-295	171	28	heart	heart	NOUN
admet-295	171	29	disease	disease	NOUN
admet-295	171	30	and	and	CCONJ
admet-295	171	31	cerebrovascular	cerebrovascular	ADJ
admet-295	171	32	accidents	accident	NOUN
admet-295	171	33	are	be	AUX
admet-295	171	34	not	not	PART
admet-295	171	35	increased	increase	VERB
admet-295	171	36	.	.	PUNCT
admet-295	172	1	jang	jang	PROPN
admet-295	172	2	et	et	PROPN
admet-295	172	3	al	al	PROPN
admet-295	172	4	.	.	PUNCT
admet-295	173	1	[	[	X
admet-295	173	2	93	93	NUM
admet-295	173	3	]	]	PUNCT
admet-295	173	4	have	have	AUX
admet-295	173	5	recently	recently	ADV
admet-295	173	6	reported	report	VERB
admet-295	173	7	cardiovascular	cardiovascular	ADJ
admet-295	173	8	events	event	NOUN
admet-295	173	9	in	in	ADP
admet-295	173	10	171	171	NUM
admet-295	173	11	(	(	PUNCT
admet-295	173	12	26	26	NUM
admet-295	173	13	%	%	NOUN
admet-295	173	14	)	)	PUNCT
admet-295	173	15	of	of	ADP
admet-295	173	16	the	the	DET
admet-295	173	17	670	670	NUM
admet-295	173	18	patients	patient	NOUN
admet-295	173	19	aged	age	VERB
admet-295	173	20	>	>	X
admet-295	173	21	65	65	NUM
admet-295	173	22	years	year	NOUN
admet-295	173	23	treated	treat	VERB
admet-295	173	24	with	with	ADP
admet-295	173	25	sunitinib	sunitinib	NOUN
admet-295	173	26	or	or	CCONJ
admet-295	173	27	sorafenib	sorafenib	NOUN
admet-295	173	28	.	.	PUNCT
admet-295	174	1	the	the	DET
admet-295	174	2	incidence	incidence	NOUN
admet-295	174	3	rates	rate	NOUN
admet-295	174	4	for	for	ADP
admet-295	174	5	chf	chf	NOUN
admet-295	174	6	or	or	CCONJ
admet-295	174	7	cardiomyopathy	cardiomyopathy	ADJ
admet-295	174	8	,	,	PUNCT
admet-295	174	9	acute	acute	ADJ
admet-295	174	10	myocardial	myocardial	ADJ
admet-295	174	11	infarction	infarction	NOUN
admet-295	174	12	and	and	CCONJ
admet-295	174	13	stroke	stroke	NOUN
admet-295	174	14	were	be	AUX
admet-295	174	15	0.87	0.87	NUM
admet-295	174	16	,	,	PUNCT
admet-295	174	17	0.14	0.14	NUM
admet-295	174	18	,	,	PUNCT
admet-295	174	19	and	and	CCONJ
admet-295	174	20	0.14	0.14	NUM
admet-295	174	21	per	per	ADP
admet-295	174	22	1000	1000	NUM
admet-295	174	23	person	person	NOUN
admet-295	174	24	-	-	PUNCT
admet-295	174	25	days	day	NOUN
admet-295	174	26	,	,	PUNCT
admet-295	174	27	respectively	respectively	ADV
admet-295	174	28	.	.	PUNCT
admet-295	175	1	the	the	DET
admet-295	175	2	use	use	NOUN
admet-295	175	3	of	of	ADP
admet-295	175	4	either	either	DET
admet-295	175	5	agent	agent	NOUN
admet-295	175	6	was	be	AUX
admet-295	175	7	associated	associate	VERB
admet-295	175	8	with	with	ADP
admet-295	175	9	an	an	DET
admet-295	175	10	increased	increase	VERB
admet-295	175	11	risk	risk	NOUN
admet-295	175	12	of	of	ADP
admet-295	175	13	cardiovascular	cardiovascular	ADJ
admet-295	175	14	events	event	NOUN
admet-295	175	15	(	(	PUNCT
admet-295	175	16	hazard	hazard	NOUN
admet-295	175	17	ratio	ratio	NOUN
admet-295	175	18	(	(	PUNCT
admet-295	175	19	hr	hr	NOUN
admet-295	175	20	)	)	PUNCT
admet-295	175	21	1.38	1.38	NUM
admet-295	175	22	;	;	PUNCT
admet-295	175	23	95	95	NUM
admet-295	175	24	%	%	NOUN
admet-295	175	25	ci	ci	NOUN
admet-295	175	26	:	:	PUNCT
admet-295	175	27	1.02	1.02	NUM
admet-295	175	28	-	-	SYM
admet-295	175	29	1.87	1.87	NUM
admet-295	175	30	)	)	PUNCT
admet-295	175	31	and	and	CCONJ
admet-295	175	32	stroke	stroke	NOUN
admet-295	175	33	(	(	PUNCT
admet-295	175	34	hr	hr	NOUN
admet-295	175	35	2.84	2.84	NUM
admet-295	175	36	;	;	PUNCT
admet-295	175	37	95	95	NUM
admet-295	175	38	%	%	NOUN
admet-295	175	39	ci	ci	NOUN
admet-295	175	40	:	:	PUNCT
admet-295	175	41	1.52	1.52	NUM
admet-295	175	42	-	-	SYM
admet-295	175	43	5.31	5.31	NUM
admet-295	175	44	)	)	PUNCT
admet-295	175	45	in	in	ADP
admet-295	175	46	comparison	comparison	NOUN
admet-295	175	47	with	with	ADP
admet-295	175	48	788	788	NUM
admet-295	175	49	patients	patient	NOUN
admet-295	175	50	diagnosed	diagnose	VERB
admet-295	175	51	with	with	ADP
admet-295	175	52	advanced	advanced	ADJ
admet-295	175	53	renal	renal	ADJ
admet-295	175	54	cell	cell	NOUN
admet-295	175	55	carcinoma	carcinoma	NOUN
admet-295	175	56	who	who	PRON
admet-295	175	57	did	do	AUX
admet-295	175	58	not	not	PART
admet-295	175	59	receive	receive	VERB
admet-295	175	60	either	either	DET
admet-295	175	61	agent	agent	NOUN
admet-295	175	62	.	.	PUNCT
admet-295	176	1	case	case	NOUN
admet-295	176	2	of	of	ADP
admet-295	176	3	ponatinib	ponatinib	NOUN
admet-295	176	4	when	when	SCONJ
admet-295	176	5	first	first	ADV
admet-295	176	6	approved	approve	VERB
admet-295	176	7	in	in	ADP
admet-295	176	8	december	december	PROPN
admet-295	176	9	2012	2012	NUM
admet-295	176	10	,	,	PUNCT
admet-295	176	11	ponatinib	ponatinib	NOUN
admet-295	176	12	was	be	AUX
admet-295	176	13	already	already	ADV
admet-295	176	14	strongly	strongly	ADV
admet-295	176	15	associated	associate	VERB
admet-295	176	16	with	with	ADP
admet-295	176	17	cardiovascular	cardiovascular	ADJ
admet-295	176	18	,	,	PUNCT
admet-295	176	19	cerebrovascular	cerebrovascular	ADJ
admet-295	176	20	,	,	PUNCT
admet-295	176	21	and	and	CCONJ
admet-295	176	22	peripheral	peripheral	ADJ
admet-295	176	23	vascular	vascular	ADJ
admet-295	176	24	thrombosis	thrombosis	NOUN
admet-295	176	25	,	,	PUNCT
admet-295	176	26	including	include	VERB
admet-295	176	27	fatal	fatal	ADJ
admet-295	176	28	myocardial	myocardial	ADJ
admet-295	176	29	infarctions	infarction	NOUN
admet-295	176	30	and	and	CCONJ
admet-295	176	31	strokes	stroke	NOUN
admet-295	176	32	[	[	X
admet-295	176	33	94	94	NUM
admet-295	176	34	]	]	PUNCT
admet-295	176	35	.	.	PUNCT
admet-295	177	1	overall	overall	ADJ
admet-295	177	2	,	,	PUNCT
admet-295	177	3	fifty	fifty	NUM
admet-295	177	4	-	-	PUNCT
admet-295	177	5	one	one	NUM
admet-295	177	6	(	(	PUNCT
admet-295	177	7	11	11	NUM
admet-295	177	8	%	%	NOUN
admet-295	177	9	)	)	PUNCT
admet-295	177	10	of	of	ADP
admet-295	177	11	the	the	DET
admet-295	177	12	449	449	NUM
admet-295	177	13	patients	patient	NOUN
admet-295	177	14	experienced	experience	VERB
admet-295	177	15	an	an	DET
admet-295	177	16	arterial	arterial	ADJ
admet-295	177	17	thrombotic	thrombotic	ADJ
admet-295	177	18	event	event	NOUN
admet-295	177	19	of	of	ADP
admet-295	177	20	any	any	DET
admet-295	177	21	grade	grade	NOUN
admet-295	177	22	.	.	PUNCT
admet-295	178	1	myocardial	myocardial	ADJ
admet-295	178	2	infarction	infarction	NOUN
admet-295	178	3	or	or	CCONJ
admet-295	178	4	worsening	worsen	VERB
admet-295	178	5	coronary	coronary	ADJ
admet-295	178	6	artery	artery	NOUN
admet-295	178	7	disease	disease	NOUN
admet-295	178	8	was	be	AUX
admet-295	178	9	the	the	DET
admet-295	178	10	most	most	ADV
admet-295	178	11	common	common	ADJ
admet-295	178	12	event	event	NOUN
admet-295	178	13	which	which	PRON
admet-295	178	14	occurred	occur	VERB
admet-295	178	15	in	in	ADP
admet-295	178	16	21	21	NUM
admet-295	178	17	patients	patient	NOUN
admet-295	178	18	(	(	PUNCT
admet-295	178	19	5	5	NUM
admet-295	178	20	%	%	NOUN
admet-295	178	21	)	)	PUNCT
admet-295	178	22	of	of	ADP
admet-295	178	23	ponatinib	ponatinib	ADV
admet-295	178	24	-	-	PUNCT
admet-295	178	25	treated	treat	VERB
admet-295	178	26	patients	patient	NOUN
admet-295	178	27	.	.	PUNCT
admet-295	179	1	the	the	DET
admet-295	179	2	range	range	NOUN
admet-295	179	3	of	of	ADP
admet-295	179	4	events	event	NOUN
admet-295	179	5	included	include	VERB
admet-295	179	6	congestive	congestive	ADJ
admet-295	179	7	heart	heart	NOUN
admet-295	179	8	failure	failure	NOUN
admet-295	179	9	(	(	PUNCT
admet-295	179	10	concurrent	concurrent	ADJ
admet-295	179	11	or	or	CCONJ
admet-295	179	12	subsequent	subsequent	ADJ
admet-295	179	13	to	to	ADP
admet-295	179	14	the	the	DET
admet-295	179	15	myocardial	myocardial	PROPN
admet-295	179	16	ischaemia	ischaemia	PROPN
admet-295	179	17	)	)	PUNCT
admet-295	179	18	,	,	PUNCT
admet-295	179	19	cerebrovascular	cerebrovascular	ADJ
admet-295	179	20	events	event	NOUN
admet-295	179	21	,	,	PUNCT
admet-295	179	22	hemorrhagic	hemorrhagic	NOUN
admet-295	179	23	conversion	conversion	NOUN
admet-295	179	24	of	of	ADP
admet-295	179	25	the	the	DET
admet-295	179	26	initial	initial	ADJ
admet-295	179	27	ischemic	ischemic	ADJ
admet-295	179	28	event	event	NOUN
admet-295	179	29	,	,	PUNCT
admet-295	179	30	stenosis	stenosis	NOUN
admet-295	179	31	of	of	ADP
admet-295	179	32	large	large	ADJ
admet-295	179	33	arterial	arterial	ADJ
admet-295	179	34	vessels	vessel	NOUN
admet-295	179	35	of	of	ADP
admet-295	179	36	the	the	DET
admet-295	179	37	brain	brain	NOUN
admet-295	179	38	and	and	CCONJ
admet-295	179	39	peripheral	peripheral	ADJ
admet-295	179	40	arterial	arterial	ADJ
admet-295	179	41	events	event	NOUN
admet-295	179	42	with	with	ADP
admet-295	179	43	digital	digital	ADJ
admet-295	179	44	or	or	CCONJ
admet-295	179	45	distal	distal	ADJ
admet-295	179	46	extremity	extremity	NOUN
admet-295	179	47	necrosis	necrosis	NOUN
admet-295	179	48	.	.	PUNCT
admet-295	180	1	serious	serious	ADJ
admet-295	180	2	arterial	arterial	ADJ
admet-295	180	3	thrombosis	thrombosis	NOUN
admet-295	180	4	occurred	occur	VERB
admet-295	180	5	in	in	ADP
admet-295	180	6	34	34	NUM
admet-295	180	7	(	(	PUNCT
admet-295	180	8	8	8	NUM
admet-295	180	9	%	%	NOUN
admet-295	180	10	)	)	PUNCT
admet-295	180	11	of	of	ADP
admet-295	180	12	the	the	DET
admet-295	180	13	449	449	NUM
admet-295	180	14	of	of	ADP
admet-295	180	15	ponatinib	ponatinib	ADV
admet-295	180	16	-	-	PUNCT
admet-295	180	17	treated	treat	VERB
admet-295	180	18	patients	patient	NOUN
admet-295	180	19	,	,	PUNCT
admet-295	180	20	as	as	ADP
admet-295	180	21	a	a	DET
admet-295	180	22	consequence	consequence	NOUN
admet-295	180	23	of	of	ADP
admet-295	180	24	which	which	PRON
admet-295	180	25	21	21	NUM
admet-295	180	26	patients	patient	NOUN
admet-295	180	27	required	require	VERB
admet-295	180	28	various	various	ADJ
admet-295	180	29	revascularization	revascularization	NOUN
admet-295	180	30	procedures	procedure	NOUN
admet-295	180	31	.	.	PUNCT
admet-295	181	1	thirty	thirty	NUM
admet-295	181	2	of	of	ADP
admet-295	181	3	these	these	DET
admet-295	181	4	34	34	NUM
admet-295	181	5	patients	patient	NOUN
admet-295	181	6	had	have	VERB
admet-295	181	7	one	one	NUM
admet-295	181	8	or	or	CCONJ
admet-295	181	9	more	more	ADJ
admet-295	181	10	of	of	ADP
admet-295	181	11	the	the	DET
admet-295	181	12	well	well	ADV
admet-295	181	13	recognised	recognise	VERB
admet-295	181	14	cardiovascular	cardiovascular	ADJ
admet-295	181	15	risk	risk	NOUN
admet-295	181	16	factors	factor	NOUN
admet-295	181	17	.	.	PUNCT
admet-295	182	1	patients	patient	NOUN
admet-295	182	2	with	with	ADP
admet-295	182	3	cardiovascular	cardiovascular	ADJ
admet-295	182	4	risk	risk	NOUN
admet-295	182	5	factors	factor	NOUN
admet-295	182	6	appeared	appear	VERB
admet-295	182	7	to	to	PART
admet-295	182	8	be	be	AUX
admet-295	182	9	at	at	ADP
admet-295	182	10	increased	increase	VERB
admet-295	182	11	risk	risk	NOUN
admet-295	182	12	for	for	ADP
admet-295	182	13	arterial	arterial	ADJ
admet-295	182	14	thrombosis	thrombosis	NOUN
admet-295	182	15	following	follow	VERB
admet-295	182	16	treatment	treatment	NOUN
admet-295	182	17	with	with	ADP
admet-295	182	18	ponatinib	ponatinib	NOUN
admet-295	182	19	.	.	PUNCT
admet-295	183	1	as	as	ADP
admet-295	183	2	a	a	DET
admet-295	183	3	condition	condition	NOUN
admet-295	183	4	of	of	ADP
admet-295	183	5	approval	approval	NOUN
admet-295	183	6	,	,	PUNCT
admet-295	183	7	the	the	DET
admet-295	183	8	fda	fda	PROPN
admet-295	183	9	had	have	AUX
admet-295	183	10	required	require	VERB
admet-295	183	11	the	the	DET
admet-295	183	12	sponsor	sponsor	NOUN
admet-295	183	13	to	to	PART
admet-295	183	14	characterize	characterize	VERB
admet-295	183	15	the	the	DET
admet-295	183	16	safety	safety	NOUN
admet-295	183	17	of	of	ADP
admet-295	183	18	ponatinib	ponatinib	NOUN
admet-295	183	19	and	and	CCONJ
admet-295	183	20	submit	submit	VERB
admet-295	183	21	long	long	ADJ
admet-295	183	22	-	-	PUNCT
admet-295	183	23	term	term	NOUN
admet-295	183	24	safety	safety	NOUN
admet-295	183	25	data	datum	NOUN
admet-295	183	26	over	over	ADP
admet-295	183	27	a	a	DET
admet-295	183	28	follow	follow	NOUN
admet-295	183	29	-	-	PUNCT
admet-295	183	30	up	up	NOUN
admet-295	183	31	period	period	NOUN
admet-295	183	32	of	of	ADP
admet-295	183	33	at	at	ADV
admet-295	183	34	least	least	ADV
admet-295	183	35	12	12	NUM
admet-295	183	36	months	month	NOUN
admet-295	183	37	from	from	ADP
admet-295	183	38	all	all	DET
admet-295	183	39	ongoing	ongoing	ADJ
admet-295	183	40	patients	patient	NOUN
admet-295	183	41	in	in	ADP
admet-295	183	42	a	a	DET
admet-295	183	43	specific	specific	ADJ
admet-295	183	44	randomized	randomized	ADJ
admet-295	183	45	controlled	control	VERB
admet-295	183	46	trial	trial	NOUN
admet-295	183	47	(	(	PUNCT
admet-295	183	48	referred	refer	VERB
admet-295	183	49	to	to	ADP
admet-295	183	50	as	as	ADP
admet-295	183	51	ap24534	ap24534	PROPN
admet-295	183	52	-	-	PUNCT
admet-295	183	53	12	12	NUM
admet-295	183	54	-	-	NUM
admet-295	183	55	301	301	NUM
admet-295	183	56	)	)	PUNCT
admet-295	183	57	that	that	PRON
admet-295	183	58	adequately	adequately	ADV
admet-295	183	59	isolated	isolate	VERB
admet-295	183	60	the	the	DET
admet-295	183	61	effect	effect	NOUN
admet-295	183	62	of	of	ADP
admet-295	183	63	the	the	DET
admet-295	183	64	drug	drug	NOUN
admet-295	183	65	[	[	X
admet-295	183	66	95	95	NUM
admet-295	183	67	]	]	PUNCT
admet-295	183	68	.	.	PUNCT
admet-295	184	1	however	however	ADV
admet-295	184	2	,	,	PUNCT
admet-295	184	3	just	just	ADV
admet-295	184	4	over	over	ADP
admet-295	184	5	10	10	NUM
admet-295	184	6	months	month	NOUN
admet-295	184	7	later	later	ADV
admet-295	184	8	as	as	ADP
admet-295	184	9	of	of	ADP
admet-295	184	10	31	31	NUM
admet-295	184	11	october	october	NOUN
admet-295	184	12	2013	2013	NUM
admet-295	184	13	,	,	PUNCT
admet-295	184	14	approximately	approximately	ADV
admet-295	184	15	24	24	NUM
admet-295	184	16	%	%	NOUN
admet-295	184	17	of	of	ADP
admet-295	184	18	patients	patient	NOUN
admet-295	184	19	in	in	ADP
admet-295	184	20	one	one	NUM
admet-295	184	21	phase	phase	NOUN
admet-295	184	22	ii	ii	NOUN
admet-295	184	23	clinical	clinical	ADJ
admet-295	184	24	trial	trial	NOUN
admet-295	184	25	(	(	PUNCT
admet-295	184	26	median	median	ADJ
admet-295	184	27	treatment	treatment	NOUN
admet-295	184	28	duration	duration	NOUN
admet-295	184	29	1.3	1.3	NUM
admet-295	184	30	years	year	NOUN
admet-295	184	31	)	)	PUNCT
admet-295	184	32	and	and	CCONJ
admet-295	184	33	approximately	approximately	ADV
admet-295	184	34	48	48	NUM
admet-295	184	35	%	%	NOUN
admet-295	184	36	of	of	ADP
admet-295	184	37	patients	patient	NOUN
admet-295	184	38	in	in	ADP
admet-295	184	39	a	a	DET
admet-295	184	40	phase	phase	NOUN
admet-295	184	41	i	i	PRON
admet-295	184	42	clinical	clinical	ADJ
admet-295	184	43	trial	trial	NOUN
admet-295	184	44	(	(	PUNCT
admet-295	184	45	median	median	ADJ
admet-295	184	46	treatment	treatment	NOUN
admet-295	184	47	duration	duration	NOUN
admet-295	184	48	2.7	2.7	NUM
admet-295	184	49	years	year	NOUN
admet-295	184	50	)	)	PUNCT
admet-295	184	51	had	have	AUX
admet-295	184	52	experienced	experience	VERB
admet-295	184	53	serious	serious	ADJ
admet-295	184	54	adverse	adverse	ADJ
admet-295	184	55	vascular	vascular	ADJ
admet-295	184	56	events	event	NOUN
admet-295	184	57	[	[	X
admet-295	184	58	96	96	NUM
admet-295	184	59	]	]	PUNCT
admet-295	184	60	.	.	PUNCT
admet-295	185	1	a	a	DET
admet-295	185	2	rashmi	rashmi	PROPN
admet-295	185	3	shah	shah	PROPN
admet-295	185	4	admet	admet	PROPN
admet-295	185	5	&	&	CCONJ
admet-295	185	6	dmpk	dmpk	PROPN
admet-295	185	7	4(3	4(3	NUM
admet-295	185	8	)	)	PUNCT
admet-295	185	9	(	(	PUNCT
admet-295	185	10	2016	2016	NUM
admet-295	185	11	)	)	PUNCT
admet-295	185	12	212	212	NUM
admet-295	185	13	-	-	SYM
admet-295	185	14	231	231	NUM
admet-295	185	15	222	222	NUM
admet-295	185	16	number	number	NOUN
admet-295	185	17	of	of	ADP
admet-295	185	18	these	these	DET
admet-295	185	19	patients	patient	NOUN
admet-295	185	20	required	require	VERB
admet-295	185	21	urgent	urgent	ADJ
admet-295	185	22	surgical	surgical	ADJ
admet-295	185	23	procedures	procedure	NOUN
admet-295	185	24	to	to	PART
admet-295	185	25	restore	restore	VERB
admet-295	185	26	blood	blood	NOUN
admet-295	185	27	flow	flow	NOUN
admet-295	185	28	.	.	PUNCT
admet-295	186	1	in	in	ADP
admet-295	186	2	some	some	DET
admet-295	186	3	patients	patient	NOUN
admet-295	186	4	,	,	PUNCT
admet-295	186	5	fatal	fatal	ADJ
admet-295	186	6	and	and	CCONJ
admet-295	186	7	serious	serious	ADJ
admet-295	186	8	adverse	adverse	ADJ
admet-295	186	9	events	event	NOUN
admet-295	186	10	occurred	occur	VERB
admet-295	186	11	as	as	ADV
admet-295	186	12	early	early	ADV
admet-295	186	13	as	as	ADP
admet-295	186	14	2	2	NUM
admet-295	186	15	weeks	week	NOUN
admet-295	187	1	after	after	ADP
admet-295	187	2	starting	start	VERB
admet-295	187	3	ponatinib	ponatinib	NOUN
admet-295	187	4	therapy	therapy	NOUN
admet-295	187	5	.	.	PUNCT
admet-295	188	1	since	since	SCONJ
admet-295	188	2	a	a	DET
admet-295	188	3	safe	safe	ADJ
admet-295	188	4	dose	dose	NOUN
admet-295	188	5	or	or	CCONJ
admet-295	188	6	duration	duration	NOUN
admet-295	188	7	of	of	ADP
admet-295	188	8	exposure	exposure	NOUN
admet-295	188	9	could	could	AUX
admet-295	188	10	not	not	PART
admet-295	188	11	be	be	AUX
admet-295	188	12	identified	identify	VERB
admet-295	188	13	,	,	PUNCT
admet-295	188	14	the	the	DET
admet-295	188	15	sponsor	sponsor	NOUN
admet-295	188	16	agreed	agree	VERB
admet-295	188	17	to	to	ADP
admet-295	188	18	the	the	DET
admet-295	188	19	request	request	NOUN
admet-295	188	20	from	from	ADP
admet-295	188	21	the	the	DET
admet-295	188	22	fda	fda	PROPN
admet-295	188	23	to	to	PART
admet-295	188	24	suspend	suspend	VERB
admet-295	188	25	marketing	marketing	NOUN
admet-295	188	26	and	and	CCONJ
admet-295	188	27	sales	sale	NOUN
admet-295	188	28	of	of	ADP
admet-295	188	29	ponatinib	ponatinib	NOUN
admet-295	188	30	[	[	X
admet-295	188	31	96	96	NUM
admet-295	188	32	]	]	PUNCT
admet-295	188	33	.	.	PUNCT
admet-295	189	1	following	follow	VERB
admet-295	189	2	a	a	DET
admet-295	189	3	thorough	thorough	ADJ
admet-295	189	4	assessment	assessment	NOUN
admet-295	189	5	of	of	ADP
admet-295	189	6	all	all	DET
admet-295	189	7	available	available	ADJ
admet-295	189	8	data	datum	NOUN
admet-295	189	9	,	,	PUNCT
admet-295	189	10	the	the	DET
admet-295	189	11	fda	fda	PROPN
admet-295	189	12	on	on	ADP
admet-295	189	13	20	20	NUM
admet-295	189	14	december	december	PROPN
admet-295	189	15	2013	2013	NUM
admet-295	189	16	required	require	VERB
admet-295	189	17	several	several	ADJ
admet-295	189	18	new	new	ADJ
admet-295	189	19	safety	safety	NOUN
admet-295	189	20	measures	measure	NOUN
admet-295	189	21	to	to	PART
admet-295	189	22	be	be	AUX
admet-295	189	23	implemented	implement	VERB
admet-295	189	24	,	,	PUNCT
admet-295	189	25	including	include	VERB
admet-295	189	26	restricted	restrict	VERB
admet-295	189	27	indication	indication	NOUN
admet-295	189	28	and	and	CCONJ
admet-295	189	29	additional	additional	ADJ
admet-295	189	30	warnings	warning	NOUN
admet-295	189	31	and	and	CCONJ
admet-295	189	32	precautions	precaution	NOUN
admet-295	189	33	,	,	PUNCT
admet-295	189	34	before	before	ADP
admet-295	189	35	resumption	resumption	NOUN
admet-295	189	36	of	of	ADP
admet-295	189	37	marketing	marketing	NOUN
admet-295	189	38	to	to	AUX
admet-295	189	39	appropriate	appropriate	ADJ
admet-295	189	40	patients	patient	NOUN
admet-295	189	41	[	[	X
admet-295	189	42	97	97	NUM
admet-295	189	43	]	]	PUNCT
admet-295	189	44	.	.	PUNCT
admet-295	190	1	the	the	DET
admet-295	190	2	fda	fda	PROPN
admet-295	190	3	also	also	ADV
admet-295	190	4	required	require	VERB
admet-295	190	5	a	a	DET
admet-295	190	6	risk	risk	NOUN
admet-295	190	7	evaluation	evaluation	NOUN
admet-295	190	8	and	and	CCONJ
admet-295	190	9	mitigation	mitigation	NOUN
admet-295	190	10	strategy	strategy	NOUN
admet-295	190	11	(	(	PUNCT
admet-295	190	12	rems	rem	NOUN
admet-295	190	13	)	)	PUNCT
admet-295	190	14	and	and	CCONJ
admet-295	190	15	the	the	DET
admet-295	190	16	sponsor	sponsor	NOUN
admet-295	190	17	to	to	PART
admet-295	190	18	conduct	conduct	VERB
admet-295	190	19	post	post	ADJ
admet-295	190	20	-	-	ADJ
admet-295	190	21	marketing	marketing	ADJ
admet-295	190	22	investigations	investigation	NOUN
admet-295	190	23	to	to	PART
admet-295	190	24	further	far	ADV
admet-295	190	25	characterise	characterise	VERB
admet-295	190	26	the	the	DET
admet-295	190	27	dose	dose	NOUN
admet-295	190	28	and	and	CCONJ
admet-295	190	29	the	the	DET
admet-295	190	30	safety	safety	NOUN
admet-295	190	31	of	of	ADP
admet-295	190	32	the	the	DET
admet-295	190	33	drug	drug	NOUN
admet-295	190	34	.	.	PUNCT
admet-295	191	1	the	the	DET
admet-295	191	2	most	most	ADV
admet-295	191	3	current	current	ADJ
admet-295	191	4	label	label	NOUN
admet-295	191	5	for	for	ADP
admet-295	191	6	ponatinib	ponatinib	NOUN
admet-295	191	7	,	,	PUNCT
admet-295	191	8	dated	date	VERB
admet-295	191	9	2	2	NUM
admet-295	191	10	june	june	PROPN
admet-295	191	11	2016	2016	NUM
admet-295	192	1	[	[	X
admet-295	192	2	98	98	NUM
admet-295	192	3	]	]	PUNCT
admet-295	192	4	,	,	PUNCT
admet-295	192	5	includes	include	VERB
admet-295	192	6	a	a	DET
admet-295	192	7	more	more	ADV
admet-295	192	8	detailed	detailed	ADJ
admet-295	192	9	account	account	NOUN
admet-295	192	10	of	of	ADP
admet-295	192	11	vascular	vascular	ADJ
admet-295	192	12	occlusion	occlusion	NOUN
admet-295	192	13	with	with	ADP
admet-295	192	14	age	age	NOUN
admet-295	192	15	-	-	PUNCT
admet-295	192	16	related	relate	VERB
admet-295	192	17	increase	increase	NOUN
admet-295	192	18	in	in	ADP
admet-295	192	19	incidence	incidence	NOUN
admet-295	192	20	(	(	PUNCT
admet-295	192	21	18	18	NUM
admet-295	192	22	%	%	NOUN
admet-295	192	23	,	,	PUNCT
admet-295	192	24	33	33	NUM
admet-295	192	25	%	%	NOUN
admet-295	192	26	and	and	CCONJ
admet-295	192	27	56	56	NUM
admet-295	192	28	%	%	NOUN
admet-295	192	29	for	for	ADP
admet-295	192	30	those	those	DET
admet-295	192	31	aged	age	VERB
admet-295	192	32			NOUN
admet-295	192	33	49	49	NUM
admet-295	192	34	,	,	PUNCT
admet-295	192	35	50	50	NUM
admet-295	192	36	-	-	SYM
admet-295	192	37	74	74	NUM
admet-295	192	38	and	and	CCONJ
admet-295	192	39			NUM
admet-295	192	40	75	75	NUM
admet-295	192	41	years	year	NOUN
admet-295	192	42	,	,	PUNCT
admet-295	192	43	respectively	respectively	ADV
admet-295	192	44	and	and	CCONJ
admet-295	192	45	prior	prior	ADJ
admet-295	192	46	history	history	NOUN
admet-295	192	47	of	of	ADP
admet-295	192	48	risk	risk	NOUN
admet-295	192	49	factors	factor	NOUN
admet-295	192	50	and	and	CCONJ
admet-295	192	51	12	12	NUM
admet-295	192	52	%	%	NOUN
admet-295	192	53	,	,	PUNCT
admet-295	192	54	18	18	NUM
admet-295	192	55	%	%	NOUN
admet-295	192	56	and	and	CCONJ
admet-295	192	57	46	46	NUM
admet-295	192	58	%	%	NOUN
admet-295	192	59	respectively	respectively	ADV
admet-295	192	60	for	for	ADP
admet-295	192	61	those	those	PRON
admet-295	192	62	without	without	ADP
admet-295	192	63	prior	prior	ADJ
admet-295	192	64	risk	risk	NOUN
admet-295	192	65	factors	factor	NOUN
admet-295	192	66	.	.	PUNCT
admet-295	193	1	the	the	DET
admet-295	193	2	overall	overall	ADJ
admet-295	193	3	incidence	incidence	NOUN
admet-295	193	4	is	be	AUX
admet-295	193	5	computed	compute	VERB
admet-295	193	6	to	to	PART
admet-295	193	7	be	be	AUX
admet-295	193	8	24	24	NUM
admet-295	193	9	%	%	NOUN
admet-295	193	10	for	for	ADP
admet-295	193	11	vascular	vascular	ADJ
admet-295	193	12	occlusion	occlusion	NOUN
admet-295	193	13	and	and	CCONJ
admet-295	193	14	20	20	NUM
admet-295	193	15	%	%	NOUN
admet-295	193	16	for	for	ADP
admet-295	193	17	arterial	arterial	ADJ
admet-295	193	18	thrombosis	thrombosis	NOUN
admet-295	193	19	and	and	CCONJ
admet-295	193	20	occlusion	occlusion	NOUN
admet-295	193	21	.	.	PUNCT
admet-295	194	1	it	it	PRON
admet-295	194	2	was	be	AUX
admet-295	194	3	also	also	ADV
admet-295	194	4	found	find	VERB
admet-295	194	5	to	to	PART
admet-295	194	6	cause	cause	VERB
admet-295	194	7	renal	renal	ADJ
admet-295	194	8	artery	artery	NOUN
admet-295	194	9	stenosis	stenosis	NOUN
admet-295	194	10	,	,	PUNCT
admet-295	194	11	associated	associate	VERB
admet-295	194	12	with	with	ADP
admet-295	194	13	worsening	worsen	VERB
admet-295	194	14	,	,	PUNCT
admet-295	194	15	labile	labile	ADJ
admet-295	194	16	or	or	CCONJ
admet-295	194	17	treatment	treatment	NOUN
admet-295	194	18	-	-	PUNCT
admet-295	194	19	resistant	resistant	ADJ
admet-295	194	20	hypertension	hypertension	NOUN
admet-295	194	21	in	in	ADP
admet-295	194	22	some	some	DET
admet-295	194	23	patients	patient	NOUN
admet-295	194	24	.	.	PUNCT
admet-295	195	1	however	however	ADV
admet-295	195	2	,	,	PUNCT
admet-295	195	3	the	the	DET
admet-295	195	4	dose	dose	NOUN
admet-295	195	5	that	that	PRON
admet-295	195	6	was	be	AUX
admet-295	195	7	approved	approve	VERB
admet-295	195	8	initially	initially	ADV
admet-295	195	9	has	have	AUX
admet-295	195	10	remained	remain	VERB
admet-295	195	11	unchanged	unchanged	ADJ
admet-295	195	12	over	over	ADP
admet-295	195	13	time	time	NOUN
admet-295	195	14	at	at	ADP
admet-295	195	15	45	45	NUM
admet-295	195	16	mg	mg	NOUN
admet-295	195	17	once	once	ADV
admet-295	195	18	daily	daily	ADV
admet-295	195	19	[	[	X
admet-295	195	20	94	94	NUM
admet-295	195	21	,	,	PUNCT
admet-295	195	22	98	98	NUM
admet-295	195	23	]	]	PUNCT
admet-295	195	24	.	.	PUNCT
admet-295	196	1	leaving	leave	VERB
admet-295	196	2	aside	aside	ADV
admet-295	196	3	the	the	DET
admet-295	196	4	rather	rather	ADV
admet-295	196	5	atypical	atypical	ADJ
admet-295	196	6	example	example	NOUN
admet-295	196	7	of	of	ADP
admet-295	196	8	ponatinib	ponatinib	NOUN
admet-295	196	9	,	,	PUNCT
admet-295	196	10	it	it	PRON
admet-295	196	11	is	be	AUX
admet-295	196	12	still	still	ADV
admet-295	196	13	sufficiently	sufficiently	ADV
admet-295	196	14	evident	evident	ADJ
admet-295	196	15	that	that	SCONJ
admet-295	196	16	pki	pki	NOUN
admet-295	196	17	-	-	ADJ
admet-295	196	18	induced	induced	ADJ
admet-295	196	19	ates	ate	NOUN
admet-295	196	20	,	,	PUNCT
admet-295	196	21	rather	rather	ADV
admet-295	196	22	than	than	ADP
admet-295	196	23	their	their	PRON
admet-295	196	24	qt	qt	NOUN
admet-295	196	25	-	-	PUNCT
admet-295	196	26	liability	liability	NOUN
admet-295	196	27	,	,	PUNCT
admet-295	196	28	have	have	VERB
admet-295	196	29	a	a	DET
admet-295	196	30	far	far	ADV
admet-295	196	31	greater	great	ADJ
admet-295	196	32	impact	impact	NOUN
admet-295	196	33	on	on	ADP
admet-295	196	34	quality	quality	NOUN
admet-295	196	35	of	of	ADP
admet-295	196	36	life	life	NOUN
admet-295	196	37	,	,	PUNCT
admet-295	196	38	morbidity	morbidity	NOUN
admet-295	196	39	and	and	CCONJ
admet-295	196	40	mortality	mortality	NOUN
admet-295	196	41	of	of	ADP
admet-295	196	42	patients	patient	NOUN
admet-295	196	43	receiving	receive	VERB
admet-295	196	44	pki	pki	PROPN
admet-295	196	45	therapy	therapy	NOUN
admet-295	196	46	.	.	PUNCT
admet-295	197	1	protein	protein	NOUN
admet-295	197	2	kinase	kinase	VERB
admet-295	197	3	inhibitors	inhibitor	NOUN
admet-295	197	4	and	and	CCONJ
admet-295	197	5	fatalities	fatality	NOUN
admet-295	197	6	due	due	ADJ
admet-295	197	7	to	to	ADP
admet-295	197	8	non	non	ADJ
admet-295	197	9	-	-	ADJ
admet-295	197	10	qt	qt	ADV
admet-295	197	11	related	relate	VERB
admet-295	197	12	cardiovascular	cardiovascular	ADJ
admet-295	197	13	adverse	adverse	ADJ
admet-295	197	14	events	event	NOUN
admet-295	197	15	from	from	ADP
admet-295	197	16	the	the	DET
admet-295	197	17	foregoing	foregoing	NOUN
admet-295	197	18	,	,	PUNCT
admet-295	197	19	it	it	PRON
admet-295	197	20	is	be	AUX
admet-295	197	21	not	not	PART
admet-295	197	22	surprising	surprising	ADJ
admet-295	197	23	that	that	SCONJ
admet-295	197	24	non	non	ADJ
admet-295	197	25	-	-	ADJ
admet-295	197	26	qt	qt	ADV
admet-295	197	27	related	relate	VERB
admet-295	197	28	cardiovascular	cardiovascular	ADJ
admet-295	197	29	effects	effect	NOUN
admet-295	197	30	feature	feature	VERB
admet-295	197	31	heavily	heavily	ADV
admet-295	197	32	in	in	ADP
admet-295	197	33	various	various	ADJ
admet-295	197	34	studies	study	NOUN
admet-295	197	35	of	of	ADP
admet-295	197	36	fatal	fatal	ADJ
admet-295	197	37	adverse	adverse	ADJ
admet-295	197	38	events	event	NOUN
admet-295	197	39	(	(	PUNCT
admet-295	197	40	fae	fae	PROPN
admet-295	197	41	)	)	PUNCT
admet-295	197	42	associated	associate	VERB
admet-295	197	43	with	with	ADP
admet-295	197	44	pkis	pki	NOUN
admet-295	197	45	,	,	PUNCT
admet-295	197	46	especially	especially	ADV
admet-295	197	47	those	those	DET
admet-295	197	48	agents	agent	NOUN
admet-295	197	49	that	that	PRON
admet-295	197	50	target	target	VERB
admet-295	197	51	angiogenesis	angiogenesis	NOUN
admet-295	197	52	(	(	PUNCT
admet-295	197	53	vegfr	vegfr	ADJ
admet-295	197	54	inhibitors	inhibitor	NOUN
admet-295	197	55	)	)	PUNCT
admet-295	197	56	.	.	PUNCT
admet-295	198	1	vegfr	vegfr	ADJ
admet-295	198	2	inhibitors	inhibitor	NOUN
admet-295	198	3	three	three	NUM
admet-295	198	4	large	large	ADJ
admet-295	198	5	and	and	CCONJ
admet-295	198	6	independent	independent	ADJ
admet-295	198	7	meta	meta	NOUN
admet-295	198	8	-	-	PUNCT
admet-295	198	9	analyses	analysis	NOUN
admet-295	198	10	[	[	X
admet-295	198	11	99	99	NUM
admet-295	198	12	-	-	SYM
admet-295	198	13	101	101	NUM
admet-295	198	14	]	]	PUNCT
admet-295	198	15	,	,	PUNCT
admet-295	198	16	summarised	summarise	VERB
admet-295	198	17	in	in	ADP
admet-295	198	18	table	table	NOUN
admet-295	198	19	3	3	NUM
admet-295	198	20	,	,	PUNCT
admet-295	198	21	involving	involve	VERB
admet-295	198	22	12,870	12,870	NUM
admet-295	198	23	patients	patient	NOUN
admet-295	198	24	receiving	receive	VERB
admet-295	198	25	vegfr	vegfr	NOUN
admet-295	198	26	inhibiting	inhibit	VERB
admet-295	198	27	pki	pki	NOUN
admet-295	198	28	and	and	CCONJ
admet-295	198	29	11,114	11,114	NUM
admet-295	198	30	control	control	NOUN
admet-295	198	31	patients	patient	NOUN
admet-295	198	32	have	have	AUX
admet-295	198	33	quantified	quantify	VERB
admet-295	198	34	the	the	DET
admet-295	198	35	incidence	incidence	NOUN
admet-295	198	36	of	of	ADP
admet-295	198	37	fae	fae	NOUN
admet-295	198	38	to	to	PART
admet-295	198	39	be	be	AUX
admet-295	198	40	in	in	ADP
admet-295	198	41	the	the	DET
admet-295	198	42	range	range	NOUN
admet-295	198	43	of	of	ADP
admet-295	198	44	1.50	1.50	NUM
admet-295	198	45	-	-	SYM
admet-295	198	46	2.26	2.26	NUM
admet-295	198	47	%	%	NOUN
admet-295	198	48	with	with	ADP
admet-295	198	49	a	a	DET
admet-295	198	50	rr	rr	NOUN
admet-295	198	51	in	in	ADP
admet-295	198	52	the	the	DET
admet-295	198	53	range	range	NOUN
admet-295	198	54	of	of	ADP
admet-295	198	55	1.64	1.64	NUM
admet-295	198	56	-	-	SYM
admet-295	198	57	2.23	2.23	NUM
admet-295	198	58	.	.	PUNCT
admet-295	199	1	the	the	DET
admet-295	199	2	pkis	pkis	NOUN
admet-295	199	3	studied	study	VERB
admet-295	199	4	were	be	AUX
admet-295	199	5	sunitinib	sunitinib	NOUN
admet-295	199	6	,	,	PUNCT
admet-295	199	7	sorafenib	sorafenib	NOUN
admet-295	199	8	,	,	PUNCT
admet-295	199	9	pazopanib	pazopanib	PROPN
admet-295	199	10	,	,	PUNCT
admet-295	199	11	vandetanib	vandetanib	PROPN
admet-295	199	12	,	,	PUNCT
admet-295	199	13	axitinib	axitinib	NOUN
admet-295	199	14	,	,	PUNCT
admet-295	199	15	cabozantinib	cabozantinib	ADV
admet-295	199	16	,	,	PUNCT
admet-295	199	17	lapatinib	lapatinib	NOUN
admet-295	199	18	and	and	CCONJ
admet-295	199	19	regorafenib	regorafenib	NOUN
admet-295	199	20	.	.	PUNCT
admet-295	200	1	adverse	adverse	ADJ
admet-295	200	2	effects	effect	NOUN
admet-295	200	3	such	such	ADJ
admet-295	200	4	as	as	ADP
admet-295	200	5	cardiac	cardiac	ADJ
admet-295	200	6	failure	failure	NOUN
admet-295	200	7	,	,	PUNCT
admet-295	200	8	myocardial	myocardial	ADJ
admet-295	200	9	infarction	infarction	NOUN
admet-295	200	10	,	,	PUNCT
admet-295	200	11	stroke	stroke	NOUN
admet-295	200	12	,	,	PUNCT
admet-295	200	13	thrombo	thrombo	NOUN
admet-295	200	14	-	-	PUNCT
admet-295	200	15	embolism	embolism	NOUN
admet-295	200	16	,	,	PUNCT
admet-295	200	17	haemorrhage	haemorrhage	NOUN
admet-295	200	18	and	and	CCONJ
admet-295	200	19	cardiopulmonary	cardiopulmonary	ADJ
admet-295	200	20	insufficiency	insufficiency	NOUN
admet-295	200	21	feature	feature	NOUN
admet-295	200	22	prominently	prominently	ADV
admet-295	200	23	in	in	ADP
admet-295	200	24	the	the	DET
admet-295	200	25	list	list	NOUN
admet-295	200	26	of	of	ADP
admet-295	200	27	these	these	DET
admet-295	200	28	faes	faes	PROPN
admet-295	200	29	.	.	PUNCT
admet-295	201	1	other	other	ADJ
admet-295	201	2	often	often	ADV
admet-295	201	3	reported	report	VERB
admet-295	201	4	events	event	NOUN
admet-295	201	5	included	include	VERB
admet-295	201	6	hepatic	hepatic	ADJ
admet-295	201	7	failure	failure	NOUN
admet-295	201	8	,	,	PUNCT
admet-295	201	9	respiratory	respiratory	ADJ
admet-295	201	10	events	event	NOUN
admet-295	201	11	,	,	PUNCT
admet-295	201	12	intestinal	intestinal	ADJ
admet-295	201	13	perforation	perforation	NOUN
admet-295	201	14	and	and	CCONJ
admet-295	201	15	renal	renal	ADJ
admet-295	201	16	failure	failure	NOUN
admet-295	201	17	as	as	ADV
admet-295	201	18	well	well	ADV
admet-295	201	19	as	as	ADP
admet-295	201	20	sudden	sudden	ADJ
admet-295	201	21	death	death	NOUN
admet-295	201	22	.	.	PUNCT
admet-295	202	1	yang	yang	PROPN
admet-295	202	2	et	et	PROPN
admet-295	202	3	al	al	PROPN
admet-295	202	4	.	.	PUNCT
admet-295	203	1	[	[	X
admet-295	203	2	102	102	NUM
admet-295	203	3	]	]	PUNCT
admet-295	203	4	have	have	AUX
admet-295	203	5	recently	recently	ADV
admet-295	203	6	reported	report	VERB
admet-295	203	7	that	that	SCONJ
admet-295	203	8	patients	patient	NOUN
admet-295	203	9	treated	treat	VERB
admet-295	203	10	with	with	ADP
admet-295	203	11	sorafenib	sorafenib	NOUN
admet-295	203	12	had	have	VERB
admet-295	203	13	a	a	DET
admet-295	203	14	significantly	significantly	ADV
admet-295	203	15	greater	great	ADJ
admet-295	203	16	risk	risk	NOUN
admet-295	203	17	of	of	ADP
admet-295	203	18	mortality	mortality	NOUN
admet-295	203	19	than	than	ADP
admet-295	203	20	those	those	PRON
admet-295	203	21	in	in	ADP
admet-295	203	22	placebo	placebo	NOUN
admet-295	203	23	/	/	SYM
admet-295	203	24	control	control	NOUN
admet-295	203	25	groups	group	NOUN
admet-295	203	26	,	,	PUNCT
admet-295	203	27	with	with	ADP
admet-295	203	28	an	an	DET
admet-295	203	29	rr	rr	NOUN
admet-295	203	30	of	of	ADP
admet-295	203	31	1.75	1.75	NUM
admet-295	203	32	.	.	PUNCT
admet-295	204	1	among	among	ADP
admet-295	204	2	different	different	ADJ
admet-295	204	3	vegfr	vegfr	NOUN
admet-295	204	4	-	-	PUNCT
admet-295	204	5	pkis	pkis	NOUN
admet-295	204	6	,	,	PUNCT
admet-295	204	7	sorafenib	sorafenib	NOUN
admet-295	204	8	and	and	CCONJ
admet-295	204	9	sunitinib	sunitinib	NOUN
admet-295	204	10	were	be	AUX
admet-295	204	11	associated	associate	VERB
admet-295	204	12	with	with	ADP
admet-295	204	13	a	a	DET
admet-295	204	14	significant	significant	ADJ
admet-295	204	15	risk	risk	NOUN
admet-295	204	16	of	of	ADP
admet-295	204	17	death	death	NOUN
admet-295	204	18	when	when	SCONJ
admet-295	204	19	compared	compare	VERB
admet-295	204	20	with	with	ADP
admet-295	204	21	control	control	NOUN
admet-295	204	22	arms	arm	NOUN
admet-295	204	23	,	,	PUNCT
admet-295	204	24	respectively	respectively	ADV
admet-295	204	25	.	.	PUNCT
admet-295	205	1	combination	combination	NOUN
admet-295	205	2	of	of	ADP
admet-295	205	3	vegfr	vegfr	NOUN
admet-295	205	4	-	-	PUNCT
admet-295	205	5	pkis	pkis	NOUN
admet-295	205	6	with	with	ADP
admet-295	205	7	other	other	ADJ
admet-295	205	8	antineoplastic	antineoplastic	ADJ
admet-295	205	9	agents	agent	NOUN
admet-295	205	10	,	,	PUNCT
admet-295	205	11	but	but	CCONJ
admet-295	205	12	not	not	PART
admet-295	205	13	vegfr	vegfr	NOUN
admet-295	205	14	-	-	PUNCT
admet-295	205	15	pki	pki	NOUN
admet-295	205	16	monotherapy	monotherapy	NOUN
admet-295	205	17	,	,	PUNCT
admet-295	205	18	significantly	significantly	ADV
admet-295	205	19	increased	increase	VERB
admet-295	205	20	the	the	DET
admet-295	205	21	risk	risk	NOUN
admet-295	205	22	of	of	ADP
admet-295	205	23	treatment	treatment	NOUN
admet-295	205	24	-	-	PUNCT
admet-295	205	25	related	relate	VERB
admet-295	205	26	deaths	death	NOUN
admet-295	205	27	.	.	PUNCT
admet-295	206	1	subgroup	subgroup	NOUN
admet-295	206	2	analyses	analysis	NOUN
admet-295	206	3	have	have	AUX
admet-295	206	4	revealed	reveal	VERB
admet-295	206	5	some	some	DET
admet-295	206	6	interesting	interesting	ADJ
admet-295	206	7	results	result	NOUN
admet-295	206	8	.	.	PUNCT
admet-295	207	1	whereas	whereas	SCONJ
admet-295	207	2	schutz	schutz	PROPN
admet-295	207	3	et	et	PROPN
admet-295	207	4	al	al	PROPN
admet-295	207	5	.	.	PUNCT
admet-295	208	1	[	[	X
admet-295	208	2	100	100	NUM
admet-295	208	3	]	]	PUNCT
admet-295	208	4	reported	report	VERB
admet-295	208	5	no	no	DET
admet-295	208	6	difference	difference	NOUN
admet-295	208	7	in	in	ADP
admet-295	208	8	the	the	DET
admet-295	208	9	rate	rate	NOUN
admet-295	208	10	of	of	ADP
admet-295	208	11	faes	faes	PROPN
admet-295	208	12	found	find	VERB
admet-295	208	13	between	between	ADP
admet-295	208	14	different	different	ADJ
admet-295	208	15	vegfr	vegfr	ADJ
admet-295	208	16	pkis	pki	NOUN
admet-295	208	17	or	or	CCONJ
admet-295	208	18	tumour	tumour	NOUN
admet-295	208	19	types	type	NOUN
admet-295	208	20	,	,	PUNCT
admet-295	208	21	hong	hong	PROPN
admet-295	208	22	et	et	PROPN
admet-295	208	23	al	al	PROPN
admet-295	208	24	.	.	PUNCT
admet-295	209	1	[	[	X
admet-295	209	2	101	101	NUM
admet-295	209	3	]	]	PUNCT
admet-295	209	4	reported	report	VERB
admet-295	209	5	a	a	DET
admet-295	209	6	significantly	significantly	ADV
admet-295	209	7	increased	increase	VERB
admet-295	209	8	risk	risk	NOUN
admet-295	209	9	of	of	ADP
admet-295	209	10	death	death	NOUN
admet-295	209	11	in	in	ADP
admet-295	209	12	patients	patient	NOUN
admet-295	209	13	with	with	ADP
admet-295	209	14	non	non	ADJ
admet-295	209	15	-	-	ADJ
admet-295	209	16	small	small	ADJ
admet-295	209	17	cell	cell	NOUN
admet-295	209	18	lung	lung	NOUN
admet-295	209	19	cancer	cancer	NOUN
admet-295	209	20	and	and	CCONJ
admet-295	209	21	colorectal	colorectal	ADJ
admet-295	209	22	cancer	cancer	NOUN
admet-295	209	23	.	.	PUNCT
admet-295	210	1	this	this	DET
admet-295	210	2	indication	indication	NOUN
admet-295	210	3	-	-	PUNCT
admet-295	210	4	related	relate	VERB
admet-295	210	5	increased	increase	VERB
admet-295	210	6	risk	risk	NOUN
admet-295	210	7	of	of	ADP
admet-295	210	8	death	death	NOUN
admet-295	210	9	following	follow	VERB
admet-295	210	10	treatment	treatment	NOUN
admet-295	210	11	with	with	ADP
admet-295	210	12	sorafenib	sorafenib	NOUN
admet-295	210	13	has	have	AUX
admet-295	210	14	also	also	ADV
admet-295	210	15	been	be	AUX
admet-295	210	16	reported	report	VERB
admet-295	210	17	by	by	ADP
admet-295	210	18	yang	yang	PROPN
admet-295	210	19	et	et	PROPN
admet-295	210	20	al	al	PROPN
admet-295	210	21	.	.	PUNCT
admet-295	211	1	[	[	X
admet-295	211	2	102	102	NUM
admet-295	211	3	]	]	PUNCT
admet-295	211	4	who	who	PRON
admet-295	211	5	found	find	VERB
admet-295	211	6	an	an	DET
admet-295	211	7	overall	overall	ADJ
admet-295	211	8	incidence	incidence	NOUN
admet-295	211	9	of	of	ADP
admet-295	211	10	sorafenib	sorafenib	NOUN
admet-295	211	11	-	-	PUNCT
admet-295	211	12	associated	associate	VERB
admet-295	211	13	mortality	mortality	NOUN
admet-295	211	14	to	to	PART
admet-295	211	15	be	be	AUX
admet-295	211	16	3.3	3.3	NUM
admet-295	211	17	%	%	NOUN
admet-295	211	18	admet	admet	PROPN
admet-295	211	19	&	&	CCONJ
admet-295	211	20	dmpk	dmpk	PROPN
admet-295	211	21	4(3	4(3	NUM
admet-295	211	22	)	)	PUNCT
admet-295	211	23	(	(	PUNCT
admet-295	211	24	2016	2016	NUM
admet-295	211	25	)	)	PUNCT
admet-295	211	26	212	212	NUM
admet-295	211	27	-	-	SYM
admet-295	211	28	231	231	NUM
admet-295	211	29	pkis	pki	NOUN
admet-295	211	30	and	and	CCONJ
admet-295	211	31	qt	qt	NOUN
admet-295	211	32	-	-	PUNCT
admet-295	211	33	phobia	phobia	NOUN
admet-295	211	34	doi	doi	NOUN
admet-295	211	35	:	:	PUNCT
admet-295	211	36	10.5599	10.5599	NUM
admet-295	211	37	/	/	SYM
admet-295	211	38	admet.4.3.295	admet.4.3.295	NOUN
admet-295	211	39	223	223	NUM
admet-295	211	40	but	but	CCONJ
admet-295	211	41	patients	patient	NOUN
admet-295	211	42	with	with	ADP
admet-295	211	43	renal	renal	ADJ
admet-295	211	44	cell	cell	NOUN
admet-295	211	45	carcinoma	carcinoma	NOUN
admet-295	211	46	and	and	CCONJ
admet-295	211	47	thyroid	thyroid	NOUN
admet-295	211	48	cancer	cancer	NOUN
admet-295	211	49	had	have	VERB
admet-295	211	50	treatment	treatment	NOUN
admet-295	211	51	-	-	PUNCT
admet-295	211	52	related	relate	VERB
admet-295	211	53	mortality	mortality	NOUN
admet-295	211	54	≥5	≥5	NUM
admet-295	211	55	%	%	NOUN
admet-295	211	56	.	.	PUNCT
admet-295	212	1	recently	recently	ADV
admet-295	212	2	,	,	PUNCT
admet-295	212	3	jean	jean	PROPN
admet-295	212	4	et	et	PROPN
admet-295	212	5	al	al	PROPN
admet-295	212	6	.	.	PUNCT
admet-295	213	1	[	[	X
admet-295	213	2	103	103	NUM
admet-295	213	3	]	]	PUNCT
admet-295	213	4	have	have	AUX
admet-295	213	5	also	also	ADV
admet-295	213	6	reported	report	VERB
admet-295	213	7	a	a	DET
admet-295	213	8	distinct	distinct	ADJ
admet-295	213	9	increase	increase	NOUN
admet-295	213	10	in	in	ADP
admet-295	213	11	the	the	DET
admet-295	213	12	rate	rate	NOUN
admet-295	213	13	of	of	ADP
admet-295	213	14	occurrence	occurrence	NOUN
admet-295	213	15	of	of	ADP
admet-295	213	16	adverse	adverse	ADJ
admet-295	213	17	effects	effect	NOUN
admet-295	213	18	of	of	ADP
admet-295	213	19	sorafenib	sorafenib	NOUN
admet-295	213	20	when	when	SCONJ
admet-295	213	21	used	use	VERB
admet-295	213	22	in	in	ADP
admet-295	213	23	differentiated	differentiated	ADJ
admet-295	213	24	thyroid	thyroid	NOUN
admet-295	213	25	cancer	cancer	NOUN
admet-295	213	26	compared	compare	VERB
admet-295	213	27	with	with	ADP
admet-295	213	28	renal	renal	ADJ
admet-295	213	29	and	and	CCONJ
admet-295	213	30	hepatocellular	hepatocellular	ADJ
admet-295	213	31	cancer	cancer	NOUN
admet-295	213	32	.	.	PUNCT
admet-295	214	1	while	while	SCONJ
admet-295	214	2	many	many	ADJ
admet-295	214	3	theoretical	theoretical	ADJ
admet-295	214	4	explanations	explanation	NOUN
admet-295	214	5	have	have	AUX
admet-295	214	6	been	be	AUX
admet-295	214	7	advanced	advanced	ADJ
admet-295	214	8	to	to	PART
admet-295	214	9	explain	explain	VERB
admet-295	214	10	this	this	DET
admet-295	214	11	indication	indication	NOUN
admet-295	214	12	-	-	PUNCT
admet-295	214	13	related	relate	VERB
admet-295	214	14	difference	difference	NOUN
admet-295	214	15	in	in	ADP
admet-295	214	16	toxicity	toxicity	NOUN
admet-295	214	17	profile	profile	NOUN
admet-295	214	18	,	,	PUNCT
admet-295	214	19	the	the	DET
admet-295	214	20	exact	exact	ADJ
admet-295	214	21	mechanism	mechanism	NOUN
admet-295	214	22	for	for	ADP
admet-295	214	23	this	this	PRON
admet-295	214	24	remains	remain	VERB
admet-295	214	25	unclear	unclear	ADJ
admet-295	214	26	.	.	PUNCT
admet-295	215	1	table	table	NOUN
admet-295	215	2	3	3	NUM
admet-295	215	3	.	.	PUNCT
admet-295	216	1	summary	summary	NOUN
admet-295	216	2	of	of	ADP
admet-295	216	3	three	three	NUM
admet-295	216	4	meta	meta	NOUN
admet-295	216	5	-	-	PUNCT
admet-295	216	6	analyses	analysis	NOUN
admet-295	216	7	of	of	ADP
admet-295	216	8	fatal	fatal	ADJ
admet-295	216	9	adverse	adverse	ADJ
admet-295	216	10	events	event	NOUN
admet-295	216	11	(	(	PUNCT
admet-295	216	12	faes	faes	X
admet-295	216	13	)	)	PUNCT
admet-295	216	14	associated	associate	VERB
admet-295	216	15	with	with	ADP
admet-295	216	16	protein	protein	NOUN
admet-295	216	17	kinase	kinase	PROPN
admet-295	216	18	inhibitors	inhibitor	NOUN
admet-295	216	19	(	(	PUNCT
admet-295	216	20	pkis	pkis	PROPN
admet-295	216	21	)	)	PUNCT
admet-295	216	22	study	study	NOUN
admet-295	216	23	pki	pki	PROPN
admet-295	216	24	group	group	PROPN
admet-295	216	25	n	n	PROPN
admet-295	216	26	=	=	PROPN
admet-295	216	27	control	control	NOUN
admet-295	216	28	group	group	NOUN
admet-295	216	29	n	n	NOUN
admet-295	216	30	=	=	SYM
admet-295	216	31	pkis	pki	NOUN
admet-295	216	32	risk	risk	NOUN
admet-295	216	33	(	(	PUNCT
admet-295	216	34	95	95	NUM
admet-295	216	35	%	%	NOUN
admet-295	216	36	ci	ci	NOUN
admet-295	216	37	)	)	PUNCT
admet-295	216	38	incidence	incidence	NOUN
admet-295	216	39	(	(	PUNCT
admet-295	216	40	%	%	INTJ
admet-295	216	41	)	)	PUNCT
admet-295	216	42	cv	cv	NOUN
admet-295	216	43	events	event	NOUN
admet-295	216	44	ref	ref	NOUN
admet-295	216	45	.	.	PUNCT
admet-295	217	1	sivendran	sivendran	PROPN
admet-295	217	2	et	et	PROPN
admet-295	217	3	al	al	PROPN
admet-295	217	4	.	.	PROPN
admet-295	218	1	2,762	2,762	NUM
admet-295	218	2	2,401	2,401	NUM
admet-295	218	3	sunitinib	sunitinib	NOUN
admet-295	218	4	sorafenib	sorafenib	PROPN
admet-295	218	5	pazopanib	pazopanib	PROPN
admet-295	218	6	vandetanib	vandetanib	PROPN
admet-295	218	7	rr	rr	PROPN
admet-295	219	1	=	=	SYM
admet-295	219	2	1.64	1.64	NUM
admet-295	219	3	(	(	PUNCT
admet-295	219	4	1.16	1.16	NUM
admet-295	219	5	–	–	SYM
admet-295	219	6	2.32	2.32	NUM
admet-295	219	7	)	)	PUNCT
admet-295	219	8	p	p	NOUN
admet-295	219	9	=	=	NOUN
admet-295	219	10	0.01	0.01	NUM
admet-295	219	11	2.26	2.26	NUM
admet-295	219	12	vs	vs	ADP
admet-295	219	13	1.26	1.26	NUM
admet-295	219	14	cardiac	cardiac	ADJ
admet-295	219	15	failure	failure	NOUN
admet-295	219	16	pulmonary	pulmonary	NOUN
admet-295	219	17	embolism	embolism	NOUN
admet-295	219	18	[	[	X
admet-295	219	19	99	99	NUM
admet-295	219	20	]	]	X
admet-295	219	21	schutz	schutz	PROPN
admet-295	219	22	et	et	PROPN
admet-295	219	23	al	al	PROPN
admet-295	219	24	.	.	PROPN
admet-295	220	1	2,461	2,461	NUM
admet-295	220	2	2,218	2,218	NUM
admet-295	220	3	sunitinib	sunitinib	NOUN
admet-295	220	4	sorafenib	sorafenib	PROPN
admet-295	220	5	pazopanib	pazopanib	PROPN
admet-295	220	6	rr	rr	PROPN
admet-295	221	1	=	=	SYM
admet-295	221	2	2.23	2.23	NUM
admet-295	221	3	(	(	PUNCT
admet-295	221	4	1.12	1.12	NUM
admet-295	221	5	–	–	SYM
admet-295	221	6	4.44	4.44	NUM
admet-295	221	7	)	)	PUNCT
admet-295	221	8	p	p	NOUN
admet-295	221	9	=	=	PUNCT
admet-295	221	10	0.023	0.023	NUM
admet-295	221	11	1.50	1.50	NUM
admet-295	221	12	haemorrhage	haemorrhage	NOUN
admet-295	221	13	myocardial	myocardial	ADJ
admet-295	221	14	infarction	infarction	NOUN
admet-295	221	15	cardiac	cardiac	ADJ
admet-295	221	16	failure	failure	NOUN
admet-295	221	17	stroke	stroke	NOUN
admet-295	221	18	pulmonary	pulmonary	ADJ
admet-295	221	19	embolism	embolism	NOUN
admet-295	221	20	sudden	sudden	ADJ
admet-295	221	21	death	death	NOUN
admet-295	222	1	[	[	X
admet-295	222	2	100	100	NUM
admet-295	222	3	]	]	PUNCT
admet-295	222	4	hong	hong	PROPN
admet-295	222	5	et	et	PROPN
admet-295	222	6	al	al	PROPN
admet-295	222	7	.	.	PROPN
admet-295	223	1	7,644	7,644	NUM
admet-295	223	2	6,495	6,495	NUM
admet-295	223	3	axitinib	axitinib	NOUN
admet-295	223	4	cabozantinib	cabozantinib	AUX
admet-295	223	5	lapatinib	lapatinib	VERB
admet-295	223	6	pazopanib	pazopanib	PROPN
admet-295	223	7	regorafenib	regorafenib	PROPN
admet-295	223	8	sunitinib	sunitinib	PROPN
admet-295	223	9	sorafenib	sorafenib	PROPN
admet-295	223	10	vandetanib	vandetanib	PROPN
admet-295	223	11	or	or	CCONJ
admet-295	223	12	=	=	SYM
admet-295	223	13	1.85	1.85	NUM
admet-295	223	14	(	(	PUNCT
admet-295	223	15	1.33	1.33	NUM
admet-295	223	16	–	–	SYM
admet-295	223	17	2.58	2.58	NUM
admet-295	223	18	)	)	PUNCT
admet-295	223	19	p	p	NOUN
admet-295	223	20	=	=	NOUN
admet-295	223	21	0.01	0.01	NUM
admet-295	223	22	1.90	1.90	NUM
admet-295	223	23	cardiopulmonary	cardiopulmonary	ADJ
admet-295	223	24	insufficiency	insufficiency	NOUN
admet-295	223	25	thrombo	thrombo	NOUN
admet-295	223	26	-	-	PUNCT
admet-295	223	27	embolism	embolism	NOUN
admet-295	223	28	haemorrhage	haemorrhage	NOUN
admet-295	223	29	sudden	sudden	ADJ
admet-295	223	30	death	death	NOUN
admet-295	224	1	[	[	X
admet-295	224	2	101	101	NUM
admet-295	224	3	]	]	PUNCT
admet-295	224	4	egfr	egfr	ADJ
admet-295	224	5	inhibitors	inhibitor	NOUN
admet-295	224	6	in	in	ADP
admet-295	224	7	contrast	contrast	NOUN
admet-295	224	8	to	to	ADP
admet-295	224	9	vegfr	vegfr	NOUN
admet-295	224	10	-	-	PUNCT
admet-295	224	11	pkis	pkis	NOUN
admet-295	224	12	,	,	PUNCT
admet-295	224	13	qi	qi	PROPN
admet-295	224	14	et	et	NOUN
admet-295	224	15	al	al	PROPN
admet-295	224	16	.	.	PUNCT
admet-295	225	1	[	[	X
admet-295	225	2	104	104	NUM
admet-295	225	3	]	]	PUNCT
admet-295	225	4	reported	report	VERB
admet-295	225	5	a	a	DET
admet-295	225	6	meta	meta	ADJ
admet-295	225	7	-	-	PUNCT
admet-295	225	8	analysis	analysis	NOUN
admet-295	225	9	of	of	ADP
admet-295	225	10	7,508	7,508	NUM
admet-295	225	11	patients	patient	NOUN
admet-295	225	12	treated	treat	VERB
admet-295	225	13	with	with	ADP
admet-295	225	14	two	two	NUM
admet-295	225	15	widely	widely	ADV
admet-295	225	16	used	use	VERB
admet-295	225	17	egfr	egfr	NOUN
admet-295	225	18	-	-	PUNCT
admet-295	225	19	pkis	pkis	NOUN
admet-295	225	20	(	(	PUNCT
admet-295	225	21	erlotinib	erlotinib	NOUN
admet-295	225	22	and	and	CCONJ
admet-295	225	23	gefitinib	gefitinib	NOUN
admet-295	225	24	)	)	PUNCT
admet-295	225	25	and	and	CCONJ
admet-295	225	26	compared	compare	VERB
admet-295	225	27	them	they	PRON
admet-295	225	28	with	with	ADP
admet-295	225	29	6,317	6,317	NUM
admet-295	225	30	control	control	NOUN
admet-295	225	31	patients	patient	NOUN
admet-295	225	32	to	to	PART
admet-295	225	33	determine	determine	VERB
admet-295	225	34	the	the	DET
admet-295	225	35	incidence	incidence	NOUN
admet-295	225	36	and	and	CCONJ
admet-295	225	37	risk	risk	NOUN
admet-295	225	38	of	of	ADP
admet-295	225	39	faes	faes	PROPN
admet-295	225	40	.	.	PUNCT
admet-295	226	1	the	the	DET
admet-295	226	2	overall	overall	ADJ
admet-295	226	3	incidence	incidence	NOUN
admet-295	226	4	of	of	ADP
admet-295	226	5	faes	faes	PROPN
admet-295	226	6	was	be	AUX
admet-295	226	7	1.9	1.9	NUM
admet-295	226	8	%	%	NOUN
admet-295	226	9	(	(	PUNCT
admet-295	226	10	95	95	NUM
admet-295	226	11	%	%	NOUN
admet-295	226	12	ci	ci	NOUN
admet-295	226	13	:	:	PUNCT
admet-295	226	14	1.2	1.2	NUM
admet-295	226	15	2.9	2.9	NUM
admet-295	226	16	)	)	PUNCT
admet-295	226	17	,	,	PUNCT
admet-295	226	18	and	and	CCONJ
admet-295	226	19	the	the	DET
admet-295	226	20	rr	rr	PROPN
admet-295	226	21	was	be	AUX
admet-295	226	22	0.99	0.99	NUM
admet-295	226	23	(	(	PUNCT
admet-295	226	24	95	95	NUM
admet-295	226	25	%	%	NOUN
admet-295	226	26	ci	ci	NOUN
admet-295	226	27	:	:	PUNCT
admet-295	226	28	0.70	0.70	NUM
admet-295	226	29	1.41	1.41	NUM
admet-295	226	30	;	;	PUNCT
admet-295	226	31	p	p	X
admet-295	226	32	=	=	NOUN
admet-295	226	33	0.97	0.97	NUM
admet-295	226	34	)	)	PUNCT
admet-295	226	35	.	.	PUNCT
admet-295	227	1	no	no	DET
admet-295	227	2	increase	increase	NOUN
admet-295	227	3	in	in	ADP
admet-295	227	4	faes	faes	PROPN
admet-295	227	5	was	be	AUX
admet-295	227	6	detected	detect	VERB
admet-295	227	7	in	in	ADP
admet-295	227	8	any	any	DET
admet-295	227	9	pre	pre	ADJ
admet-295	227	10	-	-	ADJ
admet-295	227	11	specified	specified	ADJ
admet-295	227	12	subgroup	subgroup	NOUN
admet-295	227	13	.	.	PUNCT
admet-295	228	1	this	this	DET
admet-295	228	2	analysis	analysis	NOUN
admet-295	228	3	suggests	suggest	VERB
admet-295	228	4	that	that	SCONJ
admet-295	228	5	the	the	DET
admet-295	228	6	use	use	NOUN
admet-295	228	7	of	of	ADP
admet-295	228	8	egfr	egfr	NOUN
admet-295	228	9	-	-	PUNCT
admet-295	228	10	pkis	pki	NOUN
admet-295	228	11	does	do	AUX
admet-295	228	12	not	not	PART
admet-295	228	13	increase	increase	VERB
admet-295	228	14	the	the	DET
admet-295	228	15	risk	risk	NOUN
admet-295	228	16	of	of	ADP
admet-295	228	17	faes	faes	NOUN
admet-295	228	18	in	in	ADP
admet-295	228	19	patients	patient	NOUN
admet-295	228	20	with	with	ADP
admet-295	228	21	advanced	advanced	ADJ
admet-295	228	22	solid	solid	ADJ
admet-295	228	23	tumours	tumour	NOUN
admet-295	228	24	,	,	PUNCT
admet-295	228	25	and	and	CCONJ
admet-295	228	26	egfr	egfr	ADJ
admet-295	228	27	-	-	PUNCT
admet-295	228	28	pkis	pki	NOUN
admet-295	228	29	are	be	AUX
admet-295	228	30	safe	safe	ADJ
admet-295	228	31	and	and	CCONJ
admet-295	228	32	tolerable	tolerable	ADJ
admet-295	228	33	by	by	ADP
admet-295	228	34	cancer	cancer	NOUN
admet-295	228	35	patients	patient	NOUN
admet-295	228	36	,	,	PUNCT
admet-295	228	37	especially	especially	ADV
admet-295	228	38	for	for	ADP
admet-295	228	39	those	those	DET
admet-295	228	40	previously	previously	ADV
admet-295	228	41	treated	treat	VERB
admet-295	228	42	patients	patient	NOUN
admet-295	228	43	.	.	PUNCT
admet-295	229	1	in	in	ADP
admet-295	229	2	the	the	DET
admet-295	229	3	context	context	NOUN
admet-295	229	4	of	of	ADP
admet-295	229	5	this	this	DET
admet-295	229	6	finding	finding	NOUN
admet-295	229	7	,	,	PUNCT
admet-295	229	8	it	it	PRON
admet-295	229	9	is	be	AUX
admet-295	229	10	worth	worth	ADJ
admet-295	229	11	noting	note	VERB
admet-295	229	12	that	that	SCONJ
admet-295	229	13	typical	typical	ADJ
admet-295	229	14	egfr	egfr	NOUN
admet-295	229	15	-	-	PUNCT
admet-295	229	16	pkis	pki	NOUN
admet-295	229	17	are	be	AUX
admet-295	229	18	not	not	PART
admet-295	229	19	known	know	VERB
admet-295	229	20	to	to	PART
admet-295	229	21	induce	induce	VERB
admet-295	229	22	cardiovascular	cardiovascular	ADJ
admet-295	229	23	adverse	adverse	ADJ
admet-295	229	24	events	event	NOUN
admet-295	229	25	that	that	PRON
admet-295	229	26	are	be	AUX
admet-295	229	27	so	so	ADV
admet-295	229	28	typical	typical	ADJ
admet-295	229	29	of	of	ADP
admet-295	229	30	vegfr	vegfr	NOUN
admet-295	229	31	-	-	PUNCT
admet-295	229	32	pkis	pki	NOUN
admet-295	229	33	,	,	PUNCT
admet-295	229	34	thus	thus	ADV
admet-295	229	35	emphasising	emphasise	VERB
admet-295	229	36	the	the	DET
admet-295	229	37	impact	impact	NOUN
admet-295	229	38	of	of	ADP
admet-295	229	39	these	these	DET
admet-295	229	40	events	event	NOUN
admet-295	229	41	on	on	ADP
admet-295	229	42	the	the	DET
admet-295	229	43	risk	risk	NOUN
admet-295	229	44	/	/	SYM
admet-295	229	45	benefit	benefit	NOUN
admet-295	229	46	of	of	ADP
admet-295	229	47	pkis	pki	NOUN
admet-295	229	48	.	.	PUNCT
admet-295	230	1	pki	pki	NOUN
admet-295	230	2	in	in	ADP
admet-295	230	3	combination	combination	NOUN
admet-295	230	4	with	with	ADP
admet-295	230	5	cytotoxic	cytotoxic	ADJ
admet-295	230	6	agents	agent	NOUN
admet-295	230	7	in	in	ADP
admet-295	230	8	a	a	DET
admet-295	230	9	more	more	ADV
admet-295	230	10	comprehensive	comprehensive	ADJ
admet-295	230	11	meta	meta	ADJ
admet-295	230	12	-	-	PUNCT
admet-295	230	13	analysis	analysis	NOUN
admet-295	230	14	of	of	ADP
admet-295	230	15	43	43	NUM
admet-295	230	16	trials	trial	NOUN
admet-295	230	17	involving	involve	VERB
admet-295	230	18	16,011	16,011	NUM
admet-295	230	19	patients	patient	NOUN
admet-295	230	20	(	(	PUNCT
admet-295	230	21	8,460	8,460	NUM
admet-295	230	22	on	on	ADP
admet-295	230	23	pkis	pki	NOUN
admet-295	230	24	and	and	CCONJ
admet-295	230	25	7,551	7,551	NUM
admet-295	230	26	controls	control	NOUN
admet-295	230	27	)	)	PUNCT
admet-295	230	28	that	that	PRON
admet-295	230	29	balanced	balance	VERB
admet-295	230	30	the	the	DET
admet-295	230	31	risks	risk	NOUN
admet-295	230	32	versus	versus	ADP
admet-295	230	33	the	the	DET
admet-295	230	34	benefits	benefit	NOUN
admet-295	230	35	of	of	ADP
admet-295	230	36	pkis	pki	NOUN
admet-295	230	37	active	active	ADJ
admet-295	230	38	at	at	ADP
admet-295	230	39	vegfr	vegfr	NOUN
admet-295	230	40	and	and	CCONJ
admet-295	230	41	egfr	egfr	NOUN
admet-295	230	42	,	,	PUNCT
admet-295	230	43	funakoshi	funakoshi	VERB
admet-295	230	44	et	et	PROPN
admet-295	230	45	al	al	PROPN
admet-295	230	46	.	.	PUNCT
admet-295	231	1	[	[	X
admet-295	231	2	105	105	NUM
admet-295	231	3	]	]	PUNCT
admet-295	231	4	evaluated	evaluate	VERB
admet-295	231	5	the	the	DET
admet-295	231	6	safety	safety	NOUN
admet-295	231	7	and	and	CCONJ
admet-295	231	8	efficacy	efficacy	NOUN
admet-295	231	9	of	of	ADP
admet-295	231	10	combining	combine	VERB
admet-295	231	11	cytotoxic	cytotoxic	ADJ
admet-295	231	12	chemotherapy	chemotherapy	NOUN
admet-295	231	13	with	with	ADP
admet-295	231	14	pkis	pki	NOUN
admet-295	231	15	,	,	PUNCT
admet-295	231	16	which	which	PRON
admet-295	231	17	were	be	AUX
admet-295	231	18	divided	divide	VERB
admet-295	231	19	into	into	ADP
admet-295	231	20	two	two	NUM
admet-295	231	21	subgroups	subgroup	NOUN
admet-295	231	22	:	:	PUNCT
admet-295	231	23	vegfr	vegfr	ADJ
admet-295	231	24	pki	pki	PROPN
admet-295	231	25	(	(	PUNCT
admet-295	231	26	axitinib	axitinib	NOUN
admet-295	231	27	,	,	PUNCT
admet-295	231	28	cabozantinib	cabozantinib	NOUN
admet-295	231	29	,	,	PUNCT
admet-295	231	30	pazopanib	pazopanib	NOUN
admet-295	231	31	,	,	PUNCT
admet-295	231	32	regorafenib	regorafenib	NOUN
admet-295	231	33	,	,	PUNCT
admet-295	231	34	sorafenib	sorafenib	NOUN
admet-295	231	35	,	,	PUNCT
admet-295	231	36	sunitinib	sunitinib	NOUN
admet-295	231	37	and	and	CCONJ
admet-295	231	38	vandetanib	vandetanib	NOUN
admet-295	231	39	)	)	PUNCT
admet-295	231	40	,	,	PUNCT
admet-295	231	41	and	and	CCONJ
admet-295	231	42	egfr	egfr	ADJ
admet-295	231	43	-	-	PUNCT
admet-295	231	44	family	family	NOUN
admet-295	231	45	pki	pki	PROPN
admet-295	231	46	(	(	PUNCT
admet-295	231	47	erlotinib	erlotinib	PROPN
admet-295	231	48	,	,	PUNCT
admet-295	231	49	gefitinib	gefitinib	NOUN
admet-295	231	50	and	and	CCONJ
admet-295	231	51	lapatinib	lapatinib	NOUN
admet-295	231	52	)	)	PUNCT
admet-295	231	53	.	.	PUNCT
admet-295	232	1	they	they	PRON
admet-295	232	2	found	find	VERB
admet-295	232	3	that	that	SCONJ
admet-295	232	4	compared	compare	VERB
admet-295	232	5	with	with	ADP
admet-295	232	6	chemotherapy	chemotherapy	NOUN
admet-295	232	7	alone	alone	ADV
admet-295	232	8	,	,	PUNCT
admet-295	232	9	the	the	DET
admet-295	232	10	addition	addition	NOUN
admet-295	232	11	of	of	ADP
admet-295	232	12	a	a	DET
admet-295	232	13	pki	pki	NOUN
admet-295	232	14	was	be	AUX
admet-295	232	15	associated	associate	VERB
admet-295	232	16	with	with	ADP
admet-295	232	17	a	a	DET
admet-295	232	18	significant	significant	ADJ
admet-295	232	19	improvement	improvement	NOUN
admet-295	232	20	in	in	ADP
admet-295	232	21	progression	progression	NOUN
admet-295	232	22	free	free	ADJ
admet-295	232	23	survival	survival	NOUN
admet-295	232	24	(	(	PUNCT
admet-295	232	25	hazard	hazard	NOUN
admet-295	232	26	ratio	ratio	NOUN
admet-295	232	27	0.82	0.82	NUM
admet-295	232	28	;	;	PUNCT
admet-295	232	29	9	9	NUM
admet-295	232	30	5	5	NUM
admet-295	232	31	%	%	NOUN
admet-295	232	32	ci	ci	NOUN
admet-295	232	33	:	:	PUNCT
admet-295	232	34	0.76–0.89	0.76–0.89	NUM
admet-295	232	35	)	)	PUNCT
admet-295	232	36	,	,	PUNCT
admet-295	232	37	but	but	CCONJ
admet-295	232	38	not	not	PART
admet-295	232	39	overall	overall	ADJ
admet-295	232	40	survival	survival	NOUN
admet-295	232	41	(	(	PUNCT
admet-295	232	42	hazard	hazard	NOUN
admet-295	232	43	ratio	ratio	NOUN
admet-295	232	44	0.99	0.99	NUM
admet-295	232	45	;	;	PUNCT
admet-295	232	46	95	95	NUM
admet-295	232	47	%	%	NOUN
admet-295	232	48	ci	ci	NOUN
admet-295	232	49	:	:	PUNCT
admet-295	232	50	0.95–1.03	0.95–1.03	NUM
admet-295	232	51	)	)	PUNCT
admet-295	232	52	.	.	PUNCT
admet-295	233	1	however	however	ADV
admet-295	233	2	,	,	PUNCT
admet-295	233	3	the	the	DET
admet-295	233	4	addition	addition	NOUN
admet-295	233	5	of	of	ADP
admet-295	233	6	a	a	DET
admet-295	233	7	pki	pki	PROPN
admet-295	233	8	significantly	significantly	ADV
admet-295	233	9	increased	increase	VERB
admet-295	233	10	the	the	DET
admet-295	233	11	risk	risk	NOUN
admet-295	233	12	of	of	ADP
admet-295	233	13	faes	faes	X
admet-295	233	14	(	(	PUNCT
admet-295	233	15	rr	rr	NOUN
admet-295	233	16	=	=	SYM
admet-295	233	17	1.63	1.63	NUM
admet-295	233	18	,	,	PUNCT
admet-295	233	19	95	95	NUM
admet-295	233	20	%	%	NOUN
admet-295	233	21	ci	ci	NOUN
admet-295	233	22	:	:	PUNCT
admet-295	233	23	1.32	1.32	NUM
admet-295	233	24	–	–	PUNCT
admet-295	233	25	2.01	2.01	NUM
admet-295	233	26	)	)	PUNCT
admet-295	233	27	,	,	PUNCT
admet-295	233	28	treatment	treatment	NOUN
admet-295	233	29	discontinuation	discontinuation	NOUN
admet-295	233	30	(	(	PUNCT
admet-295	233	31	rr	rr	NOUN
admet-295	233	32	=	=	SYM
admet-295	233	33	1.80	1.80	NUM
admet-295	233	34	,	,	PUNCT
admet-295	233	35	95	95	NUM
admet-295	233	36	%	%	NOUN
admet-295	233	37	ci	ci	NOUN
admet-295	233	38	:	:	PUNCT
admet-295	233	39	1.58–2.06	1.58–2.06	NUM
admet-295	233	40	)	)	PUNCT
admet-295	233	41	,	,	PUNCT
admet-295	233	42	and	and	CCONJ
admet-295	233	43	any	any	DET
admet-295	233	44	severe	severe	ADJ
admet-295	233	45	adverse	adverse	ADJ
admet-295	233	46	event	event	NOUN
admet-295	233	47	(	(	PUNCT
admet-295	233	48	rr	rr	PROPN
admet-295	233	49	=	=	SYM
admet-295	233	50	1.25	1.25	NUM
admet-295	233	51	,	,	PUNCT
admet-295	233	52	95	95	NUM
admet-295	233	53	%	%	NOUN
admet-295	233	54	ci	ci	NOUN
admet-295	233	55	:	:	PUNCT
admet-295	233	56	1.16–1.36	1.16–1.36	NUM
admet-295	233	57	)	)	PUNCT
admet-295	233	58	.	.	PUNCT
admet-295	234	1	surprisingly	surprisingly	ADV
admet-295	234	2	,	,	PUNCT
admet-295	234	3	the	the	DET
admet-295	234	4	rr	rr	NOUN
admet-295	234	5	associated	associate	VERB
admet-295	234	6	with	with	ADP
admet-295	234	7	addition	addition	NOUN
admet-295	234	8	of	of	ADP
admet-295	234	9	a	a	DET
admet-295	234	10	pki	pki	PROPN
admet-295	234	11	was	be	AUX
admet-295	234	12	1.49	1.49	NUM
admet-295	234	13	(	(	PUNCT
admet-295	234	14	95	95	NUM
admet-295	234	15	%	%	NOUN
admet-295	234	16	ci	ci	NOUN
admet-295	234	17	:	:	PUNCT
admet-295	234	18	1.16	1.16	NUM
admet-295	234	19	-	-	SYM
admet-295	234	20	1.90	1.90	NUM
admet-295	234	21	)	)	PUNCT
admet-295	234	22	with	with	ADP
admet-295	234	23	rashmi	rashmi	PROPN
admet-295	234	24	shah	shah	PROPN
admet-295	234	25	admet	admet	PROPN
admet-295	234	26	&	&	CCONJ
admet-295	234	27	dmpk	dmpk	PROPN
admet-295	234	28	4(3	4(3	NUM
admet-295	234	29	)	)	PUNCT
admet-295	234	30	(	(	PUNCT
admet-295	234	31	2016	2016	NUM
admet-295	234	32	)	)	PUNCT
admet-295	234	33	212	212	NUM
admet-295	234	34	-	-	SYM
admet-295	234	35	231	231	NUM
admet-295	234	36	224	224	NUM
admet-295	234	37	vegfr	vegfr	ADJ
admet-295	234	38	inhibitors	inhibitor	NOUN
admet-295	234	39	compared	compare	VERB
admet-295	234	40	to	to	ADP
admet-295	234	41	2.04	2.04	NUM
admet-295	234	42	(	(	PUNCT
admet-295	234	43	95	95	NUM
admet-295	234	44	%	%	NOUN
admet-295	234	45	ci	ci	NOUN
admet-295	234	46	:	:	PUNCT
admet-295	234	47	1.38	1.38	NUM
admet-295	234	48	-	-	SYM
admet-295	234	49	3.01	3.01	NUM
admet-295	234	50	)	)	PUNCT
admet-295	234	51	with	with	ADP
admet-295	234	52	egfr	egfr	ADJ
admet-295	234	53	inhibitors	inhibitor	NOUN
admet-295	234	54	.	.	PUNCT
admet-295	235	1	these	these	DET
admet-295	235	2	findings	finding	NOUN
admet-295	235	3	serve	serve	VERB
admet-295	235	4	to	to	PART
admet-295	235	5	caution	caution	VERB
admet-295	235	6	the	the	DET
admet-295	235	7	physicians	physician	NOUN
admet-295	235	8	to	to	PART
admet-295	235	9	weigh	weigh	VERB
admet-295	235	10	the	the	DET
admet-295	235	11	risk	risk	NOUN
admet-295	235	12	of	of	ADP
admet-295	235	13	toxicity	toxicity	NOUN
admet-295	235	14	versus	versus	ADP
admet-295	235	15	the	the	DET
admet-295	235	16	modest	modest	ADJ
admet-295	235	17	benefit	benefit	NOUN
admet-295	235	18	in	in	ADP
admet-295	235	19	terms	term	NOUN
admet-295	235	20	of	of	ADP
admet-295	235	21	progression	progression	NOUN
admet-295	235	22	free	free	ADJ
admet-295	235	23	survival	survival	NOUN
admet-295	235	24	associated	associate	VERB
admet-295	235	25	with	with	ADP
admet-295	235	26	chemotherapy	chemotherapy	NOUN
admet-295	235	27	plus	plus	CCONJ
admet-295	235	28	a	a	DET
admet-295	235	29	pki	pki	X
admet-295	235	30	in	in	ADP
admet-295	235	31	patients	patient	NOUN
admet-295	235	32	with	with	ADP
admet-295	235	33	solid	solid	ADJ
admet-295	235	34	cancers	cancer	NOUN
admet-295	235	35	.	.	PUNCT
admet-295	236	1	safety	safety	NOUN
admet-295	236	2	of	of	ADP
admet-295	236	3	protein	protein	NOUN
admet-295	236	4	kinase	kinase	PROPN
admet-295	236	5	inhibitors	inhibitor	NOUN
admet-295	236	6	in	in	ADP
admet-295	236	7	routine	routine	ADJ
admet-295	236	8	clinical	clinical	ADJ
admet-295	236	9	practice	practice	NOUN
admet-295	236	10	in	in	ADP
admet-295	236	11	routine	routine	ADJ
admet-295	236	12	clinical	clinical	ADJ
admet-295	236	13	practice	practice	NOUN
admet-295	236	14	,	,	PUNCT
admet-295	236	15	however	however	ADV
admet-295	236	16	,	,	PUNCT
admet-295	236	17	the	the	DET
admet-295	236	18	risk	risk	NOUN
admet-295	236	19	/	/	SYM
admet-295	236	20	benefit	benefit	NOUN
admet-295	236	21	is	be	AUX
admet-295	236	22	likely	likely	ADJ
admet-295	236	23	to	to	PART
admet-295	236	24	be	be	AUX
admet-295	236	25	inferior	inferior	ADJ
admet-295	236	26	to	to	ADP
admet-295	236	27	that	that	PRON
admet-295	236	28	determined	determine	VERB
admet-295	236	29	from	from	ADP
admet-295	236	30	highly	highly	ADV
admet-295	236	31	controlled	control	VERB
admet-295	236	32	clinical	clinical	ADJ
admet-295	236	33	trials	trial	NOUN
admet-295	236	34	.	.	PUNCT
admet-295	237	1	whereas	whereas	SCONJ
admet-295	237	2	patients	patient	NOUN
admet-295	237	3	in	in	ADP
admet-295	237	4	pre	pre	ADJ
admet-295	237	5	-	-	ADJ
admet-295	237	6	approval	approval	ADJ
admet-295	237	7	clinical	clinical	ADJ
admet-295	237	8	trials	trial	NOUN
admet-295	237	9	are	be	AUX
admet-295	237	10	carefully	carefully	ADV
admet-295	237	11	selected	select	VERB
admet-295	237	12	,	,	PUNCT
admet-295	237	13	treatment	treatment	NOUN
admet-295	237	14	of	of	ADP
admet-295	237	15	wider	wide	ADJ
admet-295	237	16	and	and	CCONJ
admet-295	237	17	less	less	ADV
admet-295	237	18	selected	select	VERB
admet-295	237	19	patient	patient	ADJ
admet-295	237	20	population	population	NOUN
admet-295	237	21	in	in	ADP
admet-295	237	22	routine	routine	ADJ
admet-295	237	23	oncologic	oncologic	NOUN
admet-295	237	24	practice	practice	NOUN
admet-295	237	25	may	may	AUX
admet-295	237	26	increase	increase	VERB
admet-295	237	27	the	the	DET
admet-295	237	28	likelihood	likelihood	NOUN
admet-295	237	29	of	of	ADP
admet-295	237	30	toxicity	toxicity	NOUN
admet-295	237	31	and	and	CCONJ
admet-295	237	32	lower	low	ADJ
admet-295	237	33	the	the	DET
admet-295	237	34	probability	probability	NOUN
admet-295	237	35	of	of	ADP
admet-295	237	36	benefit	benefit	NOUN
admet-295	237	37	[	[	X
admet-295	237	38	106	106	NUM
admet-295	237	39	]	]	PUNCT
admet-295	237	40	.	.	PUNCT
admet-295	238	1	the	the	DET
admet-295	238	2	problem	problem	NOUN
admet-295	238	3	may	may	AUX
admet-295	238	4	be	be	AUX
admet-295	238	5	further	far	ADV
admet-295	238	6	compounded	compound	VERB
admet-295	238	7	by	by	ADP
admet-295	238	8	off	off	ADP
admet-295	238	9	-	-	PUNCT
admet-295	238	10	label	label	NOUN
admet-295	238	11	use	use	NOUN
admet-295	238	12	of	of	ADP
admet-295	238	13	oncology	oncology	NOUN
admet-295	238	14	drugs	drug	NOUN
admet-295	238	15	.	.	PUNCT
admet-295	239	1	one	one	NUM
admet-295	239	2	study	study	NOUN
admet-295	239	3	from	from	ADP
admet-295	239	4	switzerland	switzerland	PROPN
admet-295	239	5	reported	report	VERB
admet-295	239	6	a	a	DET
admet-295	239	7	total	total	NOUN
admet-295	239	8	of	of	ADP
admet-295	239	9	985	985	NUM
admet-295	239	10	consecutive	consecutive	ADJ
admet-295	239	11	patients	patient	NOUN
admet-295	239	12	receiving	receive	VERB
admet-295	239	13	1,737	1,737	NUM
admet-295	239	14	anticancer	anticancer	NOUN
admet-295	239	15	drug	drug	NOUN
admet-295	239	16	treatments	treatment	NOUN
admet-295	239	17	and	and	CCONJ
admet-295	239	18	found	find	VERB
admet-295	239	19	that	that	SCONJ
admet-295	239	20	overall	overall	ADJ
admet-295	239	21	,	,	PUNCT
admet-295	239	22	32.4	32.4	NUM
admet-295	239	23	%	%	NOUN
admet-295	239	24	of	of	ADP
admet-295	239	25	all	all	DET
admet-295	239	26	patients	patient	NOUN
admet-295	239	27	received	receive	VERB
admet-295	239	28	at	at	ADV
admet-295	239	29	least	least	ADV
admet-295	239	30	one	one	NUM
admet-295	239	31	off	off	ADP
admet-295	239	32	-	-	PUNCT
admet-295	239	33	label	label	NOUN
admet-295	239	34	drug	drug	NOUN
admet-295	239	35	,	,	PUNCT
admet-295	239	36	corresponding	correspond	VERB
admet-295	239	37	to	to	ADP
admet-295	239	38	27.2	27.2	NUM
admet-295	239	39	%	%	NOUN
admet-295	239	40	of	of	ADP
admet-295	239	41	all	all	DET
admet-295	239	42	anticancer	anticancer	NOUN
admet-295	239	43	drugs	drug	NOUN
admet-295	239	44	administered	administer	VERB
admet-295	239	45	[	[	PUNCT
admet-295	239	46	107	107	NUM
admet-295	239	47	]	]	PUNCT
admet-295	239	48	.	.	PUNCT
admet-295	240	1	following	follow	VERB
admet-295	240	2	a	a	DET
admet-295	240	3	detailed	detailed	ADJ
admet-295	240	4	analysis	analysis	NOUN
admet-295	240	5	of	of	ADP
admet-295	240	6	the	the	DET
admet-295	240	7	adverse	adverse	ADJ
admet-295	240	8	drug	drug	NOUN
admet-295	240	9	reactions	reaction	NOUN
admet-295	240	10	of	of	ADP
admet-295	240	11	targeted	target	VERB
admet-295	240	12	anticancer	anticancer	NOUN
admet-295	240	13	agents	agent	NOUN
admet-295	240	14	from	from	ADP
admet-295	240	15	their	their	PRON
admet-295	240	16	reporting	reporting	NOUN
admet-295	240	17	in	in	ADP
admet-295	240	18	pivotal	pivotal	ADJ
admet-295	240	19	randomized	randomized	ADJ
admet-295	240	20	clinical	clinical	ADJ
admet-295	240	21	trials	trial	NOUN
admet-295	240	22	and	and	CCONJ
admet-295	240	23	subsequently	subsequently	ADV
admet-295	240	24	updated	update	VERB
admet-295	240	25	drug	drug	NOUN
admet-295	240	26	labels	label	NOUN
admet-295	240	27	,	,	PUNCT
admet-295	240	28	seruga	seruga	ADJ
admet-295	240	29	et	et	PROPN
admet-295	240	30	al	al	PROPN
admet-295	240	31	.	.	PUNCT
admet-295	241	1	[	[	X
admet-295	241	2	108	108	NUM
admet-295	241	3	]	]	PUNCT
admet-295	241	4	concluded	conclude	VERB
admet-295	241	5	that	that	SCONJ
admet-295	241	6	many	many	ADJ
admet-295	241	7	rare	rare	ADJ
admet-295	241	8	but	but	CCONJ
admet-295	241	9	serious	serious	ADJ
admet-295	241	10	and	and	CCONJ
admet-295	241	11	potentially	potentially	ADV
admet-295	241	12	fatal	fatal	ADJ
admet-295	241	13	adverse	adverse	ADJ
admet-295	241	14	drug	drug	NOUN
admet-295	241	15	reactions	reaction	NOUN
admet-295	241	16	associated	associate	VERB
admet-295	241	17	with	with	ADP
admet-295	241	18	these	these	DET
admet-295	241	19	agents	agent	NOUN
admet-295	241	20	are	be	AUX
admet-295	241	21	not	not	PART
admet-295	241	22	reported	report	VERB
admet-295	241	23	in	in	ADP
admet-295	241	24	clinical	clinical	ADJ
admet-295	241	25	trials	trial	NOUN
admet-295	241	26	.	.	PUNCT
admet-295	242	1	one	one	NUM
admet-295	242	2	study	study	NOUN
admet-295	242	3	on	on	ADP
admet-295	242	4	cancer	cancer	NOUN
admet-295	242	5	drugs	drug	NOUN
admet-295	242	6	in	in	ADP
admet-295	242	7	japan	japan	PROPN
admet-295	242	8	reported	report	VERB
admet-295	242	9	that	that	PRON
admet-295	242	10	of	of	ADP
admet-295	242	11	the	the	DET
admet-295	242	12	111	111	NUM
admet-295	242	13	fatal	fatal	ADJ
admet-295	242	14	adverse	adverse	ADJ
admet-295	242	15	drug	drug	NOUN
admet-295	242	16	reactions	reaction	NOUN
admet-295	242	17	detected	detect	VERB
admet-295	242	18	in	in	ADP
admet-295	242	19	the	the	DET
admet-295	242	20	eight	eight	NUM
admet-295	242	21	post	post	ADJ
admet-295	242	22	-	-	ADJ
admet-295	242	23	marketing	marketing	ADJ
admet-295	242	24	surveillances	surveillance	NOUN
admet-295	242	25	,	,	PUNCT
admet-295	242	26	only	only	ADV
admet-295	242	27	28	28	NUM
admet-295	242	28	(	(	PUNCT
admet-295	242	29	25.0	25.0	NUM
admet-295	242	30	%	%	NOUN
admet-295	242	31	)	)	PUNCT
admet-295	242	32	and	and	CCONJ
admet-295	242	33	22	22	NUM
admet-295	242	34	(	(	PUNCT
admet-295	242	35	19.6	19.6	NUM
admet-295	242	36	%	%	NOUN
admet-295	242	37	)	)	PUNCT
admet-295	242	38	were	be	AUX
admet-295	242	39	described	describe	VERB
admet-295	242	40	on	on	ADP
admet-295	242	41	the	the	DET
admet-295	242	42	initial	initial	ADJ
admet-295	242	43	global	global	ADJ
admet-295	242	44	and	and	CCONJ
admet-295	242	45	the	the	DET
admet-295	242	46	initial	initial	ADJ
admet-295	242	47	japanese	japanese	ADJ
admet-295	242	48	drug	drug	NOUN
admet-295	242	49	label	label	NOUN
admet-295	242	50	,	,	PUNCT
admet-295	242	51	respectively	respectively	ADV
admet-295	242	52	,	,	PUNCT
admet-295	242	53	and	and	CCONJ
admet-295	242	54	58	58	NUM
admet-295	242	55	(	(	PUNCT
admet-295	242	56	52.3	52.3	NUM
admet-295	242	57	%	%	NOUN
admet-295	242	58	)	)	PUNCT
admet-295	242	59	fatal	fatal	ADJ
admet-295	242	60	adverse	adverse	ADJ
admet-295	242	61	drug	drug	NOUN
admet-295	242	62	reactions	reaction	NOUN
admet-295	242	63	were	be	AUX
admet-295	242	64	first	first	ADV
admet-295	242	65	described	describe	VERB
admet-295	242	66	in	in	ADP
admet-295	242	67	the	the	DET
admet-295	242	68	all	all	DET
admet-295	242	69	-	-	PUNCT
admet-295	242	70	case	case	NOUN
admet-295	242	71	post	post	ADJ
admet-295	242	72	-	-	ADJ
admet-295	242	73	marketing	marketing	ADJ
admet-295	242	74	surveillance	surveillance	NOUN
admet-295	242	75	reports	report	VERB
admet-295	242	76	[	[	X
admet-295	242	77	109	109	NUM
admet-295	242	78	]	]	PUNCT
admet-295	242	79	.	.	PUNCT
admet-295	243	1	herg	herg	PROPN
admet-295	243	2	blockade	blockade	NOUN
admet-295	243	3	in	in	ADP
admet-295	243	4	oncology	oncology	NOUN
admet-295	243	5	–	–	PUNCT
admet-295	243	6	a	a	DET
admet-295	243	7	friend	friend	NOUN
admet-295	243	8	or	or	CCONJ
admet-295	243	9	a	a	DET
admet-295	243	10	foe	foe	NOUN
admet-295	243	11	?	?	PUNCT
admet-295	244	1	most	most	ADJ
admet-295	244	2	of	of	ADP
admet-295	244	3	the	the	DET
admet-295	244	4	14	14	NUM
admet-295	244	5	drugs	drug	NOUN
admet-295	244	6	withdrawn	withdraw	VERB
admet-295	244	7	from	from	ADP
admet-295	244	8	the	the	DET
admet-295	244	9	market	market	NOUN
admet-295	244	10	due	due	ADP
admet-295	244	11	to	to	ADP
admet-295	244	12	their	their	PRON
admet-295	244	13	qt	qt	NOUN
admet-295	244	14	-	-	PUNCT
admet-295	244	15	related	relate	VERB
admet-295	244	16	proarrhythmic	proarrhythmic	ADJ
admet-295	244	17	proclivity	proclivity	NOUN
admet-295	244	18	were	be	AUX
admet-295	244	19	either	either	CCONJ
admet-295	244	20	old	old	ADJ
admet-295	244	21	drugs	drug	NOUN
admet-295	244	22	with	with	ADP
admet-295	244	23	more	more	ADV
admet-295	244	24	effective	effective	ADJ
admet-295	244	25	newer	new	ADJ
admet-295	244	26	alternatives	alternative	NOUN
admet-295	244	27	or	or	CCONJ
admet-295	244	28	were	be	AUX
admet-295	244	29	indicated	indicate	VERB
admet-295	244	30	for	for	ADP
admet-295	244	31	relatively	relatively	ADV
admet-295	244	32	benign	benign	ADJ
admet-295	244	33	indications	indication	NOUN
admet-295	244	34	.	.	PUNCT
admet-295	245	1	as	as	ADP
admet-295	245	2	a	a	DET
admet-295	245	3	result	result	NOUN
admet-295	245	4	,	,	PUNCT
admet-295	245	5	their	their	PRON
admet-295	245	6	risk	risk	NOUN
admet-295	245	7	/	/	SYM
admet-295	245	8	benefit	benefit	NOUN
admet-295	245	9	was	be	AUX
admet-295	245	10	considered	consider	VERB
admet-295	245	11	unfavourable	unfavourable	ADJ
admet-295	245	12	and	and	CCONJ
admet-295	245	13	it	it	PRON
admet-295	245	14	was	be	AUX
admet-295	245	15	prudent	prudent	ADJ
admet-295	245	16	to	to	PART
admet-295	245	17	have	have	AUX
admet-295	245	18	withdrawn	withdraw	VERB
admet-295	245	19	them	they	PRON
admet-295	245	20	form	form	VERB
admet-295	245	21	the	the	DET
admet-295	245	22	market	market	NOUN
admet-295	245	23	.	.	PUNCT
admet-295	246	1	however	however	ADV
admet-295	246	2	,	,	PUNCT
admet-295	246	3	for	for	ADP
admet-295	246	4	the	the	DET
admet-295	246	5	pkis	pki	NOUN
admet-295	246	6	,	,	PUNCT
admet-295	246	7	the	the	DET
admet-295	246	8	risk	risk	NOUN
admet-295	246	9	/	/	SYM
admet-295	246	10	benefit	benefit	NOUN
admet-295	246	11	components	component	NOUN
admet-295	246	12	are	be	AUX
admet-295	246	13	different	different	ADJ
admet-295	246	14	.	.	PUNCT
admet-295	247	1	not	not	PART
admet-295	247	2	only	only	ADV
admet-295	247	3	are	be	AUX
admet-295	247	4	they	they	PRON
admet-295	247	5	indicated	indicate	VERB
admet-295	247	6	for	for	ADP
admet-295	247	7	life	life	NOUN
admet-295	247	8	-	-	PUNCT
admet-295	247	9	threatening	threaten	VERB
admet-295	247	10	conditions	condition	NOUN
admet-295	247	11	with	with	ADP
admet-295	247	12	potentially	potentially	ADV
admet-295	247	13	no	no	DET
admet-295	247	14	alternatives	alternative	NOUN
admet-295	247	15	but	but	CCONJ
admet-295	247	16	also	also	ADV
admet-295	247	17	,	,	PUNCT
admet-295	247	18	their	their	PRON
admet-295	247	19	post	post	ADJ
admet-295	247	20	-	-	ADJ
admet-295	247	21	marketing	marketing	ADJ
admet-295	247	22	performance	performance	NOUN
admet-295	247	23	suggests	suggest	VERB
admet-295	247	24	that	that	SCONJ
admet-295	247	25	the	the	DET
admet-295	247	26	risk	risk	NOUN
admet-295	247	27	of	of	ADP
admet-295	247	28	qt	qt	NOUN
admet-295	247	29	-	-	PUNCT
admet-295	247	30	related	relate	VERB
admet-295	247	31	proarrhythmia	proarrhythmia	NOUN
admet-295	247	32	may	may	AUX
admet-295	247	33	have	have	AUX
admet-295	247	34	been	be	AUX
admet-295	247	35	over	over	ADV
admet-295	247	36	-	-	PUNCT
admet-295	247	37	estimated	estimate	VERB
admet-295	247	38	.	.	PUNCT
admet-295	248	1	critically	critically	ADV
admet-295	248	2	,	,	PUNCT
admet-295	248	3	as	as	SCONJ
admet-295	248	4	explained	explain	VERB
admet-295	248	5	earlier	early	ADV
admet-295	248	6	,	,	PUNCT
admet-295	248	7	the	the	DET
admet-295	248	8	risk	risk	NOUN
admet-295	248	9	assessment	assessment	NOUN
admet-295	248	10	is	be	AUX
admet-295	248	11	based	base	VERB
admet-295	248	12	on	on	ADP
admet-295	248	13	a	a	DET
admet-295	248	14	parameter	parameter	NOUN
admet-295	248	15	(	(	PUNCT
admet-295	248	16	qt	qt	NOUN
admet-295	248	17	prolongation	prolongation	NOUN
admet-295	248	18	)	)	PUNCT
admet-295	248	19	that	that	PRON
admet-295	248	20	is	be	AUX
admet-295	248	21	known	know	VERB
admet-295	248	22	to	to	PART
admet-295	248	23	be	be	AUX
admet-295	248	24	a	a	DET
admet-295	248	25	poor	poor	ADJ
admet-295	248	26	predictor	predictor	NOUN
admet-295	248	27	of	of	ADP
admet-295	248	28	the	the	DET
admet-295	248	29	risk	risk	NOUN
admet-295	248	30	.	.	PUNCT
admet-295	249	1	if	if	SCONJ
admet-295	249	2	pkis	pki	NOUN
admet-295	249	3	can	can	AUX
admet-295	249	4	be	be	AUX
admet-295	249	5	approved	approve	VERB
admet-295	249	6	and	and	CCONJ
admet-295	249	7	continue	continue	VERB
admet-295	249	8	to	to	PART
admet-295	249	9	be	be	AUX
admet-295	249	10	marketed	market	VERB
admet-295	249	11	and	and	CCONJ
admet-295	249	12	used	use	VERB
admet-295	249	13	clinically	clinically	ADV
admet-295	249	14	despite	despite	SCONJ
admet-295	249	15	clinically	clinically	ADV
admet-295	249	16	the	the	DET
admet-295	249	17	most	most	ADV
admet-295	249	18	relevant	relevant	ADJ
admet-295	249	19	risks	risk	NOUN
admet-295	249	20	of	of	ADP
admet-295	249	21	lv	lv	PRON
admet-295	249	22	dysfunction	dysfunction	NOUN
admet-295	249	23	and	and	CCONJ
admet-295	249	24	arterial	arterial	ADJ
admet-295	249	25	thrombotic	thrombotic	ADJ
admet-295	249	26	events	event	NOUN
admet-295	249	27	,	,	PUNCT
admet-295	249	28	there	there	PRON
admet-295	249	29	seems	seem	VERB
admet-295	249	30	no	no	DET
admet-295	249	31	reason	reason	NOUN
admet-295	249	32	why	why	SCONJ
admet-295	249	33	they	they	PRON
admet-295	249	34	should	should	AUX
admet-295	249	35	be	be	AUX
admet-295	249	36	abandoned	abandon	VERB
admet-295	249	37	early	early	ADV
admet-295	249	38	during	during	ADP
admet-295	249	39	the	the	DET
admet-295	249	40	course	course	NOUN
admet-295	249	41	of	of	ADP
admet-295	249	42	their	their	PRON
admet-295	249	43	development	development	NOUN
admet-295	249	44	because	because	SCONJ
admet-295	249	45	of	of	ADP
admet-295	249	46	the	the	DET
admet-295	249	47	phobia	phobia	NOUN
admet-295	249	48	about	about	ADP
admet-295	249	49	qt	qt	NOUN
admet-295	249	50	-	-	PUNCT
admet-295	249	51	related	relate	VERB
admet-295	249	52	over	over	ADP
admet-295	249	53	-	-	PUNCT
admet-295	249	54	estimated	estimate	VERB
admet-295	249	55	risks	risk	NOUN
admet-295	249	56	of	of	ADP
admet-295	249	57	proarrhythmias	proarrhythmia	NOUN
admet-295	249	58	.	.	PUNCT
admet-295	250	1	since	since	SCONJ
admet-295	250	2	both	both	DET
admet-295	250	3	ich	ich	NOUN
admet-295	250	4	s7b	s7b	PROPN
admet-295	250	5	and	and	CCONJ
admet-295	250	6	ich	ich	PROPN
admet-295	250	7	e14	e14	PROPN
admet-295	250	8	are	be	AUX
admet-295	250	9	principally	principally	ADV
admet-295	250	10	“	"	PUNCT
admet-295	250	11	herg	herg	PROPN
admet-295	250	12	-	-	PUNCT
admet-295	250	13	centric	centric	NOUN
admet-295	250	14	”	"	PUNCT
admet-295	250	15	and	and	CCONJ
admet-295	250	16	“	"	PUNCT
admet-295	250	17	qt	qt	NOUN
admet-295	250	18	-	-	PUNCT
admet-295	250	19	centric	centric	NOUN
admet-295	250	20	”	"	PUNCT
admet-295	250	21	,	,	PUNCT
admet-295	250	22	respectively	respectively	ADV
admet-295	250	23	,	,	PUNCT
admet-295	250	24	a	a	DET
admet-295	250	25	new	new	ADJ
admet-295	250	26	paradigm	paradigm	NOUN
admet-295	250	27	,	,	PUNCT
admet-295	250	28	referred	refer	VERB
admet-295	250	29	to	to	ADP
admet-295	250	30	as	as	ADP
admet-295	250	31	the	the	DET
admet-295	250	32	comprehensive	comprehensive	ADJ
admet-295	250	33	in	in	ADP
admet-295	250	34	vitro	vitro	X
admet-295	250	35	proarrhythmia	proarrhythmia	PROPN
admet-295	250	36	assay	assay	PROPN
admet-295	250	37	(	(	PUNCT
admet-295	250	38	cipa	cipa	NOUN
admet-295	250	39	)	)	PUNCT
admet-295	250	40	,	,	PUNCT
admet-295	250	41	is	be	AUX
admet-295	250	42	now	now	ADV
admet-295	250	43	gathering	gather	VERB
admet-295	250	44	momentum	momentum	NOUN
admet-295	250	45	among	among	ADP
admet-295	250	46	all	all	DET
admet-295	250	47	the	the	DET
admet-295	250	48	stake	stake	NOUN
admet-295	250	49	holders	holder	NOUN
admet-295	250	50	,	,	PUNCT
admet-295	250	51	including	include	VERB
admet-295	250	52	the	the	DET
admet-295	250	53	regulatory	regulatory	ADJ
admet-295	250	54	authorities	authority	NOUN
admet-295	250	55	[	[	X
admet-295	250	56	110	110	NUM
admet-295	250	57	]	]	PUNCT
admet-295	250	58	.	.	PUNCT
admet-295	251	1	this	this	DET
admet-295	251	2	paradigm	paradigm	NOUN
admet-295	251	3	,	,	PUNCT
admet-295	251	4	aiming	aim	VERB
admet-295	251	5	to	to	PART
admet-295	251	6	characterise	characterise	VERB
admet-295	251	7	the	the	DET
admet-295	251	8	risk	risk	NOUN
admet-295	251	9	of	of	ADP
admet-295	251	10	proarrhythmias	proarrhythmia	NOUN
admet-295	251	11	as	as	SCONJ
admet-295	251	12	opposed	oppose	VERB
admet-295	251	13	to	to	ADP
admet-295	251	14	qtc	qtc	PROPN
admet-295	251	15	prolongation	prolongation	PROPN
admet-295	251	16	,	,	PUNCT
admet-295	251	17	recognises	recognise	VERB
admet-295	251	18	the	the	DET
admet-295	251	19	critical	critical	ADJ
admet-295	251	20	role	role	NOUN
admet-295	251	21	of	of	ADP
admet-295	251	22	multiple	multiple	ADJ
admet-295	251	23	ion	ion	NOUN
admet-295	251	24	channels	channel	NOUN
admet-295	251	25	blockade	blockade	VERB
admet-295	251	26	and	and	CCONJ
admet-295	251	27	among	among	ADP
admet-295	251	28	other	other	ADJ
admet-295	251	29	recommendations	recommendation	NOUN
admet-295	251	30	,	,	PUNCT
admet-295	251	31	calls	call	VERB
admet-295	251	32	for	for	ADP
admet-295	251	33	all	all	DET
admet-295	251	34	new	new	ADJ
admet-295	251	35	drugs	drug	NOUN
admet-295	251	36	to	to	PART
admet-295	251	37	be	be	AUX
admet-295	251	38	studied	study	VERB
admet-295	251	39	for	for	ADP
admet-295	251	40	their	their	PRON
admet-295	251	41	effects	effect	NOUN
admet-295	251	42	on	on	ADP
admet-295	251	43	multiple	multiple	ADJ
admet-295	251	44	ion	ion	NOUN
admet-295	251	45	channels	channel	NOUN
admet-295	251	46	and	and	CCONJ
admet-295	251	47	incorporation	incorporation	NOUN
admet-295	251	48	of	of	ADP
admet-295	251	49	these	these	DET
admet-295	251	50	effects	effect	NOUN
admet-295	251	51	in	in	ADP
admet-295	251	52	an	an	DET
admet-295	251	53	in	in	ADP
admet-295	251	54	silico	silico	NOUN
admet-295	251	55	computer	computer	NOUN
admet-295	251	56	modelling	modelling	NOUN
admet-295	251	57	of	of	ADP
admet-295	251	58	human	human	ADJ
admet-295	251	59	ventricular	ventricular	ADJ
admet-295	251	60	electrophysiology	electrophysiology	NOUN
admet-295	251	61	to	to	PART
admet-295	251	62	predict	predict	VERB
admet-295	251	63	a	a	DET
admet-295	251	64	drug	drug	NOUN
admet-295	251	65	’s	’s	PART
admet-295	251	66	proarrhythmic	proarrhythmic	ADJ
admet-295	251	67	potential	potential	NOUN
admet-295	251	68	.	.	PUNCT
admet-295	252	1	of	of	ADP
admet-295	252	2	greater	great	ADJ
admet-295	252	3	concern	concern	NOUN
admet-295	252	4	is	be	AUX
admet-295	252	5	the	the	DET
admet-295	252	6	real	real	ADJ
admet-295	252	7	possibility	possibility	NOUN
admet-295	252	8	that	that	SCONJ
admet-295	252	9	discarding	discard	VERB
admet-295	252	10	a	a	DET
admet-295	252	11	pki	pki	NOUN
admet-295	252	12	because	because	SCONJ
admet-295	252	13	it	it	PRON
admet-295	252	14	inhibits	inhibit	VERB
admet-295	252	15	herg	herg	PROPN
admet-295	252	16	channel	channel	PROPN
admet-295	252	17	may	may	AUX
admet-295	252	18	prove	prove	VERB
admet-295	252	19	to	to	PART
admet-295	252	20	be	be	AUX
admet-295	252	21	counter	counter	ADJ
admet-295	252	22	-	-	ADJ
admet-295	252	23	productive	productive	ADJ
admet-295	252	24	since	since	SCONJ
admet-295	252	25	herg	herg	PROPN
admet-295	252	26	is	be	AUX
admet-295	252	27	expressed	express	VERB
admet-295	252	28	in	in	ADP
admet-295	252	29	a	a	DET
admet-295	252	30	variety	variety	NOUN
admet-295	252	31	of	of	ADP
admet-295	252	32	malignancies	malignancy	NOUN
admet-295	252	33	[	[	X
admet-295	252	34	111	111	NUM
admet-295	252	35	-	-	SYM
admet-295	252	36	113	113	NUM
admet-295	252	37	]	]	PUNCT
admet-295	252	38	.	.	PUNCT
admet-295	253	1	early	early	ADJ
admet-295	253	2	indications	indication	NOUN
admet-295	253	3	are	be	AUX
admet-295	253	4	that	that	SCONJ
admet-295	253	5	herg	herg	PROPN
admet-295	253	6	channel	channel	NOUN
admet-295	253	7	blockers	blocker	NOUN
admet-295	253	8	attenuate	attenuate	VERB
admet-295	253	9	the	the	DET
admet-295	253	10	progression	progression	NOUN
admet-295	253	11	of	of	ADP
admet-295	253	12	both	both	DET
admet-295	253	13	hematologic	hematologic	ADJ
admet-295	253	14	malignancies	malignancy	NOUN
admet-295	253	15	and	and	CCONJ
admet-295	253	16	solid	solid	ADJ
admet-295	253	17	tumours	tumour	NOUN
admet-295	254	1	[	[	X
admet-295	254	2	114	114	NUM
admet-295	254	3	-	-	SYM
admet-295	254	4	119	119	NUM
admet-295	254	5	]	]	PUNCT
admet-295	254	6	.	.	PUNCT
admet-295	255	1	not	not	PART
admet-295	255	2	surprisingly	surprisingly	ADV
admet-295	255	3	,	,	PUNCT
admet-295	255	4	herg	herg	PROPN
admet-295	255	5	channel	channel	NOUN
admet-295	255	6	has	have	AUX
admet-295	255	7	been	be	AUX
admet-295	255	8	suggested	suggest	VERB
admet-295	255	9	as	as	ADP
admet-295	255	10	a	a	DET
admet-295	255	11	potential	potential	ADJ
admet-295	255	12	target	target	NOUN
admet-295	255	13	for	for	ADP
admet-295	255	14	admet	admet	PROPN
admet-295	255	15	&	&	CCONJ
admet-295	255	16	dmpk	dmpk	PROPN
admet-295	255	17	4(3	4(3	NUM
admet-295	255	18	)	)	PUNCT
admet-295	255	19	(	(	PUNCT
admet-295	255	20	2016	2016	NUM
admet-295	255	21	)	)	PUNCT
admet-295	255	22	212	212	NUM
admet-295	255	23	-	-	SYM
admet-295	255	24	231	231	NUM
admet-295	255	25	pkis	pki	NOUN
admet-295	255	26	and	and	CCONJ
admet-295	255	27	qt	qt	NOUN
admet-295	255	28	-	-	PUNCT
admet-295	255	29	phobia	phobia	NOUN
admet-295	255	30	doi	doi	NOUN
admet-295	255	31	:	:	PUNCT
admet-295	255	32	10.5599	10.5599	NUM
admet-295	255	33	/	/	SYM
admet-295	255	34	admet.4.3.295	admet.4.3.295	NOUN
admet-295	255	35	225	225	NUM
admet-295	255	36	anticancer	anticancer	NOUN
admet-295	255	37	drugs	drug	NOUN
admet-295	255	38	[	[	X
admet-295	255	39	112	112	NUM
admet-295	255	40	,	,	PUNCT
admet-295	255	41	120	120	NUM
admet-295	255	42	]	]	PUNCT
admet-295	255	43	.	.	PUNCT
admet-295	256	1	among	among	ADP
admet-295	256	2	the	the	DET
admet-295	256	3	interesting	interesting	ADJ
admet-295	256	4	such	such	ADJ
admet-295	256	5	drugs	drug	NOUN
admet-295	256	6	is	be	AUX
admet-295	256	7	astemizole	astemizole	NOUN
admet-295	256	8	,	,	PUNCT
admet-295	256	9	withdrawn	withdraw	VERB
admet-295	256	10	from	from	ADP
admet-295	256	11	the	the	DET
admet-295	256	12	market	market	NOUN
admet-295	256	13	in	in	ADP
admet-295	256	14	1999	1999	NUM
admet-295	256	15	for	for	ADP
admet-295	256	16	its	its	PRON
admet-295	256	17	torsadogenic	torsadogenic	ADJ
admet-295	256	18	potential	potential	NOUN
admet-295	256	19	[	[	X
admet-295	256	20	46	46	NUM
admet-295	256	21	]	]	PUNCT
admet-295	256	22	,	,	PUNCT
admet-295	256	23	which	which	PRON
admet-295	256	24	is	be	AUX
admet-295	256	25	not	not	PART
admet-295	256	26	only	only	ADV
admet-295	256	27	a	a	DET
admet-295	256	28	herg	herg	PROPN
admet-295	256	29	blocker	blocker	NOUN
admet-295	256	30	but	but	CCONJ
admet-295	256	31	also	also	ADV
admet-295	256	32	an	an	DET
admet-295	256	33	antihistamine	antihistamine	NOUN
admet-295	256	34	[	[	X
admet-295	256	35	121	121	NUM
admet-295	256	36	]	]	PUNCT
admet-295	256	37	and	and	CCONJ
admet-295	256	38	histamine	histamine	NOUN
admet-295	256	39	favours	favour	VERB
admet-295	256	40	proliferation	proliferation	NOUN
admet-295	256	41	of	of	ADP
admet-295	256	42	normal	normal	ADJ
admet-295	256	43	and	and	CCONJ
admet-295	256	44	cancerous	cancerous	ADJ
admet-295	256	45	cells	cell	NOUN
admet-295	256	46	.	.	PUNCT
admet-295	257	1	if	if	SCONJ
admet-295	257	2	herg	herg	PROPN
admet-295	257	3	channel	channel	NOUN
admet-295	257	4	were	be	AUX
admet-295	257	5	to	to	PART
admet-295	257	6	prove	prove	VERB
admet-295	257	7	to	to	PART
admet-295	257	8	be	be	AUX
admet-295	257	9	a	a	DET
admet-295	257	10	valuable	valuable	ADJ
admet-295	257	11	therapeutic	therapeutic	ADJ
admet-295	257	12	target	target	NOUN
admet-295	257	13	in	in	ADP
admet-295	257	14	oncology	oncology	NOUN
admet-295	257	15	,	,	PUNCT
admet-295	257	16	new	new	ADJ
admet-295	257	17	paradigms	paradigm	NOUN
admet-295	257	18	will	will	AUX
admet-295	257	19	have	have	VERB
admet-295	257	20	to	to	PART
admet-295	257	21	evolve	evolve	VERB
admet-295	257	22	regarding	regard	VERB
admet-295	257	23	the	the	DET
admet-295	257	24	management	management	NOUN
admet-295	257	25	of	of	ADP
admet-295	257	26	pki	pki	PROPN
admet-295	257	27	-	-	ADJ
admet-295	257	28	induced	induced	ADJ
admet-295	257	29	qt	qt	NOUN
admet-295	257	30	interval	interval	NOUN
admet-295	257	31	prolongation	prolongation	NOUN
admet-295	257	32	.	.	PUNCT
admet-295	258	1	discussion	discussion	NOUN
admet-295	258	2	and	and	CCONJ
admet-295	258	3	conclusions	conclusion	NOUN
admet-295	258	4	in	in	ADP
admet-295	258	5	contrast	contrast	NOUN
admet-295	258	6	to	to	ADP
admet-295	258	7	their	their	PRON
admet-295	258	8	qt	qt	NOUN
admet-295	258	9	-	-	PUNCT
admet-295	258	10	liability	liability	NOUN
admet-295	258	11	,	,	PUNCT
admet-295	258	12	the	the	DET
admet-295	258	13	hepatotoxic	hepatotoxic	ADJ
admet-295	258	14	potential	potential	NOUN
admet-295	258	15	of	of	ADP
admet-295	258	16	pkis	pki	NOUN
admet-295	258	17	is	be	AUX
admet-295	258	18	far	far	ADV
admet-295	258	19	greater	great	ADJ
admet-295	258	20	.	.	PUNCT
admet-295	259	1	nineteen	nineteen	NUM
admet-295	259	2	(	(	PUNCT
admet-295	259	3	68	68	NUM
admet-295	259	4	%	%	NOUN
admet-295	259	5	)	)	PUNCT
admet-295	259	6	of	of	ADP
admet-295	259	7	the	the	DET
admet-295	259	8	28	28	NUM
admet-295	259	9	pkis	pki	NOUN
admet-295	259	10	are	be	AUX
admet-295	259	11	labelled	label	VERB
admet-295	259	12	as	as	ADP
admet-295	259	13	potentially	potentially	ADV
admet-295	259	14	hepatotoxic	hepatotoxic	ADJ
admet-295	259	15	with	with	ADP
admet-295	259	16	five	five	NUM
admet-295	259	17	them	they	PRON
admet-295	259	18	carrying	carry	VERB
admet-295	259	19	a	a	DET
admet-295	259	20	black	black	ADJ
admet-295	259	21	box	box	NOUN
admet-295	259	22	warning	warning	NOUN
admet-295	259	23	(	(	PUNCT
admet-295	259	24	table	table	NOUN
admet-295	259	25	2	2	NUM
admet-295	259	26	)	)	PUNCT
admet-295	259	27	.	.	PUNCT
admet-295	260	1	twelve	twelve	NUM
admet-295	260	2	(	(	PUNCT
admet-295	260	3	75	75	NUM
admet-295	260	4	%	%	NOUN
admet-295	260	5	)	)	PUNCT
admet-295	260	6	of	of	ADP
admet-295	260	7	the	the	DET
admet-295	260	8	16	16	NUM
admet-295	260	9	pkis	pki	NOUN
admet-295	260	10	approved	approve	VERB
admet-295	260	11	in	in	ADP
admet-295	260	12	period	period	NOUN
admet-295	260	13	1	1	NUM
admet-295	260	14	and	and	CCONJ
admet-295	260	15	7	7	NUM
admet-295	260	16	(	(	PUNCT
admet-295	260	17	58	58	NUM
admet-295	260	18	%	%	NOUN
admet-295	260	19	)	)	PUNCT
admet-295	260	20	of	of	ADP
admet-295	260	21	the	the	DET
admet-295	260	22	12	12	NUM
admet-295	260	23	approved	approve	VERB
admet-295	260	24	in	in	ADP
admet-295	260	25	period	period	NOUN
admet-295	260	26	2	2	NUM
admet-295	260	27	are	be	AUX
admet-295	260	28	deemed	deem	VERB
admet-295	260	29	to	to	PART
admet-295	260	30	be	be	AUX
admet-295	260	31	hepatotoxic	hepatotoxic	ADJ
admet-295	260	32	.	.	PUNCT
admet-295	261	1	four	four	NUM
admet-295	261	2	of	of	ADP
admet-295	261	3	the	the	DET
admet-295	261	4	12	12	NUM
admet-295	261	5	from	from	ADP
admet-295	261	6	period	period	NOUN
admet-295	261	7	1	1	NUM
admet-295	261	8	and	and	CCONJ
admet-295	261	9	one	one	NUM
admet-295	261	10	of	of	ADP
admet-295	261	11	the	the	DET
admet-295	261	12	7	7	NUM
admet-295	261	13	from	from	ADP
admet-295	261	14	period	period	NOUN
admet-295	261	15	2	2	NUM
admet-295	261	16	carry	carry	VERB
admet-295	261	17	black	black	ADJ
admet-295	261	18	box	box	NOUN
admet-295	261	19	warning	warning	NOUN
admet-295	261	20	(	(	PUNCT
admet-295	261	21	lapatinib	lapatinib	PROPN
admet-295	261	22	,	,	PUNCT
admet-295	261	23	pazopanib	pazopanib	NOUN
admet-295	261	24	,	,	PUNCT
admet-295	261	25	regorafenib	regorafenib	NOUN
admet-295	261	26	and	and	CCONJ
admet-295	261	27	sunitinib	sunitinib	NOUN
admet-295	261	28	,	,	PUNCT
admet-295	261	29	and	and	CCONJ
admet-295	261	30	ponatinib	ponatinib	NOUN
admet-295	261	31	,	,	PUNCT
admet-295	261	32	respectively	respectively	ADV
admet-295	261	33	)	)	PUNCT
admet-295	261	34	.	.	PUNCT
admet-295	262	1	although	although	SCONJ
admet-295	262	2	the	the	DET
admet-295	262	3	potential	potential	NOUN
admet-295	262	4	for	for	ADP
admet-295	262	5	clinically	clinically	ADV
admet-295	262	6	relevant	relevant	ADJ
admet-295	262	7	hepatic	hepatic	ADJ
admet-295	262	8	injury	injury	NOUN
admet-295	262	9	is	be	AUX
admet-295	262	10	typically	typically	ADV
admet-295	262	11	evaluated	evaluate	VERB
admet-295	262	12	on	on	ADP
admet-295	262	13	the	the	DET
admet-295	262	14	basis	basis	NOUN
admet-295	262	15	of	of	ADP
admet-295	262	16	the	the	DET
admet-295	262	17	magnitude	magnitude	NOUN
admet-295	262	18	of	of	ADP
admet-295	262	19	increases	increase	NOUN
admet-295	262	20	in	in	ADP
admet-295	262	21	serum	serum	NOUN
admet-295	262	22	aspartate	aspartate	NOUN
admet-295	262	23	and	and	CCONJ
admet-295	262	24	alanine	alanine	NOUN
admet-295	262	25	transaminases	transaminase	NOUN
admet-295	262	26	(	(	PUNCT
admet-295	262	27	ast	ast	NOUN
admet-295	262	28	and	and	CCONJ
admet-295	262	29	alt	alt	ADJ
admet-295	262	30	)	)	PUNCT
admet-295	262	31	,	,	PUNCT
admet-295	262	32	alkaline	alkaline	NOUN
admet-295	262	33	phosphatase	phosphatase	NOUN
admet-295	262	34	(	(	PUNCT
admet-295	262	35	alp	alp	PROPN
admet-295	262	36	)	)	PUNCT
admet-295	262	37	and	and	CCONJ
admet-295	262	38	bilirubin	bilirubin	NOUN
admet-295	262	39	,	,	PUNCT
admet-295	262	40	the	the	DET
admet-295	262	41	risk	risk	NOUN
admet-295	262	42	assessment	assessment	NOUN
admet-295	262	43	and	and	CCONJ
admet-295	262	44	labelling	labelling	NOUN
admet-295	262	45	are	be	AUX
admet-295	262	46	based	base	VERB
admet-295	262	47	on	on	ADP
admet-295	262	48	the	the	DET
admet-295	262	49	number	number	NOUN
admet-295	262	50	of	of	ADP
admet-295	262	51	cases	case	NOUN
admet-295	262	52	that	that	PRON
admet-295	262	53	meet	meet	VERB
admet-295	262	54	“	"	PUNCT
admet-295	262	55	hy	hy	PROPN
admet-295	262	56	’s	’s	PART
admet-295	262	57	rule	rule	NOUN
admet-295	262	58	”	"	PUNCT
admet-295	262	59	.	.	PUNCT
admet-295	263	1	according	accord	VERB
admet-295	263	2	to	to	ADP
admet-295	263	3	this	this	DET
admet-295	263	4	rule	rule	NOUN
admet-295	263	5	,	,	PUNCT
admet-295	263	6	a	a	DET
admet-295	263	7	significant	significant	ADJ
admet-295	263	8	risk	risk	NOUN
admet-295	263	9	of	of	ADP
admet-295	263	10	severe	severe	ADJ
admet-295	263	11	hepatotoxicity	hepatotoxicity	NOUN
admet-295	263	12	is	be	AUX
admet-295	263	13	associated	associate	VERB
admet-295	263	14	with	with	ADP
admet-295	263	15	medications	medication	NOUN
admet-295	263	16	which	which	PRON
admet-295	263	17	cause	cause	VERB
admet-295	263	18	hepatic	hepatic	ADJ
admet-295	263	19	injury	injury	NOUN
admet-295	263	20	(	(	PUNCT
admet-295	263	21	elevation	elevation	NOUN
admet-295	263	22	in	in	ADP
admet-295	263	23	alt	alt	ADJ
admet-295	263	24	)	)	PUNCT
admet-295	263	25	together	together	ADV
admet-295	263	26	with	with	ADP
admet-295	263	27	reduction	reduction	NOUN
admet-295	263	28	in	in	ADP
admet-295	263	29	hepatic	hepatic	ADJ
admet-295	263	30	function	function	NOUN
admet-295	263	31	(	(	PUNCT
admet-295	263	32	the	the	DET
admet-295	263	33	synthesis	synthesis	NOUN
admet-295	263	34	and	and	CCONJ
admet-295	263	35	transportation	transportation	NOUN
admet-295	263	36	of	of	ADP
admet-295	263	37	bilirubin	bilirubin	NOUN
admet-295	263	38	)	)	PUNCT
admet-295	263	39	in	in	ADP
admet-295	263	40	absence	absence	NOUN
admet-295	263	41	of	of	ADP
admet-295	263	42	any	any	DET
admet-295	263	43	evidence	evidence	NOUN
admet-295	263	44	of	of	ADP
admet-295	263	45	biliary	biliary	ADJ
admet-295	263	46	obstruction	obstruction	NOUN
admet-295	263	47	(	(	PUNCT
admet-295	263	48	e.g.	e.g.	ADV
admet-295	263	49	elevation	elevation	NOUN
admet-295	263	50	of	of	ADP
admet-295	263	51	alp	alp	PROPN
admet-295	263	52	)	)	PUNCT
admet-295	263	53	or	or	CCONJ
admet-295	263	54	of	of	ADP
admet-295	263	55	other	other	ADJ
admet-295	263	56	causes	cause	NOUN
admet-295	263	57	that	that	PRON
admet-295	263	58	can	can	AUX
admet-295	263	59	reasonably	reasonably	ADV
admet-295	263	60	explain	explain	VERB
admet-295	263	61	these	these	DET
admet-295	263	62	elevations	elevation	NOUN
admet-295	263	63	in	in	ADP
admet-295	263	64	alt	alt	NOUN
admet-295	263	65	and	and	CCONJ
admet-295	263	66	bilirubin	bilirubin	NOUN
admet-295	263	67	.	.	PUNCT
admet-295	264	1	hy	hy	PROPN
admet-295	264	2	’s	’s	PART
admet-295	264	3	rule	rule	NOUN
admet-295	264	4	has	have	AUX
admet-295	264	5	been	be	AUX
admet-295	264	6	validated	validate	VERB
admet-295	264	7	and	and	CCONJ
admet-295	264	8	confirmed	confirm	VERB
admet-295	264	9	in	in	ADP
admet-295	264	10	two	two	NUM
admet-295	264	11	large	large	ADJ
admet-295	264	12	studies	study	NOUN
admet-295	264	13	of	of	ADP
admet-295	264	14	drug	drug	NOUN
admet-295	264	15	-	-	PUNCT
admet-295	264	16	induced	induce	VERB
admet-295	264	17	liver	liver	NOUN
admet-295	264	18	injury	injury	NOUN
admet-295	264	19	in	in	ADP
admet-295	264	20	which	which	PRON
admet-295	264	21	approximately	approximately	ADV
admet-295	264	22	10	10	NUM
admet-295	264	23	percent	percent	NOUN
admet-295	264	24	of	of	ADP
admet-295	264	25	subjects	subject	NOUN
admet-295	264	26	with	with	ADP
admet-295	264	27	hyperbilirubinaemia	hyperbilirubinaemia	NOUN
admet-295	264	28	or	or	CCONJ
admet-295	264	29	jaundice	jaundice	NOUN
admet-295	264	30	died	die	VERB
admet-295	264	31	or	or	CCONJ
admet-295	264	32	needed	need	VERB
admet-295	264	33	liver	liver	NOUN
admet-295	264	34	transplant	transplant	NOUN
admet-295	264	35	[	[	X
admet-295	264	36	122	122	NUM
admet-295	264	37	,	,	PUNCT
admet-295	264	38	123	123	NUM
admet-295	264	39	]	]	PUNCT
admet-295	264	40	.	.	PUNCT
admet-295	265	1	finding	find	VERB
admet-295	265	2	one	one	NUM
admet-295	265	3	hy	hy	NOUN
admet-295	265	4	’s	’s	PART
admet-295	265	5	rule	rule	NOUN
admet-295	265	6	case	case	NOUN
admet-295	265	7	in	in	ADP
admet-295	265	8	the	the	DET
admet-295	265	9	clinical	clinical	ADJ
admet-295	265	10	trial	trial	NOUN
admet-295	265	11	database	database	NOUN
admet-295	265	12	is	be	AUX
admet-295	265	13	worrisome	worrisome	ADJ
admet-295	265	14	;	;	PUNCT
admet-295	265	15	finding	find	VERB
admet-295	265	16	two	two	NUM
admet-295	265	17	is	be	AUX
admet-295	265	18	considered	consider	VERB
admet-295	265	19	highly	highly	ADV
admet-295	265	20	predictive	predictive	ADJ
admet-295	265	21	of	of	ADP
admet-295	265	22	the	the	DET
admet-295	265	23	drug	drug	NOUN
admet-295	265	24	having	have	VERB
admet-295	265	25	the	the	DET
admet-295	265	26	potential	potential	NOUN
admet-295	265	27	to	to	PART
admet-295	265	28	cause	cause	VERB
admet-295	265	29	severe	severe	ADJ
admet-295	265	30	drug	drug	NOUN
admet-295	265	31	-	-	PUNCT
admet-295	265	32	induced	induce	VERB
admet-295	265	33	liver	liver	NOUN
admet-295	265	34	injury	injury	NOUN
admet-295	265	35	when	when	SCONJ
admet-295	265	36	given	give	VERB
admet-295	265	37	to	to	ADP
admet-295	265	38	a	a	DET
admet-295	265	39	larger	large	ADJ
admet-295	265	40	population	population	NOUN
admet-295	266	1	[	[	X
admet-295	266	2	124	124	NUM
admet-295	266	3	]	]	PUNCT
admet-295	266	4	.	.	PUNCT
admet-295	267	1	in	in	ADP
admet-295	267	2	pre	pre	ADJ
admet-295	267	3	-	-	ADJ
admet-295	267	4	approval	approval	ADJ
admet-295	267	5	clinical	clinical	ADJ
admet-295	267	6	trials	trial	NOUN
admet-295	267	7	of	of	ADP
admet-295	267	8	relevant	relevant	ADJ
admet-295	267	9	pkis	pki	NOUN
admet-295	267	10	,	,	PUNCT
admet-295	267	11	there	there	PRON
admet-295	267	12	were	be	VERB
admet-295	267	13	cases	case	NOUN
admet-295	267	14	that	that	PRON
admet-295	267	15	met	meet	VERB
admet-295	267	16	hy	hy	PROPN
admet-295	267	17	’s	’s	PART
admet-295	267	18	rule	rule	NOUN
admet-295	267	19	or	or	CCONJ
admet-295	267	20	fatal	fatal	ADJ
admet-295	267	21	cases	case	NOUN
admet-295	267	22	of	of	ADP
admet-295	267	23	hepatic	hepatic	ADJ
admet-295	267	24	failure	failure	NOUN
admet-295	267	25	.	.	PUNCT
admet-295	268	1	attribution	attribution	NOUN
admet-295	268	2	of	of	ADP
admet-295	268	3	the	the	DET
admet-295	268	4	risk	risk	NOUN
admet-295	268	5	of	of	ADP
admet-295	268	6	clinically	clinically	ADV
admet-295	268	7	relevant	relevant	ADJ
admet-295	268	8	hepatotoxicity	hepatotoxicity	NOUN
admet-295	268	9	has	have	AUX
admet-295	268	10	been	be	AUX
admet-295	268	11	justified	justify	VERB
admet-295	268	12	by	by	ADP
admet-295	268	13	numerous	numerous	ADJ
admet-295	268	14	post	post	ADJ
admet-295	268	15	-	-	ADJ
admet-295	268	16	marketing	marketing	ADJ
admet-295	268	17	reports	report	NOUN
admet-295	268	18	of	of	ADP
admet-295	268	19	pki	pki	NOUN
admet-295	268	20	-	-	ADJ
admet-295	268	21	induced	induced	ADJ
admet-295	268	22	hepatotoxicity	hepatotoxicity	NOUN
admet-295	268	23	that	that	SCONJ
admet-295	268	24	required	require	VERB
admet-295	268	25	revisions	revision	NOUN
admet-295	268	26	to	to	ADP
admet-295	268	27	the	the	DET
admet-295	268	28	labelling	labelling	NOUN
admet-295	268	29	of	of	ADP
admet-295	268	30	several	several	ADJ
admet-295	268	31	pkis	pki	NOUN
admet-295	268	32	.	.	PUNCT
admet-295	269	1	interestingly	interestingly	ADV
admet-295	269	2	,	,	PUNCT
admet-295	269	3	however	however	ADV
admet-295	269	4	,	,	PUNCT
admet-295	269	5	although	although	SCONJ
admet-295	269	6	bosutinib	bosutinib	NOUN
admet-295	269	7	is	be	AUX
admet-295	269	8	labelled	label	VERB
admet-295	269	9	as	as	ADP
admet-295	269	10	potentially	potentially	ADV
admet-295	269	11	hepatotoxic	hepatotoxic	ADJ
admet-295	269	12	,	,	PUNCT
admet-295	269	13	a	a	DET
admet-295	269	14	post	post	ADJ
admet-295	269	15	-	-	ADJ
admet-295	269	16	approval	approval	ADJ
admet-295	269	17	observational	observational	ADJ
admet-295	269	18	study	study	NOUN
admet-295	269	19	in	in	ADP
admet-295	269	20	which	which	PRON
admet-295	269	21	248	248	NUM
admet-295	269	22	patients	patient	NOUN
admet-295	269	23	received	receive	VERB
admet-295	269	24	bosutinib	bosutinib	NOUN
admet-295	269	25	for	for	ADP
admet-295	269	26	a	a	DET
admet-295	269	27	median	median	ADJ
admet-295	269	28	duration	duration	NOUN
admet-295	269	29	of	of	ADP
admet-295	269	30	27.5	27.5	NUM
admet-295	269	31	months	month	NOUN
admet-295	269	32	revealed	reveal	VERB
admet-295	269	33	no	no	DET
admet-295	269	34	cases	case	NOUN
admet-295	269	35	in	in	ADP
admet-295	269	36	the	the	DET
admet-295	269	37	bosutinib	bosutinib	NOUN
admet-295	269	38	arm	arm	NOUN
admet-295	269	39	that	that	PRON
admet-295	269	40	led	lead	VERB
admet-295	269	41	to	to	ADP
admet-295	269	42	hospitalization	hospitalization	NOUN
admet-295	269	43	,	,	PUNCT
admet-295	269	44	were	be	AUX
admet-295	269	45	associated	associate	VERB
admet-295	269	46	with	with	ADP
admet-295	269	47	permanent	permanent	ADJ
admet-295	269	48	hepatic	hepatic	ADJ
admet-295	269	49	injury	injury	NOUN
admet-295	269	50	or	or	CCONJ
admet-295	269	51	liver	liver	NOUN
admet-295	269	52	-	-	PUNCT
admet-295	269	53	related	relate	VERB
admet-295	269	54	deaths	death	NOUN
admet-295	269	55	,	,	PUNCT
admet-295	269	56	or	or	CCONJ
admet-295	269	57	met	meet	VERB
admet-295	269	58	hy	hy	PROPN
admet-295	269	59	’s	’s	PART
admet-295	269	60	rule	rule	NOUN
admet-295	269	61	criteria	criterion	NOUN
admet-295	269	62	[	[	X
admet-295	269	63	125	125	NUM
admet-295	269	64	]	]	PUNCT
admet-295	269	65	.	.	PUNCT
admet-295	270	1	thus	thus	ADV
admet-295	270	2	,	,	PUNCT
admet-295	270	3	although	although	SCONJ
admet-295	270	4	the	the	DET
admet-295	270	5	risks	risk	NOUN
admet-295	270	6	of	of	ADP
admet-295	270	7	proarrhythmia	proarrhythmia	NOUN
admet-295	270	8	and	and	CCONJ
admet-295	270	9	hepatotoxicity	hepatotoxicity	NOUN
admet-295	270	10	are	be	AUX
admet-295	270	11	both	both	PRON
admet-295	270	12	determined	determined	ADJ
admet-295	270	13	on	on	ADP
admet-295	270	14	the	the	DET
admet-295	270	15	basis	basis	NOUN
admet-295	270	16	of	of	ADP
admet-295	270	17	surrogate	surrogate	ADJ
admet-295	270	18	markers	marker	NOUN
admet-295	270	19	,	,	PUNCT
admet-295	270	20	the	the	DET
admet-295	270	21	assessment	assessment	NOUN
admet-295	270	22	of	of	ADP
admet-295	270	23	hepatotoxicity	hepatotoxicity	NOUN
admet-295	270	24	is	be	AUX
admet-295	270	25	based	base	VERB
admet-295	270	26	on	on	ADP
admet-295	270	27	a	a	DET
admet-295	270	28	combination	combination	NOUN
admet-295	270	29	of	of	ADP
admet-295	270	30	clinically	clinically	ADV
admet-295	270	31	relevant	relevant	ADJ
admet-295	270	32	and	and	CCONJ
admet-295	270	33	validated	validated	ADJ
admet-295	270	34	endpoints	endpoint	NOUN
admet-295	270	35	.	.	PUNCT
admet-295	271	1	there	there	PRON
admet-295	271	2	are	be	VERB
admet-295	271	3	also	also	ADV
admet-295	271	4	significant	significant	ADJ
admet-295	271	5	challenges	challenge	NOUN
admet-295	271	6	to	to	ADP
admet-295	271	7	evaluating	evaluate	VERB
admet-295	271	8	qtand	qtand	NOUN
admet-295	271	9	transaminase	transaminase	NOUN
admet-295	271	10	-	-	PUNCT
admet-295	271	11	based	base	VERB
admet-295	271	12	clinical	clinical	ADJ
admet-295	271	13	risk	risk	NOUN
admet-295	271	14	.	.	PUNCT
admet-295	272	1	whereas	whereas	SCONJ
admet-295	272	2	qt	qt	NOUN
admet-295	272	3	prolongation	prolongation	NOUN
admet-295	272	4	does	do	AUX
admet-295	272	5	not	not	PART
admet-295	272	6	correlate	correlate	VERB
admet-295	272	7	well	well	ADV
admet-295	272	8	with	with	ADP
admet-295	272	9	the	the	DET
admet-295	272	10	risk	risk	NOUN
admet-295	272	11	of	of	ADP
admet-295	272	12	proarrhythmias	proarrhythmia	NOUN
admet-295	272	13	for	for	ADP
admet-295	272	14	the	the	DET
admet-295	272	15	reasons	reason	NOUN
admet-295	272	16	already	already	ADV
admet-295	272	17	explained	explain	VERB
admet-295	272	18	earlier	early	ADV
admet-295	272	19	,	,	PUNCT
admet-295	272	20	diagnosing	diagnose	VERB
admet-295	272	21	drug	drug	NOUN
admet-295	272	22	-	-	PUNCT
admet-295	272	23	induced	induce	VERB
admet-295	272	24	liver	liver	NOUN
admet-295	272	25	injury	injury	NOUN
admet-295	272	26	can	can	AUX
admet-295	272	27	be	be	AUX
admet-295	272	28	difficult	difficult	ADJ
admet-295	272	29	in	in	ADP
admet-295	272	30	presence	presence	NOUN
admet-295	272	31	of	of	ADP
admet-295	272	32	metastasis	metastasis	NOUN
admet-295	272	33	.	.	PUNCT
admet-295	273	1	development	development	NOUN
admet-295	273	2	of	of	ADP
admet-295	273	3	newer	new	ADJ
admet-295	273	4	pkis	pki	NOUN
admet-295	273	5	should	should	AUX
admet-295	273	6	proceed	proceed	VERB
admet-295	273	7	on	on	ADP
admet-295	273	8	the	the	DET
admet-295	273	9	basis	basis	NOUN
admet-295	273	10	of	of	ADP
admet-295	273	11	assessment	assessment	NOUN
admet-295	273	12	of	of	ADP
admet-295	273	13	clinically	clinically	ADV
admet-295	273	14	meaningful	meaningful	ADJ
admet-295	273	15	risks	risk	NOUN
admet-295	273	16	and	and	CCONJ
admet-295	273	17	therapeutic	therapeutic	ADJ
admet-295	273	18	benefits	benefit	NOUN
admet-295	273	19	in	in	ADP
admet-295	273	20	terms	term	NOUN
admet-295	273	21	of	of	ADP
admet-295	273	22	morbidity	morbidity	NOUN
admet-295	273	23	,	,	PUNCT
admet-295	273	24	mortality	mortality	NOUN
admet-295	273	25	and	and	CCONJ
admet-295	273	26	quality	quality	NOUN
admet-295	273	27	of	of	ADP
admet-295	273	28	life	life	NOUN
admet-295	273	29	if	if	SCONJ
admet-295	273	30	potentially	potentially	ADV
admet-295	273	31	valuable	valuable	ADJ
admet-295	273	32	agents	agent	NOUN
admet-295	273	33	are	be	AUX
admet-295	273	34	not	not	PART
admet-295	273	35	to	to	PART
admet-295	273	36	be	be	AUX
admet-295	273	37	discarded	discard	VERB
admet-295	273	38	early	early	ADV
admet-295	273	39	in	in	ADP
admet-295	273	40	their	their	PRON
admet-295	273	41	development	development	NOUN
admet-295	273	42	programme	programme	NOUN
admet-295	273	43	without	without	ADP
admet-295	273	44	exploring	explore	VERB
admet-295	273	45	their	their	PRON
admet-295	273	46	clinically	clinically	ADV
admet-295	273	47	meaningful	meaningful	ADJ
admet-295	273	48	benefits	benefit	NOUN
admet-295	273	49	.	.	PUNCT
admet-295	274	1	safe	safe	ADJ
admet-295	274	2	and	and	CCONJ
admet-295	274	3	effective	effective	ADJ
admet-295	274	4	use	use	NOUN
admet-295	274	5	of	of	ADP
admet-295	274	6	these	these	DET
admet-295	274	7	valuable	valuable	ADJ
admet-295	274	8	drugs	drug	NOUN
admet-295	274	9	requires	require	VERB
admet-295	274	10	close	close	ADJ
admet-295	274	11	collaboration	collaboration	NOUN
admet-295	274	12	between	between	ADP
admet-295	274	13	the	the	DET
admet-295	274	14	oncologists	oncologist	NOUN
admet-295	274	15	and	and	CCONJ
admet-295	274	16	their	their	PRON
admet-295	274	17	colleagues	colleague	NOUN
admet-295	274	18	in	in	ADP
admet-295	274	19	other	other	ADJ
admet-295	274	20	specialties	specialty	NOUN
admet-295	274	21	such	such	ADJ
admet-295	274	22	as	as	ADP
admet-295	274	23	the	the	DET
admet-295	274	24	collaboration	collaboration	NOUN
admet-295	274	25	which	which	PRON
admet-295	274	26	has	have	AUX
admet-295	274	27	been	be	AUX
admet-295	274	28	forged	forge	VERB
admet-295	274	29	by	by	ADP
admet-295	274	30	oncologists	oncologist	NOUN
admet-295	274	31	and	and	CCONJ
admet-295	274	32	cardiologists	cardiologist	NOUN
admet-295	274	33	[	[	X
admet-295	274	34	3	3	NUM
admet-295	274	35	]	]	PUNCT
admet-295	274	36	.	.	PUNCT
admet-295	275	1	funding	fund	VERB
admet-295	275	2	no	no	DET
admet-295	275	3	sources	source	NOUN
admet-295	275	4	of	of	ADP
admet-295	275	5	funding	funding	NOUN
admet-295	275	6	were	be	AUX
admet-295	275	7	used	use	VERB
admet-295	275	8	to	to	PART
admet-295	275	9	assist	assist	VERB
admet-295	275	10	in	in	ADP
admet-295	275	11	the	the	DET
admet-295	275	12	preparation	preparation	NOUN
admet-295	275	13	of	of	ADP
admet-295	275	14	this	this	DET
admet-295	275	15	review	review	NOUN
admet-295	275	16	.	.	PUNCT
admet-295	276	1	rashmi	rashmi	PROPN
admet-295	276	2	shah	shah	PROPN
admet-295	276	3	admet	admet	PROPN
admet-295	276	4	&	&	CCONJ
admet-295	276	5	dmpk	dmpk	PROPN
admet-295	276	6	4(3	4(3	NUM
admet-295	276	7	)	)	PUNCT
admet-295	276	8	(	(	PUNCT
admet-295	276	9	2016	2016	NUM
admet-295	276	10	)	)	PUNCT
admet-295	276	11	212	212	NUM
admet-295	276	12	-	-	SYM
admet-295	276	13	231	231	NUM
admet-295	276	14	226	226	NUM
admet-295	276	15	conflict	conflict	NOUN
admet-295	276	16	of	of	ADP
admet-295	276	17	interest	interest	NOUN
admet-295	276	18	the	the	DET
admet-295	276	19	author	author	NOUN
admet-295	276	20	has	have	VERB
admet-295	276	21	no	no	DET
admet-295	276	22	conflicts	conflict	NOUN
admet-295	276	23	of	of	ADP
admet-295	276	24	interest	interest	NOUN
admet-295	276	25	that	that	PRON
admet-295	276	26	are	be	AUX
admet-295	276	27	directly	directly	ADV
admet-295	276	28	relevant	relevant	ADJ
admet-295	276	29	to	to	ADP
admet-295	276	30	the	the	DET
admet-295	276	31	content	content	NOUN
admet-295	276	32	of	of	ADP
admet-295	276	33	this	this	DET
admet-295	276	34	review	review	NOUN
admet-295	276	35	.	.	PUNCT
admet-295	277	1	until	until	ADP
admet-295	277	2	retirement	retirement	NOUN
admet-295	277	3	in	in	ADP
admet-295	277	4	december	december	PROPN
admet-295	277	5	2004	2004	NUM
admet-295	277	6	,	,	PUNCT
admet-295	277	7	he	he	PRON
admet-295	277	8	was	be	AUX
admet-295	277	9	a	a	DET
admet-295	277	10	senior	senior	ADJ
admet-295	277	11	clinical	clinical	ADJ
admet-295	277	12	assessor	assessor	NOUN
admet-295	277	13	at	at	ADP
admet-295	277	14	the	the	DET
admet-295	277	15	medicines	medicine	NOUN
admet-295	277	16	and	and	CCONJ
admet-295	277	17	healthcare	healthcare	NOUN
admet-295	277	18	products	product	NOUN
admet-295	277	19	regulatory	regulatory	ADJ
admet-295	277	20	agency	agency	NOUN
admet-295	277	21	(	(	PUNCT
admet-295	277	22	mhra	mhra	NOUN
admet-295	277	23	)	)	PUNCT
admet-295	277	24	,	,	PUNCT
admet-295	277	25	london	london	PROPN
admet-295	277	26	,	,	PUNCT
admet-295	277	27	uk	uk	PROPN
admet-295	277	28	,	,	PUNCT
admet-295	277	29	and	and	CCONJ
admet-295	277	30	the	the	DET
admet-295	277	31	ich	ich	NOUN
admet-295	277	32	e14	e14	NOUN
admet-295	277	33	topic	topic	NOUN
admet-295	277	34	leader	leader	NOUN
admet-295	277	35	,	,	PUNCT
admet-295	277	36	representing	represent	VERB
admet-295	277	37	the	the	DET
admet-295	277	38	eu	eu	PROPN
admet-295	277	39	.	.	PUNCT
admet-295	278	1	he	he	PRON
admet-295	278	2	now	now	ADV
admet-295	278	3	provides	provide	VERB
admet-295	278	4	expert	expert	ADJ
admet-295	278	5	consultancy	consultancy	NOUN
admet-295	278	6	services	service	NOUN
admet-295	278	7	relating	relate	VERB
admet-295	278	8	to	to	ADP
admet-295	278	9	cardiovascular	cardiovascular	ADJ
admet-295	278	10	safety	safety	NOUN
admet-295	278	11	of	of	ADP
admet-295	278	12	medicines	medicine	NOUN
admet-295	278	13	to	to	ADP
admet-295	278	14	a	a	DET
admet-295	278	15	number	number	NOUN
admet-295	278	16	of	of	ADP
admet-295	278	17	pharmaceutical	pharmaceutical	NOUN
admet-295	278	18	companies	company	NOUN
admet-295	278	19	.	.	PUNCT
admet-295	279	1	references	reference	NOUN
admet-295	279	2	[	[	X
admet-295	279	3	1	1	NUM
admet-295	279	4	]	]	PUNCT
admet-295	279	5	r.	r.	PROPN
admet-295	279	6	r.	r.	PROPN
admet-295	279	7	shah	shah	PROPN
admet-295	279	8	,	,	PUNCT
admet-295	279	9	s.	s.	PROPN
admet-295	279	10	a.	a.	PROPN
admet-295	279	11	roberts	roberts	PROPN
admet-295	279	12	,	,	PUNCT
admet-295	279	13	d.	d.	PROPN
admet-295	279	14	r.	r.	PROPN
admet-295	279	15	shah	shah	PROPN
admet-295	279	16	.	.	PUNCT
admet-295	280	1	br	br	PROPN
admet-295	280	2	.	.	PUNCT
admet-295	281	1	j.	j.	PROPN
admet-295	281	2	clin	clin	PROPN
admet-295	281	3	.	.	PUNCT
admet-295	282	1	pharmacol	pharmacol	PROPN
admet-295	282	2	.	.	PUNCT
admet-295	283	1	76(3	76(3	NOUN
admet-295	283	2	)	)	PUNCT
admet-295	283	3	(	(	PUNCT
admet-295	283	4	2013	2013	NUM
admet-295	283	5	)	)	PUNCT
admet-295	283	6	396	396	NUM
admet-295	283	7	-	-	SYM
admet-295	283	8	411	411	NUM
admet-295	283	9	.	.	PUNCT
admet-295	284	1	[	[	X
admet-295	284	2	2	2	NUM
admet-295	284	3	]	]	PUNCT
admet-295	284	4	r.	r.	PROPN
admet-295	284	5	r.	r.	PROPN
admet-295	284	6	shah	shah	PROPN
admet-295	284	7	,	,	PUNCT
admet-295	284	8	j.	j.	PROPN
admet-295	284	9	morganroth	morganroth	PROPN
admet-295	284	10	,	,	PUNCT
admet-295	284	11	d.	d.	PROPN
admet-295	284	12	r.	r.	PROPN
admet-295	284	13	shah	shah	PROPN
admet-295	284	14	.	.	PUNCT
admet-295	284	15	drug	drug	PROPN
admet-295	284	16	saf	saf	PROPN
admet-295	284	17	.	.	PROPN
admet-295	284	18	36(5	36(5	NUM
admet-295	284	19	)	)	PUNCT
admet-295	284	20	(	(	PUNCT
admet-295	284	21	2013	2013	NUM
admet-295	284	22	)	)	PUNCT
admet-295	284	23	295	295	NUM
admet-295	284	24	-	-	SYM
admet-295	284	25	316	316	NUM
admet-295	284	26	.	.	PUNCT
admet-295	285	1	[	[	X
admet-295	285	2	3	3	X
admet-295	285	3	]	]	X
admet-295	285	4	r.	r.	PROPN
admet-295	285	5	r.	r.	PROPN
admet-295	285	6	shah	shah	PROPN
admet-295	285	7	,	,	PUNCT
admet-295	285	8	j.	j.	PROPN
admet-295	285	9	morganroth	morganroth	PROPN
admet-295	285	10	.	.	PUNCT
admet-295	285	11	drug	drug	PROPN
admet-295	285	12	saf	saf	PROPN
admet-295	285	13	.	.	PUNCT
admet-295	286	1	38(8	38(8	NUM
admet-295	286	2	)	)	PUNCT
admet-295	286	3	(	(	PUNCT
admet-295	286	4	2015	2015	NUM
admet-295	286	5	)	)	PUNCT
admet-295	286	6	693	693	NUM
admet-295	286	7	-	-	SYM
admet-295	286	8	710	710	NUM
admet-295	286	9	.	.	PUNCT
admet-295	287	1	[	[	X
admet-295	287	2	4	4	X
admet-295	287	3	]	]	PUNCT
admet-295	287	4	j.	j.	PROPN
admet-295	287	5	zhang	zhang	PROPN
admet-295	287	6	,	,	PUNCT
admet-295	287	7	l.	l.	PROPN
admet-295	287	8	zhang	zhang	PROPN
admet-295	287	9	,	,	PUNCT
admet-295	287	10	y.	y.	PROPN
admet-295	287	11	wang	wang	PROPN
admet-295	287	12	,	,	PUNCT
admet-295	287	13	g.	g.	PROPN
admet-295	287	14	zhao	zhao	PROPN
admet-295	287	15	.	.	PUNCT
admet-295	288	1	cancer	cancer	NOUN
admet-295	288	2	chemother	chemother	PROPN
admet-295	288	3	.	.	PUNCT
admet-295	289	1	pharmacol	pharmacol	PROPN
admet-295	289	2	.	.	PUNCT
admet-295	290	1	77(5	77(5	NUM
admet-295	290	2	)	)	PUNCT
admet-295	290	3	(	(	PUNCT
admet-295	290	4	2016	2016	NUM
admet-295	290	5	)	)	PUNCT
admet-295	290	6	905	905	NUM
admet-295	290	7	-	-	SYM
admet-295	290	8	926	926	NUM
admet-295	290	9	.	.	PUNCT
admet-295	291	1	[	[	X
admet-295	291	2	5	5	NUM
admet-295	291	3	]	]	PUNCT
admet-295	291	4	m.	m.	NOUN
admet-295	291	5	rask	rask	PROPN
admet-295	291	6	-	-	PUNCT
admet-295	291	7	andersen	andersen	PROPN
admet-295	291	8	,	,	PUNCT
admet-295	291	9	j.	j.	PROPN
admet-295	291	10	zhang	zhang	PROPN
admet-295	291	11	,	,	PUNCT
admet-295	291	12	d.	d.	PROPN
admet-295	291	13	fabbro	fabbro	PROPN
admet-295	291	14	,	,	PUNCT
admet-295	291	15	h.	h.	PROPN
admet-295	291	16	b.	b.	PROPN
admet-295	291	17	schiöth	schiöth	PROPN
admet-295	291	18	.	.	PUNCT
admet-295	292	1	trends	trend	NOUN
admet-295	292	2	pharmacol	pharmacol	PROPN
admet-295	292	3	.	.	PUNCT
admet-295	293	1	sci	sci	PROPN
admet-295	293	2	.	.	PUNCT
admet-295	294	1	35(11	35(11	NUM
admet-295	294	2	)	)	PUNCT
admet-295	294	3	(	(	PUNCT
admet-295	294	4	2014	2014	NUM
admet-295	294	5	)	)	PUNCT
admet-295	294	6	604	604	NUM
admet-295	294	7	-	-	SYM
admet-295	294	8	620	620	NUM
admet-295	294	9	.	.	PUNCT
admet-295	295	1	[	[	X
admet-295	295	2	6	6	NUM
admet-295	295	3	]	]	PUNCT
admet-295	295	4	p.	p.	PROPN
admet-295	295	5	wu	wu	PROPN
admet-295	295	6	,	,	PUNCT
admet-295	295	7	t.	t.	PROPN
admet-295	295	8	e.	e.	PROPN
admet-295	295	9	nielsen	nielsen	PROPN
admet-295	295	10	,	,	PUNCT
admet-295	295	11	m.	m.	PROPN
admet-295	295	12	h.	h.	PROPN
admet-295	295	13	clausen	clausen	PROPN
admet-295	295	14	.	.	PROPN
admet-295	295	15	drug	drug	PROPN
admet-295	295	16	discov	discov	PROPN
admet-295	295	17	.	.	PUNCT
admet-295	296	1	today	today	NOUN
admet-295	296	2	21(1	21(1	NUM
admet-295	296	3	)	)	PUNCT
admet-295	296	4	(	(	PUNCT
admet-295	296	5	2016	2016	NUM
admet-295	296	6	)	)	PUNCT
admet-295	296	7	5	5	NUM
admet-295	296	8	-	-	SYM
admet-295	296	9	10	10	NUM
admet-295	296	10	.	.	PUNCT
admet-295	297	1	[	[	X
admet-295	297	2	7	7	X
admet-295	297	3	]	]	PUNCT
admet-295	297	4	k.	k.	PROPN
admet-295	297	5	l.	l.	PROPN
admet-295	297	6	miller	miller	PROPN
admet-295	297	7	,	,	PUNCT
admet-295	297	8	m.	m.	NOUN
admet-295	297	9	lanthier	lanthier	NOUN
admet-295	297	10	.	.	PUNCT
admet-295	298	1	nat	nat	PROPN
admet-295	298	2	.	.	PUNCT
admet-295	299	1	rev	rev	PROPN
admet-295	299	2	.	.	PROPN
admet-295	299	3	drug	drug	NOUN
admet-295	299	4	discov	discov	NOUN
admet-295	299	5	.	.	PUNCT
admet-295	300	1	14(2	14(2	NUM
admet-295	300	2	)	)	PUNCT
admet-295	300	3	(	(	PUNCT
admet-295	300	4	2015	2015	NUM
admet-295	300	5	)	)	PUNCT
admet-295	300	6	83	83	NUM
admet-295	300	7	.	.	PUNCT
admet-295	301	1	[	[	X
admet-295	301	2	8	8	NUM
admet-295	301	3	]	]	X
admet-295	301	4	d.	d.	PROPN
admet-295	301	5	r.	r.	PROPN
admet-295	301	6	shah	shah	PROPN
admet-295	301	7	,	,	PUNCT
admet-295	301	8	r.	r.	PROPN
admet-295	301	9	r.	r.	PROPN
admet-295	301	10	shah	shah	PROPN
admet-295	301	11	,	,	PUNCT
admet-295	301	12	j.	j.	PROPN
admet-295	301	13	morganroth	morganroth	PROPN
admet-295	301	14	.	.	PUNCT
admet-295	301	15	drug	drug	PROPN
admet-295	301	16	saf	saf	PROPN
admet-295	301	17	.	.	PROPN
admet-295	302	1	36(6	36(6	NUM
admet-295	302	2	)	)	PUNCT
admet-295	302	3	(	(	PUNCT
admet-295	302	4	2013	2013	NUM
admet-295	302	5	)	)	PUNCT
admet-295	302	6	413	413	NUM
admet-295	302	7	-	-	SYM
admet-295	302	8	426	426	NUM
admet-295	302	9	.	.	PUNCT
admet-295	303	1	[	[	X
admet-295	303	2	9	9	NUM
admet-295	303	3	]	]	X
admet-295	303	4	r.	r.	PROPN
admet-295	303	5	dienstmann	dienstmann	PROPN
admet-295	303	6	,	,	PUNCT
admet-295	303	7	i.	i.	PROPN
admet-295	303	8	braña	braña	PROPN
admet-295	303	9	,	,	PUNCT
admet-295	303	10	j.	j.	PROPN
admet-295	303	11	rodon	rodon	PROPN
admet-295	303	12	,	,	PUNCT
admet-295	303	13	j.	j.	PROPN
admet-295	303	14	tabernero	tabernero	PROPN
admet-295	303	15	.	.	PUNCT
admet-295	304	1	oncologist	oncologist	NOUN
admet-295	304	2	16(12	16(12	NUM
admet-295	304	3	)	)	PUNCT
admet-295	304	4	(	(	PUNCT
admet-295	304	5	2011	2011	NUM
admet-295	304	6	)	)	PUNCT
admet-295	304	7	1729	1729	NUM
admet-295	304	8	-	-	SYM
admet-295	304	9	1740	1740	NUM
admet-295	304	10	.	.	PUNCT
admet-295	305	1	[	[	X
admet-295	305	2	10	10	NUM
admet-295	305	3	]	]	X
admet-295	305	4	f.	f.	PROPN
admet-295	305	5	di	di	PROPN
admet-295	305	6	fiore	fiore	PROPN
admet-295	305	7	,	,	PUNCT
admet-295	305	8	o.	o.	NOUN
admet-295	305	9	rigal	rigal	PROPN
admet-295	305	10	,	,	PUNCT
admet-295	305	11	c.	c.	PROPN
admet-295	305	12	ménager	ménager	NOUN
admet-295	305	13	,	,	PUNCT
admet-295	305	14	p.	p.	PROPN
admet-295	305	15	michel	michel	PROPN
admet-295	305	16	,	,	PUNCT
admet-295	305	17	c.	c.	PROPN
admet-295	305	18	pfister	pfister	PROPN
admet-295	305	19	.	.	PUNCT
admet-295	306	1	br	br	PROPN
admet-295	306	2	.	.	PUNCT
admet-295	307	1	j.	j.	PROPN
admet-295	307	2	cancer	cancer	PROPN
admet-295	307	3	105(12	105(12	NUM
admet-295	307	4	)	)	PUNCT
admet-295	307	5	(	(	PUNCT
admet-295	307	6	2011	2011	NUM
admet-295	307	7	)	)	PUNCT
admet-295	307	8	1811	1811	NUM
admet-295	307	9	-	-	SYM
admet-295	307	10	1813	1813	NUM
admet-295	307	11	.	.	PUNCT
admet-295	308	1	[	[	X
admet-295	308	2	11	11	NUM
admet-295	308	3	]	]	PUNCT
admet-295	308	4	h.	h.	PROPN
admet-295	308	5	y.	y.	PROPN
admet-295	308	6	small	small	PROPN
admet-295	308	7	,	,	PUNCT
admet-295	308	8	a.	a.	PROPN
admet-295	308	9	c.	c.	PROPN
admet-295	308	10	montezano	montezano	PROPN
admet-295	308	11	,	,	PUNCT
admet-295	308	12	f.	f.	PROPN
admet-295	308	13	j.	j.	PROPN
admet-295	308	14	rios	rios	PROPN
admet-295	308	15	,	,	PUNCT
admet-295	308	16	c.	c.	PROPN
admet-295	308	17	savoia	savoia	PROPN
admet-295	308	18	,	,	PUNCT
admet-295	308	19	r.	r.	PROPN
admet-295	308	20	m.	m.	PROPN
admet-295	308	21	touyz	touyz	PROPN
admet-295	308	22	.	.	PUNCT
admet-295	308	23	can	can	AUX
admet-295	308	24	.	.	PUNCT
admet-295	309	1	j.	j.	PROPN
admet-295	309	2	cardiol	cardiol	PROPN
admet-295	309	3	.	.	PUNCT
admet-295	310	1	30(5	30(5	X
admet-295	310	2	)	)	PUNCT
admet-295	310	3	(	(	PUNCT
admet-295	310	4	2014	2014	NUM
admet-295	310	5	)	)	PUNCT
admet-295	310	6	534	534	NUM
admet-295	310	7	-	-	SYM
admet-295	310	8	543	543	NUM
admet-295	310	9	.	.	PUNCT
admet-295	311	1	[	[	X
admet-295	311	2	12	12	NUM
admet-295	311	3	]	]	PUNCT
admet-295	311	4	s.	s.	PROPN
admet-295	311	5	liu	liu	PROPN
admet-295	311	6	,	,	PUNCT
admet-295	311	7	r.	r.	PROPN
admet-295	311	8	kurzrock	kurzrock	PROPN
admet-295	311	9	.	.	PUNCT
admet-295	312	1	semin	semin	PROPN
admet-295	312	2	.	.	PUNCT
admet-295	313	1	oncol	oncol	ADJ
admet-295	313	2	.	.	PUNCT
admet-295	314	1	42(6	42(6	NOUN
admet-295	314	2	)	)	PUNCT
admet-295	314	3	(	(	PUNCT
admet-295	314	4	2015	2015	NUM
admet-295	314	5	)	)	PUNCT
admet-295	314	6	863	863	NUM
admet-295	314	7	-	-	SYM
admet-295	314	8	875	875	NUM
admet-295	314	9	.	.	PUNCT
admet-295	315	1	[	[	X
admet-295	315	2	13	13	NUM
admet-295	315	3	]	]	PUNCT
admet-295	315	4	m.	m.	NOUN
admet-295	315	5	schmidinger	schmidinger	PROPN
admet-295	315	6	,	,	PUNCT
admet-295	315	7	u.	u.	PROPN
admet-295	315	8	m.	m.	PROPN
admet-295	315	9	vogl	vogl	PROPN
admet-295	315	10	,	,	PUNCT
admet-295	315	11	m.	m.	NOUN
admet-295	315	12	bojic	bojic	NOUN
admet-295	315	13	,	,	PUNCT
admet-295	315	14	w.	w.	PROPN
admet-295	315	15	lamm	lamm	PROPN
admet-295	315	16	,	,	PUNCT
admet-295	315	17	h.	h.	PROPN
admet-295	315	18	heinzl	heinzl	PROPN
admet-295	315	19	,	,	PUNCT
admet-295	315	20	a.	a.	NOUN
admet-295	315	21	haitel	haitel	PROPN
admet-295	315	22	,	,	PUNCT
admet-295	315	23	m.	m.	NOUN
admet-295	315	24	clodi	clodi	PROPN
admet-295	315	25	,	,	PUNCT
admet-295	315	26	g.	g.	PROPN
admet-295	315	27	kramer	kramer	PROPN
admet-295	315	28	,	,	PUNCT
admet-295	315	29	c.	c.	PROPN
admet-295	315	30	c.	c.	PROPN
admet-295	315	31	zielinski	zielinski	PROPN
admet-295	315	32	.	.	PUNCT
admet-295	316	1	cancer	cancer	NOUN
admet-295	316	2	117(3	117(3	NUM
admet-295	316	3	)	)	PUNCT
admet-295	316	4	(	(	PUNCT
admet-295	316	5	2011	2011	NUM
admet-295	316	6	)	)	PUNCT
admet-295	316	7	534	534	NUM
admet-295	316	8	-	-	SYM
admet-295	316	9	544	544	NUM
admet-295	316	10	.	.	PUNCT
admet-295	317	1	[	[	X
admet-295	317	2	14	14	NUM
admet-295	317	3	]	]	PUNCT
admet-295	317	4	a.	a.	NOUN
admet-295	317	5	nearchou	nearchou	PROPN
admet-295	317	6	,	,	PUNCT
admet-295	317	7	a.	a.	NOUN
admet-295	317	8	valachis	valachis	NOUN
admet-295	317	9	,	,	PUNCT
admet-295	317	10	p.	p.	PROPN
admet-295	317	11	lind	lind	PROPN
admet-295	317	12	,	,	PUNCT
admet-295	317	13	o.	o.	PROPN
admet-295	317	14	akre	akre	PROPN
admet-295	317	15	,	,	PUNCT
admet-295	317	16	p.	p.	PROPN
admet-295	317	17	sandström	sandström	NOUN
admet-295	317	18	.	.	PUNCT
admet-295	318	1	clin	clin	PROPN
admet-295	318	2	.	.	PUNCT
admet-295	318	3	genitourin	genitourin	NOUN
admet-295	318	4	.	.	PUNCT
admet-295	319	1	cancer	cancer	NOUN
admet-295	319	2	13(4	13(4	PROPN
admet-295	319	3	)	)	PUNCT
admet-295	319	4	(	(	PUNCT
admet-295	319	5	2015	2015	NUM
admet-295	319	6	)	)	PUNCT
admet-295	319	7	280286	280286	NUM
admet-295	319	8	.	.	PUNCT
admet-295	320	1	[	[	X
admet-295	320	2	15	15	NUM
admet-295	320	3	]	]	X
admet-295	320	4	e.	e.	PROPN
admet-295	320	5	b.	b.	PROPN
admet-295	320	6	bailey	bailey	PROPN
admet-295	320	7	,	,	PUNCT
admet-295	320	8	s.	s.	PROPN
admet-295	320	9	k.	k.	PROPN
admet-295	320	10	tantravahi	tantravahi	PROPN
admet-295	320	11	,	,	PUNCT
admet-295	320	12	a.	a.	NOUN
admet-295	320	13	poole	poole	PROPN
admet-295	320	14	,	,	PUNCT
admet-295	320	15	a.	a.	NOUN
admet-295	320	16	m.	m.	PROPN
admet-295	320	17	agarwal	agarwal	PROPN
admet-295	320	18	,	,	PUNCT
admet-295	320	19	a.	a.	NOUN
admet-295	320	20	m.	m.	PROPN
admet-295	320	21	straubhar	straubhar	PROPN
admet-295	320	22	,	,	PUNCT
admet-295	320	23	j.	j.	PROPN
admet-295	320	24	a.	a.	PROPN
admet-295	320	25	batten	batten	PROPN
admet-295	320	26	,	,	PUNCT
admet-295	320	27	s.	s.	PROPN
admet-295	320	28	b.	b.	PROPN
admet-295	320	29	patel	patel	PROPN
admet-295	320	30	,	,	PUNCT
admet-295	320	31	c.	c.	PROPN
admet-295	320	32	e.	e.	PROPN
admet-295	320	33	wells	wells	PROPN
admet-295	320	34	,	,	PUNCT
admet-295	320	35	d.	d.	PROPN
admet-295	320	36	d.	d.	PROPN
admet-295	320	37	stenehjem	stenehjem	PROPN
admet-295	320	38	,	,	PUNCT
admet-295	320	39	n.	n.	PROPN
admet-295	320	40	agarwal	agarwal	PROPN
admet-295	320	41	.	.	PUNCT
admet-295	321	1	clin	clin	PROPN
admet-295	321	2	.	.	PUNCT
admet-295	321	3	genitourin	genitourin	NOUN
admet-295	321	4	.	.	PUNCT
admet-295	322	1	cancer	cancer	NOUN
admet-295	322	2	13(3	13(3	NUM
admet-295	322	3	)	)	PUNCT
admet-295	322	4	(	(	PUNCT
admet-295	322	5	2015	2015	NUM
admet-295	322	6	)	)	PUNCT
admet-295	323	1	e131	e131	NUM
admet-295	323	2	-	-	SYM
admet-295	323	3	137	137	NUM
admet-295	323	4	.	.	PUNCT
admet-295	324	1	[	[	X
admet-295	324	2	16	16	NUM
admet-295	324	3	]	]	X
admet-295	324	4	g.	g.	PROPN
admet-295	324	5	lombardi	lombardi	PROPN
admet-295	324	6	,	,	PUNCT
admet-295	324	7	f.	f.	PROPN
admet-295	324	8	zustovich	zustovich	PROPN
admet-295	324	9	,	,	PUNCT
admet-295	324	10	p.	p.	PROPN
admet-295	324	11	farina	farina	PROPN
admet-295	324	12	,	,	PUNCT
admet-295	324	13	p.	p.	PROPN
admet-295	324	14	fiduccia	fiduccia	PROPN
admet-295	324	15	,	,	PUNCT
admet-295	324	16	a.	a.	PROPN
admet-295	324	17	della	della	PROPN
admet-295	324	18	puppa	puppa	PROPN
admet-295	324	19	,	,	PUNCT
admet-295	324	20	v.	v.	ADP
admet-295	324	21	polo	polo	PROPN
admet-295	324	22	,	,	PUNCT
admet-295	324	23	r.	r.	PROPN
admet-295	324	24	bertorelle	bertorelle	PROPN
admet-295	324	25	,	,	PUNCT
admet-295	324	26	m.	m.	NOUN
admet-295	324	27	p.	p.	NOUN
admet-295	324	28	gardiman	gardiman	NOUN
admet-295	324	29	,	,	PUNCT
admet-295	324	30	a.	a.	NOUN
admet-295	324	31	banzato	banzato	NOUN
admet-295	324	32	,	,	PUNCT
admet-295	324	33	p.	p.	PROPN
admet-295	324	34	ciccarino	ciccarino	PROPN
admet-295	324	35	,	,	PUNCT
admet-295	324	36	l.	l.	PROPN
admet-295	324	37	denaro	denaro	PROPN
admet-295	324	38	,	,	PUNCT
admet-295	324	39	v.	v.	PROPN
admet-295	324	40	zagonel	zagonel	PROPN
admet-295	324	41	.	.	PUNCT
admet-295	325	1	anticancer	anticancer	NOUN
admet-295	325	2	drugs	drug	NOUN
admet-295	325	3	24(1	24(1	NUM
admet-295	325	4	)	)	PUNCT
admet-295	325	5	(	(	PUNCT
admet-295	325	6	2013	2013	NUM
admet-295	325	7	)	)	PUNCT
admet-295	325	8	90	90	NUM
admet-295	325	9	-	-	SYM
admet-295	325	10	97	97	NUM
admet-295	325	11	.	.	PUNCT
admet-295	326	1	[	[	X
admet-295	326	2	17	17	NUM
admet-295	326	3	]	]	PUNCT
admet-295	326	4	a.	a.	NOUN
admet-295	326	5	poprach	poprach	NOUN
admet-295	326	6	,	,	PUNCT
admet-295	326	7	t.	t.	PROPN
admet-295	326	8	pavlik	pavlik	PROPN
admet-295	326	9	,	,	PUNCT
admet-295	326	10	b.	b.	PROPN
admet-295	326	11	melichar	melichar	PROPN
admet-295	326	12	,	,	PUNCT
admet-295	326	13	i.	i.	PROPN
admet-295	326	14	puzanov	puzanov	PROPN
admet-295	326	15	,	,	PUNCT
admet-295	326	16	l.	l.	PROPN
admet-295	326	17	dusek	dusek	PROPN
admet-295	326	18	,	,	PUNCT
admet-295	326	19	z.	z.	PROPN
admet-295	326	20	bortlicek	bortlicek	PROPN
admet-295	326	21	,	,	PUNCT
admet-295	326	22	r.	r.	PROPN
admet-295	326	23	vyzula	vyzula	PROPN
admet-295	326	24	,	,	PUNCT
admet-295	326	25	j.	j.	PROPN
admet-295	326	26	abrahamova	abrahamova	PROPN
admet-295	326	27	,	,	PUNCT
admet-295	326	28	t.	t.	PROPN
admet-295	326	29	buchler	buchler	NOUN
admet-295	326	30	:	:	PUNCT
admet-295	326	31	czech	czech	ADJ
admet-295	326	32	renal	renal	ADJ
admet-295	326	33	cancer	cancer	NOUN
admet-295	326	34	cooperative	cooperative	ADJ
admet-295	326	35	group	group	NOUN
admet-295	326	36	.	.	PUNCT
admet-295	327	1	ann	ann	PROPN
admet-295	327	2	.	.	PUNCT
admet-295	327	3	oncol	oncol	PROPN
admet-295	327	4	.	.	PUNCT
admet-295	328	1	23(12	23(12	NUM
admet-295	328	2	)	)	PUNCT
admet-295	328	3	(	(	PUNCT
admet-295	328	4	2012	2012	NUM
admet-295	328	5	)	)	PUNCT
admet-295	328	6	3137	3137	NUM
admet-295	328	7	-	-	SYM
admet-295	328	8	3143	3143	NUM
admet-295	328	9	.	.	PUNCT
admet-295	329	1	[	[	X
admet-295	329	2	18	18	NUM
admet-295	329	3	]	]	X
admet-295	329	4	r.	r.	PROPN
admet-295	329	5	b.	b.	PROPN
admet-295	329	6	cohen	cohen	PROPN
admet-295	329	7	,	,	PUNCT
admet-295	329	8	s.	s.	PROPN
admet-295	329	9	oudard	oudard	PROPN
admet-295	329	10	.	.	PUNCT
admet-295	330	1	invest	invest	VERB
admet-295	330	2	.	.	PUNCT
admet-295	331	1	new	new	ADJ
admet-295	331	2	drugs	drug	NOUN
admet-295	331	3	30(5	30(5	NUM
admet-295	331	4	)	)	PUNCT
admet-295	331	5	(	(	PUNCT
admet-295	331	6	2012	2012	NUM
admet-295	331	7	)	)	PUNCT
admet-295	331	8	2066	2066	NUM
admet-295	331	9	-	-	SYM
admet-295	331	10	2079	2079	NUM
admet-295	331	11	.	.	PUNCT
admet-295	332	1	[	[	X
admet-295	332	2	19	19	NUM
admet-295	332	3	]	]	PUNCT
admet-295	332	4	m.	m.	NOUN
admet-295	332	5	schmidinger	schmidinger	PROPN
admet-295	332	6	.	.	PUNCT
admet-295	333	1	ejc	ejc	PROPN
admet-295	333	2	suppl	suppl	PROPN
admet-295	333	3	.	.	PUNCT
admet-295	334	1	11(2	11(2	X
admet-295	334	2	)	)	PUNCT
admet-295	334	3	(	(	PUNCT
admet-295	334	4	2013	2013	NUM
admet-295	334	5	)	)	PUNCT
admet-295	334	6	172	172	NUM
admet-295	334	7	-	-	SYM
admet-295	334	8	191	191	NUM
admet-295	334	9	.	.	PUNCT
admet-295	335	1	[	[	X
admet-295	335	2	20	20	NUM
admet-295	335	3	]	]	PUNCT
admet-295	335	4	w.	w.	PROPN
admet-295	335	5	x.	x.	PROPN
admet-295	335	6	qi	qi	PROPN
admet-295	335	7	,	,	PUNCT
admet-295	335	8	a.	a.	PROPN
admet-295	335	9	n.	n.	PROPN
admet-295	336	1	he	he	PRON
admet-295	336	2	,	,	PUNCT
admet-295	336	3	z.	z.	PROPN
admet-295	336	4	shen	shen	PROPN
admet-295	336	5	,	,	PUNCT
admet-295	336	6	y.	y.	PROPN
admet-295	336	7	yao	yao	PROPN
admet-295	336	8	.	.	PUNCT
admet-295	337	1	br	br	PROPN
admet-295	337	2	.	.	PUNCT
admet-295	338	1	j.	j.	PROPN
admet-295	338	2	clin	clin	PROPN
admet-295	338	3	.	.	PUNCT
admet-295	339	1	pharmacol	pharmacol	PROPN
admet-295	339	2	.	.	PUNCT
admet-295	340	1	76(3	76(3	NOUN
admet-295	340	2	)	)	PUNCT
admet-295	340	3	(	(	PUNCT
admet-295	340	4	2013	2013	NUM
admet-295	340	5	)	)	PUNCT
admet-295	340	6	348	348	NUM
admet-295	340	7	-	-	SYM
admet-295	340	8	357	357	NUM
admet-295	340	9	.	.	PUNCT
admet-295	341	1	[	[	X
admet-295	341	2	21	21	NUM
admet-295	341	3	]	]	X
admet-295	341	4	p.	p.	PROPN
admet-295	341	5	ghatalia	ghatalia	PROPN
admet-295	341	6	,	,	PUNCT
admet-295	341	7	c.	c.	PROPN
admet-295	341	8	j.	j.	PROPN
admet-295	341	9	morgan	morgan	PROPN
admet-295	341	10	,	,	PUNCT
admet-295	341	11	y.	y.	PROPN
admet-295	341	12	je	je	PROPN
admet-295	341	13	,	,	PUNCT
admet-295	341	14	p.	p.	PROPN
admet-295	341	15	l.	l.	PROPN
admet-295	341	16	nguyen	nguyen	PROPN
admet-295	341	17	,	,	PUNCT
admet-295	341	18	q.	q.	PROPN
admet-295	341	19	d.	d.	PROPN
admet-295	341	20	trinh	trinh	PROPN
admet-295	341	21	,	,	PUNCT
admet-295	341	22	t.	t.	PROPN
admet-295	341	23	k.	k.	PROPN
admet-295	341	24	choueiri	choueiri	PROPN
admet-295	341	25	,	,	PUNCT
admet-295	341	26	g.	g.	PROPN
admet-295	341	27	sonpavde	sonpavde	PROPN
admet-295	341	28	.	.	PUNCT
admet-295	342	1	crit	crit	PROPN
admet-295	342	2	.	.	PUNCT
admet-295	343	1	rev	rev	PROPN
admet-295	343	2	.	.	PROPN
admet-295	343	3	oncol	oncol	PROPN
admet-295	343	4	.	.	PUNCT
admet-295	343	5	hematol	hematol	NOUN
admet-295	343	6	.	.	PUNCT
admet-295	344	1	94(2	94(2	NOUN
admet-295	344	2	)	)	PUNCT
admet-295	344	3	(	(	PUNCT
admet-295	344	4	2015	2015	NUM
admet-295	344	5	)	)	PUNCT
admet-295	344	6	228	228	NUM
admet-295	344	7	-	-	SYM
admet-295	344	8	237	237	NUM
admet-295	344	9	.	.	PUNCT
admet-295	345	1	[	[	X
admet-295	345	2	22	22	NUM
admet-295	345	3	]	]	X
admet-295	345	4	w.	w.	PROPN
admet-295	345	5	x.	x.	PROPN
admet-295	345	6	qi	qi	PROPN
admet-295	345	7	,	,	PUNCT
admet-295	345	8	z.	z.	PROPN
admet-295	345	9	shen	shen	PROPN
admet-295	345	10	,	,	PUNCT
admet-295	345	11	l.	l.	PROPN
admet-295	345	12	n.	n.	PROPN
admet-295	345	13	tang	tang	PROPN
admet-295	345	14	,	,	PUNCT
admet-295	345	15	y.	y.	PROPN
admet-295	345	16	yao	yao	PROPN
admet-295	345	17	.	.	PUNCT
admet-295	346	1	br	br	PROPN
admet-295	346	2	.	.	PUNCT
admet-295	347	1	j.	j.	PROPN
admet-295	347	2	clin	clin	PROPN
admet-295	347	3	.	.	PUNCT
admet-295	348	1	pharmacol	pharmacol	PROPN
admet-295	348	2	.	.	PUNCT
admet-295	349	1	78(4	78(4	NUM
admet-295	349	2	)	)	PUNCT
admet-295	349	3	(	(	PUNCT
admet-295	349	4	2014	2014	NUM
admet-295	349	5	)	)	PUNCT
admet-295	349	6	748	748	NUM
admet-295	349	7	-	-	SYM
admet-295	349	8	762	762	NUM
admet-295	349	9	.	.	PUNCT
admet-295	350	1	[	[	X
admet-295	350	2	23	23	NUM
admet-295	350	3	]	]	PUNCT
admet-295	350	4	t.	t.	PROPN
admet-295	350	5	k.	k.	PROPN
admet-295	350	6	choueiri	choueiri	PROPN
admet-295	350	7	,	,	PUNCT
admet-295	350	8	f.	f.	PROPN
admet-295	350	9	a.	a.	PROPN
admet-295	350	10	schutz	schutz	PROPN
admet-295	350	11	,	,	PUNCT
admet-295	350	12	y.	y.	PROPN
admet-295	350	13	je	je	PROPN
admet-295	350	14	,	,	PUNCT
admet-295	350	15	j.	j.	PROPN
admet-295	350	16	e.	e.	PROPN
admet-295	350	17	rosenberg	rosenberg	PROPN
admet-295	350	18	,	,	PUNCT
admet-295	350	19	j.	j.	PROPN
admet-295	350	20	bellmunt	bellmunt	PROPN
admet-295	350	21	.	.	PUNCT
admet-295	351	1	j.	j.	PROPN
admet-295	351	2	clin	clin	PROPN
admet-295	351	3	.	.	PUNCT
admet-295	352	1	oncol	oncol	ADJ
admet-295	352	2	.	.	PUNCT
admet-295	353	1	28(13	28(13	NUM
admet-295	353	2	)	)	PUNCT
admet-295	353	3	(	(	PUNCT
admet-295	353	4	2010	2010	NUM
admet-295	353	5	)	)	PUNCT
admet-295	353	6	2280	2280	NUM
admet-295	353	7	-	-	SYM
admet-295	353	8	2285	2285	NUM
admet-295	353	9	.	.	PUNCT
admet-295	354	1	[	[	X
admet-295	354	2	24	24	NUM
admet-295	354	3	]	]	X
admet-295	354	4	w.	w.	PROPN
admet-295	354	5	x.	x.	PROPN
admet-295	354	6	qi	qi	PROPN
admet-295	354	7	,	,	PUNCT
admet-295	354	8	z.	z.	PROPN
admet-295	354	9	shen	shen	PROPN
admet-295	354	10	,	,	PUNCT
admet-295	354	11	l.	l.	PROPN
admet-295	354	12	n.	n.	PROPN
admet-295	354	13	tang	tang	PROPN
admet-295	354	14	,	,	PUNCT
admet-295	354	15	y.	y.	PROPN
admet-295	354	16	yao	yao	PROPN
admet-295	354	17	.	.	PUNCT
admet-295	355	1	crit	crit	PROPN
admet-295	355	2	.	.	PUNCT
admet-295	356	1	rev	rev	PROPN
admet-295	356	2	.	.	PROPN
admet-295	356	3	oncol	oncol	PROPN
admet-295	356	4	.	.	PUNCT
admet-295	356	5	hematol	hematol	NOUN
admet-295	356	6	.	.	PUNCT
admet-295	357	1	92(2	92(2	NUM
admet-295	357	2	)	)	PUNCT
admet-295	357	3	(	(	PUNCT
admet-295	357	4	2014	2014	NUM
admet-295	357	5	)	)	PUNCT
admet-295	357	6	71	71	NUM
admet-295	357	7	-	-	SYM
admet-295	357	8	82	82	NUM
admet-295	357	9	.	.	PUNCT
admet-295	358	1	[	[	X
admet-295	358	2	25	25	NUM
admet-295	358	3	]	]	X
admet-295	358	4	w.	w.	PROPN
admet-295	358	5	x.	x.	PROPN
admet-295	358	6	qi	qi	PROPN
admet-295	358	7	,	,	PUNCT
admet-295	358	8	d.	d.	PROPN
admet-295	358	9	l.	l.	PROPN
admet-295	358	10	min	min	PROPN
admet-295	358	11	,	,	PUNCT
admet-295	358	12	z.	z.	PROPN
admet-295	358	13	shen	shen	PROPN
admet-295	358	14	,	,	PUNCT
admet-295	358	15	y.	y.	PROPN
admet-295	358	16	j.	j.	PROPN
admet-295	358	17	sun	sun	PROPN
admet-295	358	18	,	,	PUNCT
admet-295	358	19	f.	f.	PROPN
admet-295	358	20	lin	lin	PROPN
admet-295	358	21	,	,	PUNCT
admet-295	358	22	l.	l.	PROPN
admet-295	358	23	n.	n.	PROPN
admet-295	358	24	tang	tang	PROPN
admet-295	358	25	,	,	PUNCT
admet-295	358	26	a.	a.	PROPN
admet-295	358	27	n.	n.	PROPN
admet-295	358	28	he	he	PRON
admet-295	358	29	,	,	PUNCT
admet-295	358	30	y.	y.	PROPN
admet-295	358	31	yao	yao	PROPN
admet-295	358	32	.	.	PUNCT
admet-295	359	1	int	int	NOUN
admet-295	359	2	.	.	PUNCT
admet-295	360	1	j.	j.	PROPN
admet-295	360	2	cancer	cancer	PROPN
admet-295	360	3	132(12	132(12	NUM
admet-295	360	4	)	)	PUNCT
admet-295	360	5	(	(	PUNCT
admet-295	360	6	2013	2013	NUM
admet-295	360	7	)	)	PUNCT
admet-295	360	8	2967	2967	NUM
admet-295	360	9	-	-	SYM
admet-295	360	10	2974	2974	NUM
admet-295	360	11	.	.	PUNCT
admet-295	361	1	[	[	X
admet-295	361	2	26	26	NUM
admet-295	361	3	]	]	X
admet-295	361	4	g.	g.	PROPN
admet-295	361	5	sonpavde	sonpavde	PROPN
admet-295	361	6	,	,	PUNCT
admet-295	361	7	y.	y.	PROPN
admet-295	361	8	je	je	PROPN
admet-295	361	9	,	,	PUNCT
admet-295	361	10	f.	f.	PROPN
admet-295	361	11	schutz	schutz	PROPN
admet-295	361	12	,	,	PUNCT
admet-295	361	13	m.	m.	NOUN
admet-295	361	14	d.	d.	PROPN
admet-295	361	15	galsky	galsky	PROPN
admet-295	361	16	,	,	PUNCT
admet-295	361	17	r.	r.	PROPN
admet-295	361	18	paluri	paluri	PROPN
admet-295	361	19	,	,	PUNCT
admet-295	361	20	j.	j.	PROPN
admet-295	361	21	e.	e.	PROPN
admet-295	361	22	rosenberg	rosenberg	PROPN
admet-295	361	23	,	,	PUNCT
admet-295	361	24	j.	j.	PROPN
admet-295	361	25	bellmunt	bellmunt	PROPN
admet-295	361	26	,	,	PUNCT
admet-295	361	27	t.	t.	PROPN
admet-295	361	28	k.	k.	PROPN
admet-295	361	29	choueiri	choueiri	PROPN
admet-295	361	30	.	.	PUNCT
admet-295	362	1	crit	crit	PROPN
admet-295	362	2	.	.	PUNCT
admet-295	363	1	rev	rev	PROPN
admet-295	363	2	.	.	PROPN
admet-295	363	3	oncol	oncol	PROPN
admet-295	363	4	.	.	PUNCT
admet-295	363	5	hematol	hematol	NOUN
admet-295	363	6	.	.	PUNCT
admet-295	364	1	87(1	87(1	NOUN
admet-295	364	2	)	)	PUNCT
admet-295	364	3	(	(	PUNCT
admet-295	364	4	2013	2013	NUM
admet-295	364	5	)	)	PUNCT
admet-295	364	6	80	80	NUM
admet-295	364	7	-	-	SYM
admet-295	364	8	89	89	NUM
admet-295	364	9	.	.	PUNCT
admet-295	365	1	[	[	X
admet-295	365	2	27	27	NUM
admet-295	365	3	]	]	X
admet-295	365	4	w.	w.	PROPN
admet-295	365	5	x.	x.	PROPN
admet-295	365	6	qi	qi	PROPN
admet-295	365	7	,	,	PUNCT
admet-295	365	8	l.	l.	PROPN
admet-295	365	9	n.	n.	PROPN
admet-295	365	10	tang	tang	PROPN
admet-295	365	11	,	,	PUNCT
admet-295	365	12	y.	y.	PROPN
admet-295	365	13	j.	j.	PROPN
admet-295	365	14	sun	sun	PROPN
admet-295	365	15	,	,	PUNCT
admet-295	365	16	a.	a.	NOUN
admet-295	365	17	n.	n.	PROPN
admet-295	365	18	he	he	PRON
admet-295	365	19	,	,	PUNCT
admet-295	365	20	f.	f.	PROPN
admet-295	365	21	lin	lin	PROPN
admet-295	365	22	,	,	PUNCT
admet-295	365	23	z.	z.	PROPN
admet-295	365	24	shen	shen	PROPN
admet-295	365	25	,	,	PUNCT
admet-295	365	26	y.	y.	PROPN
admet-295	365	27	yao	yao	PROPN
admet-295	365	28	.	.	PUNCT
admet-295	366	1	ann	ann	PROPN
admet-295	366	2	.	.	PUNCT
admet-295	366	3	oncol	oncol	PROPN
admet-295	366	4	.	.	PUNCT
admet-295	367	1	24(12	24(12	NUM
admet-295	367	2	)	)	PUNCT
admet-295	367	3	(	(	PUNCT
admet-295	367	4	2013	2013	NUM
admet-295	367	5	)	)	PUNCT
admet-295	367	6	2943	2943	NUM
admet-295	367	7	-	-	SYM
admet-295	367	8	2952	2952	NUM
admet-295	367	9	.	.	PUNCT
admet-295	368	1	[	[	X
admet-295	368	2	28	28	NUM
admet-295	368	3	]	]	X
admet-295	368	4	g.	g.	PROPN
admet-295	368	5	sonpavde	sonpavde	PROPN
admet-295	368	6	,	,	PUNCT
admet-295	368	7	j.	j.	PROPN
admet-295	368	8	bellmunt	bellmunt	PROPN
admet-295	368	9	,	,	PUNCT
admet-295	368	10	f.	f.	PROPN
admet-295	368	11	schutz	schutz	PROPN
admet-295	368	12	,	,	PUNCT
admet-295	368	13	t.	t.	PROPN
admet-295	368	14	k.	k.	PROPN
admet-295	368	15	choueiri	choueiri	PROPN
admet-295	368	16	.	.	PUNCT
admet-295	369	1	curr	curr	PROPN
admet-295	369	2	.	.	PUNCT
admet-295	370	1	oncol	oncol	PROPN
admet-295	370	2	.	.	PUNCT
admet-295	371	1	rep	rep	PROPN
admet-295	371	2	.	.	PROPN
admet-295	371	3	14(4	14(4	NUM
admet-295	371	4	)	)	PUNCT
admet-295	371	5	(	(	PUNCT
admet-295	371	6	2012	2012	NUM
admet-295	371	7	)	)	PUNCT
admet-295	371	8	295	295	NUM
admet-295	371	9	-	-	SYM
admet-295	371	10	306	306	NUM
admet-295	371	11	.	.	PUNCT
admet-295	372	1	[	[	X
admet-295	372	2	29	29	NUM
admet-295	372	3	]	]	X
admet-295	372	4	r.	r.	PROPN
admet-295	372	5	r.	r.	PROPN
admet-295	372	6	shah	shah	PROPN
admet-295	372	7	,	,	PUNCT
admet-295	372	8	j.	j.	PROPN
admet-295	372	9	morganroth	morganroth	PROPN
admet-295	372	10	,	,	PUNCT
admet-295	372	11	d.	d.	PROPN
admet-295	372	12	r.	r.	PROPN
admet-295	372	13	shah	shah	PROPN
admet-295	372	14	.	.	PUNCT
admet-295	373	1	drug	drug	PROPN
admet-295	373	2	saf	saf	PROPN
admet-295	373	3	.	.	PROPN
admet-295	373	4	36(7	36(7	PROPN
admet-295	373	5	)	)	PUNCT
admet-295	373	6	(	(	PUNCT
admet-295	373	7	2013	2013	NUM
admet-295	373	8	)	)	PUNCT
admet-295	373	9	491	491	NUM
admet-295	373	10	-	-	SYM
admet-295	373	11	503	503	NUM
admet-295	373	12	.	.	PUNCT
admet-295	374	1	admet	admet	PROPN
admet-295	374	2	&	&	CCONJ
admet-295	374	3	dmpk	dmpk	PROPN
admet-295	374	4	4(3	4(3	NUM
admet-295	374	5	)	)	PUNCT
admet-295	374	6	(	(	PUNCT
admet-295	374	7	2016	2016	NUM
admet-295	374	8	)	)	PUNCT
admet-295	374	9	212	212	NUM
admet-295	374	10	-	-	SYM
admet-295	374	11	231	231	NUM
admet-295	374	12	pkis	pki	NOUN
admet-295	374	13	and	and	CCONJ
admet-295	374	14	qt	qt	NOUN
admet-295	374	15	-	-	PUNCT
admet-295	374	16	phobia	phobia	NOUN
admet-295	374	17	doi	doi	NOUN
admet-295	374	18	:	:	PUNCT
admet-295	374	19	10.5599	10.5599	NUM
admet-295	374	20	/	/	SYM
admet-295	374	21	admet.4.3.295	admet.4.3.295	NOUN
admet-295	374	22	227	227	NUM
admet-295	375	1	[	[	SYM
admet-295	375	2	30	30	NUM
admet-295	375	3	]	]	X
admet-295	375	4	r.	r.	PROPN
admet-295	375	5	iacovelli	iacovelli	PROPN
admet-295	375	6	,	,	PUNCT
admet-295	375	7	a.	a.	NOUN
admet-295	375	8	palazzo	palazzo	PROPN
admet-295	375	9	,	,	PUNCT
admet-295	375	10	g.	g.	PROPN
admet-295	375	11	procopio	procopio	PROPN
admet-295	375	12	,	,	PUNCT
admet-295	375	13	m.	m.	NOUN
admet-295	375	14	santoni	santoni	NOUN
admet-295	375	15	,	,	PUNCT
admet-295	375	16	p.	p.	PROPN
admet-295	375	17	trenta	trenta	PROPN
admet-295	375	18	,	,	PUNCT
admet-295	375	19	a.	a.	PROPN
admet-295	375	20	de	de	X
admet-295	375	21	benedetto	benedetto	PROPN
admet-295	375	22	,	,	PUNCT
admet-295	375	23	s.	s.	PROPN
admet-295	375	24	mezi	mezi	PROPN
admet-295	375	25	,	,	PUNCT
admet-295	375	26	e.	e.	PROPN
admet-295	375	27	cortesi	cortesi	PROPN
admet-295	375	28	.	.	PUNCT
admet-295	376	1	br	br	PROPN
admet-295	376	2	.	.	PUNCT
admet-295	377	1	j.	j.	PROPN
admet-295	377	2	clin	clin	PROPN
admet-295	377	3	.	.	PUNCT
admet-295	378	1	pharmacol	pharmacol	PROPN
admet-295	378	2	.	.	PUNCT
admet-295	379	1	77(6	77(6	NUM
admet-295	379	2	)	)	PUNCT
admet-295	379	3	(	(	PUNCT
admet-295	379	4	2014	2014	NUM
admet-295	379	5	)	)	PUNCT
admet-295	379	6	929	929	NUM
admet-295	379	7	-	-	SYM
admet-295	379	8	938	938	NUM
admet-295	379	9	.	.	PUNCT
admet-295	380	1	[	[	X
admet-295	380	2	31	31	NUM
admet-295	380	3	]	]	PUNCT
admet-295	380	4	p.	p.	PROPN
admet-295	380	5	ghatalia	ghatalia	PROPN
admet-295	380	6	,	,	PUNCT
admet-295	380	7	y	y	PROPN
admet-295	380	8	je	je	PROPN
admet-295	380	9	,	,	PUNCT
admet-295	380	10	n.	n.	PROPN
admet-295	380	11	e.	e.	PROPN
admet-295	380	12	mouallem	mouallem	PROPN
admet-295	380	13	,	,	PUNCT
admet-295	380	14	p.	p.	PROPN
admet-295	380	15	l.	l.	PROPN
admet-295	380	16	nguyen	nguyen	PROPN
admet-295	380	17	,	,	PUNCT
admet-295	380	18	q.	q.	PROPN
admet-295	380	19	d.	d.	PROPN
admet-295	380	20	trinh	trinh	PROPN
admet-295	380	21	,	,	PUNCT
admet-295	380	22	g.	g.	PROPN
admet-295	380	23	sonpavde	sonpavde	PROPN
admet-295	380	24	,	,	PUNCT
admet-295	380	25	t.	t.	PROPN
admet-295	380	26	k.	k.	PROPN
admet-295	380	27	choueiri	choueiri	PROPN
admet-295	380	28	.	.	PUNCT
admet-295	381	1	crit	crit	PROPN
admet-295	381	2	.	.	PUNCT
admet-295	382	1	rev	rev	PROPN
admet-295	382	2	.	.	PROPN
admet-295	382	3	oncol	oncol	PROPN
admet-295	382	4	.	.	PUNCT
admet-295	382	5	hematol	hematol	NOUN
admet-295	382	6	.	.	PUNCT
admet-295	383	1	93(3	93(3	NUM
admet-295	383	2	)	)	PUNCT
admet-295	383	3	(	(	PUNCT
admet-295	383	4	2015	2015	NUM
admet-295	383	5	)	)	PUNCT
admet-295	383	6	257	257	NUM
admet-295	383	7	-	-	SYM
admet-295	383	8	276	276	NUM
admet-295	383	9	.	.	PUNCT
admet-295	384	1	[	[	X
admet-295	384	2	32	32	NUM
admet-295	384	3	]	]	PUNCT
admet-295	384	4	w.	w.	PROPN
admet-295	384	5	x.	x.	PROPN
admet-295	384	6	qi	qi	PROPN
admet-295	384	7	,	,	PUNCT
admet-295	384	8	y.	y.	PROPN
admet-295	384	9	j.	j.	PROPN
admet-295	384	10	sun	sun	PROPN
admet-295	384	11	,	,	PUNCT
admet-295	384	12	z.	z.	PROPN
admet-295	384	13	shen	shen	PROPN
admet-295	384	14	,	,	PUNCT
admet-295	384	15	y.	y.	PROPN
admet-295	384	16	yao	yao	PROPN
admet-295	384	17	.	.	PUNCT
admet-295	385	1	j.	j.	PROPN
admet-295	385	2	chemother	chemother	PROPN
admet-295	385	3	.	.	PUNCT
admet-295	386	1	27(1	27(1	X
admet-295	386	2	)	)	PUNCT
admet-295	386	3	(	(	PUNCT
admet-295	386	4	2015	2015	NUM
admet-295	386	5	)	)	PUNCT
admet-295	386	6	40	40	NUM
admet-295	386	7	-	-	SYM
admet-295	386	8	51	51	NUM
admet-295	386	9	.	.	PUNCT
admet-295	387	1	[	[	X
admet-295	387	2	33	33	NUM
admet-295	387	3	]	]	X
admet-295	387	4	o.	o.	PROPN
admet-295	387	5	abdel	abdel	PROPN
admet-295	387	6	-	-	PUNCT
admet-295	387	7	rahman	rahman	PROPN
admet-295	387	8	,	,	PUNCT
admet-295	387	9	h.	h.	PROPN
admet-295	387	10	elhalawani	elhalawani	PROPN
admet-295	387	11	.	.	PUNCT
admet-295	388	1	future	future	ADJ
admet-295	388	2	oncol	oncol	ADJ
admet-295	388	3	.	.	PUNCT
admet-295	389	1	11(7	11(7	NUM
admet-295	389	2	)	)	PUNCT
admet-295	389	3	(	(	PUNCT
admet-295	389	4	2015	2015	NUM
admet-295	389	5	)	)	PUNCT
admet-295	389	6	1109	1109	NUM
admet-295	389	7	-	-	SYM
admet-295	389	8	1122	1122	NUM
admet-295	389	9	.	.	PUNCT
admet-295	390	1	[	[	X
admet-295	390	2	34	34	NUM
admet-295	390	3	]	]	X
admet-295	390	4	p.	p.	PROPN
admet-295	390	5	r.	r.	PROPN
admet-295	390	6	massey	massey	PROPN
admet-295	390	7	,	,	PUNCT
admet-295	390	8	j.	j.	PROPN
admet-295	390	9	s.	s.	PROPN
admet-295	390	10	okman	okman	PROPN
admet-295	390	11	,	,	PUNCT
admet-295	390	12	j.	j.	PROPN
admet-295	390	13	wilkerson	wilkerson	PROPN
admet-295	390	14	,	,	PUNCT
admet-295	390	15	e.	e.	PROPN
admet-295	390	16	w.	w.	PROPN
admet-295	390	17	cowen	cowen	PROPN
admet-295	390	18	.	.	PUNCT
admet-295	391	1	support	support	NOUN
admet-295	391	2	care	care	NOUN
admet-295	391	3	cancer	cancer	NOUN
admet-295	391	4	23(6	23(6	NOUN
admet-295	391	5	)	)	PUNCT
admet-295	391	6	(	(	PUNCT
admet-295	391	7	2015	2015	NUM
admet-295	391	8	)	)	PUNCT
admet-295	391	9	1827	1827	NUM
admet-295	391	10	-	-	SYM
admet-295	391	11	1835	1835	NUM
admet-295	391	12	.	.	PUNCT
admet-295	392	1	[	[	X
admet-295	392	2	35	35	NUM
admet-295	392	3	]	]	X
admet-295	392	4	o.	o.	PROPN
admet-295	392	5	abdel	abdel	PROPN
admet-295	392	6	-	-	PUNCT
admet-295	392	7	rahman	rahman	PROPN
admet-295	392	8	,	,	PUNCT
admet-295	392	9	m.	m.	NOUN
admet-295	392	10	fouad	fouad	PROPN
admet-295	392	11	.	.	PUNCT
admet-295	393	1	expert	expert	PROPN
admet-295	393	2	rev	rev	PROPN
admet-295	393	3	.	.	PROPN
admet-295	393	4	anticancer	anticancer	NOUN
admet-295	393	5	ther	ther	PROPN
admet-295	393	6	.	.	PUNCT
admet-295	394	1	14(9	14(9	X
admet-295	394	2	)	)	PUNCT
admet-295	394	3	(	(	PUNCT
admet-295	394	4	2014	2014	NUM
admet-295	394	5	)	)	PUNCT
admet-295	394	6	1063	1063	NUM
admet-295	394	7	-	-	SYM
admet-295	394	8	1073	1073	NUM
admet-295	394	9	.	.	PUNCT
admet-295	395	1	[	[	X
admet-295	395	2	36	36	NUM
admet-295	395	3	]	]	X
admet-295	395	4	z	z	PROPN
admet-295	395	5	-	-	PUNCT
admet-295	395	6	f	f	PROPN
admet-295	395	7	zhang	zhang	PROPN
admet-295	395	8	,	,	PUNCT
admet-295	395	9	t.	t.	PROPN
admet-295	395	10	wang	wang	PROPN
admet-295	395	11	,	,	PUNCT
admet-295	395	12	l	l	PROPN
admet-295	395	13	-	-	NOUN
admet-295	395	14	h	h	ADJ
admet-295	395	15	liu	liu	PROPN
admet-295	395	16	,	,	PUNCT
admet-295	395	17	h	h	NOUN
admet-295	395	18	-	-	PUNCT
admet-295	395	19	q	q	ADJ
admet-295	395	20	guo	guo	PROPN
admet-295	395	21	.	.	PUNCT
admet-295	396	1	plos	plos	PROPN
admet-295	396	2	.	.	PROPN
admet-295	397	1	one	one	NUM
admet-295	397	2	9(3	9(3	NUM
admet-295	397	3	):	):	PUNCT
admet-295	397	4	(	(	PUNCT
admet-295	397	5	2014	2014	NUM
admet-295	397	6	)	)	PUNCT
admet-295	397	7	e90135	e90135	NOUN
admet-295	397	8	.	.	PUNCT
admet-295	398	1	[	[	X
admet-295	398	2	37	37	NUM
admet-295	398	3	]	]	PUNCT
admet-295	398	4	s.	s.	PROPN
admet-295	398	5	r.	r.	PROPN
admet-295	398	6	hayman	hayman	PROPN
admet-295	398	7	,	,	PUNCT
admet-295	398	8	n.	n.	PROPN
admet-295	398	9	leung	leung	PROPN
admet-295	398	10	,	,	PUNCT
admet-295	398	11	j.	j.	PROPN
admet-295	398	12	p.	p.	PROPN
admet-295	398	13	grande	grande	PROPN
admet-295	398	14	,	,	PUNCT
admet-295	398	15	v.	v.	PROPN
admet-295	398	16	d.	d.	PROPN
admet-295	398	17	garovic	garovic	PROPN
admet-295	398	18	.	.	PUNCT
admet-295	399	1	curr	curr	PROPN
admet-295	399	2	.	.	PUNCT
admet-295	399	3	oncol	oncol	PROPN
admet-295	399	4	.	.	PUNCT
admet-295	400	1	rep	rep	PROPN
admet-295	400	2	.	.	PROPN
admet-295	400	3	14(4	14(4	NUM
admet-295	400	4	)	)	PUNCT
admet-295	400	5	(	(	PUNCT
admet-295	400	6	2012	2012	NUM
admet-295	400	7	)	)	PUNCT
admet-295	400	8	285	285	NUM
admet-295	400	9	-	-	SYM
admet-295	400	10	294	294	NUM
admet-295	400	11	.	.	PUNCT
admet-295	401	1	[	[	X
admet-295	401	2	38	38	NUM
admet-295	401	3	]	]	PUNCT
admet-295	401	4	a.	a.	NOUN
admet-295	401	5	yuan	yuan	PROPN
admet-295	401	6	,	,	PUNCT
admet-295	401	7	s.	s.	PROPN
admet-295	401	8	l.	l.	PROPN
admet-295	401	9	kurtz	kurtz	PROPN
admet-295	401	10	,	,	PUNCT
admet-295	401	11	c.	c.	PROPN
admet-295	401	12	m.	m.	PROPN
admet-295	401	13	barysauskas	barysauskas	PROPN
admet-295	401	14	,	,	PUNCT
admet-295	401	15	a.	a.	NOUN
admet-295	401	16	p.	p.	NOUN
admet-295	401	17	pilotte	pilotte	NOUN
admet-295	401	18	,	,	PUNCT
admet-295	401	19	a.	a.	PROPN
admet-295	401	20	j.	j.	PROPN
admet-295	401	21	wagner	wagner	PROPN
admet-295	401	22	,	,	PUNCT
admet-295	401	23	n.	n.	PROPN
admet-295	401	24	s.	s.	PROPN
admet-295	401	25	treister	treister	PROPN
admet-295	401	26	.	.	PUNCT
admet-295	402	1	oral	oral	ADJ
admet-295	402	2	oncol	oncol	ADJ
admet-295	402	3	.	.	PUNCT
admet-295	403	1	51(11	51(11	NUM
admet-295	403	2	)	)	PUNCT
admet-295	403	3	(	(	PUNCT
admet-295	403	4	2015	2015	NUM
admet-295	403	5	)	)	PUNCT
admet-295	403	6	1026	1026	NUM
admet-295	403	7	-	-	SYM
admet-295	403	8	1033	1033	NUM
admet-295	403	9	.	.	PUNCT
admet-295	404	1	[	[	X
admet-295	404	2	39	39	NUM
admet-295	404	3	]	]	PUNCT
admet-295	404	4	p.	p.	PROPN
admet-295	404	5	ghatalia	ghatalia	PROPN
admet-295	404	6	,	,	PUNCT
admet-295	404	7	c.	c.	PROPN
admet-295	404	8	j.	j.	PROPN
admet-295	404	9	morgan	morgan	PROPN
admet-295	404	10	,	,	PUNCT
admet-295	404	11	t.	t.	PROPN
admet-295	404	12	k.	k.	PROPN
admet-295	404	13	choueiri	choueiri	PROPN
admet-295	404	14	,	,	PUNCT
admet-295	404	15	p.	p.	PROPN
admet-295	404	16	rocha	rocha	PROPN
admet-295	404	17	,	,	PUNCT
admet-295	404	18	g.	g.	PROPN
admet-295	404	19	naik	naik	PROPN
admet-295	404	20	,	,	PUNCT
admet-295	404	21	g.	g.	PROPN
admet-295	404	22	sonpavde	sonpavde	PROPN
admet-295	404	23	.	.	PUNCT
admet-295	405	1	crit	crit	PROPN
admet-295	405	2	.	.	PUNCT
admet-295	406	1	rev	rev	PROPN
admet-295	406	2	.	.	PROPN
admet-295	406	3	oncol	oncol	PROPN
admet-295	406	4	.	.	PUNCT
admet-295	406	5	hematol	hematol	NOUN
admet-295	406	6	.	.	PUNCT
admet-295	407	1	94(1	94(1	NUM
admet-295	407	2	)	)	PUNCT
admet-295	407	3	(	(	PUNCT
admet-295	407	4	2015	2015	NUM
admet-295	407	5	)	)	PUNCT
admet-295	407	6	136	136	NUM
admet-295	407	7	-	-	SYM
admet-295	407	8	145	145	NUM
admet-295	407	9	.	.	PUNCT
admet-295	408	1	[	[	X
admet-295	408	2	40	40	NUM
admet-295	408	3	]	]	PUNCT
admet-295	408	4	food	food	NOUN
admet-295	408	5	and	and	CCONJ
admet-295	408	6	drug	drug	NOUN
admet-295	408	7	administration	administration	NOUN
admet-295	408	8	.	.	PUNCT
admet-295	409	1	guidance	guidance	NOUN
admet-295	409	2	for	for	ADP
admet-295	409	3	industry	industry	NOUN
admet-295	409	4	:	:	PUNCT
admet-295	409	5	premarketing	premarkete	VERB
admet-295	409	6	risk	risk	NOUN
admet-295	409	7	assessment	assessment	NOUN
admet-295	409	8	(	(	PUNCT
admet-295	409	9	march	march	PROPN
admet-295	409	10	2005	2005	NUM
admet-295	409	11	)	)	PUNCT
admet-295	409	12	.	.	PUNCT
admet-295	410	1	food	food	NOUN
admet-295	410	2	and	and	CCONJ
admet-295	410	3	drug	drug	PROPN
admet-295	410	4	administration	administration	PROPN
admet-295	410	5	,	,	PUNCT
admet-295	410	6	rockville	rockville	PROPN
admet-295	410	7	,	,	PUNCT
admet-295	410	8	md	md	PROPN
admet-295	410	9	20857	20857	NUM
admet-295	410	10	,	,	PUNCT
admet-295	410	11	usa	usa	PROPN
admet-295	410	12	.	.	PROPN
admet-295	410	13	available	available	ADJ
admet-295	410	14	at	at	ADP
admet-295	410	15	:	:	PUNCT
admet-295	410	16	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm	PUNCT
admet-295	410	17	072002.pdf	072002.pdf	NOUN
admet-295	410	18	,	,	PUNCT
admet-295	410	19	[	[	X
admet-295	410	20	accessed	access	VERB
admet-295	410	21	on	on	ADP
admet-295	410	22	1	1	NUM
admet-295	410	23	march	march	NOUN
admet-295	410	24	2016	2016	NUM
admet-295	410	25	]	]	PUNCT
admet-295	410	26	.	.	PUNCT
admet-295	411	1	[	[	X
admet-295	411	2	41	41	NUM
admet-295	411	3	]	]	X
admet-295	411	4	g.	g.	PROPN
admet-295	411	5	michels	michels	PROPN
admet-295	411	6	,	,	PUNCT
admet-295	411	7	m.	m.	NOUN
admet-295	411	8	kochanek	kochanek	PROPN
admet-295	411	9	,	,	PUNCT
admet-295	411	10	r.	r.	PROPN
admet-295	411	11	pfister	pfister	PROPN
admet-295	411	12	.	.	PUNCT
admet-295	412	1	med	med	PROPN
admet-295	412	2	.	.	PUNCT
admet-295	413	1	klin	klin	PROPN
admet-295	413	2	.	.	PROPN
admet-295	413	3	intensivmed	intensivme	VERB
admet-295	413	4	.	.	PUNCT
admet-295	414	1	notfmed	notfme	VERB
admet-295	414	2	.	.	PUNCT
admet-295	415	1	2015	2015	NUM
admet-295	415	2	sep	sep	NOUN
admet-295	415	3	4	4	NUM
admet-295	415	4	.	.	PUNCT
admet-295	416	1	[	[	X
admet-295	416	2	epub	epub	NOUN
admet-295	416	3	ahead	ahead	ADV
admet-295	416	4	of	of	ADP
admet-295	416	5	print	print	NOUN
admet-295	416	6	]	]	PUNCT
admet-295	416	7	.	.	PUNCT
admet-295	417	1	[	[	X
admet-295	417	2	42	42	NUM
admet-295	417	3	]	]	PUNCT
admet-295	417	4	w.	w.	PROPN
admet-295	417	5	haverkamp	haverkamp	PROPN
admet-295	417	6	,	,	PUNCT
admet-295	417	7	g.	g.	PROPN
admet-295	417	8	breithardt	breithardt	PROPN
admet-295	417	9	,	,	PUNCT
admet-295	417	10	a.	a.	PROPN
admet-295	417	11	j.	j.	PROPN
admet-295	417	12	camm	camm	PROPN
admet-295	417	13	,	,	PUNCT
admet-295	417	14	m.	m.	PROPN
admet-295	417	15	j.	j.	PROPN
admet-295	417	16	janse	janse	PROPN
admet-295	417	17	,	,	PUNCT
admet-295	417	18	m.	m.	PROPN
admet-295	417	19	r.	r.	PROPN
admet-295	417	20	rosen	rosen	PROPN
admet-295	417	21	,	,	PUNCT
admet-295	417	22	c.	c.	PROPN
admet-295	417	23	antzelevitch	antzelevitch	PROPN
admet-295	417	24	,	,	PUNCT
admet-295	417	25	d.	d.	PROPN
admet-295	417	26	escande	escande	PROPN
admet-295	417	27	,	,	PUNCT
admet-295	417	28	m.	m.	NOUN
admet-295	417	29	franz	franz	PROPN
admet-295	417	30	,	,	PUNCT
admet-295	417	31	m.	m.	NOUN
admet-295	417	32	malik	malik	PROPN
admet-295	417	33	,	,	PUNCT
admet-295	417	34	a.	a.	NOUN
admet-295	417	35	moss	moss	PROPN
admet-295	417	36	,	,	PUNCT
admet-295	417	37	r.	r.	PROPN
admet-295	417	38	shah	shah	PROPN
admet-295	417	39	.	.	PUNCT
admet-295	418	1	cardiovasc	cardiovasc	PROPN
admet-295	418	2	.	.	PUNCT
admet-295	419	1	res	res	PROPN
admet-295	419	2	.	.	PUNCT
admet-295	420	1	47(2	47(2	PROPN
admet-295	420	2	)	)	PUNCT
admet-295	420	3	(	(	PUNCT
admet-295	420	4	2000	2000	NUM
admet-295	420	5	)	)	PUNCT
admet-295	420	6	219	219	NUM
admet-295	420	7	-	-	SYM
admet-295	420	8	233	233	NUM
admet-295	420	9	.	.	PUNCT
admet-295	421	1	[	[	X
admet-295	421	2	43	43	NUM
admet-295	421	3	]	]	X
admet-295	421	4	p.	p.	NOUN
admet-295	421	5	salle	salle	PROPN
admet-295	421	6	,	,	PUNCT
admet-295	421	7	j.	j.	PROPN
admet-295	421	8	l.	l.	PROPN
admet-295	421	9	rey	rey	PROPN
admet-295	421	10	,	,	PUNCT
admet-295	421	11	p.	p.	PROPN
admet-295	421	12	bernasconi	bernasconi	PROPN
admet-295	421	13	,	,	PUNCT
admet-295	421	14	j.	j.	PROPN
admet-295	421	15	c.	c.	PROPN
admet-295	421	16	quiret	quiret	PROPN
admet-295	421	17	,	,	PUNCT
admet-295	421	18	m.	m.	NOUN
admet-295	421	19	lombaert	lombaert	PROPN
admet-295	421	20	.	.	PUNCT
admet-295	422	1	ann	ann	PROPN
admet-295	422	2	.	.	PUNCT
admet-295	423	1	cardiol	cardiol	PROPN
admet-295	423	2	.	.	PUNCT
admet-295	424	1	angeiol	angeiol	PROPN
admet-295	424	2	.	.	PUNCT
admet-295	425	1	(	(	PUNCT
admet-295	425	2	paris	paris	PROPN
admet-295	425	3	)	)	PUNCT
admet-295	425	4	.	.	PUNCT
admet-295	426	1	34(6	34(6	X
admet-295	426	2	)	)	PUNCT
admet-295	426	3	(	(	PUNCT
admet-295	426	4	1985	1985	NUM
admet-295	426	5	)	)	PUNCT
admet-295	426	6	381	381	NUM
admet-295	426	7	-	-	SYM
admet-295	426	8	388	388	NUM
admet-295	426	9	.	.	PUNCT
admet-295	427	1	french	french	PROPN
admet-295	427	2	.	.	PUNCT
admet-295	428	1	[	[	X
admet-295	428	2	44	44	NUM
admet-295	428	3	]	]	PUNCT
admet-295	428	4	d.	d.	PROPN
admet-295	428	5	k.	k.	PROPN
admet-295	428	6	wysowski	wysowski	PROPN
admet-295	428	7	,	,	PUNCT
admet-295	428	8	a.	a.	PROPN
admet-295	428	9	corken	corken	PROPN
admet-295	428	10	,	,	PUNCT
admet-295	428	11	h.	h.	PROPN
admet-295	428	12	gallo	gallo	PROPN
admet-295	428	13	-	-	PUNCT
admet-295	428	14	torres	torre	NOUN
admet-295	428	15	,	,	PUNCT
admet-295	428	16	l.	l.	PROPN
admet-295	428	17	talarico	talarico	PROPN
admet-295	428	18	,	,	PUNCT
admet-295	428	19	e.	e.	PROPN
admet-295	428	20	m.	m.	PROPN
admet-295	428	21	rodriguez	rodriguez	PROPN
admet-295	428	22	.	.	PUNCT
admet-295	428	23	am	be	AUX
admet-295	428	24	.	.	PUNCT
admet-295	429	1	j.	j.	PROPN
admet-295	429	2	gastroenterol	gastroenterol	PROPN
admet-295	429	3	.	.	PUNCT
admet-295	430	1	96(6	96(6	X
admet-295	430	2	)	)	PUNCT
admet-295	430	3	(	(	PUNCT
admet-295	430	4	2001	2001	NUM
admet-295	430	5	)	)	PUNCT
admet-295	430	6	1698	1698	NUM
admet-295	430	7	-	-	SYM
admet-295	430	8	1703	1703	NUM
admet-295	430	9	.	.	PUNCT
admet-295	431	1	[	[	X
admet-295	431	2	45	45	NUM
admet-295	431	3	]	]	PUNCT
admet-295	431	4	r.	r.	PROPN
admet-295	431	5	r.	r.	PROPN
admet-295	431	6	shah	shah	PROPN
admet-295	431	7	.	.	PUNCT
admet-295	432	1	pharmacogenomics	pharmacogenomic	NOUN
admet-295	432	2	7(6	7(6	NUM
admet-295	432	3	)	)	PUNCT
admet-295	432	4	(	(	PUNCT
admet-295	432	5	2006	2006	NUM
admet-295	432	6	)	)	PUNCT
admet-295	432	7	889	889	NUM
admet-295	432	8	-	-	SYM
admet-295	432	9	908	908	NUM
admet-295	432	10	.	.	PUNCT
admet-295	433	1	[	[	X
admet-295	433	2	46	46	NUM
admet-295	433	3	]	]	X
admet-295	433	4	n.	n.	PROPN
admet-295	433	5	stockbridge	stockbridge	PROPN
admet-295	433	6	,	,	PUNCT
admet-295	433	7	j.	j.	PROPN
admet-295	433	8	morganroth	morganroth	PROPN
admet-295	433	9	,	,	PUNCT
admet-295	433	10	r.	r.	PROPN
admet-295	433	11	r.	r.	PROPN
admet-295	433	12	shah	shah	PROPN
admet-295	433	13	,	,	PUNCT
admet-295	433	14	c.	c.	PROPN
admet-295	433	15	garnett	garnett	PROPN
admet-295	433	16	.	.	PUNCT
admet-295	433	17	drug	drug	PROPN
admet-295	433	18	saf	saf	PROPN
admet-295	433	19	.	.	PROPN
admet-295	433	20	36(3	36(3	NUM
admet-295	433	21	)	)	PUNCT
admet-295	433	22	(	(	PUNCT
admet-295	433	23	2013	2013	NUM
admet-295	433	24	)	)	PUNCT
admet-295	433	25	167	167	NUM
admet-295	433	26	-	-	SYM
admet-295	433	27	182	182	NUM
admet-295	433	28	.	.	PUNCT
admet-295	434	1	[	[	X
admet-295	434	2	47	47	NUM
admet-295	434	3	]	]	X
admet-295	434	4	r.	r.	PROPN
admet-295	434	5	r.	r.	PROPN
admet-295	434	6	shah	shah	PROPN
admet-295	434	7	.	.	PUNCT
admet-295	434	8	drug	drug	PROPN
admet-295	434	9	saf	saf	PROPN
admet-295	434	10	.	.	PUNCT
admet-295	435	1	30(12	30(12	NUM
admet-295	435	2	)	)	PUNCT
admet-295	435	3	(	(	PUNCT
admet-295	435	4	2007	2007	NUM
admet-295	435	5	)	)	PUNCT
admet-295	435	6	1093	1093	NUM
admet-295	435	7	-	-	SYM
admet-295	435	8	1110	1110	NUM
admet-295	435	9	.	.	PUNCT
admet-295	436	1	[	[	X
admet-295	436	2	48	48	NUM
admet-295	436	3	]	]	PUNCT
admet-295	436	4	l.	l.	PROPN
admet-295	436	5	johannesen	johannesen	PROPN
admet-295	436	6	,	,	PUNCT
admet-295	436	7	j.	j.	PROPN
admet-295	436	8	vicente	vicente	PROPN
admet-295	436	9	,	,	PUNCT
admet-295	436	10	j.	j.	PROPN
admet-295	436	11	w.	w.	PROPN
admet-295	436	12	mason	mason	PROPN
admet-295	436	13	,	,	PUNCT
admet-295	436	14	c.	c.	PROPN
admet-295	436	15	erato	erato	PROPN
admet-295	436	16	,	,	PUNCT
admet-295	436	17	c.	c.	PROPN
admet-295	436	18	sanabria	sanabria	PROPN
admet-295	436	19	,	,	PUNCT
admet-295	436	20	k.	k.	PROPN
admet-295	436	21	waite	waite	PROPN
admet-295	436	22	-	-	PUNCT
admet-295	436	23	labott	labott	PROPN
admet-295	436	24	,	,	PUNCT
admet-295	436	25	m.	m.	NOUN
admet-295	436	26	hong	hong	PROPN
admet-295	436	27	,	,	PUNCT
admet-295	436	28	j.	j.	PROPN
admet-295	436	29	lin	lin	PROPN
admet-295	436	30	,	,	PUNCT
admet-295	436	31	p.	p.	PROPN
admet-295	436	32	guo	guo	PROPN
admet-295	436	33	,	,	PUNCT
admet-295	436	34	a.	a.	NOUN
admet-295	436	35	mutlib	mutlib	PROPN
admet-295	436	36	,	,	PUNCT
admet-295	436	37	j.	j.	PROPN
admet-295	436	38	wang	wang	PROPN
admet-295	436	39	,	,	PUNCT
admet-295	436	40	w.	w.	PROPN
admet-295	436	41	j.	j.	PROPN
admet-295	436	42	crumb	crumb	PROPN
admet-295	436	43	,	,	PUNCT
admet-295	436	44	k.	k.	PROPN
admet-295	436	45	blinova	blinova	PROPN
admet-295	436	46	,	,	PUNCT
admet-295	436	47	d.	d.	PROPN
admet-295	436	48	chan	chan	PROPN
admet-295	436	49	,	,	PUNCT
admet-295	436	50	j.	j.	PROPN
admet-295	436	51	stohlman	stohlman	PROPN
admet-295	436	52	,	,	PUNCT
admet-295	436	53	j.	j.	PROPN
admet-295	436	54	florian	florian	PROPN
admet-295	436	55	,	,	PUNCT
admet-295	436	56	m.	m.	NOUN
admet-295	436	57	ugander	ugander	NOUN
admet-295	436	58	,	,	PUNCT
admet-295	436	59	n.	n.	PROPN
admet-295	436	60	stockbridge	stockbridge	PROPN
admet-295	436	61	,	,	PUNCT
admet-295	436	62	d.	d.	PROPN
admet-295	436	63	g.	g.	PROPN
admet-295	436	64	strauss	strauss	PROPN
admet-295	436	65	.	.	PUNCT
admet-295	437	1	clin	clin	PROPN
admet-295	437	2	.	.	PUNCT
admet-295	438	1	pharmacol	pharmacol	PROPN
admet-295	438	2	.	.	PUNCT
admet-295	439	1	ther	ther	PROPN
admet-295	439	2	.	.	PUNCT
admet-295	440	1	99(2	99(2	X
admet-295	440	2	)	)	PUNCT
admet-295	440	3	(	(	PUNCT
admet-295	440	4	2016	2016	NUM
admet-295	440	5	)	)	PUNCT
admet-295	440	6	214	214	NUM
admet-295	440	7	-	-	SYM
admet-295	440	8	223	223	NUM
admet-295	440	9	.	.	PUNCT
admet-295	441	1	[	[	X
admet-295	441	2	49	49	NUM
admet-295	441	3	]	]	PUNCT
admet-295	441	4	m.	m.	NOUN
admet-295	441	5	c.	c.	PROPN
admet-295	441	6	makielski	makielski	PROPN
admet-295	441	7	.	.	PUNCT
admet-295	442	1	trends	trend	NOUN
admet-295	442	2	cardiovasc	cardiovasc	PROPN
admet-295	442	3	.	.	PROPN
admet-295	442	4	med	med	PROPN
admet-295	442	5	.	.	PUNCT
admet-295	442	6	26(2	26(2	NUM
admet-295	442	7	)	)	PUNCT
admet-295	442	8	(	(	PUNCT
admet-295	442	9	2016	2016	NUM
admet-295	442	10	)	)	PUNCT
admet-295	442	11	115	115	NUM
admet-295	442	12	-	-	SYM
admet-295	442	13	122	122	NUM
admet-295	442	14	.	.	PUNCT
admet-295	443	1	[	[	X
admet-295	443	2	50	50	NUM
admet-295	443	3	]	]	PUNCT
admet-295	443	4	z.	z.	PROPN
admet-295	443	5	j.	j.	PROPN
admet-295	443	6	huang	huang	PROPN
admet-295	443	7	,	,	PUNCT
admet-295	443	8	d.	d.	PROPN
admet-295	443	9	z.	z.	PROPN
admet-295	443	10	dai	dai	PROPN
admet-295	443	11	,	,	PUNCT
admet-295	443	12	n.	n.	PROPN
admet-295	443	13	li	li	PROPN
admet-295	443	14	,	,	PUNCT
admet-295	443	15	t.	t.	PROPN
admet-295	443	16	na	na	PROPN
admet-295	443	17	,	,	PUNCT
admet-295	443	18	m.	m.	NOUN
admet-295	443	19	ji	ji	PROPN
admet-295	443	20	,	,	PUNCT
admet-295	443	21	y.	y.	PROPN
admet-295	443	22	dai	dai	PROPN
admet-295	443	23	.	.	PUNCT
admet-295	444	1	clin	clin	PROPN
admet-295	444	2	.	.	PUNCT
admet-295	445	1	exp	exp	PROPN
admet-295	445	2	.	.	PUNCT
admet-295	445	3	pharmacol	pharmacol	PROPN
admet-295	445	4	.	.	PUNCT
admet-295	445	5	physiol	physiol	PROPN
admet-295	445	6	.	.	PUNCT
admet-295	446	1	34(4	34(4	X
admet-295	446	2	)	)	PUNCT
admet-295	446	3	(	(	PUNCT
admet-295	446	4	2007	2007	NUM
admet-295	446	5	)	)	PUNCT
admet-295	446	6	310	310	NUM
admet-295	446	7	-	-	SYM
admet-295	446	8	317	317	NUM
admet-295	446	9	.	.	PUNCT
admet-295	447	1	[	[	X
admet-295	447	2	51	51	NUM
admet-295	447	3	]	]	X
admet-295	447	4	l.	l.	PROPN
admet-295	447	5	johannesen	johannesen	PROPN
admet-295	447	6	,	,	PUNCT
admet-295	447	7	j.	j.	PROPN
admet-295	447	8	vicente	vicente	PROPN
admet-295	447	9	,	,	PUNCT
admet-295	447	10	j.	j.	PROPN
admet-295	447	11	w.	w.	PROPN
admet-295	447	12	mason	mason	PROPN
admet-295	447	13	,	,	PUNCT
admet-295	447	14	c.	c.	PROPN
admet-295	447	15	sanabria	sanabria	PROPN
admet-295	447	16	,	,	PUNCT
admet-295	447	17	k.	k.	PROPN
admet-295	447	18	waite	waite	PROPN
admet-295	447	19	-	-	PUNCT
admet-295	447	20	labott	labott	PROPN
admet-295	447	21	,	,	PUNCT
admet-295	447	22	m.	m.	NOUN
admet-295	447	23	hong	hong	PROPN
admet-295	447	24	,	,	PUNCT
admet-295	447	25	p.	p.	PROPN
admet-295	447	26	guo	guo	PROPN
admet-295	447	27	,	,	PUNCT
admet-295	447	28	j.	j.	PROPN
admet-295	447	29	lin	lin	PROPN
admet-295	447	30	,	,	PUNCT
admet-295	447	31	j.	j.	PROPN
admet-295	447	32	s.	s.	PROPN
admet-295	447	33	sørensen	sørensen	PROPN
admet-295	447	34	,	,	PUNCT
admet-295	447	35	l.	l.	PROPN
admet-295	447	36	galeotti	galeotti	PROPN
admet-295	447	37	,	,	PUNCT
admet-295	447	38	j.	j.	PROPN
admet-295	447	39	florian	florian	PROPN
admet-295	447	40	,	,	PUNCT
admet-295	447	41	m.	m.	NOUN
admet-295	447	42	ugander	ugander	NOUN
admet-295	447	43	,	,	PUNCT
admet-295	447	44	n.	n.	PROPN
admet-295	447	45	stockbridge	stockbridge	PROPN
admet-295	447	46	,	,	PUNCT
admet-295	447	47	d.	d.	PROPN
admet-295	447	48	g.	g.	PROPN
admet-295	447	49	strauss	strauss	PROPN
admet-295	447	50	.	.	PUNCT
admet-295	448	1	clin	clin	PROPN
admet-295	448	2	.	.	PUNCT
admet-295	449	1	pharmacol	pharmacol	PROPN
admet-295	449	2	.	.	PUNCT
admet-295	450	1	ther	ther	PROPN
admet-295	450	2	.	.	PUNCT
admet-295	451	1	96(5	96(5	NUM
admet-295	451	2	)	)	PUNCT
admet-295	451	3	(	(	PUNCT
admet-295	451	4	2014	2014	NUM
admet-295	451	5	)	)	PUNCT
admet-295	451	6	549	549	NUM
admet-295	451	7	-	-	SYM
admet-295	451	8	558	558	NUM
admet-295	451	9	.	.	PUNCT
admet-295	452	1	[	[	X
admet-295	452	2	52	52	NUM
admet-295	452	3	]	]	PUNCT
admet-295	452	4	g.	g.	NOUN
admet-295	452	5	antoons	antoons	PROPN
admet-295	452	6	,	,	PUNCT
admet-295	452	7	a.	a.	PROPN
admet-295	452	8	oros	oros	PROPN
admet-295	452	9	,	,	PUNCT
admet-295	452	10	j.	j.	PROPN
admet-295	452	11	d.	d.	PROPN
admet-295	452	12	beekman	beekman	PROPN
admet-295	452	13	,	,	PUNCT
admet-295	452	14	m.	m.	NOUN
admet-295	452	15	a.	a.	NOUN
admet-295	452	16	engelen	engelen	PROPN
admet-295	452	17	,	,	PUNCT
admet-295	452	18	m.	m.	NOUN
admet-295	452	19	j.	j.	PROPN
admet-295	452	20	houtman	houtman	PROPN
admet-295	452	21	,	,	PUNCT
admet-295	452	22	l.	l.	PROPN
admet-295	452	23	belardinelli	belardinelli	PROPN
admet-295	452	24	,	,	PUNCT
admet-295	452	25	m.	m.	NOUN
admet-295	452	26	stengl	stengl	PROPN
admet-295	452	27	,	,	PUNCT
admet-295	452	28	m.	m.	NOUN
admet-295	452	29	a.	a.	PROPN
admet-295	452	30	vos	vos	PROPN
admet-295	452	31	ma	ma	PROPN
admet-295	452	32	.	.	PROPN
admet-295	452	33	j.	j.	PROPN
admet-295	452	34	am	am	PROPN
admet-295	452	35	.	.	PUNCT
admet-295	453	1	coll	coll	PROPN
admet-295	453	2	.	.	PUNCT
admet-295	454	1	cardiol	cardiol	PROPN
admet-295	454	2	.	.	PUNCT
admet-295	455	1	55(8	55(8	NUM
admet-295	455	2	)	)	PUNCT
admet-295	455	3	(	(	PUNCT
admet-295	455	4	2010	2010	NUM
admet-295	455	5	)	)	PUNCT
admet-295	455	6	801	801	NUM
admet-295	455	7	-	-	NUM
admet-295	455	8	809	809	NUM
admet-295	455	9	.	.	PUNCT
admet-295	456	1	[	[	X
admet-295	456	2	53	53	NUM
admet-295	456	3	]	]	PUNCT
admet-295	456	4	s.	s.	PROPN
admet-295	456	5	jia	jia	PROPN
admet-295	456	6	,	,	PUNCT
admet-295	456	7	j.	j.	PROPN
admet-295	456	8	lian	lian	PROPN
admet-295	456	9	,	,	PUNCT
admet-295	456	10	d.	d.	PROPN
admet-295	456	11	guo	guo	PROPN
admet-295	456	12	,	,	PUNCT
admet-295	456	13	x.	x.	PROPN
admet-295	456	14	xue	xue	PROPN
admet-295	456	15	,	,	PUNCT
admet-295	456	16	c.	c.	PROPN
admet-295	456	17	patel	patel	PROPN
admet-295	456	18	,	,	PUNCT
admet-295	456	19	l.	l.	PROPN
admet-295	456	20	yang	yang	PROPN
admet-295	456	21	,	,	PUNCT
admet-295	456	22	z.	z.	PROPN
admet-295	456	23	yuan	yuan	PROPN
admet-295	456	24	,	,	PUNCT
admet-295	456	25	a.	a.	PROPN
admet-295	456	26	ma	ma	PROPN
admet-295	456	27	,	,	PUNCT
admet-295	456	28	g.	g.	PROPN
admet-295	456	29	x.	x.	PROPN
admet-295	456	30	yan	yan	PROPN
admet-295	456	31	.	.	PUNCT
admet-295	457	1	br	br	PROPN
admet-295	457	2	.	.	PUNCT
admet-295	458	1	j.	j.	PROPN
admet-295	458	2	pharmacol	pharmacol	PROPN
admet-295	458	3	.	.	PUNCT
admet-295	459	1	164(2	164(2	NUM
admet-295	459	2	)	)	PUNCT
admet-295	459	3	(	(	PUNCT
admet-295	459	4	2011	2011	NUM
admet-295	459	5	)	)	PUNCT
admet-295	459	6	308	308	NUM
admet-295	459	7	-	-	SYM
admet-295	459	8	316	316	NUM
admet-295	459	9	.	.	PUNCT
admet-295	460	1	[	[	X
admet-295	460	2	54	54	NUM
admet-295	460	3	]	]	PUNCT
admet-295	460	4	d.	d.	PROPN
admet-295	460	5	rampe	rampe	PROPN
admet-295	460	6	,	,	PUNCT
admet-295	460	7	m.	m.	PROPN
admet-295	460	8	k.	k.	PROPN
admet-295	460	9	murawsky	murawsky	PROPN
admet-295	460	10	,	,	PUNCT
admet-295	460	11	j.	j.	PROPN
admet-295	460	12	grau	grau	PROPN
admet-295	460	13	,	,	PUNCT
admet-295	460	14	e.	e.	PROPN
admet-295	460	15	w.	w.	PROPN
admet-295	460	16	lewis	lewis	PROPN
admet-295	460	17	.	.	PUNCT
admet-295	461	1	j.	j.	PROPN
admet-295	461	2	pharmacol	pharmacol	PROPN
admet-295	461	3	.	.	PUNCT
admet-295	462	1	exp	exp	PROPN
admet-295	462	2	.	.	PUNCT
admet-295	463	1	ther	ther	PROPN
admet-295	463	2	.	.	PUNCT
admet-295	464	1	286(2	286(2	NUM
admet-295	464	2	)	)	PUNCT
admet-295	464	3	(	(	PUNCT
admet-295	464	4	1998	1998	NUM
admet-295	464	5	)	)	PUNCT
admet-295	464	6	788	788	NUM
admet-295	464	7	-	-	SYM
admet-295	464	8	793	793	NUM
admet-295	464	9	.	.	PUNCT
admet-295	465	1	[	[	X
admet-295	465	2	55	55	NUM
admet-295	465	3	]	]	X
admet-295	465	4	l.	l.	PROPN
admet-295	465	5	eckardt	eckardt	PROPN
admet-295	465	6	,	,	PUNCT
admet-295	465	7	g.	g.	PROPN
admet-295	465	8	breithardt	breithardt	PROPN
admet-295	465	9	,	,	PUNCT
admet-295	465	10	w.	w.	PROPN
admet-295	465	11	haverkamp	haverkamp	PROPN
admet-295	465	12	.	.	PUNCT
admet-295	466	1	j.	j.	PROPN
admet-295	466	2	pharmacol	pharmacol	PROPN
admet-295	466	3	.	.	PUNCT
admet-295	467	1	exp	exp	PROPN
admet-295	467	2	.	.	PUNCT
admet-295	468	1	ther	ther	PROPN
admet-295	468	2	.	.	PUNCT
admet-295	469	1	300(1	300(1	NUM
admet-295	469	2	)	)	PUNCT
admet-295	469	3	(	(	PUNCT
admet-295	469	4	2002	2002	NUM
admet-295	469	5	)	)	PUNCT
admet-295	469	6	64	64	NUM
admet-295	469	7	-	-	SYM
admet-295	469	8	71	71	NUM
admet-295	469	9	.	.	PUNCT
admet-295	470	1	[	[	X
admet-295	470	2	56	56	NUM
admet-295	470	3	]	]	PUNCT
admet-295	470	4	k.	k.	NOUN
admet-295	470	5	titier	titier	PROPN
admet-295	470	6	,	,	PUNCT
admet-295	470	7	p.	p.	PROPN
admet-295	470	8	o.	o.	PROPN
admet-295	470	9	girodet	girodet	PROPN
admet-295	470	10	,	,	PUNCT
admet-295	470	11	h.	h.	PROPN
admet-295	470	12	verdoux	verdoux	PROPN
admet-295	470	13	,	,	PUNCT
admet-295	470	14	m.	m.	NOUN
admet-295	470	15	molimard	molimard	PROPN
admet-295	470	16	,	,	PUNCT
admet-295	470	17	b.	b.	PROPN
admet-295	470	18	bégaud	bégaud	PROPN
admet-295	470	19	,	,	PUNCT
admet-295	470	20	w.	w.	PROPN
admet-295	470	21	haverkamp	haverkamp	PROPN
admet-295	470	22	,	,	PUNCT
admet-295	470	23	m.	m.	NOUN
admet-295	470	24	lader	lader	PROPN
admet-295	470	25	,	,	PUNCT
admet-295	470	26	n.	n.	PROPN
admet-295	470	27	moore	moore	PROPN
admet-295	470	28	.	.	PUNCT
admet-295	470	29	drug	drug	PROPN
admet-295	470	30	saf	saf	PROPN
admet-295	470	31	.	.	PUNCT
admet-295	471	1	28(1	28(1	NOUN
admet-295	471	2	)	)	PUNCT
admet-295	471	3	(	(	PUNCT
admet-295	471	4	2005	2005	NUM
admet-295	471	5	)	)	PUNCT
admet-295	471	6	35	35	NUM
admet-295	471	7	-	-	SYM
admet-295	471	8	51	51	NUM
admet-295	471	9	.	.	PUNCT
admet-295	472	1	[	[	X
admet-295	472	2	57	57	NUM
admet-295	472	3	]	]	PUNCT
admet-295	472	4	z.	z.	PROPN
admet-295	472	5	laksman	laksman	PROPN
admet-295	472	6	,	,	PUNCT
admet-295	472	7	b.	b.	PROPN
admet-295	472	8	momciu	momciu	PROPN
admet-295	472	9	,	,	PUNCT
admet-295	472	10	y.	y.	PROPN
admet-295	472	11	w.	w.	PROPN
admet-295	472	12	seong	seong	PROPN
admet-295	472	13	,	,	PUNCT
admet-295	472	14	p.	p.	PROPN
admet-295	472	15	burrows	burrow	NOUN
admet-295	472	16	,	,	PUNCT
admet-295	472	17	s.	s.	PROPN
admet-295	472	18	conacher	conacher	PROPN
admet-295	472	19	,	,	PUNCT
admet-295	472	20	j.	j.	PROPN
admet-295	472	21	manlucu	manlucu	PROPN
admet-295	472	22	,	,	PUNCT
admet-295	472	23	p.	p.	NOUN
admet-295	472	24	leong	leong	PROPN
admet-295	472	25	-	-	PUNCT
admet-295	472	26	sit	sit	PROPN
admet-295	472	27	,	,	PUNCT
admet-295	472	28	l.	l.	PROPN
admet-295	472	29	j.	j.	PROPN
admet-295	472	30	gula	gula	PROPN
admet-295	472	31	,	,	PUNCT
admet-295	472	32	a.	a.	PROPN
admet-295	472	33	c.	c.	PROPN
admet-295	472	34	skanes	skanes	PROPN
admet-295	472	35	,	,	PUNCT
admet-295	472	36	r.	r.	PROPN
admet-295	472	37	yee	yee	PROPN
admet-295	472	38	,	,	PUNCT
admet-295	472	39	g.	g.	PROPN
admet-295	472	40	j.	j.	PROPN
admet-295	472	41	klein	klein	PROPN
admet-295	472	42	,	,	PUNCT
admet-295	472	43	a.	a.	PROPN
admet-295	472	44	d.	d.	PROPN
admet-295	472	45	krahn	krahn	PROPN
admet-295	472	46	.	.	PUNCT
admet-295	473	1	am	be	AUX
admet-295	473	2	.	.	PUNCT
admet-295	474	1	j.	j.	PROPN
admet-295	474	2	cardiol	cardiol	PROPN
admet-295	474	3	.	.	PUNCT
admet-295	475	1	115(7	115(7	NUM
admet-295	475	2	)	)	PUNCT
admet-295	475	3	(	(	PUNCT
admet-295	475	4	2015	2015	NUM
admet-295	475	5	)	)	PUNCT
admet-295	475	6	907	907	NUM
admet-295	475	7	-	-	SYM
admet-295	475	8	911	911	NUM
admet-295	475	9	.	.	PUNCT
admet-295	476	1	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072002.pdf	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072002.pdf	PROPN
admet-295	476	2	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072002.pdf	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072002.pdf	PROPN
admet-295	476	3	rashmi	rashmi	PROPN
admet-295	476	4	shah	shah	PROPN
admet-295	476	5	admet	admet	PROPN
admet-295	476	6	&	&	CCONJ
admet-295	476	7	dmpk	dmpk	PROPN
admet-295	476	8	4(3	4(3	NUM
admet-295	476	9	)	)	PUNCT
admet-295	476	10	(	(	PUNCT
admet-295	476	11	2016	2016	NUM
admet-295	476	12	)	)	PUNCT
admet-295	476	13	212	212	NUM
admet-295	476	14	-	-	SYM
admet-295	476	15	231	231	NUM
admet-295	476	16	228	228	NUM
admet-295	477	1	[	[	X
admet-295	477	2	58	58	NUM
admet-295	477	3	]	]	PUNCT
admet-295	477	4	d.	d.	PROPN
admet-295	477	5	m.	m.	PROPN
admet-295	477	6	roden	roden	PROPN
admet-295	477	7	.	.	PUNCT
admet-295	478	1	j.	j.	PROPN
admet-295	478	2	physiol	physiol	PROPN
admet-295	478	3	.	.	PUNCT
admet-295	479	1	594(9	594(9	NUM
admet-295	479	2	)	)	PUNCT
admet-295	479	3	(	(	PUNCT
admet-295	479	4	2016	2016	NUM
admet-295	479	5	)	)	PUNCT
admet-295	479	6	2459	2459	NUM
admet-295	479	7	-	-	SYM
admet-295	479	8	2468	2468	NUM
admet-295	479	9	.	.	PUNCT
admet-295	480	1	[	[	X
admet-295	480	2	59	59	NUM
admet-295	480	3	]	]	PUNCT
admet-295	480	4	committee	committee	NOUN
admet-295	480	5	for	for	ADP
admet-295	480	6	proprietary	proprietary	ADJ
admet-295	480	7	medicinal	medicinal	ADJ
admet-295	480	8	products	product	NOUN
admet-295	480	9	(	(	PUNCT
admet-295	480	10	cpmp	cpmp	NOUN
admet-295	480	11	)	)	PUNCT
admet-295	480	12	.	.	PUNCT
admet-295	481	1	points	point	VERB
admet-295	481	2	to	to	PART
admet-295	481	3	consider	consider	VERB
admet-295	481	4	:	:	PUNCT
admet-295	481	5	the	the	DET
admet-295	481	6	assessment	assessment	NOUN
admet-295	481	7	of	of	ADP
admet-295	481	8	the	the	DET
admet-295	481	9	potential	potential	NOUN
admet-295	481	10	for	for	ADP
admet-295	481	11	qt	qt	NOUN
admet-295	481	12	interval	interval	NOUN
admet-295	481	13	prolongation	prolongation	NOUN
admet-295	481	14	by	by	ADP
admet-295	481	15	non	non	ADJ
admet-295	481	16	-	-	ADJ
admet-295	481	17	cardiovascular	cardiovascular	ADJ
admet-295	481	18	medicinal	medicinal	ADJ
admet-295	481	19	products	product	NOUN
admet-295	481	20	(	(	PUNCT
admet-295	481	21	cpmp/986/96	cpmp/986/96	PROPN
admet-295	481	22	)	)	PUNCT
admet-295	481	23	.	.	PUNCT
admet-295	482	1	european	european	PROPN
admet-295	482	2	medicines	medicines	PROPN
admet-295	482	3	agency	agency	PROPN
admet-295	482	4	,	,	PUNCT
admet-295	482	5	london	london	PROPN
admet-295	482	6	,	,	PUNCT
admet-295	482	7	17	17	NUM
admet-295	482	8	december	december	PROPN
admet-295	482	9	1997	1997	NUM
admet-295	482	10	.	.	PUNCT
admet-295	483	1	available	available	ADJ
admet-295	483	2	at	at	ADP
admet-295	483	3	:	:	PUNCT
admet-295	483	4	http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf	http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf	PROPN
admet-295	483	5	,	,	PUNCT
admet-295	483	6	[	[	X
admet-295	483	7	accessed	access	VERB
admet-295	483	8	on	on	ADP
admet-295	483	9	5	5	NUM
admet-295	483	10	april	april	PROPN
admet-295	483	11	2012	2012	NUM
admet-295	483	12	]	]	PUNCT
admet-295	484	1	[	[	X
admet-295	484	2	60	60	NUM
admet-295	484	3	]	]	X
admet-295	484	4	international	international	ADJ
admet-295	484	5	conference	conference	NOUN
admet-295	484	6	on	on	ADP
admet-295	484	7	harmonisation	harmonisation	NOUN
admet-295	484	8	(	(	PUNCT
admet-295	484	9	ich	ich	NOUN
admet-295	484	10	)	)	PUNCT
admet-295	484	11	.	.	PUNCT
admet-295	485	1	ich	ich	NOUN
admet-295	485	2	note	note	VERB
admet-295	485	3	for	for	ADP
admet-295	485	4	guidance	guidance	NOUN
admet-295	485	5	on	on	ADP
admet-295	485	6	:	:	PUNCT
admet-295	485	7	the	the	DET
admet-295	485	8	nonclinical	nonclinical	ADJ
admet-295	485	9	evaluation	evaluation	NOUN
admet-295	485	10	of	of	ADP
admet-295	485	11	the	the	DET
admet-295	485	12	potential	potential	NOUN
admet-295	485	13	for	for	ADP
admet-295	485	14	delayed	delay	VERB
admet-295	485	15	ventricular	ventricular	ADJ
admet-295	485	16	repolarization	repolarization	NOUN
admet-295	485	17	(	(	PUNCT
admet-295	485	18	qt	qt	NOUN
admet-295	485	19	interval	interval	NOUN
admet-295	485	20	prolongation	prolongation	PROPN
admet-295	485	21	)	)	PUNCT
admet-295	485	22	by	by	ADP
admet-295	485	23	human	human	ADJ
admet-295	485	24	pharmaceuticals	pharmaceutical	NOUN
admet-295	485	25	(	(	PUNCT
admet-295	485	26	ich	ich	PROPN
admet-295	485	27	s7b	s7b	PROPN
admet-295	485	28	)	)	PUNCT
admet-295	485	29	.	.	PUNCT
admet-295	486	1	international	international	ADJ
admet-295	486	2	conference	conference	NOUN
admet-295	486	3	on	on	ADP
admet-295	486	4	harmonisation	harmonisation	NOUN
admet-295	486	5	,	,	PUNCT
admet-295	486	6	geneva	geneva	PROPN
admet-295	486	7	,	,	PUNCT
admet-295	486	8	may	may	PROPN
admet-295	486	9	2005	2005	NUM
admet-295	486	10	.	.	PUNCT
admet-295	487	1	available	available	ADJ
admet-295	487	2	at	at	ADP
admet-295	487	3	:	:	PUNCT
admet-295	487	4	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/safety/s7b/step4/s7b_gu	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/safety/s7b/step4/s7b_gu	X
admet-295	487	5	ideline.pdf	ideline.pdf	X
admet-295	487	6	,	,	PUNCT
admet-295	487	7	[	[	X
admet-295	487	8	accessed	access	VERB
admet-295	487	9	on	on	ADP
admet-295	487	10	5	5	NUM
admet-295	487	11	march	march	NOUN
admet-295	487	12	2016	2016	NUM
admet-295	487	13	]	]	PUNCT
admet-295	488	1	[	[	X
admet-295	488	2	61	61	NUM
admet-295	488	3	]	]	X
admet-295	488	4	international	international	ADJ
admet-295	488	5	conference	conference	NOUN
admet-295	488	6	on	on	ADP
admet-295	488	7	harmonisation	harmonisation	NOUN
admet-295	488	8	(	(	PUNCT
admet-295	488	9	ich	ich	NOUN
admet-295	488	10	)	)	PUNCT
admet-295	488	11	.	.	PUNCT
admet-295	489	1	ich	ich	NOUN
admet-295	489	2	note	note	VERB
admet-295	489	3	for	for	ADP
admet-295	489	4	guidance	guidance	NOUN
admet-295	489	5	on	on	ADP
admet-295	489	6	:	:	PUNCT
admet-295	489	7	the	the	DET
admet-295	489	8	clinical	clinical	ADJ
admet-295	489	9	evaluation	evaluation	NOUN
admet-295	489	10	of	of	ADP
admet-295	489	11	qt	qt	PROPN
admet-295	489	12	/	/	SYM
admet-295	489	13	qtc	qtc	PROPN
admet-295	489	14	interval	interval	NOUN
admet-295	489	15	prolongation	prolongation	NOUN
admet-295	489	16	and	and	CCONJ
admet-295	489	17	proarrhythmic	proarrhythmic	ADJ
admet-295	489	18	potential	potential	NOUN
admet-295	489	19	for	for	ADP
admet-295	489	20	non	non	ADJ
admet-295	489	21	-	-	ADJ
admet-295	489	22	antiarrhythmic	antiarrhythmic	ADJ
admet-295	489	23	drugs	drug	NOUN
admet-295	489	24	(	(	PUNCT
admet-295	489	25	ich	ich	NOUN
admet-295	489	26	e14	e14	PROPN
admet-295	489	27	)	)	PUNCT
admet-295	489	28	.	.	PUNCT
admet-295	490	1	international	international	ADJ
admet-295	490	2	conference	conference	NOUN
admet-295	490	3	on	on	ADP
admet-295	490	4	harmonisation	harmonisation	NOUN
admet-295	490	5	,	,	PUNCT
admet-295	490	6	geneva	geneva	PROPN
admet-295	490	7	,	,	PUNCT
admet-295	490	8	may	may	PROPN
admet-295	490	9	2005	2005	NUM
admet-295	490	10	.	.	PUNCT
admet-295	491	1	available	available	ADJ
admet-295	491	2	at	at	ADP
admet-295	491	3	:	:	PUNCT
admet-295	491	4	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_guideli	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_guideli	ADJ
admet-295	491	5	ne.pdf	ne.pdf	NOUN
admet-295	491	6	,	,	PUNCT
admet-295	491	7	[	[	X
admet-295	491	8	accessed	access	VERB
admet-295	491	9	on	on	ADP
admet-295	491	10	5	5	NUM
admet-295	491	11	march	march	NOUN
admet-295	491	12	2016	2016	NUM
admet-295	491	13	]	]	PUNCT
admet-295	492	1	[	[	X
admet-295	492	2	62	62	NUM
admet-295	492	3	]	]	X
admet-295	492	4	international	international	ADJ
admet-295	492	5	council	council	NOUN
admet-295	492	6	for	for	ADP
admet-295	492	7	harmonisation	harmonisation	NOUN
admet-295	492	8	(	(	PUNCT
admet-295	492	9	ich	ich	NOUN
admet-295	492	10	)	)	PUNCT
admet-295	492	11	.	.	PUNCT
admet-295	493	1	ich	ich	NOUN
admet-295	493	2	e14	e14	PROPN
admet-295	493	3	implementation	implementation	NOUN
admet-295	493	4	working	working	NOUN
admet-295	493	5	group	group	NOUN
admet-295	493	6	.	.	PUNCT
admet-295	494	1	ich	ich	PROPN
admet-295	494	2	e14	e14	PROPN
admet-295	494	3	guideline	guideline	NOUN
admet-295	494	4	:	:	PUNCT
admet-295	494	5	the	the	DET
admet-295	494	6	clinical	clinical	ADJ
admet-295	494	7	evaluation	evaluation	NOUN
admet-295	494	8	of	of	ADP
admet-295	494	9	qt	qt	PROPN
admet-295	494	10	/	/	SYM
admet-295	494	11	qtc	qtc	PROPN
admet-295	494	12	interval	interval	NOUN
admet-295	494	13	prolongation	prolongation	NOUN
admet-295	494	14	and	and	CCONJ
admet-295	494	15	proarrhythmic	proarrhythmic	ADJ
admet-295	494	16	potential	potential	NOUN
admet-295	494	17	for	for	ADP
admet-295	494	18	non	non	ADJ
admet-295	494	19	-	-	ADJ
admet-295	494	20	antiarrhythmic	antiarrhythmic	ADJ
admet-295	494	21	drugs	drug	NOUN
admet-295	494	22	.	.	PUNCT
admet-295	495	1	questions	question	NOUN
admet-295	495	2	&	&	CCONJ
admet-295	495	3	answers	answer	NOUN
admet-295	495	4	(	(	PUNCT
admet-295	495	5	r3	r3	PROPN
admet-295	495	6	)	)	PUNCT
admet-295	495	7	.	.	PUNCT
admet-295	496	1	international	international	ADJ
admet-295	496	2	council	council	PROPN
admet-295	496	3	for	for	ADP
admet-295	496	4	harmonisation	harmonisation	NOUN
admet-295	496	5	,	,	PUNCT
admet-295	496	6	geneva	geneva	PROPN
admet-295	496	7	,	,	PUNCT
admet-295	496	8	december	december	PROPN
admet-295	496	9	2015	2015	NUM
admet-295	496	10	.	.	PUNCT
admet-295	497	1	available	available	ADJ
admet-295	497	2	at	at	ADP
admet-295	497	3	:	:	PUNCT
admet-295	497	4	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_q_as_r	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_q_as_r	PROPN
admet-295	497	5	3__step4.pdf	3__step4.pdf	NUM
admet-295	497	6	,	,	PUNCT
admet-295	497	7	[	[	X
admet-295	497	8	accessed	access	VERB
admet-295	497	9	on	on	ADP
admet-295	497	10	5	5	NUM
admet-295	497	11	march	march	NOUN
admet-295	497	12	2016	2016	NUM
admet-295	497	13	]	]	PUNCT
admet-295	498	1	[	[	X
admet-295	498	2	63	63	NUM
admet-295	498	3	]	]	PUNCT
admet-295	498	4	r.	r.	PROPN
admet-295	498	5	r.	r.	PROPN
admet-295	498	6	shah	shah	PROPN
admet-295	498	7	.	.	PUNCT
admet-295	499	1	br	br	PROPN
admet-295	499	2	.	.	PUNCT
admet-295	500	1	j.	j.	PROPN
admet-295	500	2	clin	clin	PROPN
admet-295	500	3	.	.	PUNCT
admet-295	501	1	pharmacol	pharmacol	PROPN
admet-295	501	2	.	.	PUNCT
admet-295	502	1	54(2	54(2	NUM
admet-295	502	2	)	)	PUNCT
admet-295	502	3	(	(	PUNCT
admet-295	502	4	2002	2002	NUM
admet-295	502	5	)	)	PUNCT
admet-295	502	6	188	188	NUM
admet-295	502	7	-	-	SYM
admet-295	502	8	202	202	NUM
admet-295	502	9	.	.	PUNCT
admet-295	503	1	[	[	X
admet-295	503	2	64	64	NUM
admet-295	503	3	]	]	X
admet-295	503	4	y.	y.	PROPN
admet-295	503	5	l.	l.	PROPN
admet-295	503	6	lin	lin	PROPN
admet-295	503	7	,	,	PUNCT
admet-295	503	8	m.	m.	PROPN
admet-295	503	9	f.	f.	PROPN
admet-295	503	10	kung	kung	PROPN
admet-295	503	11	.	.	PUNCT
admet-295	503	12	pharmacoepidemiol	pharmacoepidemiol	PROPN
admet-295	503	13	.	.	PUNCT
admet-295	504	1	drug	drug	PROPN
admet-295	504	2	saf	saf	PROPN
admet-295	504	3	.	.	PROPN
admet-295	504	4	18(3	18(3	NUM
admet-295	504	5	)	)	PUNCT
admet-295	504	6	(	(	PUNCT
admet-295	504	7	2009	2009	NUM
admet-295	504	8	)	)	PUNCT
admet-295	504	9	235	235	NUM
admet-295	504	10	-	-	SYM
admet-295	504	11	239	239	NUM
admet-295	504	12	.	.	PUNCT
admet-295	505	1	[	[	X
admet-295	505	2	65	65	NUM
admet-295	505	3	]	]	X
admet-295	505	4	e.	e.	PROPN
admet-295	505	5	i.	i.	PROPN
admet-295	505	6	heath	heath	PROPN
admet-295	505	7	,	,	PUNCT
admet-295	505	8	j.	j.	PROPN
admet-295	505	9	infante	infante	PROPN
admet-295	505	10	,	,	PUNCT
admet-295	505	11	l.	l.	PROPN
admet-295	505	12	d.	d.	PROPN
admet-295	505	13	lewis	lewis	PROPN
admet-295	505	14	,	,	PUNCT
admet-295	505	15	t.	t.	PROPN
admet-295	505	16	luu	luu	PROPN
admet-295	505	17	,	,	PUNCT
admet-295	505	18	j.	j.	PROPN
admet-295	505	19	stephenson	stephenson	PROPN
admet-295	505	20	,	,	PUNCT
admet-295	505	21	a.	a.	PROPN
admet-295	505	22	r.	r.	PROPN
admet-295	505	23	tan	tan	PROPN
admet-295	505	24	,	,	PUNCT
admet-295	505	25	s.	s.	PROPN
admet-295	505	26	kasubhai	kasubhai	PROPN
admet-295	505	27	,	,	PUNCT
admet-295	505	28	p.	p.	PROPN
admet-295	505	29	lorusso	lorusso	PROPN
admet-295	505	30	,	,	PUNCT
admet-295	505	31	b.	b.	PROPN
admet-295	505	32	ma	ma	PROPN
admet-295	505	33	,	,	PUNCT
admet-295	505	34	a.	a.	PROPN
admet-295	505	35	b.	b.	PROPN
admet-295	505	36	suttle	suttle	PROPN
admet-295	505	37	,	,	PUNCT
admet-295	505	38	j.	j.	PROPN
admet-295	505	39	f.	f.	PROPN
admet-295	505	40	kleha	kleha	PROPN
admet-295	505	41	,	,	PUNCT
admet-295	505	42	h.	h.	PROPN
admet-295	505	43	a.	a.	NOUN
admet-295	505	44	ball	ball	PROPN
admet-295	505	45	,	,	PUNCT
admet-295	505	46	m.	m.	NOUN
admet-295	505	47	m.	m.	PROPN
admet-295	505	48	dar	dar	PROPN
admet-295	505	49	.	.	PUNCT
admet-295	505	50	cancer	cancer	PROPN
admet-295	505	51	chemother	chemother	PROPN
admet-295	505	52	.	.	PUNCT
admet-295	506	1	pharmacol	pharmacol	PROPN
admet-295	506	2	.	.	PUNCT
admet-295	507	1	71(3	71(3	NUM
admet-295	507	2	)	)	PUNCT
admet-295	507	3	(	(	PUNCT
admet-295	507	4	2013	2013	NUM
admet-295	507	5	)	)	PUNCT
admet-295	507	6	565	565	NUM
admet-295	507	7	-	-	SYM
admet-295	507	8	573	573	NUM
admet-295	507	9	.	.	PUNCT
admet-295	508	1	[	[	X
admet-295	508	2	66	66	NUM
admet-295	508	3	]	]	PUNCT
admet-295	508	4	k.	k.	PROPN
admet-295	508	5	s.	s.	PROPN
admet-295	508	6	kloth	kloth	PROPN
admet-295	508	7	,	,	PUNCT
admet-295	508	8	a.	a.	NOUN
admet-295	508	9	pagani	pagani	PROPN
admet-295	508	10	,	,	PUNCT
admet-295	508	11	m.	m.	PROPN
admet-295	508	12	c.	c.	PROPN
admet-295	508	13	verboom	verboom	PROPN
admet-295	508	14	,	,	PUNCT
admet-295	508	15	a.	a.	PROPN
admet-295	508	16	malovini	malovini	PROPN
admet-295	508	17	,	,	PUNCT
admet-295	508	18	c.	c.	PROPN
admet-295	508	19	napolitano	napolitano	PROPN
admet-295	508	20	,	,	PUNCT
admet-295	508	21	w.	w.	PROPN
admet-295	508	22	h.	h.	PROPN
admet-295	508	23	kruit	kruit	PROPN
admet-295	508	24	,	,	PUNCT
admet-295	508	25	s.	s.	PROPN
admet-295	508	26	sleijfer	sleijfer	VERB
admet-295	508	27	,	,	PUNCT
admet-295	508	28	n.	n.	NOUN
admet-295	508	29	steeghs	steeghs	PROPN
admet-295	508	30	,	,	PUNCT
admet-295	508	31	a.	a.	NOUN
admet-295	508	32	zambelli	zambelli	PROPN
admet-295	508	33	,	,	PUNCT
admet-295	508	34	r.	r.	PROPN
admet-295	508	35	h.	h.	PROPN
admet-295	508	36	mathijssen	mathijssen	PROPN
admet-295	508	37	.	.	PUNCT
admet-295	509	1	br	br	PROPN
admet-295	509	2	.	.	PUNCT
admet-295	510	1	j.	j.	PROPN
admet-295	510	2	cancer	cancer	PROPN
admet-295	510	3	112(6	112(6	NUM
admet-295	510	4	)	)	PUNCT
admet-295	510	5	(	(	PUNCT
admet-295	510	6	2015	2015	NUM
admet-295	510	7	)	)	PUNCT
admet-295	510	8	1011	1011	NUM
admet-295	510	9	-	-	SYM
admet-295	510	10	1016	1016	NUM
admet-295	510	11	.	.	PUNCT
admet-295	511	1	[	[	X
admet-295	511	2	67	67	NUM
admet-295	511	3	]	]	PUNCT
admet-295	511	4	z.	z.	PROPN
admet-295	511	5	lu	lu	PROPN
admet-295	511	6	,	,	PUNCT
admet-295	511	7	c.	c.	PROPN
admet-295	511	8	y.	y.	PROPN
admet-295	511	9	wu	wu	PROPN
admet-295	511	10	,	,	PUNCT
admet-295	511	11	y.	y.	PROPN
admet-295	511	12	p.	p.	PROPN
admet-295	511	13	jiang	jiang	PROPN
admet-295	511	14	,	,	PUNCT
admet-295	511	15	l.	l.	PROPN
admet-295	511	16	m.	m.	PROPN
admet-295	511	17	ballou	ballou	PROPN
admet-295	511	18	,	,	PUNCT
admet-295	511	19	c.	c.	PROPN
admet-295	511	20	clausen	clausen	PROPN
admet-295	511	21	,	,	PUNCT
admet-295	511	22	i.	i.	PROPN
admet-295	511	23	s.	s.	PROPN
admet-295	511	24	cohen	cohen	PROPN
admet-295	511	25	,	,	PUNCT
admet-295	511	26	r.	r.	PROPN
admet-295	511	27	z.	z.	PROPN
admet-295	511	28	lin	lin	PROPN
admet-295	511	29	.	.	PUNCT
admet-295	512	1	sci	sci	PROPN
admet-295	512	2	.	.	PROPN
admet-295	512	3	transl	transl	PROPN
admet-295	512	4	.	.	PUNCT
admet-295	513	1	med	med	PROPN
admet-295	513	2	.	.	PUNCT
admet-295	514	1	4(131	4(131	NUM
admet-295	514	2	)	)	PUNCT
admet-295	514	3	(	(	PUNCT
admet-295	514	4	2012	2012	NUM
admet-295	514	5	)	)	PUNCT
admet-295	515	1	131ra50	131ra50	NUM
admet-295	515	2	.	.	PUNCT
admet-295	516	1	[	[	X
admet-295	516	2	68	68	NUM
admet-295	516	3	]	]	X
admet-295	516	4	l.	l.	PROPN
admet-295	516	5	m.	m.	PROPN
admet-295	516	6	ballou	ballou	PROPN
admet-295	516	7	,	,	PUNCT
admet-295	516	8	r.	r.	PROPN
admet-295	516	9	z.	z.	PROPN
admet-295	516	10	lin	lin	PROPN
admet-295	516	11	,	,	PUNCT
admet-295	516	12	i.	i.	PROPN
admet-295	516	13	s.	s.	PROPN
admet-295	516	14	cohen	cohen	PROPN
admet-295	516	15	.	.	PUNCT
admet-295	517	1	circ	circ	PROPN
admet-295	517	2	.	.	PUNCT
admet-295	518	1	res	re	NOUN
admet-295	518	2	.	.	PUNCT
admet-295	519	1	116(1	116(1	NUM
admet-295	519	2	)	)	PUNCT
admet-295	519	3	(	(	PUNCT
admet-295	519	4	2015	2015	NUM
admet-295	519	5	)	)	PUNCT
admet-295	519	6	127	127	NUM
admet-295	519	7	-	-	SYM
admet-295	519	8	137	137	NUM
admet-295	519	9	.	.	PUNCT
admet-295	520	1	[	[	X
admet-295	520	2	69	69	NUM
admet-295	520	3	]	]	PUNCT
admet-295	520	4	j.	j.	PROPN
admet-295	520	5	s.	s.	PROPN
admet-295	520	6	lowe	lowe	PROPN
admet-295	520	7	,	,	PUNCT
admet-295	520	8	d.	d.	PROPN
admet-295	520	9	m.	m.	PROPN
admet-295	520	10	stroud	stroud	PROPN
admet-295	520	11	,	,	PUNCT
admet-295	520	12	t.	t.	PROPN
admet-295	520	13	yang	yang	PROPN
admet-295	520	14	,	,	PUNCT
admet-295	520	15	l.	l.	PROPN
admet-295	520	16	hall	hall	PROPN
admet-295	520	17	,	,	PUNCT
admet-295	520	18	t.	t.	PROPN
admet-295	520	19	c.	c.	PROPN
admet-295	520	20	atack	atack	PROPN
admet-295	520	21	,	,	PUNCT
admet-295	520	22	d.	d.	PROPN
admet-295	520	23	m.	m.	PROPN
admet-295	520	24	roden	roden	PROPN
admet-295	520	25	.	.	PUNCT
admet-295	521	1	cardiovasc	cardiovasc	PROPN
admet-295	521	2	.	.	PUNCT
admet-295	522	1	res	re	NOUN
admet-295	522	2	.	.	PUNCT
admet-295	523	1	95(3	95(3	NUM
admet-295	523	2	)	)	PUNCT
admet-295	523	3	(	(	PUNCT
admet-295	523	4	2012	2012	NUM
admet-295	523	5	)	)	PUNCT
admet-295	523	6	300307	300307	NUM
admet-295	523	7	.	.	PUNCT
admet-295	524	1	[	[	X
admet-295	524	2	70	70	X
admet-295	524	3	]	]	X
admet-295	524	4	d.	d.	PROPN
admet-295	524	5	h.	h.	PROPN
admet-295	524	6	staniforth	staniforth	PROPN
admet-295	524	7	.	.	PUNCT
admet-295	525	1	br	br	PROPN
admet-295	525	2	.	.	PUNCT
admet-295	526	1	j.	j.	PROPN
admet-295	526	2	clin	clin	PROPN
admet-295	526	3	.	.	PUNCT
admet-295	527	1	pharmacol	pharmacol	PROPN
admet-295	527	2	.	.	PUNCT
admet-295	528	1	16(6	16(6	NUM
admet-295	528	2	)	)	PUNCT
admet-295	528	3	(	(	PUNCT
admet-295	528	4	1983	1983	NUM
admet-295	528	5	)	)	PUNCT
admet-295	528	6	615	615	NUM
admet-295	528	7	-	-	SYM
admet-295	528	8	621	621	NUM
admet-295	528	9	.	.	PUNCT
admet-295	529	1	[	[	X
admet-295	529	2	71	71	NUM
admet-295	529	3	]	]	X
admet-295	529	4	d.	d.	PROPN
admet-295	529	5	h.	h.	PROPN
admet-295	529	6	staniforth	staniforth	PROPN
admet-295	529	7	.	.	PUNCT
admet-295	530	1	br	br	PROPN
admet-295	530	2	.	.	PUNCT
admet-295	531	1	j.	j.	PROPN
admet-295	531	2	clin	clin	PROPN
admet-295	531	3	.	.	PUNCT
admet-295	532	1	pharmacol	pharmacol	PROPN
admet-295	532	2	.	.	PUNCT
admet-295	533	1	19(6	19(6	NUM
admet-295	533	2	)	)	PUNCT
admet-295	533	3	(	(	PUNCT
admet-295	533	4	1985	1985	NUM
admet-295	533	5	)	)	PUNCT
admet-295	533	6	862	862	NUM
admet-295	533	7	.	.	PUNCT
admet-295	534	1	[	[	X
admet-295	534	2	72	72	NUM
admet-295	534	3	]	]	PUNCT
admet-295	534	4	m.	m.	NOUN
admet-295	534	5	malik	malik	PROPN
admet-295	534	6	.	.	PUNCT
admet-295	535	1	pacing	pace	VERB
admet-295	535	2	clin	clin	PROPN
admet-295	535	3	.	.	PUNCT
admet-295	536	1	electrophysiol	electrophysiol	PROPN
admet-295	536	2	.	.	PUNCT
admet-295	537	1	25(2	25(2	NUM
admet-295	537	2	)	)	PUNCT
admet-295	537	3	(	(	PUNCT
admet-295	537	4	2002	2002	NUM
admet-295	537	5	)	)	PUNCT
admet-295	537	6	209	209	NUM
admet-295	537	7	-	-	SYM
admet-295	537	8	216	216	NUM
admet-295	537	9	.	.	PUNCT
admet-295	538	1	[	[	X
admet-295	538	2	73	73	NUM
admet-295	538	3	]	]	PUNCT
admet-295	538	4	m.	m.	PROPN
admet-295	538	5	desai	desai	PROPN
admet-295	538	6	,	,	PUNCT
admet-295	538	7	l.	l.	PROPN
admet-295	538	8	li	li	PROPN
admet-295	538	9	,	,	PUNCT
admet-295	538	10	z.	z.	PROPN
admet-295	538	11	desta	desta	PROPN
admet-295	538	12	,	,	PUNCT
admet-295	538	13	m.	m.	PROPN
admet-295	538	14	malik	malik	PROPN
admet-295	538	15	,	,	PUNCT
admet-295	538	16	d.	d.	PROPN
admet-295	538	17	flockhart	flockhart	PROPN
admet-295	538	18	.	.	PUNCT
admet-295	539	1	br	br	PROPN
admet-295	539	2	.	.	PUNCT
admet-295	540	1	j.	j.	PROPN
admet-295	540	2	clin	clin	PROPN
admet-295	540	3	.	.	PUNCT
admet-295	541	1	pharmacol	pharmacol	PROPN
admet-295	541	2	.	.	PUNCT
admet-295	542	1	55(6	55(6	NUM
admet-295	542	2	)	)	PUNCT
admet-295	543	1	(	(	PUNCT
admet-295	543	2	2003	2003	NUM
admet-295	543	3	)	)	PUNCT
admet-295	543	4	511	511	NUM
admet-295	543	5	-	-	SYM
admet-295	543	6	517	517	NUM
admet-295	543	7	.	.	PUNCT
admet-295	544	1	[	[	X
admet-295	544	2	74	74	NUM
admet-295	544	3	]	]	X
admet-295	544	4	national	national	PROPN
admet-295	544	5	cancer	cancer	PROPN
admet-295	544	6	institute	institute	PROPN
admet-295	544	7	.	.	PUNCT
admet-295	545	1	common	common	ADJ
admet-295	545	2	terminology	terminology	NOUN
admet-295	545	3	criteria	criterion	NOUN
admet-295	545	4	for	for	ADP
admet-295	545	5	adverse	adverse	ADJ
admet-295	545	6	events	event	NOUN
admet-295	545	7	(	(	PUNCT
admet-295	545	8	ctcae	ctcae	NOUN
admet-295	545	9	):	):	PUNCT
admet-295	545	10	version	version	NOUN
admet-295	545	11	4.0	4.0	NUM
admet-295	545	12	published	publish	VERB
admet-295	545	13	:	:	PUNCT
admet-295	545	14	may	may	AUX
admet-295	545	15	28	28	NUM
admet-295	545	16	,	,	PUNCT
admet-295	545	17	2009	2009	NUM
admet-295	545	18	(	(	PUNCT
admet-295	545	19	v4.03	v4.03	NOUN
admet-295	545	20	:	:	PUNCT
admet-295	545	21	june	june	PROPN
admet-295	545	22	14	14	NUM
admet-295	545	23	,	,	PUNCT
admet-295	545	24	2010	2010	NUM
admet-295	545	25	)	)	PUNCT
admet-295	545	26	.	.	PUNCT
admet-295	546	1	available	available	ADJ
admet-295	546	2	at	at	ADP
admet-295	546	3	:	:	PUNCT
admet-295	546	4	http://evs.nci.nih.gov/ftp1/ctcae/ctcae_4.03_2010-06-14_quickreference_5x7.pdf	http://evs.nci.nih.gov/ftp1/ctcae/ctcae_4.03_2010-06-14_quickreference_5x7.pdf	NUM
admet-295	546	5	,	,	PUNCT
admet-295	546	6	[	[	X
admet-295	546	7	accessed	access	VERB
admet-295	546	8	on	on	ADP
admet-295	546	9	2	2	NUM
admet-295	546	10	march	march	NOUN
admet-295	546	11	2016	2016	NUM
admet-295	546	12	]	]	PUNCT
admet-295	547	1	[	[	X
admet-295	547	2	75	75	NUM
admet-295	547	3	]	]	PUNCT
admet-295	547	4	m.	m.	NOUN
admet-295	547	5	schmidinger	schmidinger	PROPN
admet-295	547	6	,	,	PUNCT
admet-295	547	7	c.	c.	PROPN
admet-295	547	8	c.	c.	PROPN
admet-295	547	9	zielinski	zielinski	PROPN
admet-295	547	10	,	,	PUNCT
admet-295	547	11	u.	u.	PROPN
admet-295	547	12	m.	m.	PROPN
admet-295	547	13	vogl	vogl	PROPN
admet-295	547	14	,	,	PUNCT
admet-295	547	15	a.	a.	NOUN
admet-295	547	16	bojic	bojic	NOUN
admet-295	547	17	,	,	PUNCT
admet-295	547	18	m.	m.	NOUN
admet-295	547	19	bojic	bojic	NOUN
admet-295	547	20	,	,	PUNCT
admet-295	547	21	c.	c.	PROPN
admet-295	547	22	schukro	schukro	PROPN
admet-295	547	23	,	,	PUNCT
admet-295	547	24	m.	m.	NOUN
admet-295	547	25	ruhsam	ruhsam	PROPN
admet-295	547	26	,	,	PUNCT
admet-295	547	27	m.	m.	NOUN
admet-295	547	28	hejna	hejna	NOUN
admet-295	547	29	,	,	PUNCT
admet-295	547	30	h.	h.	PROPN
admet-295	547	31	schmidinger	schmidinger	PROPN
admet-295	547	32	.	.	PUNCT
admet-295	548	1	j.	j.	PROPN
admet-295	548	2	clin	clin	PROPN
admet-295	548	3	.	.	PUNCT
admet-295	549	1	oncol	oncol	ADJ
admet-295	549	2	.	.	PUNCT
admet-295	550	1	26(32	26(32	NUM
admet-295	550	2	)	)	PUNCT
admet-295	550	3	(	(	PUNCT
admet-295	550	4	2008	2008	NUM
admet-295	550	5	)	)	PUNCT
admet-295	550	6	5204	5204	NUM
admet-295	550	7	-	-	SYM
admet-295	550	8	5212	5212	NUM
admet-295	550	9	.	.	PUNCT
admet-295	551	1	[	[	X
admet-295	551	2	76	76	X
admet-295	551	3	]	]	X
admet-295	551	4	p.	p.	PROPN
admet-295	551	5	s.	s.	PROPN
admet-295	551	6	hall	hall	PROPN
admet-295	551	7	,	,	PUNCT
admet-295	551	8	l.	l.	PROPN
admet-295	551	9	c.	c.	PROPN
admet-295	551	10	harshman	harshman	PROPN
admet-295	551	11	,	,	PUNCT
admet-295	551	12	s.	s.	PROPN
admet-295	551	13	srinivas	srinivas	PROPN
admet-295	551	14	,	,	PUNCT
admet-295	551	15	r.	r.	PROPN
admet-295	551	16	m.	m.	PROPN
admet-295	551	17	witteles	wittele	NOUN
admet-295	551	18	.	.	PUNCT
admet-295	552	1	jacc	jacc	PROPN
admet-295	552	2	heart	heart	NOUN
admet-295	552	3	fail	fail	VERB
admet-295	552	4	.	.	PUNCT
admet-295	553	1	1(1	1(1	NUM
admet-295	553	2	)	)	PUNCT
admet-295	553	3	(	(	PUNCT
admet-295	553	4	2013	2013	NUM
admet-295	553	5	)	)	PUNCT
admet-295	553	6	72	72	NUM
admet-295	553	7	-	-	SYM
admet-295	553	8	78	78	NUM
admet-295	553	9	.	.	PUNCT
admet-295	554	1	[	[	X
admet-295	554	2	77	77	NUM
admet-295	554	3	]	]	X
admet-295	554	4	s.	s.	PROPN
admet-295	554	5	moustafa	moustafa	PROPN
admet-295	554	6	,	,	PUNCT
admet-295	554	7	t.	t.	PROPN
admet-295	554	8	h.	h.	PROPN
admet-295	554	9	ho	ho	PROPN
admet-295	554	10	,	,	PUNCT
admet-295	554	11	p.	p.	NOUN
admet-295	554	12	shah	shah	PROPN
admet-295	554	13	,	,	PUNCT
admet-295	554	14	k.	k.	PROPN
admet-295	554	15	murphy	murphy	PROPN
admet-295	554	16	,	,	PUNCT
admet-295	554	17	b.	b.	PROPN
admet-295	554	18	k.	k.	PROPN
admet-295	554	19	nelluri	nelluri	PROPN
admet-295	554	20	,	,	PUNCT
admet-295	554	21	h.	h.	PROPN
admet-295	554	22	lee	lee	PROPN
admet-295	554	23	,	,	PUNCT
admet-295	554	24	s.	s.	PROPN
admet-295	554	25	wilansky	wilansky	PROPN
admet-295	554	26	,	,	PUNCT
admet-295	554	27	f.	f.	PROPN
admet-295	554	28	mookadam	mookadam	PROPN
admet-295	554	29	.	.	PUNCT
admet-295	555	1	j.	j.	PROPN
admet-295	555	2	clin	clin	PROPN
admet-295	555	3	.	.	PUNCT
admet-295	556	1	ultrasound	ultrasound	PROPN
admet-295	556	2	44(4	44(4	PROPN
admet-295	556	3	)	)	PUNCT
admet-295	556	4	(	(	PUNCT
admet-295	556	5	2016	2016	NUM
admet-295	556	6	)	)	PUNCT
admet-295	556	7	221	221	NUM
admet-295	556	8	-	-	SYM
admet-295	556	9	230	230	NUM
admet-295	556	10	.	.	PUNCT
admet-295	557	1	[	[	X
admet-295	557	2	78	78	NUM
admet-295	557	3	]	]	X
admet-295	557	4	c.	c.	PROPN
admet-295	557	5	cheng	cheng	PROPN
admet-295	557	6	,	,	PUNCT
admet-295	557	7	t.	t.	NOUN
admet-295	557	8	force	force	NOUN
admet-295	557	9	.	.	PUNCT
admet-295	558	1	prog	prog	PROPN
admet-295	558	2	.	.	PUNCT
admet-295	559	1	cardiovasc	cardiovasc	PROPN
admet-295	559	2	.	.	PUNCT
admet-295	560	1	dis	dis	PROPN
admet-295	560	2	.	.	PUNCT
admet-295	561	1	53(2	53(2	NUM
admet-295	561	2	)	)	PUNCT
admet-295	561	3	(	(	PUNCT
admet-295	561	4	2010	2010	NUM
admet-295	561	5	)	)	PUNCT
admet-295	561	6	114	114	NUM
admet-295	561	7	-	-	SYM
admet-295	561	8	120	120	NUM
admet-295	561	9	.	.	PUNCT
admet-295	562	1	[	[	X
admet-295	562	2	79	79	NUM
admet-295	562	3	]	]	PUNCT
admet-295	562	4	t.	t.	NOUN
admet-295	562	5	force	force	NOUN
admet-295	562	6	,	,	PUNCT
admet-295	562	7	k.	k.	PROPN
admet-295	562	8	l.	l.	PROPN
admet-295	562	9	kolaja	kolaja	PROPN
admet-295	562	10	.	.	PUNCT
admet-295	563	1	nat	nat	PROPN
admet-295	563	2	.	.	PUNCT
admet-295	564	1	rev	rev	PROPN
admet-295	564	2	.	.	PROPN
admet-295	564	3	drug	drug	NOUN
admet-295	564	4	discov	discov	NOUN
admet-295	564	5	.	.	PUNCT
admet-295	565	1	10(2	10(2	NUM
admet-295	565	2	)	)	PUNCT
admet-295	565	3	(	(	PUNCT
admet-295	565	4	2011	2011	NUM
admet-295	565	5	)	)	PUNCT
admet-295	565	6	111	111	NUM
admet-295	565	7	-	-	SYM
admet-295	565	8	126	126	NUM
admet-295	565	9	.	.	PUNCT
admet-295	566	1	http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf	http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf	PROPN
admet-295	566	2	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/safety/s7b/step4/s7b_guideline.pdf	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/safety/s7b/step4/s7b_guideline.pdf	PROPN
admet-295	566	3	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/safety/s7b/step4/s7b_guideline.pdf	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/safety/s7b/step4/s7b_guideline.pdf	PROPN
admet-295	566	4	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_guideline.pdf	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_guideline.pdf	PROPN
admet-295	566	5	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_guideline.pdf	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_guideline.pdf	PROPN
admet-295	566	6	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_q_as_r3__step4.pdf	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_q_as_r3__step4.pdf	PROPN
admet-295	566	7	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_q_as_r3__step4.pdf	http://www.ich.org/fileadmin/public_web_site/ich_products/guidelines/efficacy/e14/e14_q_as_r3__step4.pdf	PROPN
admet-295	566	8	http://evs.nci.nih.gov/ftp1/ctcae/ctcae_4.03_2010-06-14_quickreference_5x7.pdf	http://evs.nci.nih.gov/ftp1/ctcae/ctcae_4.03_2010-06-14_quickreference_5x7.pdf	PROPN
admet-295	566	9	admet	admet	PROPN
admet-295	566	10	&	&	CCONJ
admet-295	566	11	dmpk	dmpk	PROPN
admet-295	566	12	4(3	4(3	NUM
admet-295	566	13	)	)	PUNCT
admet-295	566	14	(	(	PUNCT
admet-295	566	15	2016	2016	NUM
admet-295	566	16	)	)	PUNCT
admet-295	566	17	212	212	NUM
admet-295	566	18	-	-	SYM
admet-295	566	19	231	231	NUM
admet-295	566	20	pkis	pki	NOUN
admet-295	566	21	and	and	CCONJ
admet-295	566	22	qt	qt	NOUN
admet-295	566	23	-	-	PUNCT
admet-295	566	24	phobia	phobia	NOUN
admet-295	566	25	doi	doi	NOUN
admet-295	566	26	:	:	PUNCT
admet-295	566	27	10.5599	10.5599	NUM
admet-295	566	28	/	/	SYM
admet-295	566	29	admet.4.3.295	admet.4.3.295	NOUN
admet-295	566	30	229	229	NUM
admet-295	567	1	[	[	X
admet-295	567	2	80	80	NUM
admet-295	567	3	]	]	PUNCT
admet-295	567	4	m.	m.	NOUN
admet-295	567	5	svoboda	svoboda	PROPN
admet-295	567	6	,	,	PUNCT
admet-295	567	7	a.	a.	NOUN
admet-295	567	8	poprach	poprach	NOUN
admet-295	567	9	,	,	PUNCT
admet-295	567	10	s.	s.	PROPN
admet-295	567	11	dobes	dobes	PROPN
admet-295	567	12	,	,	PUNCT
admet-295	567	13	i.	i.	PROPN
admet-295	567	14	kiss	kiss	PROPN
admet-295	567	15	,	,	PUNCT
admet-295	567	16	r.	r.	PROPN
admet-295	567	17	vyzula	vyzula	PROPN
admet-295	567	18	.	.	PUNCT
admet-295	568	1	cardiovasc	cardiovasc	PROPN
admet-295	568	2	.	.	PUNCT
admet-295	569	1	toxicol	toxicol	PROPN
admet-295	569	2	.	.	PUNCT
admet-295	570	1	12(3	12(3	NUM
admet-295	570	2	)	)	PUNCT
admet-295	570	3	(	(	PUNCT
admet-295	570	4	2012	2012	NUM
admet-295	570	5	)	)	PUNCT
admet-295	570	6	191	191	NUM
admet-295	570	7	-	-	SYM
admet-295	570	8	207	207	NUM
admet-295	570	9	.	.	PUNCT
admet-295	571	1	[	[	X
admet-295	571	2	81	81	NUM
admet-295	571	3	]	]	PUNCT
admet-295	571	4	f.	f.	PROPN
admet-295	571	5	jacob	jacob	PROPN
admet-295	571	6	,	,	PUNCT
admet-295	571	7	a.	a.	PROPN
admet-295	571	8	y.	y.	PROPN
admet-295	571	9	yonis	yonis	PROPN
admet-295	571	10	,	,	PUNCT
admet-295	571	11	f.	f.	PROPN
admet-295	571	12	cuello	cuello	PROPN
admet-295	571	13	,	,	PUNCT
admet-295	571	14	p.	p.	PROPN
admet-295	571	15	luther	luther	PROPN
admet-295	571	16	,	,	PUNCT
admet-295	571	17	t.	t.	PROPN
admet-295	571	18	schulze	schulze	NOUN
admet-295	571	19	,	,	PUNCT
admet-295	571	20	a.	a.	NOUN
admet-295	571	21	eder	eder	NOUN
admet-295	571	22	,	,	PUNCT
admet-295	571	23	t.	t.	PROPN
admet-295	571	24	streichert	streichert	NOUN
admet-295	571	25	,	,	PUNCT
admet-295	571	26	i.	i.	PROPN
admet-295	571	27	mannhardt	mannhardt	PROPN
admet-295	571	28	,	,	PUNCT
admet-295	571	29	m.	m.	PROPN
admet-295	571	30	n.	n.	PROPN
admet-295	571	31	hirt	hirt	PROPN
admet-295	571	32	,	,	PUNCT
admet-295	571	33	s.	s.	PROPN
admet-295	571	34	schaaf	schaaf	PROPN
admet-295	571	35	,	,	PUNCT
admet-295	571	36	j.	j.	PROPN
admet-295	571	37	stenzig	stenzig	PROPN
admet-295	571	38	,	,	PUNCT
admet-295	571	39	t.	t.	NOUN
admet-295	571	40	force	force	NOUN
admet-295	571	41	,	,	PUNCT
admet-295	571	42	t.	t.	NOUN
admet-295	571	43	eschenhagen	eschenhagen	PROPN
admet-295	571	44	,	,	PUNCT
admet-295	571	45	a.	a.	PROPN
admet-295	571	46	hansen	hansen	PROPN
admet-295	571	47	.	.	PUNCT
admet-295	572	1	plos	plos	PROPN
admet-295	572	2	.	.	PROPN
admet-295	573	1	one	one	NUM
admet-295	573	2	11(2	11(2	NOUN
admet-295	573	3	)	)	PUNCT
admet-295	573	4	(	(	PUNCT
admet-295	573	5	2016	2016	NUM
admet-295	573	6	)	)	PUNCT
admet-295	573	7	e0145937	e0145937	X
admet-295	573	8	.	.	PUNCT
admet-295	574	1	[	[	X
admet-295	574	2	82	82	NUM
admet-295	574	3	]	]	X
admet-295	574	4	pfizer	pfizer	NOUN
admet-295	574	5	limited	limited	ADJ
admet-295	574	6	.	.	PUNCT
admet-295	575	1	dear	dear	ADJ
admet-295	575	2	healthcare	healthcare	PROPN
admet-295	575	3	professional	professional	ADJ
admet-295	575	4	letter	letter	NOUN
admet-295	575	5	(	(	PUNCT
admet-295	575	6	13	13	NUM
admet-295	575	7	october	october	PROPN
admet-295	575	8	2015	2015	NUM
admet-295	575	9	)	)	PUNCT
admet-295	575	10	.	.	PUNCT
admet-295	576	1	“	"	PUNCT
admet-295	576	2	inclusion	inclusion	NOUN
admet-295	576	3	of	of	ADP
admet-295	576	4	a	a	DET
admet-295	576	5	new	new	ADJ
admet-295	576	6	warning	warning	NOUN
admet-295	576	7	regarding	regard	VERB
admet-295	576	8	cardiac	cardiac	ADJ
admet-295	576	9	failure	failure	NOUN
admet-295	576	10	”	"	PUNCT
admet-295	576	11	.	.	PUNCT
admet-295	576	12	available	available	ADJ
admet-295	576	13	at	at	ADP
admet-295	576	14	:	:	PUNCT
admet-295	576	15	https://assets.digital.cabinetoffice.gov.uk/media/56435e1340f0b674d3000024/xalnp36__uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	https://assets.digital.cabinetoffice.gov.uk/media/56435e1340f0b674d3000024/xalnp36__uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	PROPN
admet-295	576	16	,	,	PUNCT
admet-295	576	17	[	[	X
admet-295	576	18	accessed	access	VERB
admet-295	576	19	on	on	ADP
admet-295	576	20	22	22	NUM
admet-295	576	21	march	march	NOUN
admet-295	576	22	2016	2016	NUM
admet-295	576	23	]	]	PUNCT
admet-295	577	1	[	[	X
admet-295	577	2	83	83	NUM
admet-295	577	3	]	]	SYM
admet-295	577	4	food	food	NOUN
admet-295	577	5	and	and	CCONJ
admet-295	577	6	drug	drug	NOUN
admet-295	577	7	administration	administration	NOUN
admet-295	577	8	.	.	PUNCT
admet-295	578	1	crizotinib	crizotinib	PROPN
admet-295	578	2	(	(	PUNCT
admet-295	578	3	xalkori	xalkori	NOUN
admet-295	578	4	)	)	PUNCT
admet-295	578	5	label	label	NOUN
admet-295	578	6	(	(	PUNCT
admet-295	578	7	29	29	NUM
admet-295	578	8	april	april	PROPN
admet-295	578	9	2016	2016	NUM
admet-295	578	10	)	)	PUNCT
admet-295	578	11	.	.	PUNCT
admet-295	579	1	food	food	NOUN
admet-295	579	2	and	and	CCONJ
admet-295	579	3	drug	drug	NOUN
admet-295	579	4	administration	administration	NOUN
admet-295	579	5	,	,	PUNCT
admet-295	579	6	silver	silver	NOUN
admet-295	579	7	spring	spring	NOUN
admet-295	579	8	,	,	PUNCT
admet-295	579	9	md	md	PROPN
admet-295	579	10	20993	20993	NUM
admet-295	579	11	,	,	PUNCT
admet-295	579	12	usa	usa	PROPN
admet-295	579	13	.	.	PROPN
admet-295	579	14	available	available	ADJ
admet-295	579	15	at	at	ADP
admet-295	579	16	:	:	PUNCT
admet-295	579	17	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s017lbl.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s017lbl.pdf	NOUN
admet-295	579	18	,	,	PUNCT
admet-295	579	19	[	[	X
admet-295	579	20	accessed	access	VERB
admet-295	579	21	on	on	ADP
admet-295	579	22	22	22	NUM
admet-295	579	23	march	march	NOUN
admet-295	579	24	2016	2016	NUM
admet-295	579	25	]	]	PUNCT
admet-295	579	26	.	.	PUNCT
admet-295	580	1	[	[	X
admet-295	580	2	84	84	NUM
admet-295	580	3	]	]	X
admet-295	580	4	o.	o.	PROPN
admet-295	580	5	abdel	abdel	PROPN
admet-295	580	6	-	-	PUNCT
admet-295	580	7	rahman	rahman	PROPN
admet-295	580	8	,	,	PUNCT
admet-295	580	9	m.	m.	NOUN
admet-295	580	10	fouad	fouad	PROPN
admet-295	580	11	.	.	PUNCT
admet-295	581	1	crit	crit	PROPN
admet-295	581	2	.	.	PUNCT
admet-295	582	1	rev	rev	PROPN
admet-295	582	2	.	.	PROPN
admet-295	582	3	oncol	oncol	PROPN
admet-295	582	4	.	.	PUNCT
admet-295	582	5	hematol	hematol	NOUN
admet-295	582	6	.	.	PUNCT
admet-295	583	1	92(3	92(3	X
admet-295	583	2	)	)	PUNCT
admet-295	583	3	(	(	PUNCT
admet-295	583	4	2014	2014	NUM
admet-295	583	5	)	)	PUNCT
admet-295	583	6	194–207	194–207	NUM
admet-295	583	7	.	.	PUNCT
admet-295	584	1	[	[	X
admet-295	584	2	85	85	NUM
admet-295	584	3	]	]	X
admet-295	584	4	b.	b.	PROPN
admet-295	584	5	yang	yang	PROPN
admet-295	584	6	,	,	PUNCT
admet-295	584	7	t.	t.	PROPN
admet-295	584	8	papoian	papoian	PROPN
admet-295	584	9	.	.	PUNCT
admet-295	585	1	j.	j.	PROPN
admet-295	585	2	appl	appl	PROPN
admet-295	585	3	.	.	PUNCT
admet-295	586	1	toxicol	toxicol	PROPN
admet-295	586	2	.	.	PUNCT
admet-295	587	1	32(12	32(12	NUM
admet-295	587	2	)	)	PUNCT
admet-295	587	3	(	(	PUNCT
admet-295	587	4	2012	2012	NUM
admet-295	587	5	)	)	PUNCT
admet-295	587	6	945	945	NUM
admet-295	587	7	-	-	NUM
admet-295	587	8	951	951	NUM
admet-295	587	9	.	.	PUNCT
admet-295	588	1	[	[	X
admet-295	588	2	86	86	NUM
admet-295	588	3	]	]	SYM
admet-295	588	4	food	food	NOUN
admet-295	588	5	and	and	CCONJ
admet-295	588	6	drug	drug	NOUN
admet-295	588	7	administration	administration	NOUN
admet-295	588	8	.	.	PUNCT
admet-295	589	1	pharmacology	pharmacology	NOUN
admet-295	589	2	review	review	PROPN
admet-295	589	3	of	of	ADP
admet-295	589	4	osimertinib	osimertinib	NOUN
admet-295	589	5	(	(	PUNCT
admet-295	589	6	tagrisso	tagrisso	NOUN
admet-295	589	7	)	)	PUNCT
admet-295	589	8	.	.	PUNCT
admet-295	590	1	food	food	NOUN
admet-295	590	2	and	and	CCONJ
admet-295	590	3	drug	drug	NOUN
admet-295	590	4	administration	administration	NOUN
admet-295	590	5	,	,	PUNCT
admet-295	590	6	silver	silver	NOUN
admet-295	590	7	spring	spring	NOUN
admet-295	590	8	,	,	PUNCT
admet-295	590	9	md	md	PROPN
admet-295	590	10	20993	20993	NUM
admet-295	590	11	,	,	PUNCT
admet-295	590	12	usa	usa	PROPN
admet-295	590	13	.	.	PROPN
admet-295	590	14	available	available	ADJ
admet-295	590	15	at	at	ADP
admet-295	590	16	:	:	PUNCT
admet-295	590	17	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065orig1s000pharmr.pdf	NOUN
admet-295	590	18	,	,	PUNCT
admet-295	590	19	[	[	X
admet-295	590	20	accessed	access	VERB
admet-295	590	21	on	on	ADP
admet-295	590	22	22	22	NUM
admet-295	590	23	march	march	NOUN
admet-295	590	24	2016	2016	NUM
admet-295	590	25	]	]	PUNCT
admet-295	590	26	.	.	PUNCT
admet-295	591	1	[	[	X
admet-295	591	2	87	87	NUM
admet-295	591	3	]	]	SYM
admet-295	591	4	food	food	NOUN
admet-295	591	5	and	and	CCONJ
admet-295	591	6	drug	drug	NOUN
admet-295	591	7	administration	administration	NOUN
admet-295	591	8	.	.	PUNCT
admet-295	592	1	pharmacology	pharmacology	NOUN
admet-295	592	2	review	review	NOUN
admet-295	592	3	of	of	ADP
admet-295	592	4	cobimetinib	cobimetinib	PROPN
admet-295	592	5	(	(	PUNCT
admet-295	592	6	cotellic	cotellic	NOUN
admet-295	592	7	)	)	PUNCT
admet-295	592	8	.	.	PUNCT
admet-295	593	1	food	food	NOUN
admet-295	593	2	and	and	CCONJ
admet-295	593	3	drug	drug	NOUN
admet-295	593	4	administration	administration	NOUN
admet-295	593	5	,	,	PUNCT
admet-295	593	6	silver	silver	NOUN
admet-295	593	7	spring	spring	NOUN
admet-295	593	8	,	,	PUNCT
admet-295	593	9	md	md	PROPN
admet-295	593	10	20993	20993	NUM
admet-295	593	11	,	,	PUNCT
admet-295	593	12	usa	usa	PROPN
admet-295	593	13	.	.	PROPN
admet-295	593	14	available	available	ADJ
admet-295	593	15	at	at	ADP
admet-295	593	16	:	:	PUNCT
admet-295	593	17	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192orig1s000pharmr.pdf	NOUN
admet-295	593	18	,	,	PUNCT
admet-295	593	19	[	[	X
admet-295	593	20	accessed	access	VERB
admet-295	593	21	on	on	ADP
admet-295	593	22	22	22	NUM
admet-295	593	23	march	march	NOUN
admet-295	593	24	2016	2016	NUM
admet-295	593	25	]	]	PUNCT
admet-295	593	26	.	.	PUNCT
admet-295	594	1	[	[	X
admet-295	594	2	88	88	NUM
admet-295	594	3	]	]	SYM
admet-295	594	4	food	food	NOUN
admet-295	594	5	and	and	CCONJ
admet-295	594	6	drug	drug	NOUN
admet-295	594	7	administration	administration	NOUN
admet-295	594	8	.	.	PUNCT
admet-295	595	1	pharmacology	pharmacology	NOUN
admet-295	595	2	review	review	NOUN
admet-295	595	3	of	of	ADP
admet-295	595	4	afatinib	afatinib	NOUN
admet-295	595	5	(	(	PUNCT
admet-295	595	6	gilotrif	gilotrif	NOUN
admet-295	595	7	)	)	PUNCT
admet-295	595	8	.	.	PUNCT
admet-295	596	1	food	food	NOUN
admet-295	596	2	and	and	CCONJ
admet-295	596	3	drug	drug	NOUN
admet-295	596	4	administration	administration	NOUN
admet-295	596	5	,	,	PUNCT
admet-295	596	6	silver	silver	NOUN
admet-295	596	7	spring	spring	NOUN
admet-295	596	8	,	,	PUNCT
admet-295	596	9	md	md	PROPN
admet-295	596	10	20993	20993	NUM
admet-295	596	11	,	,	PUNCT
admet-295	596	12	usa	usa	PROPN
admet-295	596	13	.	.	PROPN
admet-295	596	14	available	available	ADJ
admet-295	596	15	at	at	ADP
admet-295	596	16	:	:	PUNCT
admet-295	596	17	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292orig1s000pharmr.pdf	ADJ
admet-295	596	18	,	,	PUNCT
admet-295	596	19	[	[	X
admet-295	596	20	accessed	access	VERB
admet-295	596	21	on	on	ADP
admet-295	596	22	22	22	NUM
admet-295	596	23	march	march	NOUN
admet-295	596	24	2016	2016	NUM
admet-295	596	25	]	]	PUNCT
admet-295	596	26	.	.	PUNCT
admet-295	597	1	[	[	X
admet-295	597	2	89	89	NUM
admet-295	597	3	]	]	SYM
admet-295	597	4	food	food	NOUN
admet-295	597	5	and	and	CCONJ
admet-295	597	6	drug	drug	NOUN
admet-295	597	7	administration	administration	NOUN
admet-295	597	8	.	.	PUNCT
admet-295	598	1	pharmacology	pharmacology	NOUN
admet-295	598	2	review	review	NOUN
admet-295	598	3	of	of	ADP
admet-295	598	4	sunitinib	sunitinib	NOUN
admet-295	598	5	(	(	PUNCT
admet-295	598	6	sutent	sutent	PROPN
admet-295	598	7	)	)	PUNCT
admet-295	598	8	.	.	PUNCT
admet-295	599	1	food	food	NOUN
admet-295	599	2	and	and	CCONJ
admet-295	599	3	drug	drug	NOUN
admet-295	599	4	administration	administration	NOUN
admet-295	599	5	,	,	PUNCT
admet-295	599	6	silver	silver	NOUN
admet-295	599	7	spring	spring	NOUN
admet-295	599	8	,	,	PUNCT
admet-295	599	9	md	md	PROPN
admet-295	599	10	20993	20993	NUM
admet-295	599	11	,	,	PUNCT
admet-295	599	12	usa	usa	PROPN
admet-295	599	13	.	.	PROPN
admet-295	599	14	available	available	ADJ
admet-295	599	15	at	at	ADP
admet-295	599	16	:	:	PUNCT
admet-295	599	17	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_s000_sutent_pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_s000_sutent_pharmr.pdf	PROPN
admet-295	599	18	,	,	PUNCT
admet-295	599	19	[	[	X
admet-295	599	20	accessed	access	VERB
admet-295	599	21	on	on	ADP
admet-295	599	22	22	22	NUM
admet-295	599	23	march	march	NOUN
admet-295	599	24	2016	2016	NUM
admet-295	599	25	]	]	PUNCT
admet-295	599	26	.	.	PUNCT
admet-295	600	1	[	[	X
admet-295	600	2	90	90	NUM
admet-295	600	3	]	]	SYM
admet-295	600	4	food	food	NOUN
admet-295	600	5	and	and	CCONJ
admet-295	600	6	drug	drug	NOUN
admet-295	600	7	administration	administration	NOUN
admet-295	600	8	.	.	PUNCT
admet-295	601	1	pharmacology	pharmacology	NOUN
admet-295	601	2	review	review	NOUN
admet-295	601	3	of	of	ADP
admet-295	601	4	bosutinib	bosutinib	NOUN
admet-295	601	5	(	(	PUNCT
admet-295	601	6	bosulif	bosulif	NOUN
admet-295	601	7	)	)	PUNCT
admet-295	601	8	.	.	PUNCT
admet-295	602	1	food	food	NOUN
admet-295	602	2	and	and	CCONJ
admet-295	602	3	drug	drug	NOUN
admet-295	602	4	administration	administration	NOUN
admet-295	602	5	,	,	PUNCT
admet-295	602	6	silver	silver	NOUN
admet-295	602	7	spring	spring	NOUN
admet-295	602	8	,	,	PUNCT
admet-295	602	9	md	md	PROPN
admet-295	602	10	20993	20993	NUM
admet-295	602	11	,	,	PUNCT
admet-295	602	12	usa	usa	PROPN
admet-295	602	13	.	.	PROPN
admet-295	602	14	available	available	ADJ
admet-295	602	15	at	at	ADP
admet-295	602	16	:	:	PUNCT
admet-295	602	17	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341orig1s000pharmr.pdf	NOUN
admet-295	602	18	,	,	PUNCT
admet-295	602	19	[	[	X
admet-295	602	20	accessed	access	VERB
admet-295	602	21	on	on	ADP
admet-295	602	22	22	22	NUM
admet-295	602	23	march	march	NOUN
admet-295	602	24	2016	2016	NUM
admet-295	602	25	]	]	PUNCT
admet-295	602	26	.	.	PUNCT
admet-295	603	1	[	[	X
admet-295	603	2	91	91	NUM
admet-295	603	3	]	]	PUNCT
admet-295	603	4	k.	k.	PROPN
admet-295	603	5	r.	r.	PROPN
admet-295	603	6	doherty	doherty	PROPN
admet-295	603	7	,	,	PUNCT
admet-295	603	8	d.	d.	PROPN
admet-295	603	9	r.	r.	PROPN
admet-295	603	10	talbert	talbert	PROPN
admet-295	603	11	,	,	PUNCT
admet-295	603	12	p.	p.	PROPN
admet-295	603	13	b.	b.	PROPN
admet-295	604	1	trusk	trusk	PROPN
admet-295	604	2	,	,	PUNCT
admet-295	604	3	d.	d.	PROPN
admet-295	604	4	m.	m.	PROPN
admet-295	604	5	moran	moran	PROPN
admet-295	604	6	,	,	PUNCT
admet-295	604	7	s.	s.	PROPN
admet-295	604	8	a.	a.	PROPN
admet-295	604	9	shell	shell	PROPN
admet-295	604	10	,	,	PUNCT
admet-295	604	11	s.	s.	PROPN
admet-295	604	12	bacus	bacus	PROPN
admet-295	604	13	.	.	PUNCT
admet-295	605	1	toxicol	toxicol	PROPN
admet-295	605	2	.	.	PUNCT
admet-295	606	1	appl	appl	PROPN
admet-295	606	2	.	.	PUNCT
admet-295	607	1	pharmacol	pharmacol	PROPN
admet-295	607	2	.	.	PUNCT
admet-295	608	1	285(1	285(1	NUM
admet-295	608	2	)	)	PUNCT
admet-295	608	3	(	(	PUNCT
admet-295	608	4	2015	2015	NUM
admet-295	608	5	)	)	PUNCT
admet-295	608	6	51	51	NUM
admet-295	608	7	-	-	SYM
admet-295	608	8	60	60	NUM
admet-295	608	9	.	.	PUNCT
admet-295	609	1	[	[	X
admet-295	609	2	92	92	NUM
admet-295	609	3	]	]	PUNCT
admet-295	609	4	a.	a.	NOUN
admet-295	609	5	srikanthan	srikanthan	PROPN
admet-295	609	6	,	,	PUNCT
admet-295	609	7	j.	j.	PROPN
admet-295	609	8	l.	l.	PROPN
admet-295	609	9	ethier	ethier	PROPN
admet-295	609	10	,	,	PUNCT
admet-295	609	11	a.	a.	PROPN
admet-295	609	12	ocana	ocana	PROPN
admet-295	609	13	,	,	PUNCT
admet-295	609	14	b.	b.	PROPN
admet-295	609	15	seruga	seruga	PROPN
admet-295	609	16	,	,	PUNCT
admet-295	609	17	m.k	m.k	PROPN
admet-295	609	18	.	.	PROPN
admet-295	609	19	krzyzanowska	krzyzanowska	PROPN
admet-295	609	20	,	,	PUNCT
admet-295	609	21	e.	e.	PROPN
admet-295	609	22	amir	amir	PROPN
admet-295	609	23	.	.	PUNCT
admet-295	610	1	plos	plos	PROPN
admet-295	610	2	.	.	PROPN
admet-295	611	1	one	one	NUM
admet-295	611	2	.	.	PUNCT
admet-295	612	1	10(3	10(3	NUM
admet-295	612	2	)	)	PUNCT
admet-295	612	3	(	(	PUNCT
admet-295	612	4	2015	2015	NUM
admet-295	612	5	)	)	PUNCT
admet-295	612	6	e0122735	e0122735	NOUN
admet-295	612	7	.	.	PUNCT
admet-295	613	1	[	[	X
admet-295	613	2	93	93	NUM
admet-295	613	3	]	]	PUNCT
admet-295	613	4	s.	s.	PROPN
admet-295	613	5	jang	jang	PROPN
admet-295	613	6	,	,	PUNCT
admet-295	613	7	c.	c.	PROPN
admet-295	613	8	zheng	zheng	PROPN
admet-295	613	9	,	,	PUNCT
admet-295	613	10	h.	h.	PROPN
admet-295	613	11	t.	t.	PROPN
admet-295	613	12	tsai	tsai	PROPN
admet-295	613	13	,	,	PUNCT
admet-295	613	14	a.	a.	PROPN
admet-295	613	15	z.	z.	PROPN
admet-295	613	16	fu	fu	PROPN
admet-295	613	17	,	,	PUNCT
admet-295	613	18	a.	a.	NOUN
admet-295	613	19	barac	barac	PROPN
admet-295	613	20	,	,	PUNCT
admet-295	613	21	m.	m.	PROPN
admet-295	613	22	b.	b.	PROPN
admet-295	613	23	atkins	atkins	PROPN
admet-295	613	24	,	,	PUNCT
admet-295	613	25	a.	a.	PROPN
admet-295	613	26	n.	n.	PROPN
admet-295	613	27	freedman	freedman	PROPN
admet-295	613	28	,	,	PUNCT
admet-295	613	29	l.	l.	PROPN
admet-295	613	30	minasian	minasian	PROPN
admet-295	613	31	,	,	PUNCT
admet-295	613	32	a.	a.	PROPN
admet-295	613	33	l.	l.	PROPN
admet-295	613	34	potosky	potosky	PROPN
admet-295	613	35	.	.	PUNCT
admet-295	614	1	cancer	cancer	NOUN
admet-295	614	2	122(1	122(1	NUM
admet-295	614	3	)	)	PUNCT
admet-295	614	4	(	(	PUNCT
admet-295	614	5	2016	2016	NUM
admet-295	614	6	)	)	PUNCT
admet-295	614	7	124	124	NUM
admet-295	614	8	-	-	SYM
admet-295	614	9	130	130	NUM
admet-295	614	10	.	.	PUNCT
admet-295	615	1	[	[	X
admet-295	615	2	94	94	NUM
admet-295	615	3	]	]	X
admet-295	615	4	food	food	NOUN
admet-295	615	5	and	and	CCONJ
admet-295	615	6	drug	drug	NOUN
admet-295	615	7	administration	administration	NOUN
admet-295	615	8	.	.	PUNCT
admet-295	616	1	ponatinib	ponatinib	NOUN
admet-295	616	2	(	(	PUNCT
admet-295	616	3	iclusig	iclusig	NOUN
admet-295	616	4	)	)	PUNCT
admet-295	616	5	label	label	NOUN
admet-295	616	6	(	(	PUNCT
admet-295	616	7	14	14	NUM
admet-295	616	8	december	december	PROPN
admet-295	616	9	2012	2012	NUM
admet-295	616	10	)	)	PUNCT
admet-295	616	11	.	.	PUNCT
admet-295	617	1	food	food	NOUN
admet-295	617	2	and	and	CCONJ
admet-295	617	3	drug	drug	NOUN
admet-295	617	4	administration	administration	NOUN
admet-295	617	5	,	,	PUNCT
admet-295	617	6	silver	silver	NOUN
admet-295	617	7	spring	spring	NOUN
admet-295	617	8	,	,	PUNCT
admet-295	617	9	md	md	PROPN
admet-295	617	10	20993	20993	NUM
admet-295	617	11	,	,	PUNCT
admet-295	617	12	usa	usa	PROPN
admet-295	617	13	.	.	PROPN
admet-295	617	14	available	available	ADJ
admet-295	617	15	at	at	ADP
admet-295	617	16	:	:	PUNCT
admet-295	617	17	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	NOUN
admet-295	617	18	,	,	PUNCT
admet-295	617	19	[	[	X
admet-295	617	20	accessed	access	VERB
admet-295	617	21	on	on	ADP
admet-295	617	22	22	22	NUM
admet-295	617	23	march	march	NOUN
admet-295	617	24	2016	2016	NUM
admet-295	617	25	]	]	PUNCT
admet-295	617	26	.	.	PUNCT
admet-295	618	1	[	[	X
admet-295	618	2	95	95	NUM
admet-295	618	3	]	]	X
admet-295	618	4	food	food	NOUN
admet-295	618	5	and	and	CCONJ
admet-295	618	6	drug	drug	NOUN
admet-295	618	7	administration	administration	NOUN
admet-295	618	8	.	.	PUNCT
admet-295	619	1	ponatinib	ponatinib	NOUN
admet-295	619	2	(	(	PUNCT
admet-295	619	3	iclusig	iclusig	NOUN
admet-295	619	4	)	)	PUNCT
admet-295	619	5	approval	approval	NOUN
admet-295	619	6	letter	letter	NOUN
admet-295	619	7	(	(	PUNCT
admet-295	619	8	14	14	NUM
admet-295	619	9	december	december	PROPN
admet-295	619	10	2012	2012	NUM
admet-295	619	11	)	)	PUNCT
admet-295	619	12	.	.	PUNCT
admet-295	620	1	food	food	NOUN
admet-295	620	2	and	and	CCONJ
admet-295	620	3	drug	drug	NOUN
admet-295	620	4	administration	administration	NOUN
admet-295	620	5	,	,	PUNCT
admet-295	620	6	silver	silver	NOUN
admet-295	620	7	spring	spring	NOUN
admet-295	620	8	,	,	PUNCT
admet-295	620	9	md	md	PROPN
admet-295	620	10	20993	20993	NUM
admet-295	620	11	,	,	PUNCT
admet-295	620	12	usa	usa	PROPN
admet-295	620	13	.	.	PROPN
admet-295	620	14	available	available	ADJ
admet-295	620	15	at	at	ADP
admet-295	620	16	:	:	PUNCT
admet-295	620	17	http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203469orig1s000ltr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203469orig1s000ltr.pdf	PROPN
admet-295	620	18	,	,	PUNCT
admet-295	620	19	[	[	X
admet-295	620	20	accessed	access	VERB
admet-295	620	21	on	on	ADP
admet-295	620	22	22	22	NUM
admet-295	620	23	march	march	NOUN
admet-295	620	24	2016	2016	NUM
admet-295	620	25	]	]	PUNCT
admet-295	620	26	.	.	PUNCT
admet-295	621	1	[	[	X
admet-295	621	2	96	96	NUM
admet-295	621	3	]	]	X
admet-295	621	4	food	food	NOUN
admet-295	621	5	and	and	CCONJ
admet-295	621	6	drug	drug	NOUN
admet-295	621	7	administration	administration	NOUN
admet-295	621	8	.	.	PUNCT
admet-295	622	1	fda	fda	PROPN
admet-295	622	2	drug	drug	PROPN
admet-295	622	3	safety	safety	NOUN
admet-295	622	4	communication	communication	NOUN
admet-295	622	5	:	:	PUNCT
admet-295	622	6	fda	fda	PROPN
admet-295	622	7	asks	ask	VERB
admet-295	622	8	manufacturer	manufacturer	NOUN
admet-295	622	9	of	of	ADP
admet-295	622	10	the	the	DET
admet-295	622	11	leukemia	leukemia	NOUN
admet-295	622	12	drug	drug	NOUN
admet-295	622	13	iclusig	iclusig	NOUN
admet-295	622	14	(	(	PUNCT
admet-295	622	15	ponatinib	ponatinib	NOUN
admet-295	622	16	)	)	PUNCT
admet-295	622	17	to	to	PART
admet-295	622	18	suspend	suspend	VERB
admet-295	622	19	marketing	marketing	NOUN
admet-295	622	20	and	and	CCONJ
admet-295	622	21	sales	sale	NOUN
admet-295	622	22	.	.	PUNCT
admet-295	623	1	food	food	NOUN
admet-295	623	2	and	and	CCONJ
admet-295	623	3	drug	drug	NOUN
admet-295	623	4	administration	administration	NOUN
admet-295	623	5	,	,	PUNCT
admet-295	624	1	https://assets.digital.cabinet-office.gov.uk/media/56435e1340f0b674d3000024/xalnp36_-_uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	https://assets.digital.cabinet-office.gov.uk/media/56435e1340f0b674d3000024/xalnp36_-_uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	PROPN
admet-295	624	2	https://assets.digital.cabinet-office.gov.uk/media/56435e1340f0b674d3000024/xalnp36_-_uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	https://assets.digital.cabinet-office.gov.uk/media/56435e1340f0b674d3000024/xalnp36_-_uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	PROPN
admet-295	624	3	https://assets.digital.cabinet-office.gov.uk/media/56435e1340f0b674d3000024/xalnp36_-_uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	https://assets.digital.cabinet-office.gov.uk/media/56435e1340f0b674d3000024/xalnp36_-_uk_xalkori_dhcp_letter_cardiac_failure__2_.pdf	PROPN
admet-295	624	4	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s017lbl.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s017lbl.pdf	PROPN
admet-295	624	5	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065orig1s000pharmr.pdf	NOUN
admet-295	624	6	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192orig1s000pharmr.pdf	PROPN
admet-295	624	7	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292orig1s000pharmr.pdf	PROPN
admet-295	624	8	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_s000_sutent_pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_s000_sutent_pharmr.pdf	PROPN
admet-295	624	9	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341orig1s000pharmr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341orig1s000pharmr.pdf	X
admet-295	624	10	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	VERB
admet-295	624	11	http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203469orig1s000ltr.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203469orig1s000ltr.pdf	PROPN
admet-295	624	12	rashmi	rashmi	PROPN
admet-295	624	13	shah	shah	PROPN
admet-295	624	14	admet	admet	PROPN
admet-295	624	15	&	&	CCONJ
admet-295	624	16	dmpk	dmpk	PROPN
admet-295	624	17	4(3	4(3	NUM
admet-295	624	18	)	)	PUNCT
admet-295	624	19	(	(	PUNCT
admet-295	624	20	2016	2016	NUM
admet-295	624	21	)	)	PUNCT
admet-295	624	22	212	212	NUM
admet-295	624	23	-	-	SYM
admet-295	624	24	231	231	NUM
admet-295	624	25	230	230	NUM
admet-295	624	26	silver	silver	NOUN
admet-295	624	27	spring	spring	NOUN
admet-295	624	28	,	,	PUNCT
admet-295	624	29	md	md	PROPN
admet-295	624	30	20993	20993	NUM
admet-295	624	31	,	,	PUNCT
admet-295	624	32	usa	usa	PROPN
admet-295	624	33	.	.	PROPN
admet-295	624	34	available	available	ADJ
admet-295	624	35	at	at	ADP
admet-295	624	36	:	:	PUNCT
admet-295	624	37	http://www.fda.gov/drugs/drugsafety/ucm373040.htm	http://www.fda.gov/drugs/drugsafety/ucm373040.htm	NOUN
admet-295	624	38	,	,	PUNCT
admet-295	624	39	[	[	X
admet-295	624	40	accessed	access	VERB
admet-295	624	41	on	on	ADP
admet-295	624	42	22	22	NUM
admet-295	624	43	march	march	NOUN
admet-295	624	44	2016	2016	NUM
admet-295	624	45	]	]	PUNCT
admet-295	624	46	.	.	PUNCT
admet-295	625	1	[	[	X
admet-295	625	2	97	97	NUM
admet-295	625	3	]	]	SYM
admet-295	625	4	food	food	NOUN
admet-295	625	5	and	and	CCONJ
admet-295	625	6	drug	drug	NOUN
admet-295	625	7	administration	administration	NOUN
admet-295	625	8	.	.	PUNCT
admet-295	626	1	fda	fda	PROPN
admet-295	626	2	drug	drug	PROPN
admet-295	626	3	safety	safety	NOUN
admet-295	626	4	communication	communication	NOUN
admet-295	626	5	:	:	PUNCT
admet-295	626	6	fda	fda	PROPN
admet-295	626	7	requires	require	VERB
admet-295	626	8	multiple	multiple	ADJ
admet-295	626	9	new	new	ADJ
admet-295	626	10	safety	safety	NOUN
admet-295	626	11	measures	measure	NOUN
admet-295	626	12	for	for	ADP
admet-295	626	13	leukemia	leukemia	NOUN
admet-295	626	14	drug	drug	NOUN
admet-295	626	15	iclusig	iclusig	NOUN
admet-295	626	16	;	;	PUNCT
admet-295	626	17	company	company	NOUN
admet-295	626	18	expected	expect	VERB
admet-295	626	19	to	to	PART
admet-295	626	20	resume	resume	VERB
admet-295	626	21	marketing	marketing	NOUN
admet-295	626	22	.	.	PUNCT
admet-295	627	1	food	food	NOUN
admet-295	627	2	and	and	CCONJ
admet-295	627	3	drug	drug	NOUN
admet-295	627	4	administration	administration	NOUN
admet-295	627	5	,	,	PUNCT
admet-295	627	6	silver	silver	NOUN
admet-295	627	7	spring	spring	NOUN
admet-295	627	8	,	,	PUNCT
admet-295	627	9	md	md	PROPN
admet-295	627	10	20993	20993	NUM
admet-295	627	11	,	,	PUNCT
admet-295	627	12	usa	usa	PROPN
admet-295	627	13	.	.	PROPN
admet-295	627	14	available	available	ADJ
admet-295	627	15	at	at	ADP
admet-295	627	16	:	:	PUNCT
admet-295	627	17	http://www.fda.gov/drugs/drugsafety/ucm379554.htm	http://www.fda.gov/drugs/drugsafety/ucm379554.htm	PROPN
admet-295	627	18	,	,	PUNCT
admet-295	627	19	[	[	X
admet-295	627	20	accessed	access	VERB
admet-295	627	21	on	on	ADP
admet-295	627	22	22	22	NUM
admet-295	627	23	march	march	NOUN
admet-295	627	24	2016	2016	NUM
admet-295	627	25	]	]	PUNCT
admet-295	627	26	.	.	PUNCT
admet-295	628	1	[	[	X
admet-295	628	2	98	98	NUM
admet-295	628	3	]	]	X
admet-295	628	4	food	food	NOUN
admet-295	628	5	and	and	CCONJ
admet-295	628	6	drug	drug	NOUN
admet-295	628	7	administration	administration	NOUN
admet-295	628	8	.	.	PUNCT
admet-295	629	1	ponatinib	ponatinib	NOUN
admet-295	629	2	(	(	PUNCT
admet-295	629	3	iclusig	iclusig	NOUN
admet-295	629	4	)	)	PUNCT
admet-295	629	5	label	label	NOUN
admet-295	629	6	(	(	PUNCT
admet-295	629	7	2	2	NUM
admet-295	629	8	june	june	PROPN
admet-295	629	9	2016	2016	NUM
admet-295	629	10	)	)	PUNCT
admet-295	629	11	.	.	PUNCT
admet-295	630	1	food	food	NOUN
admet-295	630	2	and	and	CCONJ
admet-295	630	3	drug	drug	NOUN
admet-295	630	4	administration	administration	NOUN
admet-295	630	5	,	,	PUNCT
admet-295	630	6	silver	silver	NOUN
admet-295	630	7	spring	spring	NOUN
admet-295	630	8	,	,	PUNCT
admet-295	630	9	md	md	PROPN
admet-295	630	10	20993	20993	NUM
admet-295	630	11	,	,	PUNCT
admet-295	630	12	usa	usa	PROPN
admet-295	630	13	.	.	PROPN
admet-295	630	14	available	available	ADJ
admet-295	630	15	at	at	ADP
admet-295	630	16	:	:	PUNCT
admet-295	630	17	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s021lbl.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s021lbl.pdf	X
admet-295	630	18	,	,	PUNCT
admet-295	630	19	[	[	X
admet-295	630	20	accessed	access	VERB
admet-295	630	21	on	on	ADP
admet-295	630	22	22	22	NUM
admet-295	630	23	march	march	NOUN
admet-295	630	24	2016	2016	NUM
admet-295	630	25	]	]	PUNCT
admet-295	630	26	.	.	PUNCT
admet-295	631	1	[	[	X
admet-295	631	2	99	99	NUM
admet-295	631	3	]	]	X
admet-295	631	4	s.	s.	PROPN
admet-295	631	5	sivendran	sivendran	PROPN
admet-295	631	6	,	,	PUNCT
admet-295	631	7	z.	z.	PROPN
admet-295	631	8	liu	liu	PROPN
admet-295	631	9	,	,	PUNCT
admet-295	631	10	l.	l.	PROPN
admet-295	631	11	j.	j.	PROPN
admet-295	631	12	portas	portas	PROPN
admet-295	631	13	jr	jr	PROPN
admet-295	631	14	,	,	PUNCT
admet-295	631	15	m.	m.	PROPN
admet-295	631	16	yu	yu	PROPN
admet-295	631	17	,	,	PUNCT
admet-295	631	18	n.	n.	PROPN
admet-295	631	19	hahn	hahn	PROPN
admet-295	631	20	,	,	PUNCT
admet-295	631	21	g.	g.	PROPN
admet-295	631	22	sonpavde	sonpavde	PROPN
admet-295	631	23	,	,	PUNCT
admet-295	631	24	w.	w.	PROPN
admet-295	631	25	k.	k.	PROPN
admet-295	632	1	oh	oh	INTJ
admet-295	632	2	,	,	PUNCT
admet-295	632	3	m.	m.	NOUN
admet-295	632	4	d.	d.	PROPN
admet-295	632	5	galsky	galsky	PROPN
admet-295	632	6	.	.	PUNCT
admet-295	633	1	cancer	cancer	NOUN
admet-295	633	2	treat	treat	PROPN
admet-295	633	3	.	.	PUNCT
admet-295	634	1	rev	rev	PROPN
admet-295	634	2	.	.	PROPN
admet-295	634	3	38(7	38(7	NUM
admet-295	634	4	)	)	PUNCT
admet-295	634	5	(	(	PUNCT
admet-295	634	6	2012	2012	NUM
admet-295	634	7	)	)	PUNCT
admet-295	634	8	919	919	NUM
admet-295	634	9	-	-	SYM
admet-295	634	10	925	925	NUM
admet-295	634	11	.	.	PUNCT
admet-295	635	1	[	[	X
admet-295	635	2	100	100	NUM
admet-295	635	3	]	]	PUNCT
admet-295	635	4	f.	f.	PROPN
admet-295	635	5	a.	a.	PROPN
admet-295	635	6	schutz	schutz	PROPN
admet-295	635	7	,	,	PUNCT
admet-295	635	8	y.	y.	PROPN
admet-295	635	9	je	je	PROPN
admet-295	635	10	,	,	PUNCT
admet-295	635	11	c.	c.	PROPN
admet-295	635	12	j.	j.	PROPN
admet-295	635	13	richards	richards	PROPN
admet-295	635	14	,	,	PUNCT
admet-295	635	15	t.	t.	PROPN
admet-295	635	16	k.	k.	PROPN
admet-295	635	17	choueiri	choueiri	PROPN
admet-295	635	18	.	.	PUNCT
admet-295	636	1	j.	j.	PROPN
admet-295	636	2	clin	clin	PROPN
admet-295	636	3	.	.	PUNCT
admet-295	637	1	oncol	oncol	ADJ
admet-295	637	2	.	.	PUNCT
admet-295	638	1	30(8	30(8	NUM
admet-295	638	2	)	)	PUNCT
admet-295	638	3	(	(	PUNCT
admet-295	638	4	2012	2012	NUM
admet-295	638	5	)	)	PUNCT
admet-295	638	6	871	871	NUM
admet-295	638	7	-	-	SYM
admet-295	638	8	877	877	NUM
admet-295	638	9	.	.	PUNCT
admet-295	639	1	[	[	X
admet-295	639	2	101	101	X
admet-295	639	3	]	]	PUNCT
admet-295	639	4	s.	s.	PROPN
admet-295	639	5	hong	hong	PROPN
admet-295	639	6	,	,	PUNCT
admet-295	639	7	w.	w.	PROPN
admet-295	639	8	fang	fang	PROPN
admet-295	639	9	,	,	PUNCT
admet-295	639	10	w.	w.	PROPN
admet-295	639	11	liang	liang	PROPN
admet-295	639	12	,	,	PUNCT
admet-295	639	13	y.	y.	PROPN
admet-295	639	14	yan	yan	PROPN
admet-295	639	15	,	,	PUNCT
admet-295	639	16	t.	t.	PROPN
admet-295	639	17	zhou	zhou	PROPN
admet-295	639	18	,	,	PUNCT
admet-295	639	19	t.	t.	PROPN
admet-295	639	20	qin	qin	PROPN
admet-295	639	21	,	,	PUNCT
admet-295	639	22	x.	x.	PROPN
admet-295	639	23	wu	wu	PROPN
admet-295	639	24	,	,	PUNCT
admet-295	639	25	y.	y.	PROPN
admet-295	639	26	ma	ma	PROPN
admet-295	639	27	,	,	PUNCT
admet-295	639	28	y.	y.	PROPN
admet-295	639	29	zhao	zhao	PROPN
admet-295	639	30	,	,	PUNCT
admet-295	639	31	y.	y.	PROPN
admet-295	639	32	yang	yang	PROPN
admet-295	639	33	,	,	PUNCT
admet-295	639	34	z.	z.	PROPN
admet-295	639	35	hu	hu	PROPN
admet-295	639	36	,	,	PUNCT
admet-295	639	37	c.	c.	PROPN
admet-295	639	38	xue	xue	PROPN
admet-295	639	39	,	,	PUNCT
admet-295	639	40	x.	x.	NOUN
admet-295	639	41	hou	hou	PROPN
admet-295	639	42	,	,	PUNCT
admet-295	639	43	y.	y.	PROPN
admet-295	639	44	chen	chen	PROPN
admet-295	639	45	,	,	PUNCT
admet-295	639	46	y.	y.	PROPN
admet-295	639	47	huang	huang	PROPN
admet-295	639	48	,	,	PUNCT
admet-295	639	49	h.	h.	PROPN
admet-295	639	50	zhao	zhao	PROPN
admet-295	639	51	,	,	PUNCT
admet-295	639	52	l.	l.	PROPN
admet-295	639	53	zhang	zhang	PROPN
admet-295	639	54	.	.	PUNCT
admet-295	640	1	onco	onco	PROPN
admet-295	640	2	.	.	PUNCT
admet-295	641	1	targets	target	NOUN
admet-295	641	2	ther	ther	ADV
admet-295	641	3	.	.	PUNCT
admet-295	642	1	7	7	NUM
admet-295	642	2	(	(	PUNCT
admet-295	642	3	2014	2014	NUM
admet-295	642	4	)	)	PUNCT
admet-295	642	5	1851	1851	NUM
admet-295	642	6	-	-	SYM
admet-295	642	7	1867	1867	NUM
admet-295	642	8	.	.	PUNCT
admet-295	643	1	[	[	X
admet-295	643	2	102	102	NUM
admet-295	643	3	]	]	X
admet-295	643	4	x.	x.	PROPN
admet-295	643	5	yang	yang	PROPN
admet-295	643	6	,	,	PUNCT
admet-295	643	7	x.	x.	PROPN
admet-295	643	8	pan	pan	PROPN
admet-295	643	9	,	,	PUNCT
admet-295	643	10	x.	x.	PROPN
admet-295	643	11	cheng	cheng	PROPN
admet-295	643	12	,	,	PUNCT
admet-295	643	13	y.	y.	PROPN
admet-295	643	14	cheng	cheng	PROPN
admet-295	643	15	,	,	PUNCT
admet-295	643	16	y.	y.	PROPN
admet-295	643	17	kuang	kuang	PROPN
admet-295	643	18	.	.	PUNCT
admet-295	644	1	int	int	PROPN
admet-295	644	2	.	.	PUNCT
admet-295	645	1	j.	j.	PROPN
admet-295	645	2	clin	clin	PROPN
admet-295	645	3	.	.	PUNCT
admet-295	646	1	pharm	pharm	PROPN
admet-295	646	2	.	.	PUNCT
admet-295	647	1	37(6	37(6	NUM
admet-295	647	2	)	)	PUNCT
admet-295	647	3	(	(	PUNCT
admet-295	647	4	2015	2015	NUM
admet-295	647	5	)	)	PUNCT
admet-295	647	6	1047	1047	NUM
admet-295	647	7	-	-	SYM
admet-295	647	8	1056	1056	NUM
admet-295	647	9	.	.	PUNCT
admet-295	648	1	[	[	X
admet-295	648	2	103	103	NUM
admet-295	648	3	]	]	X
admet-295	648	4	g.	g.	PROPN
admet-295	648	5	w.	w.	PROPN
admet-295	648	6	jean	jean	PROPN
admet-295	648	7	,	,	PUNCT
admet-295	648	8	r.	r.	PROPN
admet-295	648	9	m.	m.	PROPN
admet-295	648	10	mani	mani	PROPN
admet-295	648	11	,	,	PUNCT
admet-295	648	12	a.	a.	PROPN
admet-295	648	13	jaffry	jaffry	PROPN
admet-295	648	14	,	,	PUNCT
admet-295	648	15	s.	s.	PROPN
admet-295	648	16	a.	a.	PROPN
admet-295	648	17	khan	khan	PROPN
admet-295	648	18	.	.	PUNCT
admet-295	649	1	jama	jama	PROPN
admet-295	649	2	oncol	oncol	PROPN
admet-295	649	3	.	.	PUNCT
admet-295	650	1	2(4	2(4	NUM
admet-295	650	2	)	)	PUNCT
admet-295	650	3	(	(	PUNCT
admet-295	650	4	2016	2016	NUM
admet-295	650	5	)	)	PUNCT
admet-295	650	6	529	529	NUM
admet-295	650	7	-	-	SYM
admet-295	650	8	534	534	NUM
admet-295	650	9	.	.	PUNCT
admet-295	651	1	[	[	X
admet-295	651	2	104	104	X
admet-295	651	3	]	]	X
admet-295	651	4	w.	w.	PROPN
admet-295	651	5	x.	x.	PROPN
admet-295	651	6	qi	qi	PROPN
admet-295	651	7	,	,	PUNCT
admet-295	651	8	l.	l.	PROPN
admet-295	651	9	n.	n.	PROPN
admet-295	651	10	tang	tang	PROPN
admet-295	651	11	,	,	PUNCT
admet-295	651	12	a.	a.	PROPN
admet-295	651	13	n.	n.	PROPN
admet-295	651	14	he	he	PRON
admet-295	651	15	,	,	PUNCT
admet-295	651	16	y.	y.	PROPN
admet-295	651	17	yao	yao	PROPN
admet-295	651	18	,	,	PUNCT
admet-295	651	19	z.	z.	PROPN
admet-295	651	20	shen	shen	PROPN
admet-295	651	21	.	.	PUNCT
admet-295	652	1	respir	respir	PROPN
admet-295	652	2	.	.	PUNCT
admet-295	653	1	med	me	VERB
admet-295	653	2	.	.	PUNCT
admet-295	654	1	107(8	107(8	NUM
admet-295	654	2	)	)	PUNCT
admet-295	654	3	(	(	PUNCT
admet-295	654	4	2013	2013	NUM
admet-295	654	5	)	)	PUNCT
admet-295	654	6	1280	1280	NUM
admet-295	654	7	-	-	SYM
admet-295	654	8	1283	1283	NUM
admet-295	654	9	.	.	PUNCT
admet-295	655	1	[	[	X
admet-295	655	2	105	105	NUM
admet-295	655	3	]	]	X
admet-295	655	4	t.	t.	NOUN
admet-295	655	5	funakoshi	funakoshi	PROPN
admet-295	655	6	,	,	PUNCT
admet-295	655	7	a.	a.	PROPN
admet-295	655	8	latif	latif	PROPN
admet-295	655	9	,	,	PUNCT
admet-295	655	10	m.	m.	NOUN
admet-295	655	11	d.	d.	PROPN
admet-295	655	12	galsky	galsky	PROPN
admet-295	655	13	.	.	PUNCT
admet-295	656	1	cancer	cancer	NOUN
admet-295	656	2	treat	treat	PROPN
admet-295	656	3	.	.	PUNCT
admet-295	657	1	rev	rev	PROPN
admet-295	657	2	.	.	PROPN
admet-295	657	3	40(5	40(5	PROPN
admet-295	657	4	)	)	PUNCT
admet-295	657	5	(	(	PUNCT
admet-295	657	6	2014	2014	NUM
admet-295	657	7	)	)	PUNCT
admet-295	657	8	636	636	NUM
admet-295	657	9	-	-	NUM
admet-295	657	10	647	647	NUM
admet-295	657	11	.	.	PUNCT
admet-295	658	1	[	[	X
admet-295	658	2	106	106	X
admet-295	658	3	]	]	X
admet-295	658	4	s.	s.	PROPN
admet-295	658	5	niraula	niraula	PROPN
admet-295	658	6	,	,	PUNCT
admet-295	658	7	b.	b.	PROPN
admet-295	658	8	seruga	seruga	PROPN
admet-295	658	9	,	,	PUNCT
admet-295	658	10	a.	a.	PROPN
admet-295	658	11	ocana	ocana	PROPN
admet-295	658	12	,	,	PUNCT
admet-295	658	13	t.	t.	PROPN
admet-295	658	14	shao	shao	PROPN
admet-295	658	15	,	,	PUNCT
admet-295	658	16	r.	r.	PROPN
admet-295	658	17	goldstein	goldstein	PROPN
admet-295	658	18	,	,	PUNCT
admet-295	658	19	i.	i.	PROPN
admet-295	658	20	f.	f.	PROPN
admet-295	658	21	tannock	tannock	PROPN
admet-295	658	22	,	,	PUNCT
admet-295	658	23	e.	e.	PROPN
admet-295	658	24	amir	amir	PROPN
admet-295	658	25	.	.	PUNCT
admet-295	659	1	j.	j.	PROPN
admet-295	659	2	clin	clin	PROPN
admet-295	659	3	.	.	PUNCT
admet-295	660	1	oncol	oncol	PROPN
admet-295	660	2	.	.	PUNCT
admet-295	661	1	30(24	30(24	NUM
admet-295	661	2	)	)	PUNCT
admet-295	661	3	(	(	PUNCT
admet-295	661	4	2012	2012	NUM
admet-295	661	5	)	)	PUNCT
admet-295	661	6	3012	3012	NUM
admet-295	661	7	-	-	SYM
admet-295	661	8	3019	3019	NUM
admet-295	661	9	.	.	PUNCT
admet-295	662	1	[	[	X
admet-295	662	2	107	107	NUM
admet-295	662	3	]	]	PUNCT
admet-295	662	4	m.	m.	NOUN
admet-295	662	5	joerger	joerger	NOUN
admet-295	662	6	,	,	PUNCT
admet-295	662	7	c.	c.	PROPN
admet-295	662	8	schaer	schaer	PROPN
admet-295	662	9	-	-	PUNCT
admet-295	662	10	thuer	thuer	PROPN
admet-295	662	11	,	,	PUNCT
admet-295	662	12	d.	d.	PROPN
admet-295	662	13	koeberle	koeberle	PROPN
admet-295	662	14	,	,	PUNCT
admet-295	662	15	k.	k.	PROPN
admet-295	662	16	matter	matter	NOUN
admet-295	662	17	-	-	PUNCT
admet-295	662	18	walstra	walstra	PROPN
admet-295	662	19	,	,	PUNCT
admet-295	662	20	j.	j.	PROPN
admet-295	662	21	gibbons	gibbons	PROPN
admet-295	662	22	-	-	PUNCT
admet-295	662	23	marsico	marsico	PROPN
admet-295	662	24	,	,	PUNCT
admet-295	662	25	s.	s.	PROPN
admet-295	662	26	diem	diem	PROPN
admet-295	662	27	,	,	PUNCT
admet-295	662	28	b.	b.	PROPN
admet-295	662	29	thuerlimann	thuerlimann	PROPN
admet-295	662	30	,	,	PUNCT
admet-295	662	31	t.	t.	PROPN
admet-295	662	32	cerny	cerny	NOUN
admet-295	662	33	.	.	PUNCT
admet-295	663	1	eur	eur	PROPN
admet-295	663	2	.	.	PUNCT
admet-295	664	1	j.	j.	PROPN
admet-295	664	2	clin	clin	PROPN
admet-295	664	3	.	.	PUNCT
admet-295	665	1	pharmacol	pharmacol	PROPN
admet-295	665	2	.	.	PUNCT
admet-295	666	1	70(6	70(6	VERB
admet-295	666	2	)	)	PUNCT
admet-295	666	3	(	(	PUNCT
admet-295	666	4	2014	2014	NUM
admet-295	666	5	)	)	PUNCT
admet-295	666	6	719	719	NUM
admet-295	666	7	-	-	SYM
admet-295	666	8	725	725	NUM
admet-295	666	9	.	.	PUNCT
admet-295	667	1	[	[	X
admet-295	667	2	108	108	NUM
admet-295	667	3	]	]	PUNCT
admet-295	667	4	b.	b.	PROPN
admet-295	667	5	seruga	seruga	PROPN
admet-295	667	6	,	,	PUNCT
admet-295	667	7	l.	l.	PROPN
admet-295	667	8	sterling	sterling	PROPN
admet-295	667	9	,	,	PUNCT
admet-295	667	10	l.	l.	PROPN
admet-295	667	11	wang	wang	PROPN
admet-295	667	12	,	,	PUNCT
admet-295	667	13	i.	i.	PROPN
admet-295	667	14	f.	f.	PROPN
admet-295	667	15	tannock	tannock	PROPN
admet-295	667	16	.	.	PUNCT
admet-295	668	1	j.	j.	PROPN
admet-295	668	2	clin	clin	PROPN
admet-295	668	3	.	.	PUNCT
admet-295	669	1	oncol	oncol	ADJ
admet-295	669	2	.	.	PUNCT
admet-295	670	1	29(2	29(2	X
admet-295	670	2	)	)	PUNCT
admet-295	670	3	(	(	PUNCT
admet-295	670	4	2011	2011	NUM
admet-295	670	5	)	)	PUNCT
admet-295	670	6	174	174	NUM
admet-295	670	7	-	-	SYM
admet-295	670	8	185	185	NUM
admet-295	670	9	.	.	PUNCT
admet-295	671	1	[	[	X
admet-295	671	2	109	109	NUM
admet-295	671	3	]	]	PUNCT
admet-295	671	4	j.	j.	PROPN
admet-295	671	5	mori	mori	PROPN
admet-295	671	6	,	,	PUNCT
admet-295	671	7	t.	t.	PROPN
admet-295	671	8	tanimoto	tanimoto	PROPN
admet-295	671	9	,	,	PUNCT
admet-295	671	10	y.	y.	PROPN
admet-295	671	11	miura	miura	PROPN
admet-295	671	12	,	,	PUNCT
admet-295	671	13	m.	m.	PROPN
admet-295	671	14	kami	kami	PROPN
admet-295	671	15	.	.	PUNCT
admet-295	672	1	jpn	jpn	PROPN
admet-295	672	2	.	.	PUNCT
admet-295	673	1	j.	j.	PROPN
admet-295	673	2	clin	clin	PROPN
admet-295	673	3	.	.	PUNCT
admet-295	674	1	oncol	oncol	ADJ
admet-295	674	2	.	.	PUNCT
admet-295	675	1	45(6	45(6	NUM
admet-295	675	2	)	)	PUNCT
admet-295	675	3	(	(	PUNCT
admet-295	675	4	2015	2015	NUM
admet-295	675	5	)	)	PUNCT
admet-295	675	6	588	588	NUM
admet-295	675	7	-	-	SYM
admet-295	675	8	594	594	NUM
admet-295	675	9	.	.	PUNCT
admet-295	676	1	[	[	X
admet-295	676	2	110	110	NUM
admet-295	676	3	]	]	X
admet-295	676	4	g.	g.	PROPN
admet-295	676	5	gintant	gintant	PROPN
admet-295	676	6	,	,	PUNCT
admet-295	676	7	p.t	p.t	PROPN
admet-295	676	8	.	.	PROPN
admet-295	676	9	sager	sager	PROPN
admet-295	676	10	,	,	PUNCT
admet-295	676	11	n.	n.	PROPN
admet-295	676	12	stockbridge	stockbridge	PROPN
admet-295	676	13	.	.	PUNCT
admet-295	677	1	nat	nat	PROPN
admet-295	677	2	.	.	PUNCT
admet-295	678	1	rev	rev	PROPN
admet-295	678	2	.	.	PROPN
admet-295	678	3	drug	drug	NOUN
admet-295	678	4	discov	discov	NOUN
admet-295	678	5	.	.	PUNCT
admet-295	679	1	15	15	NUM
admet-295	679	2	(	(	PUNCT
admet-295	679	3	2016	2016	NUM
admet-295	679	4	)	)	PUNCT
admet-295	679	5	457	457	NUM
admet-295	679	6	-	-	SYM
admet-295	679	7	471	471	NUM
admet-295	679	8	.	.	PUNCT
admet-295	680	1	[	[	X
admet-295	680	2	111	111	NUM
admet-295	680	3	]	]	PUNCT
admet-295	680	4	x.	x.	PROPN
admet-295	680	5	d.	d.	PROPN
admet-295	680	6	shao	shao	PROPN
admet-295	680	7	,	,	PUNCT
admet-295	680	8	k.	k.	PROPN
admet-295	680	9	c.	c.	PROPN
admet-295	680	10	wu	wu	PROPN
admet-295	680	11	,	,	PUNCT
admet-295	680	12	x.	x.	PROPN
admet-295	680	13	z.	z.	PROPN
admet-295	680	14	guo	guo	PROPN
admet-295	680	15	,	,	PUNCT
admet-295	680	16	m.	m.	PROPN
admet-295	680	17	j.	j.	PROPN
admet-295	680	18	xie	xie	PROPN
admet-295	680	19	,	,	PUNCT
admet-295	680	20	j.	j.	PROPN
admet-295	680	21	zhang	zhang	PROPN
admet-295	680	22	,	,	PUNCT
admet-295	680	23	d.	d.	PROPN
admet-295	680	24	m.	m.	PROPN
admet-295	680	25	fan	fan	PROPN
admet-295	680	26	.	.	PUNCT
admet-295	681	1	cancer	cancer	PROPN
admet-295	681	2	biol	biol	PROPN
admet-295	681	3	.	.	PUNCT
admet-295	682	1	ther	ther	ADV
admet-295	682	2	.	.	PUNCT
admet-295	683	1	7(1	7(1	NUM
admet-295	683	2	)	)	PUNCT
admet-295	683	3	(	(	PUNCT
admet-295	683	4	2008	2008	NUM
admet-295	683	5	)	)	PUNCT
admet-295	683	6	45	45	NUM
admet-295	683	7	-	-	SYM
admet-295	683	8	50	50	NUM
admet-295	683	9	.	.	PUNCT
admet-295	684	1	[	[	X
admet-295	684	2	112	112	NUM
admet-295	684	3	]	]	PUNCT
admet-295	684	4	j.	j.	PROPN
admet-295	684	5	i.	i.	PROPN
admet-295	684	6	vandenberg	vandenberg	PROPN
admet-295	684	7	,	,	PUNCT
admet-295	684	8	m.	m.	PROPN
admet-295	684	9	d.	d.	PROPN
admet-295	684	10	perry	perry	PROPN
admet-295	684	11	,	,	PUNCT
admet-295	684	12	m.	m.	PROPN
admet-295	684	13	j.	j.	PROPN
admet-295	684	14	perrin	perrin	PROPN
admet-295	684	15	,	,	PUNCT
admet-295	684	16	s.	s.	PROPN
admet-295	684	17	a.	a.	PROPN
admet-295	684	18	mann	mann	PROPN
admet-295	684	19	,	,	PUNCT
admet-295	684	20	y.	y.	PROPN
admet-295	684	21	ke	ke	PROPN
admet-295	684	22	,	,	PUNCT
admet-295	684	23	a.	a.	PROPN
admet-295	684	24	p.	p.	PROPN
admet-295	684	25	hill	hill	PROPN
admet-295	684	26	.	.	PUNCT
admet-295	685	1	physiol	physiol	PROPN
admet-295	685	2	.	.	PUNCT
admet-295	686	1	rev	rev	PROPN
admet-295	686	2	.	.	PROPN
admet-295	687	1	92(3	92(3	X
admet-295	687	2	)	)	PUNCT
admet-295	687	3	(	(	PUNCT
admet-295	687	4	2012	2012	NUM
admet-295	687	5	)	)	PUNCT
admet-295	687	6	13931478	13931478	NUM
admet-295	687	7	.	.	PUNCT
admet-295	688	1	[	[	X
admet-295	688	2	113	113	NUM
admet-295	688	3	]	]	PUNCT
admet-295	688	4	j.	j.	PROPN
admet-295	688	5	j.	j.	PROPN
admet-295	688	6	babcock	babcock	PROPN
admet-295	688	7	,	,	PUNCT
admet-295	688	8	m.	m.	PROPN
admet-295	688	9	li	li	PROPN
admet-295	688	10	.	.	PROPN
admet-295	688	11	acta	acta	PROPN
admet-295	688	12	pharmacol	pharmacol	PROPN
admet-295	688	13	.	.	PUNCT
admet-295	688	14	sin	sin	PROPN
admet-295	688	15	.	.	PUNCT
admet-295	689	1	34(3	34(3	NUM
admet-295	689	2	)	)	PUNCT
admet-295	689	3	(	(	PUNCT
admet-295	689	4	2013	2013	NUM
admet-295	689	5	)	)	PUNCT
admet-295	689	6	329	329	NUM
admet-295	689	7	-	-	SYM
admet-295	689	8	335	335	NUM
admet-295	689	9	.	.	PUNCT
admet-295	690	1	[	[	X
admet-295	690	2	114	114	NUM
admet-295	690	3	]	]	PUNCT
admet-295	690	4	g.	g.	PROPN
admet-295	690	5	a.	a.	PROPN
admet-295	690	6	smith	smith	PROPN
admet-295	690	7	,	,	PUNCT
admet-295	690	8	h.	h.	PROPN
admet-295	690	9	w.	w.	PROPN
admet-295	690	10	tsui	tsui	PROPN
admet-295	690	11	,	,	PUNCT
admet-295	690	12	e.	e.	PROPN
admet-295	690	13	w.	w.	PROPN
admet-295	690	14	newell	newell	PROPN
admet-295	690	15	,	,	PUNCT
admet-295	690	16	x.	x.	PROPN
admet-295	690	17	jiang	jiang	PROPN
admet-295	690	18	,	,	PUNCT
admet-295	690	19	x.	x.	PROPN
admet-295	690	20	p.	p.	PROPN
admet-295	690	21	zhu	zhu	PROPN
admet-295	690	22	,	,	PUNCT
admet-295	690	23	f.	f.	PROPN
admet-295	690	24	w.	w.	PROPN
admet-295	690	25	tsui	tsui	PROPN
admet-295	690	26	,	,	PUNCT
admet-295	690	27	l.	l.	PROPN
admet-295	690	28	c.	c.	PROPN
admet-295	690	29	schlichter	schlichter	PROPN
admet-295	690	30	.	.	PUNCT
admet-295	691	1	j.	j.	PROPN
admet-295	691	2	biol	biol	PROPN
admet-295	691	3	.	.	PUNCT
admet-295	692	1	chem	chem	NOUN
admet-295	692	2	.	.	PUNCT
admet-295	693	1	277(21	277(21	NUM
admet-295	693	2	)	)	PUNCT
admet-295	693	3	(	(	PUNCT
admet-295	693	4	2002	2002	NUM
admet-295	693	5	)	)	PUNCT
admet-295	693	6	18528	18528	NUM
admet-295	693	7	-	-	SYM
admet-295	693	8	18534	18534	NUM
admet-295	693	9	.	.	PUNCT
admet-295	694	1	[	[	X
admet-295	694	2	115	115	NUM
admet-295	694	3	]	]	PUNCT
admet-295	694	4	a.	a.	NOUN
admet-295	694	5	arcangeli	arcangeli	PROPN
admet-295	694	6	,	,	PUNCT
admet-295	694	7	o.	o.	PROPN
admet-295	694	8	crociani	crociani	PROPN
admet-295	694	9	,	,	PUNCT
admet-295	694	10	e.	e.	PROPN
admet-295	694	11	lastraioli	lastraioli	PROPN
admet-295	694	12	,	,	PUNCT
admet-295	694	13	a.	a.	PROPN
admet-295	694	14	masi	masi	PROPN
admet-295	694	15	,	,	PUNCT
admet-295	694	16	s.	s.	PROPN
admet-295	694	17	pillozzi	pillozzi	PROPN
admet-295	694	18	,	,	PUNCT
admet-295	694	19	a.	a.	NOUN
admet-295	694	20	becchetti	becchetti	PROPN
admet-295	694	21	.	.	PUNCT
admet-295	695	1	curr	curr	AUX
admet-295	695	2	.	.	PUNCT
admet-295	695	3	med	med	PROPN
admet-295	695	4	.	.	PROPN
admet-295	695	5	chem	chem	PROPN
admet-295	695	6	.	.	PUNCT
admet-295	696	1	16(1	16(1	X
admet-295	696	2	)	)	PUNCT
admet-295	696	3	(	(	PUNCT
admet-295	696	4	2009	2009	NUM
admet-295	696	5	)	)	PUNCT
admet-295	696	6	66	66	NUM
admet-295	696	7	-	-	SYM
admet-295	696	8	93	93	NUM
admet-295	696	9	.	.	PUNCT
admet-295	697	1	[	[	X
admet-295	697	2	116	116	X
admet-295	697	3	]	]	X
admet-295	697	4	g.	g.	PROPN
admet-295	697	5	glassmeier	glassmeier	PROPN
admet-295	697	6	,	,	PUNCT
admet-295	697	7	k.	k.	PROPN
admet-295	697	8	hempel	hempel	PROPN
admet-295	697	9	,	,	PUNCT
admet-295	697	10	i.	i.	PROPN
admet-295	697	11	wulfsen	wulfsen	PROPN
admet-295	697	12	,	,	PUNCT
admet-295	697	13	c.	c.	PROPN
admet-295	697	14	k.	k.	PROPN
admet-295	697	15	bauer	bauer	PROPN
admet-295	697	16	,	,	PUNCT
admet-295	697	17	u.	u.	PROPN
admet-295	697	18	schumacher	schumacher	PROPN
admet-295	697	19	,	,	PUNCT
admet-295	697	20	j.	j.	PROPN
admet-295	697	21	r.	r.	PROPN
admet-295	697	22	schwarz	schwarz	PROPN
admet-295	697	23	.	.	PUNCT
admet-295	697	24	pflugers	pfluger	NOUN
admet-295	697	25	.	.	PUNCT
admet-295	698	1	arch	arch	NOUN
admet-295	698	2	.	.	PUNCT
admet-295	699	1	463(2	463(2	NUM
admet-295	699	2	)	)	PUNCT
admet-295	699	3	(	(	PUNCT
admet-295	699	4	2012	2012	NUM
admet-295	699	5	)	)	PUNCT
admet-295	699	6	365	365	NUM
admet-295	699	7	-	-	SYM
admet-295	699	8	376	376	NUM
admet-295	699	9	.	.	PUNCT
admet-295	700	1	[	[	X
admet-295	700	2	117	117	NUM
admet-295	700	3	]	]	PUNCT
admet-295	700	4	a.	a.	NOUN
admet-295	700	5	arcangeli	arcangeli	PROPN
admet-295	700	6	,	,	PUNCT
admet-295	700	7	a.	a.	NOUN
admet-295	700	8	becchetti	becchetti	PROPN
admet-295	700	9	.	.	PUNCT
admet-295	701	1	drug	drug	NOUN
admet-295	701	2	resist	resist	NOUN
admet-295	701	3	.	.	PUNCT
admet-295	702	1	updat	updat	PROPN
admet-295	702	2	.	.	PROPN
admet-295	702	3	2015	2015	NUM
admet-295	702	4	jul	jul	PROPN
admet-295	702	5	-	-	PUNCT
admet-295	702	6	aug;21	aug;21	PROPN
admet-295	702	7	-	-	PUNCT
admet-295	702	8	22:11	22:11	NUM
admet-295	702	9	-	-	SYM
admet-295	702	10	9	9	NUM
admet-295	702	11	.	.	PUNCT
admet-295	703	1	[	[	X
admet-295	703	2	118	118	NUM
admet-295	703	3	]	]	X
admet-295	703	4	e.	e.	PROPN
admet-295	703	5	lastraioli	lastraioli	PROPN
admet-295	703	6	,	,	PUNCT
admet-295	703	7	t.	t.	PROPN
admet-295	703	8	lottini	lottini	PROPN
admet-295	703	9	,	,	PUNCT
admet-295	703	10	l.	l.	PROPN
admet-295	703	11	bencini	bencini	PROPN
admet-295	703	12	,	,	PUNCT
admet-295	703	13	m.	m.	NOUN
admet-295	703	14	bernini	bernini	PROPN
admet-295	703	15	,	,	PUNCT
admet-295	703	16	a.	a.	NOUN
admet-295	703	17	arcangeli	arcangeli	PROPN
admet-295	703	18	.	.	PUNCT
admet-295	703	19	biomed	biome	VERB
admet-295	703	20	.	.	PUNCT
admet-295	704	1	res	re	NOUN
admet-295	704	2	.	.	PUNCT
admet-295	705	1	int	int	NOUN
admet-295	705	2	.	.	PUNCT
admet-295	706	1	2015	2015	NUM
admet-295	706	2	(	(	PUNCT
admet-295	706	3	2015	2015	NUM
admet-295	706	4	)	)	PUNCT
admet-295	706	5	896432	896432	NUM
admet-295	706	6	.	.	PUNCT
admet-295	707	1	[	[	X
admet-295	707	2	119	119	NUM
admet-295	707	3	]	]	X
admet-295	707	4	l.	l.	PROPN
admet-295	707	5	leanza	leanza	PROPN
admet-295	707	6	,	,	PUNCT
admet-295	707	7	a.	a.	NOUN
admet-295	707	8	managò	managò	PROPN
admet-295	707	9	,	,	PUNCT
admet-295	707	10	m.	m.	NOUN
admet-295	707	11	zoratti	zoratti	PROPN
admet-295	707	12	,	,	PUNCT
admet-295	707	13	e.	e.	PROPN
admet-295	707	14	gulbins	gulbins	PROPN
admet-295	707	15	,	,	PUNCT
admet-295	707	16	i.	i.	PROPN
admet-295	707	17	szabo	szabo	PROPN
admet-295	707	18	.	.	PUNCT
admet-295	708	1	biochim	biochim	PROPN
admet-295	708	2	biophys	biophy	NOUN
admet-295	708	3	acta	acta	PROPN
admet-295	708	4	.	.	PUNCT
admet-295	709	1	1863	1863	NUM
admet-295	709	2	(	(	PUNCT
admet-295	709	3	2016	2016	NUM
admet-295	709	4	)	)	PUNCT
admet-295	709	5	1385	1385	NUM
admet-295	709	6	-	-	SYM
admet-295	709	7	1397	1397	NUM
admet-295	709	8	.	.	PUNCT
admet-295	710	1	[	[	X
admet-295	710	2	120	120	NUM
admet-295	710	3	]	]	X
admet-295	710	4	v.	v.	PROPN
admet-295	710	5	r.	r.	PROPN
admet-295	710	6	rao	rao	PROPN
admet-295	710	7	,	,	PUNCT
admet-295	710	8	m.	m.	PROPN
admet-295	710	9	perez	perez	PROPN
admet-295	710	10	-	-	PUNCT
admet-295	710	11	neut	neut	PROPN
admet-295	710	12	,	,	PUNCT
admet-295	710	13	s.	s.	PROPN
admet-295	710	14	kaja	kaja	PROPN
admet-295	710	15	,	,	PUNCT
admet-295	710	16	s.	s.	PROPN
admet-295	710	17	gentile	gentile	NOUN
admet-295	710	18	.	.	PUNCT
admet-295	711	1	cancers	cancer	NOUN
admet-295	711	2	7(2	7(2	PRON
admet-295	711	3	)	)	PUNCT
admet-295	711	4	(	(	PUNCT
admet-295	711	5	2015	2015	NUM
admet-295	711	6	)	)	PUNCT
admet-295	711	7	849	849	NUM
admet-295	711	8	-	-	SYM
admet-295	711	9	875	875	NUM
admet-295	711	10	.	.	PUNCT
admet-295	712	1	[	[	X
admet-295	712	2	121	121	NUM
admet-295	712	3	]	]	PUNCT
admet-295	712	4	j.	j.	PROPN
admet-295	712	5	garcia	garcia	PROPN
admet-295	712	6	-	-	PUNCT
admet-295	712	7	quiroz	quiroz	PROPN
admet-295	712	8	,	,	PUNCT
admet-295	712	9	j.	j.	PROPN
admet-295	712	10	camacho	camacho	PROPN
admet-295	712	11	.	.	PUNCT
admet-295	713	1	anti	anti	ADJ
admet-295	713	2	-	-	ADJ
admet-295	713	3	cancer	cancer	ADJ
admet-295	713	4	agents	agent	NOUN
admet-295	713	5	med	me	VERB
admet-295	713	6	.	.	PUNCT
admet-295	713	7	chem	chem	PROPN
admet-295	713	8	.	.	PUNCT
admet-295	714	1	11(3	11(3	NUM
admet-295	714	2	)	)	PUNCT
admet-295	714	3	(	(	PUNCT
admet-295	714	4	2011	2011	NUM
admet-295	714	5	)	)	PUNCT
admet-295	715	1	307–314	307–314	NUM
admet-295	715	2	.	.	PUNCT
admet-295	716	1	[	[	X
admet-295	716	2	122	122	NUM
admet-295	716	3	]	]	X
admet-295	716	4	r.	r.	PROPN
admet-295	716	5	j.	j.	PROPN
admet-295	716	6	andrade	andrade	PROPN
admet-295	716	7	,	,	PUNCT
admet-295	716	8	m.	m.	PROPN
admet-295	716	9	i.	i.	PROPN
admet-295	716	10	lucena	lucena	PROPN
admet-295	716	11	,	,	PUNCT
admet-295	716	12	m.	m.	NOUN
admet-295	716	13	c.	c.	PROPN
admet-295	716	14	fernández	fernández	PROPN
admet-295	716	15	,	,	PUNCT
admet-295	716	16	g.	g.	PROPN
admet-295	716	17	pelaez	pelaez	PROPN
admet-295	716	18	,	,	PUNCT
admet-295	716	19	k.	k.	PROPN
admet-295	716	20	pachkoria	pachkoria	PROPN
admet-295	716	21	,	,	PUNCT
admet-295	716	22	e.	e.	PROPN
admet-295	716	23	garcía	garcía	PROPN
admet-295	716	24	-	-	PUNCT
admet-295	716	25	ruiz	ruiz	NOUN
admet-295	716	26	,	,	PUNCT
admet-295	716	27	b.	b.	PROPN
admet-295	716	28	garcía	garcía	PROPN
admet-295	716	29	-	-	PUNCT
admet-295	716	30	muñoz	muñoz	PROPN
admet-295	716	31	,	,	PUNCT
admet-295	716	32	r.	r.	PROPN
admet-295	716	33	gonzález	gonzález	PROPN
admet-295	716	34	-	-	PUNCT
admet-295	716	35	grande	grande	PROPN
admet-295	716	36	,	,	PUNCT
admet-295	716	37	a.	a.	NOUN
admet-295	716	38	pizarro	pizarro	PROPN
admet-295	716	39	,	,	PUNCT
admet-295	716	40	j.	j.	PROPN
admet-295	716	41	a.	a.	NOUN
admet-295	716	42	durán	durán	PROPN
admet-295	716	43	,	,	PUNCT
admet-295	716	44	m.	m.	NOUN
admet-295	716	45	jiménez	jiménez	PROPN
admet-295	716	46	,	,	PUNCT
admet-295	716	47	l.	l.	PROPN
admet-295	716	48	rodrigo	rodrigo	PROPN
admet-295	716	49	,	,	PUNCT
admet-295	716	50	m.	m.	PROPN
admet-295	716	51	romero	romero	PROPN
admet-295	716	52	-	-	PUNCT
admet-295	716	53	gomez	gomez	PROPN
admet-295	716	54	,	,	PUNCT
admet-295	716	55	j.	j.	PROPN
admet-295	716	56	m.	m.	PROPN
admet-295	716	57	navarro	navarro	PROPN
admet-295	716	58	,	,	PUNCT
admet-295	716	59	r.	r.	PROPN
admet-295	716	60	planas	planas	PROPN
admet-295	716	61	,	,	PUNCT
admet-295	716	62	j.	j.	PROPN
admet-295	716	63	costa	costa	PROPN
admet-295	716	64	,	,	PUNCT
admet-295	716	65	a.	a.	NOUN
admet-295	716	66	borras	borra	NOUN
admet-295	716	67	,	,	PUNCT
admet-295	716	68	a.	a.	NOUN
admet-295	716	69	soler	soler	PROPN
admet-295	716	70	,	,	PUNCT
admet-295	716	71	j.	j.	PROPN
admet-295	716	72	salmerón	salmerón	PROPN
admet-295	716	73	,	,	PUNCT
admet-295	716	74	r.	r.	PROPN
admet-295	716	75	martin	martin	PROPN
admet-295	716	76	-	-	PUNCT
admet-295	716	77	vivaldi	vivaldi	PROPN
admet-295	716	78	:	:	PUNCT
admet-295	716	79	spanish	spanish	ADJ
admet-295	716	80	group	group	NOUN
admet-295	716	81	for	for	ADP
admet-295	716	82	the	the	DET
admet-295	716	83	study	study	NOUN
admet-295	716	84	of	of	ADP
admet-295	716	85	drug	drug	NOUN
admet-295	716	86	-	-	PUNCT
admet-295	716	87	induced	induce	VERB
admet-295	716	88	liver	liver	NOUN
admet-295	716	89	disease	disease	NOUN
admet-295	716	90	.	.	PUNCT
admet-295	717	1	gastroenterology	gastroenterology	NOUN
admet-295	717	2	129(2	129(2	NUM
admet-295	717	3	)	)	PUNCT
admet-295	717	4	(	(	PUNCT
admet-295	717	5	2005	2005	NUM
admet-295	717	6	)	)	PUNCT
admet-295	717	7	512	512	NUM
admet-295	717	8	-	-	SYM
admet-295	717	9	521	521	NUM
admet-295	717	10	.	.	PUNCT
admet-295	718	1	[	[	X
admet-295	718	2	123	123	NUM
admet-295	718	3	]	]	PUNCT
admet-295	718	4	e.	e.	PROPN
admet-295	718	5	björnsson	björnsson	PROPN
admet-295	718	6	,	,	PUNCT
admet-295	718	7	r.	r.	PROPN
admet-295	718	8	olsson	olsson	PROPN
admet-295	718	9	.	.	PUNCT
admet-295	718	10	hepatology	hepatology	PROPN
admet-295	718	11	42(2	42(2	PROPN
admet-295	718	12	)	)	PUNCT
admet-295	718	13	(	(	PUNCT
admet-295	718	14	2005	2005	NUM
admet-295	718	15	)	)	PUNCT
admet-295	718	16	481	481	NUM
admet-295	718	17	-	-	SYM
admet-295	718	18	489	489	NUM
admet-295	718	19	.	.	PUNCT
admet-295	719	1	http://www.fda.gov/drugs/drugsafety/ucm373040.htm	http://www.fda.gov/drugs/drugsafety/ucm373040.htm	PROPN
admet-295	719	2	http://www.fda.gov/drugs/drugsafety/ucm379554.htm	http://www.fda.gov/drugs/drugsafety/ucm379554.htm	PROPN
admet-295	719	3	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s021lbl.pdf	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s021lbl.pdf	PROPN
admet-295	719	4	admet	admet	PROPN
admet-295	719	5	&	&	CCONJ
admet-295	719	6	dmpk	dmpk	PROPN
admet-295	719	7	4(3	4(3	NUM
admet-295	719	8	)	)	PUNCT
admet-295	719	9	(	(	PUNCT
admet-295	719	10	2016	2016	NUM
admet-295	719	11	)	)	PUNCT
admet-295	719	12	212	212	NUM
admet-295	719	13	-	-	SYM
admet-295	719	14	231	231	NUM
admet-295	719	15	pkis	pki	NOUN
admet-295	719	16	and	and	CCONJ
admet-295	719	17	qt	qt	NOUN
admet-295	719	18	-	-	PUNCT
admet-295	719	19	phobia	phobia	NOUN
admet-295	719	20	doi	doi	NOUN
admet-295	719	21	:	:	PUNCT
admet-295	719	22	10.5599	10.5599	NUM
admet-295	719	23	/	/	SYM
admet-295	719	24	admet.4.3.295	admet.4.3.295	NOUN
admet-295	719	25	231	231	NUM
admet-295	719	26	[	[	SYM
admet-295	719	27	124	124	NUM
admet-295	719	28	]	]	PUNCT
admet-295	719	29	food	food	NOUN
admet-295	719	30	and	and	CCONJ
admet-295	719	31	drug	drug	NOUN
admet-295	719	32	administration	administration	NOUN
admet-295	719	33	.	.	PUNCT
admet-295	720	1	guidance	guidance	NOUN
admet-295	720	2	for	for	ADP
admet-295	720	3	industry	industry	NOUN
admet-295	720	4	drug	drug	NOUN
admet-295	720	5	-	-	PUNCT
admet-295	720	6	induced	induce	VERB
admet-295	720	7	liver	liver	NOUN
admet-295	720	8	injury	injury	NOUN
admet-295	720	9	:	:	PUNCT
admet-295	720	10	premarketing	premarkete	VERB
admet-295	720	11	clinical	clinical	ADJ
admet-295	720	12	evaluation	evaluation	NOUN
admet-295	720	13	(	(	PUNCT
admet-295	720	14	july	july	PROPN
admet-295	720	15	2009	2009	NUM
admet-295	720	16	)	)	PUNCT
admet-295	720	17	.	.	PUNCT
admet-295	721	1	food	food	NOUN
admet-295	721	2	and	and	CCONJ
admet-295	721	3	drug	drug	NOUN
admet-295	721	4	administration	administration	NOUN
admet-295	721	5	,	,	PUNCT
admet-295	721	6	silver	silver	NOUN
admet-295	721	7	spring	spring	NOUN
admet-295	721	8	,	,	PUNCT
admet-295	721	9	md	md	PROPN
admet-295	721	10	20993	20993	NUM
admet-295	721	11	-	-	SYM
admet-295	721	12	0002	0002	NUM
admet-295	721	13	,	,	PUNCT
admet-295	721	14	usa	usa	PROPN
admet-295	721	15	.	.	PROPN
admet-295	721	16	available	available	ADJ
admet-295	721	17	at	at	ADP
admet-295	721	18	:	:	PUNCT
admet-295	721	19	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm	PUNCT
admet-295	721	20	174090.pdf	174090.pdf	NOUN
admet-295	721	21	,	,	PUNCT
admet-295	721	22	[	[	X
admet-295	721	23	accessed	access	VERB
admet-295	721	24	on	on	ADP
admet-295	721	25	1	1	NUM
admet-295	721	26	march	march	NOUN
admet-295	721	27	2016	2016	NUM
admet-295	721	28	]	]	PUNCT
admet-295	721	29	.	.	PUNCT
admet-295	722	1	[	[	X
admet-295	722	2	125	125	NUM
admet-295	722	3	]	]	PUNCT
admet-295	722	4	t.	t.	PROPN
admet-295	722	5	h.	h.	PROPN
admet-295	722	6	brümmendorf	brümmendorf	PROPN
admet-295	722	7	,	,	PUNCT
admet-295	722	8	j.	j.	PROPN
admet-295	722	9	e.	e.	PROPN
admet-295	722	10	cortes	cortes	PROPN
admet-295	722	11	,	,	PUNCT
admet-295	722	12	c.	c.	PROPN
admet-295	722	13	a.	a.	PROPN
admet-295	722	14	de	de	PROPN
admet-295	722	15	souza	souza	PROPN
admet-295	722	16	,	,	PUNCT
admet-295	722	17	f.	f.	PROPN
admet-295	722	18	guilhot	guilhot	PROPN
admet-295	722	19	,	,	PUNCT
admet-295	722	20	l.	l.	PROPN
admet-295	722	21	duvillié	duvillié	PROPN
admet-295	722	22	,	,	PUNCT
admet-295	722	23	d.	d.	PROPN
admet-295	722	24	pavlov	pavlov	PROPN
admet-295	722	25	,	,	PUNCT
admet-295	722	26	k.	k.	PROPN
admet-295	722	27	gogat	gogat	PROPN
admet-295	722	28	,	,	PUNCT
admet-295	722	29	a.	a.	NOUN
admet-295	722	30	m.	m.	PROPN
admet-295	722	31	countouriotis	countouriotis	PROPN
admet-295	722	32	,	,	PUNCT
admet-295	722	33	c.	c.	PROPN
admet-295	722	34	gambacorti	gambacorti	PROPN
admet-295	722	35	-	-	PUNCT
admet-295	722	36	passerini	passerini	NOUN
admet-295	722	37	.	.	PUNCT
admet-295	723	1	br	br	PROPN
admet-295	723	2	.	.	PUNCT
admet-295	724	1	j.	j.	PROPN
admet-295	724	2	haematol	haematol	PROPN
admet-295	724	3	.	.	PUNCT
admet-295	725	1	168(1	168(1	NUM
admet-295	725	2	)	)	PUNCT
admet-295	725	3	(	(	PUNCT
admet-295	725	4	2015	2015	NUM
admet-295	725	5	)	)	PUNCT
admet-295	725	6	69	69	NUM
admet-295	725	7	-	-	SYM
admet-295	725	8	81	81	NUM
admet-295	725	9	.	.	PUNCT
admet-295	726	1	©	©	PROPN
admet-295	726	2	2016	2016	NUM
admet-295	726	3	by	by	ADP
admet-295	726	4	the	the	DET
admet-295	726	5	authors	author	NOUN
admet-295	726	6	;	;	PUNCT
admet-295	726	7	licensee	licensee	PROPN
admet-295	726	8	iapc	iapc	PROPN
admet-295	726	9	,	,	PUNCT
admet-295	726	10	zagreb	zagreb	PROPN
admet-295	726	11	,	,	PUNCT
admet-295	726	12	croatia	croatia	PROPN
admet-295	726	13	.	.	PUNCT
admet-295	727	1	this	this	DET
admet-295	727	2	article	article	NOUN
admet-295	727	3	is	be	AUX
admet-295	727	4	an	an	DET
admet-295	727	5	open	open	ADJ
admet-295	727	6	-	-	PUNCT
admet-295	727	7	access	access	NOUN
admet-295	727	8	article	article	NOUN
admet-295	727	9	distributed	distribute	VERB
admet-295	727	10	under	under	ADP
admet-295	727	11	the	the	DET
admet-295	727	12	terms	term	NOUN
admet-295	727	13	and	and	CCONJ
admet-295	727	14	conditions	condition	NOUN
admet-295	727	15	of	of	ADP
admet-295	727	16	the	the	DET
admet-295	727	17	creative	creative	ADJ
admet-295	727	18	commons	common	NOUN
admet-295	727	19	attribution	attribution	NOUN
admet-295	727	20	license	license	NOUN
admet-295	727	21	(	(	PUNCT
admet-295	727	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-295	727	23	)	)	PUNCT
admet-295	727	24	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm174090.pdf	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm174090.pdf	PROPN
admet-295	727	25	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm174090.pdf	http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm174090.pdf	PROPN
admet-295	727	26	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN